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I am extremely pleased to introduce the Italian Cancer Figures
Report 2015, completely devoted to the assessment of the
burden of rare cancers in Italy.
This report is the latest valuable contribution to knowledge
and policy development in the country by the Italian Asso-
ciation of Cancer Registries (AIRTUM).
The Ministry of Health, through its Centre for Prevention
and Disease Control, has systematically supported AIRTUM,
making careful use of the wealth of information provided by
AIRTUM to orient national policies and monitor their im-
plementation.
AIRTUM reports have been the main source of information
and the benchmark for all health professionals and patient as-
sociations over the past ten years, as the share of Italian po-
pulation screened by the cancer registries has increased from
23% to 51% so far, and is set to reach 70% in the next few
years.
This year’s report is the first in Italy to analyse rare tumours
from an epidemiological perspective. It shows that one out of
four diagnosed cancer cases belongs to the category of rare
cancers; this proportion is similar to other European estimates
(24%). This means that the affected population is more than
significant and calls for highly specific care, based on cancer
patterns, as well as individual needs.
Cancers defined as “rare” challenge clinical decision making,
health care organisation and clinical research due to their low
frequency in the population and the resulting limited exper-
tise available. In their daily life experience, rare cancer patients
and their families must overcome a wide range of obstacles,
such as:
 misdiagnosis and delay in diagnosis;
 lack of scientific knowledge due to the small number of pa-
tients that may not allow for traditional clinical trial design,
and limited availability of registries and tissue banks;
 difficulties in developing therapeutic tools and defining
therapeutic strategies, and shortage of therapeutic products;
 low-quality healthcare due to poor, not experienced-based
protocols, inappropriate referral procedures by general prac-
titioners and misdiagnoses by inexperienced laboratories.
The most striking figure in this report relates to patient sur-
vival, which is shorter than for patients affected by more com-
mon cancers, at any evaluated period: at 1, 3, and 5 years.
This is a particularly challenging figure for the National He-
alth Service, health care professionals, and, of course and
above all, patients and their families.
Italy is already committed to improving its health service de-
livery system in order to provide these patients with high-qua-
lity, more effective, and fairer care.
This effort will take on concrete form in a National Network
for Rare Cancers which will include the most experienced
cancer centres and professionals. This task is not trivial, given
the current devolution and the federal structure of our natio-
nal health system. This report underlines the need to over-
come local interests, and provides sound, evidence-based,
powerful tools to enhance scientific research and elicit new
and non-traditional epidemiological, clinical, and public he-
alth analyses.
Thanks to this report we can expect an improvement in the
understanding of rare tumours that will be useful not only for
Italy, but also for a broader international scientific and me-
dical audience, while supporting patient associations, stren-
gthening their links with scientific associations, whose ac-
countability will be key in forging a new alliance between
providers and beneficiaries.
In conclusion, I would like to congratulate and thank all those
who actively carried out this work and those who enthusia-
stically contributed to it.
To their commitment we will continue to add our own, ma-
king sure that our decisions and the related resource allocation
process are based on a careful, comprehensive need asses-
sment, so as to generate equitable care for those who might
otherwise be neglected.
Ranieri Guerra
Head of Strategic direction for health prevention,
Ministry of Health
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INTRODUZIONE
This new monograph of the Italian Association of Cancer Re-
gistries (AIRTUM) deals with “rare” cancers, defined as those
diagnosed in less than 6 every 100,000 citizens per year in the
European population.
Rare cancers are a red-hot issue for all oncology stakeholders:
patients, clinicians, the pharmaceutical industry, and policy-
makers. The reason is that their rareness makes diagnosis more
difficult and causes a lack of specific drugs and widespread ex-
pertise in treatment. Moreover, the continuous developments
in cancer research have provided new insights into cancer bio-
logy, resulting in better identification of specific oncological
entities. For example, we are now able – using specific biomar-
kers – to identify two or several tumours, previously conside-
red as a single type, which differ from each other in bioche-
mical footprint, treatment, and prognosis, as well.
This is what prompted AIRTUM to address this issue, in col-
laboration with the Italian National Cancer Institute of Milan,
the “Istituto Superiore di Sanità”, and the involvement of the
Italian Association of Medical Oncology (AIOM), the Italian
Federation of Volunteer-Based Cancer Organisations (FAVO),
the Italian Society of Haematology (SIE), and the Italian So-
ciety of Surgical oncology (SICO).
AIRTUM’s huge database proved effective in providing high-
quality, reliable information even on rare cancers, with more
than 330,000 cases used to compute incidence (years: 2000s)
and 280,000 used to estimate survival. The study shows that
about 89,000 (or 25%) of new annual cancer diagnoses in
Italy are of rare cancers. The huge overall number does not
solve the peculiarities of rarity: among the 198 analysed rare
cancer types, more than two thirds have an incidence below
0.5 cases per 100,000 per year.
Some tumour types that are rare according to the European
definition (diffuse large B-cell lymphoma, squamous cell car-
cinoma of larynx, multiple myeloma, hepatocellular carci-
noma, and thyroid carcinoma) have an incidence in Italy that
exceeds the European cut-off, introducing the need for har-
monization in definition and classification to obtain reliable
international comparisons.
The monograph provides an impressive amount of informa-
tion on detailed types of rare tumours. To cite a few data, 5-
year relative survival appears to be lower on average for rare
tumours than for frequent types. The number of Italian citi-
zens living with a rare tumour diagnosis has been estimated
to be 900,000. Prevalence differs according to the different
combination of incidence and survival in each of the rare tu-
mours.
This monograph provides an invaluable amount of previously
unpublished information on the epidemiology of rare tu-
mours in Italy, both as an overall group and for each of the
198 types, which have been analysed in detail for the first
time.
As is the case for all other AIRTUM reports, the data in this
monograph are available to all interested stakeholders, and
they focus on national peculiarities, quantifying individual
burdens and outcomes, and supporting health care planners
in the laying out of case-specific health care services.
Rare cancers are not only relevant today, but their relevance
is expected to grow in the future, pending further discoveries
and major progress in ongoing cancer research.
The quality and reliability of AIRTUM data, recently confir-
med even by the Ministry of Health, support the dissemina-
tion of reliable information regarding the epidemiology of
cancer in Italy, now including rare tumours.
Steering Committee
Italian Association of Cancer Registries (AIRTUM)
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OBJECTIVES
This collaborative study, based on data collected by the net-
work of Italian Cancer Registries (AIRTUM), describes the
burden of rare cancers in Italy. Estimated number of new rare
cancer cases yearly diagnosed (incidence), proportion of pa-
tients alive after diagnosis (survival), and estimated number
of people still alive after a new cancer diagnosis (prevalence)
are provided for about 200 different cancer entities.
MATERIALS AND METHODS
Data herein presented were provided by AIRTUM popula-
tion-based cancer registries (CRs), covering nowadays 52% of
the Italian population. This monograph uses the AIRTUM
database (January 2015), which includes all malignant cancer
cases diagnosed between 1976 and 2010. All cases are coded
according to the International Classification of Diseases for
Oncology (ICD-O-3). Data underwent standard quality
checks (described in the AIRTUM data management proto-
col) and were checked against rare-cancer specific quality in-
dicators proposed and published by RARECARE and
HAEMACARE (www.rarecarenet.eu; www.haemacare.eu).
The definition and list of rare cancers proposed by the
RARECAREnet “Information Network on Rare Cancers”
project were adopted: rare cancers are entities (defined as a
combination of topographical and morphological codes of the
ICD-O-3) having an incidence rate of less than 6 per 100,000
per year in the European population.
This monograph presents 198 rare cancers grouped in 14 ma-
jor groups.
Crude incidence rates were estimated as the number of all new
cancers occurring in 2000-2010 divided by the overall pop-
ulation at risk, for males and females (also for gender-specific
tumours). The proportion of rare cancers out of the total can-
cers (rare and common) by site was also calculated. Incidence
rates by sex and age are reported. The expected number of
new cases in 2015 in Italy was estimated assuming the inci-
dence in Italy to be the same as in the AIRTUM area.
One- and 5-year relative survival estimates of cases aged 0-99
years diagnosed between 2000 and 2008 in the AIRTUM
database, and followed up to 31 December 2009, were cal-
culated using complete cohort survival analysis.
To estimate the observed prevalence in Italy, incidence and fol-
OBIETTIVI
Questo studio collaborativo, basato sui dati raccolti dalla rete dei
registri tumori italiani (AIRTUM, www. registri-tumori.it), de-
scrive l’impatto dei tumori rari in Italia. Per circa 200 diversi
tumori rari sono state calcolate: incidenza, sopravvivenza a 1 e
5 anni e prevalenza.
MATERIALI E METODI
I dati presentati sono stati forniti dai Registri tumori di popolazione
AIRTUM, che coprono oggi il 52% della popolazione italiana.
Nella presente monografia sono stati analizzati i dati della Banca
Dati AIRTUM (aggiornamento: gennaio 2015), che include
tutti i casi di tumore maligno diagnosticati tra il 1976 e il 2010.
Tutti i casi sono codificati secondo la International Classification
of Diseases for Oncology (ICD-O-3) e sono stati sottoposti a con-
trolli standard di qualità (descritti nel protocollo di gestione della
Banca Dati AIRTUM) e a controlli specifici per i tumori rari pro-
posti e pubblicati nell’ambito dei progetti RARECARE eHAEMA-
CARE (www.rarecarenet.eu, www.haemacare.eu).
La definizione e l’elenco di tumori rari sono quelli proposti dal pro-
getto RARECAREnet, Information Network on Rare Cancers: i
tumori rari sono entità (definite come combinazioni di codici to-
pografici e morfologici della ICD-O-3) con un tasso di incidenza
inferiore a 6 per 100.000 per anno nella popolazione europea.
In questa monografia sono stati analizzati tutti i 198 tumori rari
identificati da RARECAREnet, classificati in 14 grandi gruppi.
Sono stati calcolati i tassi grezzi di incidenza come numero di
tutti i nuovi casi di tumore che si sono verificati nel periodo
2000-2010 divisi per la relativa popolazione a rischio, per ma-
schi e femmine insieme (anche nel caso di tumori specifici per
sesso). E’ presentata anche la percentuale di tumori rari sul
totale di tumori (rari e frequenti) per ogni sede, oltre ai tassi spe-
cifici per sesso ed età. E’ stato stimato il numero atteso di nuovi
casi diagnosticati nel 2015 in Italia, assumendo che l’incidenza
nazionale sia uguale a quella osservata nelle aree coperte dai re-
gistri AIRTUM.
E’ stata calcolata la sopravvivenza relativa (SR) a 1 e 5 anni dalla
diagnosi per casi di età compresa fra 0 e 99 anni diagnosticati nel
periodo 2000-2008, con follow-up aggiornato al 31 dicembre
2009, usando l’analisi di sopravvivenza completa.
Per stimare la prevalenza osservata in Italia sono stati selezionati
i casi raccolti da 11 registri nel periodo 1992-2006 considerando
ABSTRACT
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low-up data from 11 CRs for the period 1992-2006 were used,
with a prevalence index date of 1 January 2007. Observed
prevalence in the general population was disentangled by time
prior to the reference date (≤2 years, 2-5 years, ≤15 years). To
calculate the complete prevalence proportion at 1 January
2007 in Italy, the 15-year observed prevalence was corrected by
the completeness index, in order to account for those cancer
survivors diagnosed before the cancer registry activity started.
The completeness index by cancer and age was obtained by
means of statistical regression models, using incidence and sur-
vival data available in the European RARECAREnet data.
RESULTS
In total, 339,403 tumours were included in the incidence
analysis. The annual incidence rate (IR) of all 198 rare cancers
in the period 2000-2010 was 147 per 100,000 per year, cor-
responding to about 89,000 new diagnoses in Italy each year,
accounting for 25% of all cancer.
Five cancers, rare at European level, were not rare in Italy be-
cause their IR was higher than 6 per 100,000; these tumours
were: diffuse large B-cell lymphoma and squamous cell car-
cinoma of larynx (whose IRs in Italy were 7 per 100,000),
multiple myeloma (IR: 8 per 100,000), hepatocellular carci-
noma (IR: 9 per 100,000) and carcinoma of thyroid gland
(IR: 14 per 100,000).
Among the remaining 193 rare cancers, more than two thirds
(No. 139) had an annual IR <0.5 per 100,000, accounting for
about 7,100 new cancers cases; for 25 cancer types, the IR
ranged between 0.5 and 1 per 100,000, accounting for about
10,000 new diagnoses; while for 29 cancer types the IR was
between 1 and 6 per 100,000, accounting for about 41,000
new cancer cases.
Among all rare cancers diagnosed in Italy, 7% were rare
haematological diseases (IR: 41 per 100,000), 18% were
solid rare cancers. Among the latter, the rare epithelial tu-
mours of the digestive system were the most common (23%,
IR: 26 per 100,000), followed by epithelial tumours of head
and neck (17%, IR: 19) and rare cancers of the female genital
system (17%, IR: 17), endocrine tumours (13% including
thyroid carcinomas and less than 1% with an IR of 0.4 ex-
cluding thyroid carcinomas), sarcomas (8%, IR: 9 per
100,000), central nervous system tumours and rare epithelial
tumours of the thoracic cavity (5% with an IR equal to 6 and
5 per 100,000, respectively).
The remaining (rare male genital tumours, IR: 4 per 100,000;
tumours of eye, IR: 0.7 per 100,000; neuroendocrine tu-
mours, IR: 4 per 100,000; embryonal tumours, IR: 0.4 per
100,000; rare skin tumours and malignant melanoma of
mucosae, IR: 0.8 per 100,000) each constituted <4% of all
solid rare cancers.
Patients with rare cancers were on average younger than
those with common cancers. Essentially, all childhood cancers
were rare, while after age 40 years, the common cancers
(breast, prostate, colon, rectum, and lung) became increas-
ingly more frequent.
For 254,821 rare cancers diagnosed in 2000-2008, 5-year RS
was on average 55%, lower than the corresponding figures for
come data di riferimento il 1 gennaio 2007. La prevalenza os-
servata nella popolazione generale è stata stratificata per durata
(≤2 anni, 2-5 anni, ≤15 anni dalla diagnosi). Per calcolare la
prevalenza completa al 1 gennaio 2007, la prevalenza di durata
limitata a 15 anni dalla diagnosi è stata corretta utilizzando un
indice di completezza che tiene conto dei soggetti che hanno af-
frontato la diagnosi prima dell’inizio dell’attività dei registri tu-
mori. L’indice di completezza è stato ottenuto mediante modelli
di regressione statistici applicati ai dati europei di incidenza e so-
pravvivenza del progetto RARECAREnet.
RISULTATI
In totale, sono stati inclusi nell’analisi di incidenza 339.403 casi.
Il tasso annuale di incidenza (TI) per tutti i 198 tumori rari,
analizzati insieme come un unico gruppo, nel periodo 2000-
2010 è risultato pari a 147 per 100.000, corrispondente a
circa 89.000 nuove diagnosi in Italia ogni anno, che rappresen-
tano il 25% di tutti i tumori.
Cinque tumori, rari a livello europeo, non sono risultati rari in
Italia, perché il loro TI era superiore a 6 per 100.000: il linfoma
diffuso a grandi cellule B e il carcinoma a cellule squamose della
laringe (il cui TI in Italia era pari a 7 per 100.000), il mieloma
multiplo (TI: 8 per 100.000), il carcinoma epatocellulare (TI:
9 per 100.000) e il carcinoma della tiroide (TI: 14 per 100.000).
Tra i restanti 193 tumori rari, più di due terzi (n. 139) avevano
unTI annuo inferiore a 0,5 per 100.000, corrispondente a circa
7.100 nuovi casi; 25 entità avevano un TI tra 0,5 e 1 per
100.000, rappresentando circa 10.000 nuove diagnosi; mentre
per 29 entità il TI è risultato compreso tra 1 e 6 per 100.000,
circa 41.000 nuovi casi.
Il 7% di tutti i tumori rari diagnosticati in Italia è costituito da
tumori ematologici rari (TI: 41 per 100.000) e il 18% da tu-
mori solidi rari. Tra questi ultimi, i tumori rari epiteliali del-
l’apparato digerente sono i più frequenti (23%, TI: 26 per
100.000), seguiti dai tumori epiteliali del distretto testa e collo
(17%,TI: 19), dai tumori rari dell’apparato genitale femminile
(17%, TI: 17), dai tumori endocrini (13% includendo i car-
cinomi della tiroide, meno dell’1 % conTI pari a 0,4 escludendo
i carcinomi della tiroide ), dai sarcomi (8%,TI: 9 per 100.000),
dai tumori del sistema nervoso centrale e dai tumori epiteliali to-
racici rari (5% con una TI uguale a 6 e 5 per 100.000, rispet-
tivamente).
I restanti tumori rari (i tumori rari genitali maschili, TI: 4 su
100.000; i tumori dell’occhio, TI: 0,7 per 100,000; i tumori
neuroendocrini, TI: 4 per 100.000; i tumori embrionali, TI: 0,4
per 100,000; i tumori rari cutanei e il melanoma maligno delle
mucose, TI: 0,8 per 100,000) rappresentavano complessivamente
meno del 4% di tutti i tumori solidi rari.
I pazienti con un tumore raro sono in media più giovani di quelli
con un tumore frequente. In generale, tutti i tumori infantili sono
rari, mentre dopo i 40 anni, i tumori di mammella, prostata, co-
lon retto e polmone diventano sempre più frequenti.
Sulla base di quanto osservato nell’analisi di sopravvivenza, basata
su 254.821 casi di tumore raro diagnosticati nel periodo 2000-
2008, con ultimo aggiornamento dello stato in vita al 31 dicembre
2009, la SR a 5 anni dalla diagnosi è in media del 55%, più bassa
rispetto alla sopravvivenza dei pazienti con tumori frequenti
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patients with common cancers (68%). RS was lower for rare
cancers than for common cancers at 1 year and continued to
diverge up to 3 years, while the gap remained constant from 3
to 5 years after diagnosis. For rare and common cancers, sur-
vival decreased with increasing age. Five-year RS was similar
and high for both rare and common cancers up to 54 years; it
decreased with age, especially after 54 years, with the elderly
(75+ years) having a 37% and 20% lower survival than those
aged 55-64 years for rare and common cancers, respectively.
We estimated that about 900,000 people were alive in Italy
with a previous diagnosis of a rare cancer in 2010 (preva-
lence). The highest prevalence was observed for rare haema-
tological diseases (278 per 100,000) and rare tumours of the
female genital system (265 per 100,000).
Very low prevalence (<10 prt 100,000) was observed for rare
epithelial skin cancers, for rare epithelial tumours of the diges-
tive system and rare epithelial tumours of the thoracic cavity.
COMMENTS
One in four cancers cases diagnosed in Italy is a rare cancer,
in agreement with estimates of 24% calculated in Europe
overall. In Italy, the group of all rare cancers combined, in-
clude 5 cancer types with an IR>6 per 100,000 in Italy, in par-
ticular thyroid cancer (IR: 14 per 100,000). The exclusion of
thyroid carcinoma from rare cancers reduces the proportion
of them in Italy in 2010 to 22%. Differences in incidence
across population can be due to the different distribution of
risk factors (whether environmental, lifestyle, occupational,
or genetic), heterogeneous diagnostic intensity activity, as
well as different diagnostic capacity; moreover heterogeneity
in accuracy of registration may determine some minor differ-
ences in the account of rare cancers.
Rare cancers had worse prognosis than common cancers
at 1, 3, and 5 years from diagnosis. Differences be-
tween rare and common cancers were small 1 year
after diagnosis, but survival for rare cancers de-
clined more markedly thereafter, consistent with
the idea that treatments for rare cancers are less
effective than those for common cancers. How-
ever, differences in stage at diagnosis could not be
excluded, as 1- and 3-year RS for rare cancers was
lower than the corresponding figures for common
cancers. Moreover, rare cancers include many cancer
entities with a bad prognosis (5-year RS <50%): cancer
of head and neck, oesophagus, small in-
testine, ovary, brain, biliary tract, liver,
pleura, multiple myeloma, acute
myeloid and lymphatic leukaemia;
in contrast, most common cancer
cases are breast, prostate, and
colorectal cancers, which have a
good prognosis.
The high prevalence observed
for rare haematological diseases
and rare tumours of the female gen-
ital system is due to their high incidence (the
majority of haematological diseases are rare and gynaecolog-
(68%). La SR è inferiore per i tumori rari rispetto ai frequenti
dopo 1 anno dalla diagnosi e continuava a divergere fino a 3 anni,
il divario è costante da 3 a 5 anni. Per i tumori rari e frequenti,
la sopravvivenza diminuisce con l’aumentare dell’età. La SR a 5
anni è simile, ed elevata, per i tumori rari e frequenti fino a 54
anni; diminuisce con l’età, soprattutto dopo i 54 anni, tra gli an-
ziani (75+ anni), che presentano una SR del 37% inferiore
rispetto alle persone di età compresa tra 55-64 anni.
Si è stimato che circa 900.000 persone fossero vive in Italia nel
2010 dopo una diagnosi di un tumore raro (prevalenza). La pre-
valenza più elevata è stata osservata per i tumori rari ematologici
(278 per 100.000) e per i tumori rari del sistema genitale fem-
minile (265 per 100.000). La prevalenza dei tumori rari cuta-
nei, dei tumori epiteliali rari del tratto digerente e dei tumori epi-
teliali rari della cavità toracica è risultata molto bassa (<10 per
100.000).
DISUSSIONE
Ogni quattro tumori diagnosticati in Italia uno è raro; questa pro-
porzione è sovrapponibile a quella osservata in Europa (24%;
www.rarecarenet.eu). In Italia l’insieme dei
tumori rari comprende anche cinque
patologie il cui tasso di incidenza è
superiore a 6 per 100.000, con
valori particolarmente elevati
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ical cancers added up to fairly high incidence rates) and rel-
atively good prognosis.
The low prevalence of rare epithelial tumours of the digestive
system was due to the low survival rates of the majority of tu-
mours included in this group (oesophagus, stomach, small in-
testine, pancreas, and liver), regardless of the high incidence
rate of rare epithelial cancers of these sites.
This AIRTUM study confirms that rare cancers are a major
public health problem in Italy and provides quantitative es-
timations, for the first time in Italy, to a problem long known
to exist.
This monograph provides detailed epidemiologic indicators
for almost 200 rare cancers, the majority of which (72%) are
very rare (IR<0.5 per 100,000). These data are of major in-
terest for different stakeholders. Health care planners can find
useful information herein to properly plan and think of how
to reorganise health care services.
Researchers now have numbers to design clinical trials con-
sidering alternative study designs and statistical approaches.
Population-based cancer registries with good quality data are
the best source of information to describe the rare cancer bur-
den in a population.
Keywords: rare cancers, incidence, survival, prevalence,
cancer registries, Italy
per il carcinoma della tiroide (TI: 14 per 100.000). Se esclu-
diamo il carcinoma della tiroide dall’insieme dei tumori rari, la
proporzione di questi ultimi sul totale dei tumori si riduce al
22%. Le differenze di incidenza dei tumori rari in popolazioni
diverse può essere dovuta alla diversa distribuzione dei fattori di
rischio (ambientali, stili di vita, professionali e genetici), alla di-
versa intensità delle attività diagnostiche, nonché alle differenti
capacità diagnostiche; inoltre, anche l’eterogeneità nella precisione
della registrazione può contribuire a determinare qualche diffe-
renza nel conteggio dei tumori rari.
La sopravvivenza dopo 1, 3 e 5 anni dalla diagnosi è risultata in-
feriore per i tumori rari rispetto a quelli frequenti. Le differenze
tra tumori rari e frequenti un anno dopo la diagnosi sono limitate,
per poi amplificarsi, coerentemente con l’idea che i trattamenti per
i tumori rari possano essere meno efficaci di quelli disponibili per
i tumori frequenti. Tuttavia, non possono essere escluse differenze
nella distribuzione per stadio alla diagnosi, essendo la sopravvi-
venza a 1 e 3 anni per tumori rari inferiore rispetto a quella os-
servata per i tumori frequenti. Inoltre, è necessario considerare che
i tumori rari includono molti tumori con una cattiva prognosi (so-
pravvivenza relativa a 5 anni inferiore al 50%), quali i tumori
del distretto testa e collo, dell’esofago, dell’intestino tenue, del-
l’ovaio, del sistema nervoso centrale, delle vie biliari, del fegato,
della pleura, il mieloma multiplo, la leucemia mieloide acuta, la
leucemia linfatica acuta; al contrario, tra i tumori più frequenti
vi sono sedi tumorali, quali la mammella femminile, la prostata
e il colon retto, caratterizzate da una buona prognosi.
L’alta prevalenza osservata per le malattie ematologiche rare e per
i tumori rari ginecologi è dovuta all’elevata incidenza (la mag-
gior parte delle malattie ematologiche sono rare e i tumori gine-
cologici hanno complessivamente tassi di incidenza abbastanza
elevati) e alla loro buona prognosi.
La bassa prevalenza dei tumori epiteliali rari del tratto digerente
è dovuta alla bassa sopravvivenza osservata per la maggior parte
dei tumori delle sedi tumorali incluse in questo gruppo (esofago,
stomaco, intestino tenue, pancreas e fegato), indipendentemente
dal loro tasso di incidenza che, per alcune sedi, risultava comun-
que elevato.
Questo studio AIRTUM ha confermato che i tumori rari sono
un rilevante problema di sanità pubblica in Italia, fornendo, per
la prima volta a livello nazionale, stime quantitative di un fe-
nomeno già noto da tempo. Questa monografia fornisce indica-
tori epidemiologici dettagliati per circa 200 tumori rari, la
maggior parte dei quali (72%) risultano estremamente rari
(TI<0,5 per 100.000). Questi dati possono essere rilevanti per
diversi portatori di interesse. Politici e operatori sanitari possono
trovare qui informazioni utili per pianificare e pensare a come
riorganizzare i servizi di assistenza sanitaria per i tumori rari
in Italia. I ricercatori hanno a disposizione i numeri per dise-
gnare sperimentazioni cliniche, considerando anche disegni di
studio alternativi e approcci statistici innovativi.
I registri tumori di popolazione con dati di buona qualità sono
una delle principali fonti informative per descrivere l’impatto dei
tumori rari in tutta la popolazione italiana.
Parole chiave: tumori rari, incidenza, sopravvivenza, prevalenza,
registri tumori, Italia
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INTRODUCTION
Until a few years ago, there was no internationally agreed definition
of rarity for cancers. According to the European Parliament and
Council of the European communities, rare diseases are defined as
those with a prevalence of <50 per 100,000,1 while, in line with
the Orphan Drug Act, in the US rare diseases are those affecting
<200,000 persons.2 However, a published analysis of rare cancers
in the US employed the definition of <15 incident cases per
100,000 per year.3 In 2010, the EU funded RARECARE – Sur-
veillance of rare cancers in Europe project4 proposed a new defi-
nition of rarity for cancers and a list of rare cancers in Europe.
The objective of this Italian Network of Cancer Registries (AIR-
TUM)monograph is to describe the burden of rare cancers in Italy,
in order to give information on rare cancers to the community at
large (oncologists, general practitioners, researchers, health author-
ities, patients and their families).
In detail, this monograph provides estimations of incidence, sur-
vival, and prevalence of rare cancers in Italy, based on the definition
and list of rare cancers proposed by RARECARE and recently
(2012) updated by the RARECAREnet – Information Network on
Rare Cancers project.5
This is the first time that such a comprehensive and detailed de-
scription of rare cancers has been provided in Italy and it was pos-
sible only thanks to the availability of AIRTUM’s large database.6
THE RARECARE DEFINITION OF RARE CANCERS
RARECARE defined rare cancers as those with an incidence rate
(IR) of <6 per 100,000 per year in the European population. It is
important to stress that rare cancers among the RARECARE list of
cancers (please refer to Annex 1, see supplementary material on-line)
are identified based on the above criterion, in other words, on the
basis of the European population and not of a country-specific pop-
ulation. Thus, rare cancers are always the same in all European
countries. It is also important to note that this is an incidence-based
rather than prevalence-based definition, since incidence was recog-
nised as the best indicator to define rarity for tumours.4
Prevalence has shortcomings as a measure for rarity for tumours, al-
though it is appropriate for non-neoplastic diseases. Many non-neo-
plastic diseases are chronic conditions, so prevalence, which reflects
the total number of cases at any given time in a population, truly re-
flects the burden that a disease poses at a population level. On the
contrary, tumours are sub-acute diseases in which everything tends to
happen once: in the natural history of a tumour, there will be one po-
tentially eradicating surgery, one local radiation therapy, one first
chemotherapy, and each of these will take place in a definite time in-
terval. Thus, the total amount of resources that tumours mobilise is
proportional to the yearly rate of new diagnoses (incidence) and not
to the total number of persons with previous cancer diagnosis (preva-
lence), some of whom have been cured. Incidence, which reflects the
yearly number of new cases occurring in a population, might thus be
a better indicator to describe the burden posed by a tumour.
Moreover, the prevalence of a disease depends on two time-depen-
dent characteristics which are independent of one another: incidence
and survival. With the prevalence threshold adopted as a definition
of cancer rarity, some commonly occurring diseases for which survival
is very poor, such as most cancers of the stomach (adenocarcinoma
of stomach), pancreas, adenocarcinoma of lung, and squamous cell
carcinoma of lung, will be defined as rare, since the proportion of
the general population who are survivors is very low. By contrast,
some neoplasms that occur very infrequently (“rare” in the sense of
incidence) but which have very good survival, such as cancer of the
testis and squamous cell carcinoma of the uterine cervix, will be de-
fined as common on the basis of prevalence, because, although they
occur infrequently, most people who develop the disease survive for
long periods.
For these reasons, incidence seems to be a more useful indicator to
select a threshold for rarity in the case of tumours, as opposed to
non-neoplastic diseases. In addition, it is worth stressing that:
 incidence is a direct measure of the burden imposed by the need
for first-line cancer treatment;
 the number of patients amenable to enter a clinical study is re-
flected by cancer incidence.
Any threshold for cancer rarity should be considered as merely indica-
tive. The RARECARE rarity threshold at <6 per 100,000 per year might
be considered too high. However, if the lower threshold of <3 per
100,000 per year were adopted, glial tumours, epithelial cancers of the
oral cavity, epithelial cancers of gallbladder and extrahepatic biliary tract,
soft tissue sarcomas, tumours of testis and paratestis, myeloproliferative
neoplasms, and acute myeloid leukaemia would all be excluded. Yet
these cancers are often inadequately diagnosed and treated in relation
to both lack of knowledge and lack of clinical expertise, and clinical tri-
als are rarely performed. They are all diseases that are best treated in
specialised centres.
Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tu-
mours in Europe. Eur J Cancer 2012;48(10):1532-1542.
Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Eu-
rope: report from the RARECARE project. Eur J Cancer 2013;49(3):684-695.
INCIDENCE vs. PREVALENCE
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THE RARECARE LIST OF CANCERS
Usually, cancer statistics are provided for broad cancer categories,
based on the anatomic site of the malignancies as defined by the
International Classification of Diseases (ICD) codes. Rare tumour
entities, because of their specific problems related to health care or-
ganisation and clinical management, might be more appropriately
defined as a combination of topographical and morphological
characteristics, as both defined by the International Classification
of Diseases for Oncology, 3rd edition (ICD-O-3).7
Each tumour entity in the ICD-O list has a pathologic basis; how-
ever, in order to define clinically distinct diseases, the pathological
entities have to be grouped. This grouping exercise, necessary to
identify a list of clinically distinct entities, was undertaken in the
context of the RARECARE project by an international group of
experts, including oncologists, epidemiologists, pathologists, and
organisations of patients.4
As a first step, the two large groups of epithelial and non-epithelial
tumours were disentangled and, within them, broad anatomic cat-
egories were identified. Thus, the list of rare cancers starts with ep-
ithelial tumours of different sites and continues with non-epithelial
tumours such as sarcomas, neuroendocrine, central nervous system,
and haematological tumours (please refer to Annex 1).
TheRARECARE list is organised into three tiers, as illustrated, for ex-
ample, in Table 1 for epithelial tumours of nasal cavity and sinuses.
The bottom tier (tier 3) on the list is the WHO name of individual
cancer entities8 and its corresponding ICD-O-3morphology and to-
pography codes.7 ICD-O-3 entities are grouped into categories (tier
2) of cancers, considered similar from the point of view of clinicalman-
agement and research.These categories are then further grouped into
more general categories of tumours (tier 1), considered to involve the
same clinical expertise and patient referral structure.
Tier 2 entities, by definition, include only specific morphologies;
thus, rare cancers are identified in this tier. Not Otherwise Spec-
ified (NOS) morphology codes (NOS: 8000, 8001 for solid can-
cers, and 9590,9591,9760,9800,9801,9820,9860 for haematolog-
ical diseases) are never assigned to tier 2, but to tier 1, which aims
at identifying tumours with the same referral structure.
The choice of basing the definition of rare cancer on topography and
morphology according to ICD-O-3 was made for two reasons.The
first reason was to follow the existing tumour classifications. Any list
of rare tumours will always be a subset of a standard list of tumours.
International agencies preside over such classifications, constantly up-
dating them. This list of rare tumours was based on the ICD-O-3
classification because this is the worldwide-recognised classification
of tumours.
The second reason was data availability. Population-based cancer
registry (CR) data, the only data available to calculate population-
based incidence and prevalence indicators, refer to cases classified
only according to ICD-O. Other, even attractive, classification cri-
teria, such as biomarkers or gene expression, cannot be used for any
quantitative description of cancer burden in a wide population.
The new RARECAREnet project on rare cancers reviewed the
RARECARE list of cancers in 2012 and identified 198 rare cancers
in tier 2 with a European IR (independently of the country-specific
IR) <6 per 100,000 per year.The complete list of the 198 tier 2 rare
cancers is provided in Annex 1 (rare cancers are identified by the R).
This monograph considers all these 198 rare cancers, including 5
cancers which have an IR that is higher than 6 per 100,000 per year
in Italy: • hepatocellular carcinoma of liver (Italy 9.4 vs. EU 3.1),
• squamous cell carcinoma of larynx (Italy 7.2 vs. EU 4.6),
• carcinoma of thyroid gland (Italy 14.2 vs. EU 3.7), • multiple
myeloma (Italy 8.4 vs. EU 5.9), • diffuse and follicular B-cell lym-
phoma (Italy 9.8 vs. EU 4.9). Thyroid carcinoma is not presented
in the site-specific commentaries because of the peculiar charac-
teristics of thyroid carcinoma in Italy (see paragraph «Methodolog-
ical issue», pp. 20-21). The 198 rare cancers are classified, for this
monograph, in 14 major groups (Table 2) considering the clinical
referral pattern and the interest of clinicians. Thus, all sarcomas of
soft tissue (regardless of the site of origin), bone and gastro-intesti-
nal stromal tumours are grouped together in the sarcoma group.
The rationale behind this choice was that all sarcomas should be
referred to sarcoma specialists and these experts are very likely in-
terested in having data on all different types of sarcoma. The
main rare cancers of the thoracic cavity (thymoma, trachea, ma-
TIER TUMOUR TOPOGRAPHY MORPHOLOGY
ICD-O-3 CODE ICD-O-3 CODE
1 EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES C30.0, C31 8000, 8001, 8004, 8010, 8011, 8020-8022, 8032,
8050-8076, 8078, 8082-8084, 8123, 8144, 8560, 8980
2 Squamous cell carcinoma and variants C30.0, C31 8004, 8032, 8050-8076, 8078, 8083-8084, 8123,
of nasal cavity and sinuses 8560, 8980
3 Squamous cell carcinoma C30.0, C31 8070
3 Verrucous carcinoma C30.0, C31 8051
3 Squamous cell carcinoma, spindle cell C30.0, C31 8004, 8032, 8074, 8980
3 Papillary squamous cell carcinoma C30.0, C31 8052
3 Adenosquamous carcinoma C30.0, C31 8560
3 Squamous cell carcinoma, adenoid C30.0, C31 8075
3 Basaloid squamous cell carcinoma C30.0, C31 8083
2 Lymphoepithelial carcinoma of nasal cavity and sinuses C30.0, C31 8082
2 Undifferentiated carcinoma of nasal cavity and sinuses C30.0, C31 8020-8022
2 Intestinal type adenocarcinoma of nasal cavity and sinuses C30.0, C31 8144
Table 1. The hierarchical three-tier structure of the RARECARE list of cancers illustrated for epithelial tumours of nasal cavity and sinuses.
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lignant pleural mesothelioma, and rare histotypes of lung) are
placed together in the group of rare epithelial thoracic cavity tu-
mours (including pleural mesothelioma) because all these tumours
should be referred to experts of lung and thoracic cavity cancers.
With the same rationale, cancers of the nasal cavity and sinuses,
nasopharynx, major salivary glands and salivary gland type tu-
mours, hypopharynx, larynx, oropharynx, oral cavity, and lip are
grouped together as head and neck cancers because they should all
be referred to head and neck cancer experts. The same rationale was
applied to the other rare cancers arising in the major sites of the
body: digestive system, female genital system, urological tract,
male genital system, central nervous system, eye, skin. In addition
to these sites, 4 other groups included are neuroendocrine tumours
regardless of their site of origin, all endocrine tumours (carcinoma
of thyroid excluded), all embryonal tumours, and all rare haema-
tological diseases.
MATERIALS AND METHODS
Epidemiology of rare cancers presented in this monograph is based
on incidence, survival, and prevalence estimates. On the basis of na-
tional or local data, mortality rates for each RARECAREnet con-
sidered cancer entity cannot be computed. Besides, the available
mortality rates by major cancer site pose some limits, as in the case
of uterine cancers: the poor specification of the subsites in official
death statistics makes it impossible to disentangle mortality between
cervix and corpus uteri; this is confirmed by a high proportion of
deaths attributed to not otherwise specified uterine cancer.9
The AIRTUM database
This monograph is based on the AIRTUM database updated to
January 2015. The AIRTUM6 at present includes 40 general pop-
ulation-based CRs and 5 specialised CRs.
Since 2005, AIRTUM has had a central database, which stores data
from all accredited CRs. Accreditation indicates a CR meets the
quality standards set by AIRTUM,10 which verifies data quality and
completeness and uses data for collaborative studies on cancer epi-
demiology in Italy.11-14
All cases in the AIRTUM database are coded according to the third
edition of the ICD-O.7 Data are double checked (by the Registry and
by the centralised database) with theDEPedits program. In addition,
other checks are carried out based on software developed by AIR-
TUM,CheckAIRTUM, that compares data from a specified registry
to the weighted average of the other registries of the database.6
Quality checks
The following data quality indicators, usually considered in inter-
national population-based survival studies like EUROCARE and
RARECARE, were calculated for incident malignant cancers col-
lected between 2000 and 2010, by CR:
1. proportion of cases known from death certificate only (DCO);
2. proportion of microscopically verified (MV) cases;
3. proportion of cases with survival time of zero days (date of di-
agnosis coincident with date of life status ascertainment);
4. proportion of cases diagnosed incidentally at autopsy;
5. proportion of Not Otherwise Specified (NOS) cases.
MAJOR GROUPS RARE TUMOURS
Epithelial tumours of head and neck Epithelial tumours of nasal cavity and sinuses, nasopharynx, hypopharynx and larynx, oropharynx,
oral cavity and lip, middle ear, major salivary glands and salivary gland type tumours
Tumours of the eye Epithelial tumours of eye and adnexa, malignant melanoma of uvea
Rare epithelial tumours Rare epithelial tumours of stomach, colon, rectum, pancreas, epithelial tumours of oesophagus,
of the digestive system small intestine, anal canal, liver and intrahepatic bile tract, gallbladder, and extrahepatic biliary tract,
and mesothelioma of peritoneum and mesothelioma of peritoneum
Rare epithelial tumours of the thoracic cavity Epithelial tumours of trachea, thymus, rare epithelial tumours lung, and mesothelioma of pleura
and mesothelioma of pleura and pericardium and pericardium
Rare tumours of the female genital system Rare epithelial tumours of breast, and corpus uteri, epithelial tumours of cervix uteri, ovary and fallopian tube,
vulva and vagina, trophoblastic tumours of placenta, non epithelial tumours of ovary and epithelial tumours
of males breast
Rare epithelial tumours of the urinary system Epithelial tumours of renal pelvis and ureter, and urethra; rare epithelial tumours of kidney and bladder
Rare tumours of the male genital system Epithelial tumours of penis, testicular and paratesticular cancers, extragonadal germ cells tumours,
rare epithelial tumours of prostate, and mesothelioma of tunica vaginalis
Rare skin tumours and malignant melanoma Rare skin tumours (adnexal carcinoma of skin) and malignant melanoma of mucosa
of mucosa (extracutaneaous melanoma) (extracutaneous melanoma)
Embryonal tumours Neuroblastoma and ganglioneuroblastoma, nephroblastoma, retinoblastoma, hepatoblastoma,
pleuropulmonary blastoma, pancreatoblastoma, olfactory neuroblastoma, odontogenic malignant tumours
Sarcomas Soft tissue sarcomas, bone sarcomas, gastrointestinal stromal tumours, Kaposi sarcoma
Neuroendocrine tumours Neuroendocrine tumours of lung, gastroenteropancreatic tract, skin, thyroid, of other sites,
pheochromocytoma, paraganglioma
Tumours of the Central Nervous System (CNS) Central Nervous System tumours and embryonal tumours of CNS
Tumours of the endocrine organs Carcinoma of pituitary gland, parathyroid gland, and adrenal cortex
Rare haematological diseases Rare lymphoid diseases, acute myeloid leukemia and related precursor neoplasms, myeloproliferative
neoplasms, myelodysplastic syndrome and myelodysplastic/myeloproliferative diseases, hystiocytic and
dendritic cell neoplasms
Table 2. List of the 14 major groups of rare cancers included in this AIRTUM monograph.
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All standard indicators of data quality for Italian CRs are satisfac-
tory according to international standards.15
The new and most relevant indicator to evaluate the accuracy of
diagnosis for rare cancers, with respect to the other routinely ap-
plied indicators, is the proportion of cases with a NOS category
(ICD-O-3 8000-8001 for solid cancers, and ICD-O-3 9590-
9591, 9760, 9800-9801, 9820, 9860 for haematological diseases).
For rare cancers, the most likely quality problem is lack of speci-
ficity of morphology codes, which make it impossible to assign such
cases to a specific (rare) cancer entity, resulting in underestimation
of the true incidence and prevalence of such entities. Unspecified
morphology can be due to genuine difficulty in assigning a specific
morphological category or because inadequate documentation was
supplied to the CR when the case was registered. The latter prob-
lem is registration bias and results in incidence and prevalence un-
derestimation. To assess the extent of registration bias at European
level, RARECARE reviewed the original data (mainly pathologic
reports) of a selected sample (about 18,000 cases) of eight rare can-
cers (for details see RARECARE web site).5 Briefly, the great ma-
jority of NOSmorphology cases were confirmed as NOS.The few
NOS cases that changed to a more specific diagnosis generally in-
creased the incidence of the more common cancer forms. For ex-
ample, 11% of epithelial oral cavity cancers were reclassified from
NOS to more specific diagnoses: 8% were reclassified as squamous
AREA MALIGNANT NOS$ DCO AUTOPSY CASES MICROSCO LOST TO
MAJOR GROUPS CASES DIAGNOSED ONLY WITH ZERO PICALLY FOLLOW-UP
BETWEEN CASES SURVIVAL CONFIRMED CASES
2000 AND 2010 TIME CASES
No. % % % % % %
AIRTUM POOL
Epithelial tumours of head and neck 43 163 0.3 0.2 0.2 97.1 0.8
Tumours of the eye 1 530 0.6 0.2 0.2 58.9 0.7
Digestive system tumours 358 109 1.4 0.6 0.2 78.7 0.6
Rare epithelial tumours of the digestive system 57 891 0.7 1.2 0.2 73.5 0.6
Thoracic cavity tumours 157 478 1.6 1.0 0.2 74.4 0.5
Rare epithelial tumours of the thoracic cavity 12 027 0.1 2.8 0.2 97.4 0.5
Female genital system tumours 246 903 0.6 0.1 0.2 95.5 1.0
Rare tumours of the female genital system 41 141 0.1 0.2 0.2 99.3 1.0
Urinary system tumours 104 116 0.6 0.4 0.2 89.0 0.9
Rare epithelial tumours of the urinary system 6 394 0.2 0.5 0.2 94.5 0.6
Male genital system tumours 152 102 0.8 0.3 0.2 92.3 0.8
Rare tumours of the male genital system 9 049 0.1 0.1 0.3 95.4 1.8
Tumours of the Central Nervous System 13 071 0.0 0.5 0.2 91.2 1.0
Haematological diseases 123 307 0.8 0.5 0.3 93.1 0.9
Rare haematological diseases 91 094 0.4 0.5 0.3 94.4 0.9
Skin tumours^ 33 823 0.1 0.0 0.3 97.5 5.9
Rare skin tumours 1 699 0.0 0.0 0.5 99.5 1.5
and malignant melanoma of mucosa
Embryonal tumours 859 0.1 0.0 0.5 93.2 0.9
Sarcomas 20 019 0.0 0.4 0.3 98.6 1.4
Neuroendocrine tumours 9 196 0.0 0.5 0.3 99.6 0.8
Tumours of the endocrine organs* 32 268 0.2 0.2 0.3 95.4 1.2
NORTH-WEST
All malignant cancers^ 445 918 14.7 1.1 0.1 0.3 85.7 1.0
Rare cancers 111 744 – 0.3 0.0 0.4 92.1 1.3
NORTH-EAST
All malignant cancer^ 470 760 13.4 0.8 1.1 0.1 87.3 0.2
Rare cancers 116 808 – 0.1 0.0 0.1 93.5 2.0
CENTRE
All malignant cancer^ 125 671 14.9 0.7 0.0 0.1 85.1 1.6
Rare cancers 31 005 – 0.3 0.2 0.2 90.0 0.8
SOUTH
All malignant cancer^ 282 706 19.2 2.1 0.0 0.3 82.5 0.9
Rare cancers 79 846 – 0.9 0.5 0.0 91.1 0.0
AIRTUM POOL
All malignant cancer^ 1 325 055 15.2 1.2 0.4 0.2 85.5 0.8
Rare cancers 339 403 – 0.9 0.0 0.0 92.1 0.6
$ NOS: ICD-O-3 morphological code: 8000,8001,9800,9590,9820,9760,9860,9800,9801 / * including carcinomas of thyroid gland / ^ excluding non melanoma skin cancer
Table 3. Number of cases diagnosed in 2000-2010 and data quality indicators for the 14 major groups of rare cancers and corresponding common cancers (when the group included
also common cancers), and for all malignant tumours vs. all rare cancers, by geographic area and in the overall AIRTUM Pool. Quality indicators include proportion of not otherwise
specified (NOS) morphologies (8000,8001 for solid cancers, and 9590, 9591, 9760, 9800, 9801, 9820, 9860 for haematological diseases), death certificate only (DCO) cases, autopsy
only cases, cases with zero survival time, microscopically confirmed cases, and lost to follow-up cases (follow-up time <5 years). Pool of 39 general CR of the AIRTUM database.
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cell carcinoma (more common) and only 3% as adenocarcinoma
(rarer). This finding suggests that the problem with poorly specified
morphology cases is mainly one of difficulty in reaching a precise
diagnosis, not registration bias. However, it raises an important
topic for collaboration with pathologists and CRs.
Table 3 shows quality indicators for the 14major groups of rare can-
cers included in this monograph, compared, when possible, to
common cancers, and the quality indicators for all tumours in the
AIRTUM pool and by geographic area. The overall proportion of
NOS was 15%, with a higher proportion in the CRs of the South
of Italy. Overall, the proportion of DCO cases was 1.2%, with,
again, a slightly higher proportion in the CRs of the South of Italy.
The proportion of cases discovered at autopsy was 0.4% in total. A
high proportion of cases (86% overall) wasMV. Follow-up was com-
plete for most CRs, with follow-up censored before 5 years for only
1% of cases overall. These results indicate a high quality dataset.
NOS cases were also analysed within each of the 14 major groups
of cancers presented in this monograph. As expected, grouping with
major problems were those of the digestive system (mainly liver and
pancreas), thoracic cavity, and CNS. NOS cases for these groups
were 21%, 29%, and 38%.The difficult access to these sites led to
a proportion ofMV cases lower than the one observed in other sites.
For example, the proportion of MV cases was 58% for tumours of
the pancreas and 74% for tumours of the liver. Incidence and preva-
lence indicators of rare cancers of lung, liver, and pancreas, and spe-
cific histotypes of the CNSmight therefore be underestimated. Rare
cancers always had a higher proportion of MV cases compared to
the common counterpart, except in the digestive system.This is due
to the fact that rare cancers of the digestive system include all can-
cers of liver and intrahepatic bile tract and of gallbladder and ex-
trahepatic biliary tract, for which the proportion of MV cases was
very low (70% and 58%, respectively), therefore the NOS was high.
This influenced the overall proportion of NOS cases for rare diges-
tive system cancers, making it higher than that for common cancers
of the digestive system, including cancers of more accessible sites
such as stomach and colon.
Cancer registry selection
In order to guarantee homogeneity, all indicators were computed
on the same database, therefore only general population-based CRs
were considered. Thus, we did not consider in the analyses 3 spe-
cialised (Palermo-breast cancer; Modena-colorectal cancers; Ligu-
ria-mesothelioma) CRs, and 2 other CRs which collect data on
childhood and adolescent cancers only (Piemonte, Marche).
Three CRs (Biella, Napoli, Ragusa) extended their area of registra-
tion in recent years: different areas of the same CR are therefore
analysed separately in incidence and survival analyses.
To provide estimates of epidemiological indicators, the following
inclusion criteria for AIRTUM CRs were applied:
 availability of at least three years of incidence between 2000 and
2010;
 complete follow-up for at least one year after the last year of in-
cidence (i.e. at 31st December 2009) for cases diagnosed between
2000 and 2008 in survival analysis;
 proportion of NOS cases <20%.
All AIRTUM accredited CRs had a proportion of NOS cases
MACROAREA/ REGION RESIDENT RESIDENTS IN AREAS COVERED CANCER
POPULATION BY CANCER REGISTRIES INCLUDED REGISTRIES
(ITALY 2013) IN THE PRESENT MONOGRAPH
(ITALY 2013)
No. No. % No.
Piemonte 4 374 052 1 229 824 28 2
Valle d’Aosta 127 844 0 0 0
Lombardia 9 794 525 8 307 271 85 10
Liguria 1 565 127 851 283 54 1
NORTH-WEST 15 861 548 10 388 378 65 13
Trentino-Alto Adige 1 039 934 1 039 934 100 2
Veneto 4 881 756 2 346 610 48 1
Friuli Venezia Giulia 1 221 860 1 221 860 100 1
Emilia-Romagna 4 377 487 3 500 936 80 6
NORTH-EAST 11 521 037 8 109 340 70 10
Toscana 3 692 828 1 235 646 33 1
Umbria 886 239 886 239 100 1
Marche 1 545 155 0 0 0
Lazio 5 557 276 552 090 10 1
CENTRE 11 681 498 2 673 975 23 3
Abruzzo 1 312 507 0 0 0
Molise 313 341 0 0 0
Campania 5 769 750 2 262 522 39 2
Puglia 4 050 803 1 776 450 44 3
Basilicata 576 194 0 0 0
Calabria 1 958 238 228 126 12 1
Sicilia 4 999 932 4 381 032 88 5
Sardegna 1 640 379 688 066 42 2
SOUTH AND ISLANDS 20 621 144 9 336 196 45 14
ITALY 59 685 227 30 507 889 52 39
Table 4. Distribution of the Italian resident population by region,
macroarea, and overall. Number (No.) and proportion (%) of the
resident population covered by the cancer registries included in this
monograph and number of general cancer registries by region,
macroarea, and overall. Italy, 2013. (Source: ISTAT).16

Figure 1. Italian geographical areas covered by the general cancer
registries included in the present monograph.

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<20%, thus none of the CRs were excluded because of data quality
problem. The CR of Macerata was excluded from all analyses be-
cause it did not fulfil the first inclusion criterion (it did not have
at least 3 years of incidence between 2000 and 2010). General CRs
included in this monograph cover more than 30 million people,
52% of the Italian population at 2013 (Table 4 and Figure 1).
In the framework of the RARECARE and RARECAREnet proj-
ects, all participating Italian AIRTUMCRs were considered to es-
timate the burden on rare cancers in Europe because they com-
pletely fulfilled the quality criteria and the sensitivity analyses
performed.5
In order to reduce the uncertainty due to the casual variability of
sparse data and the resulting imprecision of the estimates, we
considered three different pools of AIRTUMCRs for the different
analyses (Table 5); in detail:
 39 CRs with at least three years of available incidence data on pa-
tients registered between 2000 and 2010, for the incidence analysis;
 37 CRs with cases diagnosed between 2000 and 2008, and fol-
lowed up to 31st December 2009 or after, for the survival analysis;
 11 CRs which provided incidence and follow-up data for the
period 1992-2006 with a prevalence index date of 1st January
2007 for the prevalence analysis.
Table 5 shows data availability by year of incidence and CRs in-
cluded in the analyses.
Epidemiological indicators
The epidemiological indicators are estimated considering multiple
tumours. The inclusion of multiple tumours in the analyses implies
that each single patient may be counted several times. We consid-
ered 1,325,055 malignant cancer cases collected by 39 Italian
CRs during the 2000-2010 period and included in the AIRTUM
database as of January 2015.
For neuronal and mixed neuronal-glial tumours none of the indi-
cators are provided, since they are mainly benign or borderline tu-
mours and thus not available in the AIRTUM database. In addi-
tion, incidence of a few entities, including gastrointestinal stromal
tumours and several haematological malignancies, is underesti-
mated because the specific ICD-O codes were introduced with the
ICD-O-3 in 2000, thus during the study period.
As some rare cancers are extremely rare, estimates stratified by ge-
ographic area could not be calculated.
All estimates were computed using SeerStat, version 8.1.2.17
Incidence
Crude IRs of rare cancers were calculated as the number of new
cancers occurring in 2000-2010 divided by the population at risk
(male and female also for gender-specific rare cancers) over the
same period, expressed as person-years. In total, 339,403 rare tu-
mours were included in the incidence analysis from 39 CRs. The
proportion of rare cancers out of the total cancers (rare and com-
mon) by site is also calculated considering rare and common can-
cers of each specific cancer site. Crude incidence was obtained for
rare tumours overall, by sex, and by age class (0-54, 55-64, 65+;
0-4, 5-14, 15+ for embryonal cancers). The normal approximation
is used with the standard errors to obtain 95% confidence intervals
(95%CI) for incidence rates. Sex- and age-specific incidence rate
for 25 rare cancers with less than 15 observed cases between 2000
MACROAREA AVAILABLE INCIDENCE SURVIVAL PREVALENCE
CANCER REGISTRY/ INCIDENCE (OBS)
GEOGRAPHICAL AREA YEARS
PERIOD OF DIAGNOSIS
2000-2010 2000-2008 1992-2006
follow-up at prevalence date
31st Dec 2009 at 1st Jan 2007
CRs INCLUDED
No. YEARS INCLUDED
NORTH-WEST
Bergamo 2007-2009  (3 yrs) 
Biella
Biella 1995-2009  (9 yrs) 
Vercelli 2007-2009  (3 yrs) 
Brescia 1999-2006  (7 yrs) 
Como 2003-2009  (7 yrs) 
Cremona 2005-2009  (5 yrs) 
Genova 1986-2007  (8 yrs)  
Mantova 1999-2010  (11 yrs) 
Milano (municipality) 1999-2007  (8 yrs) 
Milano 1-2 2007-2009  (3 yrs) 
Monza e Brianza 2007-2009  (3 yrs) 
Sondrio 1998-2010  (11 yrs) 
Torino 1985-2010  (11 yrs)  
Varese 1976-2010  (11 yrs)  
NORTH-EAST
Alto Adige 1995-2007  (8 yrs) 
Ferrara 1991-2009  (10 yrs)  
Friuli Venezia Giulia 1995-2009  (10 yrs) 
Modena 1988-2010  (11 yrs)  
Parma 1978-2011  (11 yrs)  
Piacenza 2006-2010  (5 yrs) 
Reggio Emilia 1996-2010  (11 yrs) 
Romagna 1986-2009  (10 yrs)  
Trento 1995-2006  (7 yrs) 
Veneto 1987-2007  (8 yrs)  
CENTRE
Firenze-Prato 1985-2005  (6 yrs)
Latina 1990-2010  (11 yrs)  
Umbria 1994-2009  (10 yrs) 
SOUTH AND ISLANDS
Barletta 2006-2008  (3 yrs) 
Catania-Messina 2003-2008  (6 yrs) 
Catanzaro 2003-2007  (5 yrs) 
Lecce 2003-2007  (5 yrs)
Napoli
ex ASL 4 1996-2010  (11 yrs) 
ASL 3 Sud 2008-2010  (3 yrs) 
Nuoro 2003-2008  (6 yrs) 
Palermo 2003-2010  (8 yrs) 
Ragusa
Ragusa 1981-2009  (10 yrs)  
Caltanissetta 2007-2010  (4 yrs) 
Salerno 1996-2009  (10 yrs) 
Sassari 1992-2009  (10 yrs)  
Siracusa 1999-2009  (10 yrs) 
Taranto 2006-2008  (3 yrs) 
Trapani 2002-2007  (6 yrs) 
AIRTUM POOL 1976-2010 39 37 11
Table 5. Available incidence years by general cancer registries (CRs) considered in this
monograph ordered by macroarea. CRs included in incidence analysis with number of inci-
dent years considered. Cancer registries included in survival and observed prevalence analy-
ses. AIRTUM database at January 2015.
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and 2010 were considered as not estimable (NE). The expected
number of new cases in 2015 was estimated assuming incidence
in Italy to be the same as that in the AIRTUM sample, and mul-
tiplying the age- and sex-specific incidence rate by the correspon-
ding Italian population in 2015 provided by ISTAT.16
Survival
Survival analysis was performed for 254,821 rare tumours. One-
and 5-year relative survival (RS) estimates18 in Italy were obtained
considering the pool of 37 AIRTUMCRs with cases diagnosed be-
tween 2000 and 2008, and followed up to 31st December 2009 or
after. Relative survival is defined as the ratio of observed survival
to the expected survival in the general population of the same age
and sex and it is used to correct for deaths from causes other than
the cancer under investigation. RS was calculated for patients
aged 0-99. Since all patients are included (not only those followed
up for 5 years) we used a complete analysis, which is a modification
of traditional cohort approach, in which more recently diagnosed
patients are also included, even if they could not possibly have
completed the entire follow-up interval of interest.19 Cancers di-
agnosed only on the basis of DCO, or diagnosed incidentally at
autopsy or with survival time of zero days (421 tumours, 0.2%),
were excluded from the analysis. Ninety-five% CI are computed
through logarithmic transformation, so that the lower bound is al-
ways positive and the upper bound can exceed 100%. Whenever
it happens, the upper bound is put as equal to 100%. RS for 42
rare cancers with less than 30 observed cases in the period of di-
agnosis 2000-2008 was considered as not estimable.
A sensitivity analysis of survival was performed restricting the
analysis to 29 CRs with cases diagnosed between 2000 and 2010,
and follow-up available to 31st December 2011 (data not shown).
This analysis was performed to verify whether the use of more up-
dated data would have had an impact on the survival estimates pro-
vided. In the sensitivity analysis, 11 CRs were excluded. The
analysis performed on this restricted pool (29 CRs) shows percent-
age differences higher than 10% only for 18 rare cancers among
the 198 considered ones in 1-year RS and for 42 rare cancer
entities in 5-year RS. However, when considering only 29 CRs the
number of analysed cases becomes smaller and the uncertainty in
the estimates increases; therefore, considering the rarity of the phe-
nomena and the narrow changes between the two analyses, we de-
cided to present results for the 37 CR pool.
Observed and complete prevalence
To estimate the observed prevalence in Italy – the proportion of
cancer patients in a population diagnosed at age x within a given
time period (L) and who are still alive at a certain reference date
– incidence and follow-up data from 11 CRs for the period 1992-
2006 were used, with a prevalence index date of 1st January 2007.
Observed prevalence in the general population (male and female
also for gender-specific rare cancers) disentangled by time prior to
the reference date (<2 years, 2-5 years, <15 years) was calculated
using the counting method.20-22When including multiple tumours,
a patient will not contribute more than one tumour diagnosis to
a single prevalence estimate.
The life status of cases lost to follow-up or censored before the
prevalence index date was estimated from the survival probability
between the censoring and the index date, derived from a subset
of cancer patients matched by age and cancer.
The objective of the present monograph is to produce reliable
prevalence estimations for all the 198 rare cancers. In order to
achieve this objective, a standard methodology, applicable to all
these rare cancers, had to be defined. The complete prevalence pro-
portion at 1st January 2007 was estimated overall in Italy, correcting
the 15-year observed prevalence by the completeness index,23-26 to
account for those cancer survivors diagnosed before the cancer reg-
istry activity started. The completeness indices estimation requires
a long stable time series of incidence and survival indicators; the
Italian cancer registry database, even though it is continuously in-
creasing, could not guarantee such information for all the 198
analysed rare cancers. Moreover, sparse data did not allow to con-
sider the geographical variability (stratifying the estimates by ge-
ographic area) of the prevalence estimates as in the previous AIR-
TUM monograph on prevalence for common cancers.14
To allow more robust estimation, the completeness indices by can-
cer site and age (0-4, […], 75-99 years), were obtained by means
of statistical regression models using incidence and survival data
available in the European CRs participating to the RARECARE4,27
and RARECAREnet projects.
The assumptions are:
 homogeneity of time trends in incidence and survival between
Italy and Europe;
 homogeneity of prevalence proportions of rare cancers among
geographic areas in Italy.
For cancers with no observed cases within 2, 2-5, or 15 years in the
past, prior to 1st January 2007, the observed prevalence was con-
sidered as not estimable. If the 15-year observed prevalence is not
estimable (NE), then the complete prevalence has to be considered
not estimable. This is the case for 13 rare cancers.
Finally, the number of prevalent cases at 1st January 2010 in Italy
was calculated assuming the same prevalence proportion as in the
AIRTUM sample and applying the obtained complete prevalence
proportion by age (0-4, […], 75-99 years) to the corresponding
Italian population at 2010 provided by ISTAT.16
For the purpose of including as much as possible cancer registries
in the prevalence analysis, the reference date is 1st January 2007.
Different and more recent reference dates would have determined
a restriction of the analysed POOL.
The uncertainty that characterise rare cancers made impossible the
projection of prevalence estimates to 2015, therefore only the number
of prevalent cases at 1st January 2010 in Italy was calculated.
Methodological issues
The methodological decisions, taken because of the rarity of the
majority of the cancers analysed, could have led to prevalence es-
timates slightly different from those published by the AIRTUM
monograph on prevalence for common cancers.14
For prevalence, the rationale of using the same methodology for
all rare cancers made necessary the assumption of homogeneity be-
tween some European and Italian epidemiological indicators.
These assumptions are reasonable for themajority of the analysed rare
cancers; nevertheless for diseases with markedly increasing incidence
time trends and/or significant differences among geographic areas,
some caution in result interpretation should be borne in mind. This
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is the case for testicular and paratesticular cancers, rare epithelial tu-
mours of hypopharynx and larynx, carcinoma of the thyroid gland.
For cancers of testis and paratestis the estimated number of preva-
lent cases reported in the present monograph is about 45,000,
slightly higher than the national prevalence estimates for testis pre-
viously published by AIRTUM14 (about 38,000). As the incidence
rates are higher at younger ages and the prognosis very good, the
estimation of prevalent cases is mainly influenced by incidence. In
Italy, incidence is lower in the South compared to the Centre-
North, therefore the assumption of homogeneity in incidence
may have determined an overestimation of prevalence.
We estimated about 53,000 persons to be alive at 1st January
2010 with a previous diagnosis of squamous cell carcinoma with
variants of larynx (the majority of larynx cancer), slightly higher
than the national prevalence estimates previously published by
AIRTUM14 (about 50,000). These differences may be associated
with a difference in time trend among males and females,28 as-
sumed to be homogeneous for the above-mentioned reasons.
Thyroid cancer is a common cancer in Italy, with an IR higher than
6 per 100,000 per year during the analysed period, affected by a
markedly increasing incidence over time in both sexes, with signif-
icant differences across areas:28 the assumptions for rarity are
therefore violated. As a consequence, the methodology developed
for estimation of epidemiological indicators for rare cancers is not
applicable and carcinoma of the thyroid gland was excluded from
the specific commentary on endocrine tumours.
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For years, most resources and attention have been directed to
common cancers such as breast, colon, rectum, lung, and prostate,
which still affect and kill many people every year. In reality, there
are also many types of rare cancers which, taken together, account
for a relatively high proportion of newly diagnosed cancers.
Rare cancers are those cancers with an incidence rate lower than
6 per 100,000 per year in the EU population.1 Their low fre-
quency, and the consequent limited medical expertise on the mat-
ter, create specific problems in clinical decision making, clinical re-
search, and health care organisation. In addition, patients and their
families are confronted with a wide range of difficulties arising di-
rectly from the rarity of the pathologies. Such difficulties include:
 wrong diagnosis leading to inaccurate treatments;
 delays in the period between the onset of the first symptoms and
the diagnosis;2-4
 insufficient scientific knowledge: the small number of patients
undermines the possibility to organise clinical trials and registries
and tissue banks are few. This results in difficulties in developing
therapeutic tools and defining the therapeutic strategy, as well as
in shortage of therapeutic products;2-4
 lack of appropriate quality healthcare: lack of appropriate medical
expertise for the management of rare cancers, poor referral rates from
general practitioners, and pathologic misdiagnosis.2-4
The overall burden of rare cancers on society has not been ade-
quately estimated. The “Surveillance of rare cancers in Europe”
(RARECARE) project estimated that rare cancers represent 22%
of all new cancer diagnoses in Europe;1 however, country-specific
estimates of rare cancer burden are still lacking.
This paper presents the burden of rare cancers in Italy, combining
all 198 rare cancers in one group named “rare cancers”. The de-
scriptive epidemiology of each of the 198 rare cancers is presented
in the specific data sheets of this monograph. It is the first time that
such a detailed description is given for this comprehensive list of
rare cancers in Italy.
The estimates of incidence, prevalence, and survival of rare cancers
in Italy are based on the pool of the AIRTUM cancer registries
(CRs) in 2000-2010, covering more than 30 million people, 51%
of the 2013 Italian population (more information on the definition
and the list of rare cancers, as well as on methods, are provided in
the «Materials and methods» chapter, pp. 14-21).
INCIDENCE
AIRTUM estimated that about 360,000 persons were diagnosed
with new cancers in Italy in 2011.6 The annual incidence rate (IR)
of all 198 rare cancers in the period 2000-2010 was 147 per
100,000, corresponding to about 89,000 new diagnoses annually
or 25% of all cancer diagnoses.
Five cancers, rare at European level, were not rare in Italy because
their IR was higher than 6 per 100,000. These tumours were:
• diffuse large B-cell lymphoma and squamous cell carcinoma of lar-
ynx, whose IRs in Italy were 7 per 100,000; • multiple myeloma (IR:
8 per 100,000); • hepatocellular carcinoma (IR: 9 per 100,000);
• carcinoma of thyroid gland (IR: 14 per 100,000).
Figure 1a shows the proportion of rare cancers according to IR.
Figure 1b shows the estimated number of new rare cancer diag-
noses in Italy in 2010, again according to IR. The 5 cancers that
are “not rare” in Italy are excluded from Figure 1.
Seventy two percent of rare cancers (No. 139/193) had an annual
IR of <0.5 per 100,000 (Figure 1a). However, this plethora of rare
cancers accounted for only 7,119 cases in Italy (Figure 1b). Thir-
teen percent of rare cancers (No. 25/193) with IR 0.5-0.9 per
100,000, accounted for 10,000 new diagnoses in Italy in 2010. On
the opposite extreme, 2% of rare cancers (including only 3 rare
cancers out of the 193) with an IR of 4-5 per 100,000 accounted
for 8,000 new diagnoses in 2010 in Italy. This distribution of rare
cancers by IR is similar to the one observed in Europe.1
It is noteworthy that 19% of Italians with a rare cancer
(17,138/89,000) have one of the particularly rare forms that affect
<1 per 100,000 (Figure 1b) and this is important, because low in-
cidence is a major obstacle to conducting clinical trials to develop
effective treatments. The proportion of Europeans with a partic-
ularly rare form of rare cancer was 30%.1
Five cancers that are rare in Europe were common in Italy. These 5
cancers affected around 30,000 Italians (data not shown), thus rar-
ity-specific critical issues were not relevant in Italy for these 5 cancers,
unlike in Europe.
Among all rare cancers, 7% were rare haematological diseases, 18%
were solid rare cancers. Figure 2 describes the distribution of the
13 groups of solid rare cancers presented in this monograph (for
detailed definition of the grouping, please refer to «Materials and
methods», pp.14-21 ), among all rare solid tumours. Rare epithelial
tumours of the digestive system were the most common (23%),
followed by epithelial tumours of head and neck and rare tumours
of the female genital system (17%), tumours of the endocrine or-
gans (13% including thyroid carcinoma), sarcomas (8%), central
nervous system tumours, and rare epithelial tumours of the tho-
racic cavity (5%). The remaining (rare male genital tumours, tu-
mours of eye, neuroendocrine tumours, embryonal tumours, rare
skin tumours, malignant melanoma of mucosa) each comprised
<4% of all solid rare cancers (Figure 2).
Figure 3 shows age-specific IRs for rare and common cancers. Con-
sidering 3 major age-groups, IR of rare cancers was 15 per 100,000
in children (0-14 years), 45 per 100,000 in adolescents and young
adults (15-39 years) and 245 per 100,000 in adults (40+ years).The
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corresponding figures for common cancers were 0.3 per 100,000, 26
per 100,000 and 608 per 100,000 (data not shown). Essentially, all
childhood cancers were rare and, from age 40 on, the common can-
cers (breast, prostate, colon, rectum, and lung) became increasingly
prominent.
Table 1 shows incidence, 5-year relative survival (RS) and preva-
lence of rare and common cancers for 7 out of the 14 groups of
rare cancers presented in this monograph. The objective is to
present differences between rare and common cancers, thus only
the 7 groups with common and rare cancers are included. This is
the only table with estimates on common cancers. In the rare-can-
cer-specific data sheets, common cancers are not presented. Rare
cancers constituted 74% of incident haematological malignancies,
17% of incident female genital system cancers, 16% of incident
digestive system cancers, 8% of incident respiratory cancers. Rare
cancers were ≤6% of incident cancers at other sites.
Table 2 describes the number of expected cases in Italy and by Ital-
ian region in 2010 of all 198 rare cancers and of 2 groups of rare
cancers representative of very low and very high IR (within the cut-
off of rarity of <6 per 100,000): embryonal tumours (IR of 0.4 per
100,000) and neuroendocrine tumours (IR of 4.15 per 100,000).
For embryonal tumours the number of new expected cases ranged
from 1 in Valle D’Aosta andMolise to 39 in Lombardia, with most
of the other regions having less than 20 cases per year. For neuroen-
docrine tumours the number of new expected cases was relevant
in regions with a large population, such as Lombardia, Lazio, Cam-
pania, and Sicilia. However, for many of the other regions the
number of new cases was still lower than 100 per year. With these
numbers of rare cancers per region, the identification of centres of
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Figure 1. Proportion of rare cancers (A) and estimated number of new cases of rare cancers (B) in Italy in 2010 by crude
incidence rate. Crude incidence rate for 193 out of the 198 rare cancers of the RARECAREnet list grouped together and ob-
tained from the Pool of 39 AIRTUM cancer registries in 2000-2010. The 5 cancers that are not rare in Italy are excluded.
Figure 2. Distribution of the 13 groups of rare solid cancers presented in this monograph among all solid rare cancers.
AIRTUM Pool of 39 cancer registries (period of diagnosis 2000-2010).
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Figure 3. Age-specific incidence rates for rare and common cancers (solid + haematological
tumours) of the RARECAREnet list in Italy, period of diagnosis 2000-2010.AIRTUM Pool of
39 cancer registries.
expertise dedicated to specific groups of rare cancers at regional
level does not seem feasible. The number of cases per region (es-
pecially for very rare cancers such as embryonal tumours) does not
make it possible to reach adequate expertise to treat such tumours
regionally. A national (inter-regional) organisation would seem
more appropriate for rare cancers.
SURVIVAL
For patients with rare cancers diagnosed in 2000-2008, 5-year RSwas
55%; the corresponding figure for patients with common cancers was
68% (Figure 4) (p<0.001). Rare cancers had a worse prognosis than
common cancers in many sites but not in the thoracic cavity (Table
1). Relative survival was lower for rare cancers at 1 year and continued
to diverge up to 3 years, while the gap remained constant from 3 to
5 years after diagnosis (Figure 4)(p<0.001).
Figure 5 shows 5-year RS for rare and common cancers by age
class. For patients 0-54 years – most of whose cancers were rare –
survival did not differ between common and rare cancers. The sur-
vival disadvantage of having a rare cancer increased from -16% at
55-64 years to -23% at 75+ years.
PREVALENCE
We estimated that about 900,000 persons were alive in Italy in
2010 with a previous diagnosis of a rare cancer.
Table 1 shows incidence, 5-year RS, and prevalence of rare and com-
mon cancers for 7 out of the 14 groups of rare cancers presented in
this monograph. The prevalence of a disease depends on two time-
dependent characteristics which are independent of one another: in-
cidence and survival. Thus, looking at incidence and survival data,
it is possible to interpret the prevalence.This is important for the def-
inition of rare cancer (please refer to the box Incidence vs. prevalence
in the «Material and methods» chapter, p. 14).
Within the groups of cancers of Table 1, the highest prevalence was
observed for rare haematological diseases and rare tumours of the
female genital system. The high prevalence of these two groups of
rare tumours is explained by their high IR (41 per 100,000 and 19
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GROUPS OF CANCER INCIDENCE 95%CI 5-YEAR RS 95%CI COMPLETE 95%CI
RATE PREVALENCE
PROPORTION
(x100 000) (%) (x100 000)
EPITHELIAL TUMOURS OF THE DIGESTIVE SYSTEM
rare 26 25.9-26.3 20 19.2-20.1 74 72.4-76.3
common 135 134.9-135.9 51 50.8-51.4 735 728.8-741.8
EPITHELIAL TUMOURS OF THE THORACIC CAVITY
rare 5 5.3-5.5 17 15.4-17.6 17 16.3-18.3
common 66 65.3-65.9 17 16.8-17.5 112 109.4-114.3
TUMOURS OF THE FEMALE GENITAL SYSTEM
rare 19 18.4-18.7 65 64.6-65.9 265 259.5-269.6
common 93 92.4-93.2 88 87.9-88.4 1150 1135.9-1164.3
EPITHELIAL TUMOURS OF THE URINARY SYSTEM
rare 3 2.8-3.0 54 52.3-55.9 23 21.7-24.1
common 44 43.8-44.3 73 72.6-73.6 402 389.8-413.2
TUMOURS OF THE MALE GENITAL SYSTEM
rare 4 4.0-4.2 90 88.9-90.7 89 84.8-92.7
common 65 64.2-64.8 94 93.2-94.0 567 561.2-572.8
SKIN TUMOURS^
rare 1 0.7-0.8 75 71.4-79.1 8 6.8-8.2
common 14 14.3-14.7 85 84.1-85.4 238 234.0-242.6
HAEMATOLOGIAL DISEASES
rare 41 40.8-41.4 55 54.3-55.2 278 271.1-284.5
common 15 14.4-14.7 71 70.4-72.4 82 79.4-83.8
Table 1. Crude incidence rate, 5-year relative survival (RS) and complete prevalence for rare and common cancers of the RARECAREnet list for 7 out of the 14 groups of rare cancers pre-
sented in this monograph (only groups with common cancers are included). AIRTUM Pool.* 95%CI: 95% confidence intervals.
* Incidence rate obtained from 39 AIRTUM cancer registries, period of diagnosis 2000-2010; 5-year relative survival calculated on the basis of 37 AIRTUM cancer registries, period of diagnosis 2000-2008 and follow-up till 31st December 2009;
complete prevalence, obtained correcting the 15-year observed prevalence (incidence and survival data from a pool of 11 AIRTUM cancer registries, period of diagnosis 1992-2006, prevalence index date: 1st January 2007).
^ excluding non melanoma skin cancer
REGION POPULATION ESTIMATED NEW CASES OF RARE CANCER
AT 1ST JANUARY (ITALY 2010)
2010 RATE (x100 000 PER YEAR)
198 rare cancers embryonal neuroendocrine
of the tumours tumours
RARECAREnet list
grouped together
(IR: 147 per 100 000) (IR: 0.4 per 100 000) (IR: 4.15 per 100 000)
VALLE D’AOSTA 127 866 188 1 5
MOLISE 320 229 471 1 13
BASILICATA 588 879 867 2 24
UMBRIA 900 790 1 326 4 37
TRENTINO-ALTO ADIGE 1 028 260 1 514 4 43
FRIULI VENEZIA GIULIA 1 234 079 1 816 5 51
ABRUZZO 1 338 898 1 971 5 56
MARCHE 1 559 542 2 296 6 65
LIGURIA 1 615 986 2 379 6 67
SARDEGNA 1 672 404 2 462 7 69
CALABRIA 2 009 330 2 958 8 83
TOSCANA 3 730 130 5 490 15 155
PUGLIA 4 084 035 6 011 16 169
PIEMONTE 4 395 569 6 470 18 182
EMILIA-ROMAGNA 4 446 230 6 544 18 185
VENETO 4 912 438 7 231 20 204
SICILIA 5 042 992 7 423 20 209
CAMPANIA 5 681 868 8 363 23 236
LAZIO 5 824 662 8 573 23 242
LOMBARDIA 9 826 141 14 463 39 408
ITALY 60 340 328 88 816 241 2 504
Source of population data: http://demo.istat.it/pop2010/index1.html
Table 2. Estimated new cases of rare cancers, obtained applying the crude incidence rate
(IR) (AIRTUM Pool of 39 cancer registries, period of diagnosis 2000-2010) to the Italian
population in 2010. Estimated new cases for 2 groups of rare cancers (embryonal tumours
and neuroendocrine tumours) obtained applying the incidence rate of each group (0.4 and
4.15 per 100,000) to the Italian population in 2010.These 2 groups of rare cancers are rep-
resentative of rare cancers with very low IR and relatively high IR.
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per 100,000, respectively) and their intermediate 5-year RS (55%
and 65%, respectively).
Very low prevalence (<10 per 100,000) was observed for rare epithelial
skin cancers, which had a very low IR (<1 per 100,000) and a rela-
tively high 5-year RS (75%). In this case, the incidence contributes
to the low prevalence of these tumours.
The low prevalence of rare epithelial tumours of the digestive sys-
tem was due to the low survival rates of the majority of tumours
included in this group (oesophagus, stomach, small intestine,
pancreas, and liver), regardless of the high IR of the rare epithelial
cancers of these sites.
Rare epithelial tumours of the thoracic cavity had a relatively low
incidence and survival. This group included very rare cancers
with a very poor prognosis, such as mesothelioma of pleura, tra-
chea, and rare histotypes of lung.
DISCUSSION
Proportion of rare cancers in Italy
Our estimates indicate that 25% of all cancers diagnosed in Italy
in 2010 were rare, similar to the estimates reported in Europe
(24%, see www.rarecarenet.eu). In Italy, the higher proportion of
rare cancers is due to the fact that the group of all rare cancers com-
bined includes 5 cancers that are rare according to the EU rate, but
common in Italy: diffuse large B-cell lymphoma, squamous cell
carcinoma of larynx, multiple myeloma, hepatocellular carcinoma,
and carcinoma of thyroid gland. The latter is the one which con-
tributes most to the high proportion of rare cancers in Italy. Thus,
without thyroid carcinoma the proportion of rare cancers in Italy
in 2010 would be 22%.
Differences in incidence across populations can be due to the dif-
ferent distribution of risk factors (environmental, lifestyle, occu-
pational, and genetic), to heterogeneous intensity in diagnostic ac-
tivity, as well as to different diagnostic capacity. Nevertheless,
differences in IR may also be due to the heterogeneity in the pro-
portion of microscopically confirmed cases in different populations
and, more importantly, to the different capacity of pathologists of
identifying the accurate histotype. In addition, CRs might not al-
ways be able to retrieve the detailed pathological diagnosis. This
is important for rare cancers because they are defined on the basis
of morphology and topography, which require a detailed patholog-
ical diagnosis (for more information on the list of rare cancers,
please refer to «Materials and methods», pp. 14-21).
Among the cancers that are rare on the basis of the European IR
and not the Italian one, thyroid cancers show an incidence peak
in the middle age in Italy (45-49 years in women and 65-69 in
men)7 and are 3-fold more frequent in females than in males. The
female predominance of thyroid cancer remains largely unex-
plained. Considered rare until a few years ago, thyroid cancers have
shown a marked increase in incidence worldwide, with a different
pace across countries. This increased incidence seems mainly due
to small papillary tumours that show an excellent prognosis, which
could explain the stable mortality. The topic is still being discussed,
especially with regard to how much of the observed increase in in-
cidence is explained by the increased use of ultrasound in the last
decades, opportunistic screening of thyroid disease, and enhanced
health care access, which have led to an overdiagnosis of small and
indolent tumours.7-12 A greater access of women to health service
and diagnostic procedures in childbearing age could contribute to
the higher incidence of thyroid cancer in females. In Italy, the in-
cidence of thyroid carcinoma increased sharply up to mid 2000
(+11.4% per year among men and +17.5% among women) and
plateaued in recent years.7 The increasing trend can explain the
high incidence rate of thyroid cancers observed in Italy.
Over 70% of cases of primary liver cancers are attributable to
known risk factors, primarily related to the prevalence of hepatitis
C (HCV). In Italy, HCV prevalence explains the observed high IR
and the already reported regional differences in incidence, with an
atypical South-North gradient.13,14 Although infection with hepatitis
B virus (HBV) is related to the onset of the disease, its role is ex-
pected to drop as a result of vaccination campaigns in infants born
from 1978 onwards. In areas of Northern Italy, about one third of
tumours of the liver are also attributable to the abuse of alcohol.7
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Figure 4. Relative survival (%) for rare and common cancers of the RARECAREnet list in
Italy by time since diagnosis (1, 3, and 5 years). Cases diagnosed in 2000-2008, and fol-
lowed up to 31st December 2009. AIRTUM Pool of 37 cancer registries.
Figure 5. Five-year relative survival (%) for rare and common cancers of the RARECAREnet
list in Italy by age group. Cases diagnosed in 2000-2008, and followed up to 31st December
2009. AIRTUM Pool of 37 cancer registries.
I tumori in Italia • Rapporto AIRTUM 2015
Epidemiol Prev 2016; 40 (1) Suppl 2:1-120  Ulteriori dati disponibili sul sito: www.registri-tumori.it26
THE BURDEN
OF RARE CANCERS
IN ITALY
Alcohol and tobacco are the twomost important risk factors for can-
cer of the head and neck, in particular for cancers of the oral cavity,
oropharynx, hypopharynx, and larynx.15-18 At least 75% of cancers
of the head and neck are caused by tobacco and alcohol.19 People
who use both tobacco and alcohol are at increased risk of developing
these cancers than people who use just one of the two.19-21 In Italy
these neoplasms during 2007-2011 were, in bothmales and females,
more common in Northern and Southern regions than in those of
the Centre, reflecting the distribution of the well-known risk factors.
Temporal trends of head and neck tumours are associated with the
prevalence of one of the main risk factors (cigarette smoking).Thus,
a decrease in head and neck incidence was observed among men,
whereas an increase in incidence was reported among women, al-
though it was not statistically significant.22
To conclude, the high prevalence of known risk factors such as al-
cohol consumption and smoking, the prevalence of HCV, and di-
agnostic pressure seems to contribute to explain the high incidence
rates of laryngeal, thyroid, and liver cancers which are rare at Eu-
ropean level but not so rare in Italy.
Survival of rare cancers
Rare cancers had worse RS than common cancers at 1, 3, and 5
years from diagnosis. For patients with rare cancers diagnosed in
2000-2009, 1-, 3-, and 5-year RS was 77%, 61%, and 55%, re-
spectively; the corresponding figures for patients with common
cancers were 85%, 73%, and 68% (Figure 4). Differences between
rare and common cancers were small 1 year after diagnosis, but sur-
vival for rare cancers declined more markedly thereafter, consistent
with the idea that treatments for rare cancers are less effective than
those for common cancers. However, the difference between 1- and
3-year RS for rare cancers was high and higher than that for com-
mon cancers, suggesting that even stage at diagnosis could be a
contributing factor in the poorer RS for rare cancers.
Rare cancers include many cancer entities with a bad prognosis (5-
year RS<50%): cancers of head and neck, oesophagus, small intes-
tine, ovary, brain, biliary tract, liver, pleura, multiple myeloma,
acute myeloid and lymphatic leukemia.23 In contrast, most com-
mon cancer cases are breast, prostate, and colorectal cancers,
which have a good prognosis (5-year survival, 81%, 77%, and
54%, respectively).23
It is unclear why survival for rare cancers is low, especially in adults.
Possibilities include factors inherent in the diseases, and inadequacies
of care or treatment, including delayed diagnosis, lack of effective
therapies, or lack of evidence-based treatment guidelines.
Even though, overall, rare cancers seem to have a worse prognosis
than common cancers, it is worth stressing that rare cancers even
include cancers with a good prognosis. Five-year RS was highest
(≥90%) for testicular cancers, which were the most common tu-
mours among rare male genital cancers. In the group of rare can-
cers, all 198 rare cancers are considered, including thyroid carci-
noma, for which no specific commentary and data are provided
because of methodological issues (please refer to «Materials and
methods», pp.14-21). Survival was relatively high for tumours of
the eye, rare skin tumours, and embryonal tumours. Survival was
poor for rare epithelial tumours of the thoracic cavity and digestive
system, and for central nervous system tumours. The other major
groups of rare cancers had survival ranging from 50% to 65%. Fi-
nally, despite these results, examples of success do exist in rare can-
cer treatment. In the world of adult oncology, the astonishing suc-
cess of Glivec in 2 rare cancers – chronic myelogenous leukaemia
(CML) and gastrointestinal stromal tumour (GIST) – moved the
field of molecularly targeted therapies into high gear and controlled
these two killer diseases.
Regarding differences of survival by age group, it is important to
note that most cancers in children and young adults were rare (Fig-
ure 3) and usually of embryonal or haematological types, for
which effective treatments are available. In older patients, most of
the rare cancers were rare epithelial forms, for which therapies are
not as effective as those for rare paediatric cancers. In addition, ad-
vances in treatment as a result of clinical trials have markedly im-
proved prognoses for many childhood cancers over the last 30-40
years.24Perhaps this lesson can be applied to rare cancers in adults.
Challenges of rare cancers: what should be done?
Rare cancers represent 25% of all new cancers diagnosed in Italy
each year; most rare cancers are very rare (for 72% of them, the in-
cidence rate is <0.5 per 100,000).
Rare cancer patients and their families are confronted with a wide
range of difficulties specifically caused by the rarity of these dis-
eases. These difficulties are hard to overcome, but some suggestions
can be made even with the currently limited but growing knowl-
edge and means:
 both in Italy and across Europe, establish centres of expertise for
rare cancers as well as networks of these centres in order to achieve
the required organisational structure and expertise. This is also nec-
essary in order to recruit the number of patients needed to carry out
clinical trials, to develop alternative study designs and methodolog-
ical approaches. It will also help in improving the accuracy and stan-
dardisation of staging procedures and treatment for rare cancers;2
 develop a multidisciplinary clinical approach;
 spread knowledge and good clinical practice guidelines on rare
cancers;
 increase awareness about rare cancers amongst general practi-
tioners and pathologists;2
 disseminate information tailored to the needs of patients and all
concerned stakeholders;
 support patient associations to build the capacity of patient
groups;
 continue to encourage initiatives to put rare cancers on the map.
The European Commission is responding to the problems of rare
cancers in several ways, including the implementation of Directive
2011/24/EU of the European Parliament and the Council of 9
March 2011 on the application of patients’ rights in cross-border
healthcare. This Directive is meant to grant European patients the
right to access safe, good-quality treatment across European bor-
ders. Amongst its provisions, article 12 refers to the notion of Eu-
ropean Reference Networks (ERNs) for rare and complex diseases,
including rare cancers, calling for strong collaboration between
Member States.25
In Italy, the “Rete Tumori Rari” (Italian rare cancer network)26 was
first established in 1997 to provide diagnosis and care for sarcomas
with the aim of covering rare adult solid cancers. Due to the
main clinical interest of the coordinating group at the Fondazione
IRCCS, Istituto Nazionale Tumori (Italian National Cancer Insti-
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tute, Milan), sarcomas were the first and main subject of this Net-
work. In the last 15 years, the network has grown to include 100
centres of expertise and is currently working on enlarging its scope
to additional rare solid cancers. However, it is based on the volun-
tary collaboration of participating centres. Formalising the “Rete
Tumori Rari” is an urgent measure, which should include the iden-
tification of centres of expertise for rare cancers in Italy. This will
help to ensure adequate care to all Italians diagnosed with a rare
cancer and to guarantee the participation of Italy in the upcoming
European Reference Networks.
CONCLUDING REMARKS
For the first time in Italy, the present monograph has provided fig-
ures for a problem long known to exist. The data retrieved from
AIRTUM confirm that rare cancers are a major public health prob-
lem in Italy. The monograph also provides epidemiologic indicators
for 198 rare cancers, the majority of which (72%) are very rare.
Thanks to the present monograph, health care planners have all the
data of expected incident and prevalent cases to properly plan and re-
organise health care services. Researchers can now better plan clinical
trials, considering alternative study designs and statistical approaches.
These data also show that CRs can be a source of information even
to build external control groups in clinical trials.
National and regional health technology assessment agencies have
important data for their assessment.
Clinicians have data on incidence and prognosis of cancer entities
that had never been provided before, such as neuroendocrine tu-
mours and soft tissue sarcomas, as well as detailed morphologies
rarely reported in the classic statistics.
Patients have their cancers officially recognised and measured, thus
no longer hidden by the common cancers.
We believe that this monograph is a major step forward in the de-
scription of the burden of rare cancers in Italy and should provide
an opportunity to work on the quality of rare cancer data, strength-
ening collaboration with oncologists, pathologists, patients’ asso-
ciations, and the Rete tumori rari.
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GUIDA ALLA LETTURA DELLE SCHEDE
SPECIFICHE PER TUMORE
HOW TO READ THE CANCER-SPECIFIC DATA SHEETS
This guide is for laymen. For more detailed information please refer to the
«Material and methods» chapter (pp. 14-21).
Thismonograph includes 14 data sheets. Every sheet shows data of amajor group
of rare tumours identified by combining rare cancers of broad anatomic sites shar-
ing the same clinical referral pattern and expertise.
In this guide the Rare epithelial tumours of the thoracic cavity group is used
as an example to clarify how rare cancers were identified and described in
each group.
HOW THE RARE CANCER GROUPS WERE IDENTIFIED
The rare cancers included in each of the 14 groups come from the RARECARE
list of cancers (see Annex 1, supplementary material on-line). Briefly, the
RARECARE list of cancers has a hierarchal structure:
 tier 2 includes several specific cancer histotypes (identified by the ICD-O-
3 morphology and topography codes) considered to require similar clinical
management and research;
 tier 1 includes the tier 2 entities plus the Not Otherwise Specified (NOS)
morphologies. Tier 1 includes cancers considered to involve the same clinical
expertise and patient referral structure.
RARE EPITHELIAL TUMOURS TOPOGRAPHY MORPHOLOGY
OF THE THORACIC CAVITY ICD-O-3 CODE ICD-O-3 CODE
EPITHELIAL TUMOURS OF TRACHEA C33.9 8000-8001, 8004, 8010-8011, 8012, 8020-8022, 8031-8032, 8033, 8050-8076, 8078, 8082- 
8084, 8140-8141, 8143- 8144, 8147, 8190, 8200-8201, 8210-8211, 8221, 8230-8231, 8255, 
8260-8263, 8290, 8310, 8315, 8320, 8323, 8333, 8380-8384, 8430, 8440-8441, 8470, 8480-
8482, 8490, 8504, 8510, 8512, 8514, 8525, 8542, 8550-8551, 8560, 8562-8576, 8980, 8982
Squamous cell carcinoma with variants of trachea C33.9 8004, 8020-8022, 8031-8032, 8050-8076, 8078, 8082-8084, 8560, 8980
Adenocarcinoma with variants of trachea C33.9 8140-8141, 8143, 8144, 8147, 8190, 8201, 8210-8211, 8221, 8230, 8231, 8255, 8260-8263, 
8290, 8310, 8315, 8320, 8323, 8333, 8380-8384, 8440-8441, 8470, 8480-8482, 8490, 8504, 
8510, 8512, 8514, 8525, 8542, 8550-8551, 8562-8576
Salivary gland type tumours of trachea C33.9 8200, 8430, 8982
RARE EPITHELIAL TUMOURS OF LUNG C34.0-34.9 8560, 8012, 8014, 8034, 8071, 8072, 8074, 8123, 8200, 8430, 8982, 8004, 8022, 8030-
8033, 8074, 8972, 8980
Squamous cell carcinoma with variants of lung C34.0-34.9
Adenocarcinoma with variants of lung C34.0-34.9
Adenosquamous carcinoma of lung C34.0-34.9 8560
Large cell carcinoma of lung C34.0-34.9 8012, 8014, 8034, 8071-8072, 8123
Poorly differentiated endocrine carcinoma of lung C34.0-34.9
Salivary gland type tumours of lung C34.0-34.9 8200, 8430, 8982
Sarcomatoid carcinoma of lung C34.0-34.9 8004, 8022, 8030-8033, 8074, 8972, 8980 
EPITHELIAL TUMOURS OF THYMUS C37.9 8000-8001,8003, 8010-8011, 8012, 8020-8022, 8032, 8033, 8050-8076, 8078, 8082-
8084, 8123, 8140-8141, 8143-8144, 8147, 8190, 8200-8201, 8210-8211, 8221, 8230-
8231, 8255, 8260-8263, 8290, 8310, 8315, 8320, 8323, 8333, 8380-8384, 8430, 8440-
8441, 8480-8482, 8490, 8504, 8510, 8512, 8514, 8525, 8542, 8550-8551, 8560...
COMMON
COMMON
COMMON
TIER 1
Tier 2
MAJOR GROUP
TIER 1
TIER 1
In this AIRTUM monograph, tier 1 is written in green uppercase, tier 2 en-
tities are written in black below the tier 1 they belong to, and are never in all
caps.
In the RARECARE list, a tier 1 can be common or rare, but in this monograph
only data on rare cancers are presented, therefore:
 if a tier 1 is common (incidence >6 per 100,000 at EU level), such as ep-
ithelial tumours of lung, the common tier 2 entities of this tier and the NOS
histotype are excluded from the tier 1 definition (e.g., for the lung: squa-
mous cell carcinoma, adenocarcinoma, and poorly differentiated endocrine
carcinoma are excluded from tier 1 together with the NOS histotypes; see
the example below). As its common cancers and the NOS morphologies are
excluded, the tier 1 is labelled as RARE EPITHELIAL TUMOURS OF LUNG (to clarify
that only the rare histotypes are included);
 if a tier 1 is rare (incidence rate <6 per 100,000 at EU level), such as epithelial
tumours of trachea, all the corresponding tier 2 entities as well as the NOS his-
totypes are included in the tier 1 definition. The label will not include the “rare”
specification because all the included cancers are rare.
Tier 2
EPITHELIAL TUMOURS OF TRACHEA
Tier 1 includes all the corresponding tier 2 entities, as well as the NOS
histotypes. It is not necessary to add the “rare” specification to the label.
EPITHELIAL TUMOURS OF LUNG
Tier 1 includes only the rare corresponding tier 2 entities,
while common tier 2 entities and NOS morphologies are ex-
cluded. The label includes the “rare” specification.
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INCIDENCE (OF THE MAJOR GROUP)
Estimated number of Italians (M+F) diagnosed
with a rare epithelial tumour of the thoracic
cavity in 2015.
PREVALENCE (OF THE MAJOR GROUP)
Estimated number of Italians (M+F) diagnosed with
a rare epithelial tumour of the thoracic cavity who
were alive in 2010 (date of the last reliable
estimate), regardless of time since diagnosis.
} Are these actually registeredcases? No, these are estimatedcases. The AIRTUM Network covers52% of the Italian population,which is why we have to usestatistics to estimate the numberof cases at the national level.
SURVIVAL (OF THE MAJOR GROUP) 
Proportion of Italians (M+F) still alive 1 and
5 years after receiving a diagnosis of a rare
epithelial tumour of the thoracic cavity.
These figures refer to diagnoses delivered
in the period 2000-2008 and are calculated
net of deaths from other causes.
MAJOR GROUP
TIER 1
ADD UP TO
Percentage of rare epithelial
tumours of the thoracic cavity 
out of all tumours (common+rare) 
of the thoracic cavity. 
In the white circle: percentage 
of rare epithelial tumours 
out of all tumours (common+rare)
of a tier 1.
FOR EXAMPLE:
the 1,699 rare epithelial tumours
expected in Italy in 2015 represent
only 4% of all the tumours 
of the lung (common+rare) 
which are diagnosed in the country
in the same period.
Note: this percentage was 
calculated on the AIRTUM pool
cases observed in 2000-2010,
see incidence table next page.
AN EXAMPLE
RARE EPITHELIAL TUMOURS
OF THE THORACIC CAVITY
GLOSSARIO 
E GUIDA IN ITALIANO
SONO DISPONIBILI 
ON-LINE.
GLOSSARY
AVAILABLE
ON-LINE
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Note:
the absolute numbers reported in these two columns are not directly
comparable because the ones in the OBSERVED CASES column are
actually registered in the area covered by the CRs, while the others are
estimated cases for the whole Italian territory; the former refer to a
period of 11 years, while the latter are cases expected in one year only.
Note:
for RARE EPITHELIAL TUMOURS OF LUNG the sum of the observed
cases of tier 2 entities (5,722) is exactly the same as the number of observed
cases of the corresponding tier 1 (5,722) because tier 1 includes only rare
tier 2 entities and exclude common tier 2 entities and NOS morphologies.
For EPITHELIAL TUMOURS OF TRACHEA the sum (265) of the
observed cases of tier 2 entities is different from the number of observed
cases of the corresponding tier 1 (374) because tier 1 includes NOS
histotypes. NOS histotypes are never included in tier 2 because tier 2
entities include rare cancers which, by definition, are identified by detailed
morphologies.
* *
AN EXAMPLE
RARE EPITHELIAL TUMOURS
OF THE THORACIC CAVITY
The CRUDE INCIDENCE RATE is
the ratio between the number of new
cases arising in a specific population
and the total number of subjects
(males and females) at risk during the
same period. Usually it is expressed as
annual rate per 100,000 subjects.
*E.g., large cell carcinoma 
of the lung: 
Crude rate = 1.84 per
100,000/year 
means that in the areas covered 
by AIRTUM less than 2 persons 
out of 100,000 develop 
this kind of cancer.
Note: even in the case 
of gender-specific tumours – such as 
male and female genital tumours –
the denominator of the ratio is the 
resident M+F population.
The CONFIDENCE INTERVAL (CI)
is the measure of the uncertainty of
the figures we present. The larger the
interval, the more uncertain the
figures. When you read the value of an
indicator we suggest you also look at
the CI in which the value is included.
*E.g., incidence rate 
1.84, CI:1.78-1.89. 
This CI is narrow, showing
reliability of the provided
estimation.
Note: confidence intervals equal to
0.00-0.00 mean that both lower and
upper boundaries are smaller than
0.01 (e.g., 0.001-0.004), therefore
when they are rounded to two
decimal places they become 0.00.
The CRUDE INCIDENCE RATE was
calculated for populations divided into
gender groups (M-F) and age groups.
AGE GROUPS are wider than usual
because of the rarity of the tumours
and are the same for all the major
groups of tumours except for
embryonal tumours, where special
attention was paid to children and
young people.
Note: the sex- and age-specific rates 
for cancers with less than 15 observed
cases between 2000 and 2010 
were considered not estimable (NE).
17% CI 16-18 50% CI 49-51
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HOW TO READ THIS GRAPH (AN EXAMPLE) 
For RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY (major
group) we read: in the period 2000-2008 more than ten thousand rare ep-
ithelial tumours of the thoracic cavity were registered. One year after diagnosis
50% of the patients were still alive; only 17% were alive 5 years after
diagnosis. 
NOTE: CIs of tier 1 and 2 entities are wider than CIs of the major group be-
cause the smaller the number of analysed cases, the larger the uncertainty af-
fecting the estimates. 
In this monograph survival estimates were computed only if the number of
cases was sufficient to produce reliable indicators, with interpretable CIs. That
is the reason why relative survival was not computed when 30 or fewer cases
were observed in the AIRTUM pool during 2000-2008. In this case the in-
dicator is marked as not estimable (NE in the graph) and we suggest readers
consult European survival data (www.rarecarenet.eu).
HOW TO READ THIS TABLE (AN EXAMPLE) 
For RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY (major group) we read:
slightly less than seven (6.69) persons out of every 100,000 residents (M+F)
were alive in 2007 after receiving, in the previous 2 years, a diagnosis of a rare
epithelial tumour of the thoracic cavity. Slightly less than three (2.79) were
alive in 2007 after 2-5 years since diagnosis and fourteen (14.2) were alive in
2007 after being diagnosed in the previous 15 years. In the complete preva-
lence column, we read how many people diagnosed with a rare epithelial tu-
mour of the thoracic cavity out of 100,000 residents in the area covered by
AIRTUM were alive in 2007, regardless of time since diagnosis. 
AN EXAMPLE
RARE EPITHELIAL TUMOURS
OF THE THORACIC CAVITY
AN EXAMPLE
RARE EPITHELIAL TUMOURS
OF THE THORACIC CAVITY
In the bar graphs the confidence
intervals (see CI box, p. 30) are
represented by error bars 
PREVALENCE BY YEARS
SINCE DIAGNOSIS
Complete prevalence: total proportion 
of persons living with a rare cancer diagnosis
regardless of year of diagnosis
Estimated numbers of Italians diagnosed 
with a rare epithelial tumour 
of the thoracic cavity who were alive 
in 2010, regardless of time since diagnosis.
Years since
diagnosis
Proportion
per 100,000
residents
in the areas
covered by
the CRs
included 
in this study
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12 984
ESTIMATED NEW CASES
ITALY, 2015
1
YEARS AFTER DIAGNOSIS
PREVALENCE
116 200
ESTIMATED PREVALENT CASES 
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SURVIVAL
% OF RARE EPITHELIAL
TUMOURS OUT OF
ALL TUMOURS 
IN EACH SITE96
EPITHELIAL TUMOURS
OF NASOPHARYNX
8
EPITHELIAL TUMOURS OF MAJOR 
SALIVARY GLANDS AND SALIVARY 
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62EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES338
1 180
5 466
1 915
3 492
19
93%
OF HEAD AND NECK
TUMOURS ARE RARE
EPITHELIAL TUMOURS
SOURCE: AIRTUM. ITALIAN CANCER FIGURES–REPORT 2015
EPITHELIAL TUMOURS OF HEAD AND NECK 19.46 19.28-19.65 43 163 93% 31.20 30.87-31.54 8.47 8.30-8.64 5.57 5.45-5.69 42.36 41.59-43.14 52.83 52.15-53.52 12 984
EPITHELIAL TUMOURS OF NASAL CAVITY 0.50 0.47-0.53 1 114 62% 0.67 0.63-0.73 0.34 0.31-0.38 0.14 0.12-0.16 0.86 0.75-0.98 1.54 1.42-1.66 338
AND SINUSES
Squamous cell carcinoma with variants of nasal cavity 0.34 0.31-0.36 749 0.45 0.41-0.49 0.23 0.20-0.26 0.08 0.07-0.10 0.57 0.49-0.67 1.07 0.97-1.17 227
and sinuses
Lymphoepithelial carcinoma of nasal cavity and sinuses <0.01 0.00-0.01 7 NE – NE – NE – NE – NE – 2
Undifferentiated carcinoma of nasal cavity and sinuses 0.04 0.03-0.04 80 0.05 0.04-0.07 0.02 0.01-0.03 0.02 0.01-0.03 0.08 0.05-0.12 0.07 0.05-0.10 24
Intestinal type adenocarcinoma of nasal cavity 0.02 0.02-0.03 47 0.04 0.03-0.05 <0.01 0.00-0.01 <0.01 0.00-0.01 0.04 0.02-0.07 0.06 0.04-0.09 14
and sinuses
EPITHELIAL TUMOURS OF NASOPHARYNX 0.88 0.85-0.92 1 961 96% 1.34 1.27-1.41 0.46 0.42-0.50 0.59 0.55-0.63 1.72 1.57-1.89 1.38 1.28-1.50 574
Squamous cell carcinoma with variants of nasopharynx 0.67 0.64-0.71 1 489 1.03 0.97-1.09 0.34 0.30-0.37 0.45 0.42-0.49 1.35 1.22-1.50 1.00 0.91-1.09 435
Papillary adenocarcinoma of nasopharynx <0.01 0.00-0.00 1 NE – NE – NE – NE – NE – 0*
EPITHELIAL TUMOURS OF MAJOR SALIVARY 1.77 1.71-1.82 3 921 8% 2.09 2.00-2.18 1.47 1.40-1.54 0.66 0.62-0.70 2.71 2.52-2.91 4.99 4.78-5.20 1 180
GLANDS AND SALIVARY GLAND TYPE TUMOURS
Epithelial tumours of major salivary glands 1.23 1.18-1.28 2 726 1.43 1.36-1.50 1.04 0.98-1.10 0.44 0.40-0.47 1.78 1.62-1.94 3.60 3.43-3.78 829
Salivary gland type tumours of head and neck 0.54 0.51-0.57 1 195 0.66 0.61-0.71 0.43 0.39-0.46 0.22 0.20-0.24 0.93 0.82-1.05 1.39 1.28-1.50 351
EPITHELIAL TUMOURS OF HYPOPHARYNX 8.21 8.09-8.33 18 205 91% 15.28 15.05-15.52 1.58 1.51-1.66 1.81 1.74-1.88 19.98 19.45-20.52 22.82 22.38-23.27 5 466
AND LARYNX
Squamous cell carcinoma with variants of hypopharynx 1.04 0.99-1.08 2 296 1.87 1.79-1.95 0.25 0.22-0.28 0.34 0.31-0.37 2.81 2.61-3.02 2.33 2.19-2.48 686
Squamous cell carcinoma with variants of larynx 7.17 7.06-7.29 15 909 13.41 13.19-13.63 1.33 1.27-1.40 1.47 1.41-1.54 17.17 16.68-17.67 20.49 20.07-20.92 4 780
EPITHELIAL TUMOURS OF OROPHARYNX 2.89 2.82-2.96 6 410 96% 4.71 4.58-4.84 1.19 1.13-1.25 1.01 0.96-1.07 7.61 7.28-7.94 6.40 6.16-6.64 1 915
Squamous cell carcinoma with variants of oropharynx 2.67 2.60-2.74 5 914 4.35 4.23-4.48 1.09 1.03-1.15 0.95 0.90-1.00 7.10 6.79-7.43 5.81 5.59-6.04 1 762
EPITHELIAL TUMOURS OF ORAL CAVITY AND LIP 5.18 5.09-5.28 11 492 95% 7.08 6.92-7.24 3.41 3.30-3.52 1.37 1.31-1.43 9.45 9.09-9.82 15.60 15.24-15.98 3 492
Squamous cell carcinoma with variants of oral cavity 3.76 3.68-3.84 8 330 4.88 4.75-5.02 2.70 2.61-2.80 1.16 1.10-1.21 7.57 7.25-7.91 10.29 9.99-10.60 2 499
Squamous cell carcinoma with variants of lip 1.10 1.06-1.14 2 437 1.77 1.69-1.85 0.47 0.43-0.51 0.12 0.10-0.14 1.38 1.25-1.53 4.28 4.08-4.47 765
EPITHELIAL TUMOURS OF MIDDLE EAR 0.03 0.02-0.03 60 97% 0.03 0.02-0.05 0.02 0.01-0.03 <0.01 0.00-0.01 0.04 0.02-0.07 0.10 0.07-0.13 19
Squamous cell carcinoma with variants of middle ear 0.02 0.01-0.03 41 0.02 0.02-0.04 0.01 0.01-0.02 <0.01 0.00-0.01 0.03 0.01-0.05 0.07 0.05-0.10 13
Adenocarcinoma with variants of middle ear <0.01 0.00-0.01 5 NE – NE – NE – NE – NE – 1
NE: not estimable because 15 or less incident cases were observed
*One case every 3 years is expected
INCIDENCE
EPITHELIAL TUMOURS OF HEAD AND NECK. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed
cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015
in Italy.
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AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
EPITHELIAL TUMOURS
OF HEAD AND NECK
ITALY
ESTIMATED
NEW CASES  
2015
100%80%60%40%20%0%
EPITHELIAL TUMOURS OF HEAD AND NECK 36 073
EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES 900
Squamous cell carcinoma with variants of nasal cavity and sinuses 625
Lymphoepithelial carcinoma of nasal cavity and sinuses 7 NE
Undifferentiated carcinoma of nasal cavity and sinuses 63
Intestinal type adenocarcinoma of nasal cavity and sinuses 26 NE
EPITHELIAL TUMOURS OF NASOPHARYNX 1 614
Squamous cell carcinoma with variants of nasopharynx 1 241
Papillary adenocarcinoma of nasopharynx 1 NE
EPITHELIAL TUMOURS OF MAJOR SALIVARY GLANDS 3 268
AND SALIVARY GLAND TYPE TUMOURS
Epithelial tumours of major salivary glands 2 246
Salivary gland type tumours of head and neck 1 023
EPITHELIAL TUMOURS OF HYPOPHARYNX AND LARYNX 15 473
Squamous cell carcinoma with variants of hypopharynx 1 994
Squamous cell carcinoma with variants of larynx 13 519
EPITHELIAL TUMOURS OF OROPHARYNX 5 376
Squamous cell carcinoma with variants of oropharynx 4 990
EPITHELIAL TUMOURS OF ORAL CAVITY AND LIP 9 670
Squamous cell carcinoma with variants of oral cavity 7 041
Squamous cell carcinoma with variants of lip 2 107
EPITHELIAL TUMOURS OF MIDDLE EAR 48
Squamous cell carcinoma with variants of middle ear 32
Adenocarcinoma with variants of middle ear 5 NE
NE: not estimable because 30 or less incident cases were observed
EPITHELIAL TUMOURS OF HEAD AND NECK. One and 5-year relative survival. Error bars are 95% confidence interval. Cohort approach
(complete analysis), period of diagnosis 2000-2008.
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SURVIVAL
EPITHELIAL TUMOURS
OF HEAD AND NECK I tumori in Italia • Rapporto AIRTUM 2015
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
EPITHELIAL TUMOURS OF HEAD AND NECK 34.22 33.00-35.47 37.10 35.83-38.40 144.25 141.73-146.79 200.86 197.23-204.50 116 200
EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES 0.75 0.58-0.95 0.75 0.58-0.95 2.74 2.40-3.11 3.71 3.23-4.18 2 129
Squamous cell carcinoma with variants of nasal cavity and sinuses 0.53 0.39-0.71 0.63 0.48-0.82 2.17 1.88-2.51 2.97 2.54-3.40 1 706
Lymphoepithelial carcinoma of nasal cavity and sinuses 0.01 0.00-0.06 NE – 0.01 0.00-0.06 NE – NE
Undifferentiated carcinoma of nasal cavity and sinuses 0.07 0.03-0.15 0.03 0.01-0.10 0.14 0.07-0.24 0.20 0.08-0.32 110
Intestinal type adenocarcinoma of nasal cavity and sinuses 0.01 0.00-0.06 0.01 0.00-0.06 0.05 0.01-0.12 0.09 0.00-0.17 48
EPITHELIAL TUMOURS OF NASOPHARYNX 1.30 1.07-1.56 1.31 1.08-1.58 4.78 4.34-5.27 6.69 6.04-7.34 3 903
Squamous cell carcinoma with variants of nasopharynx 1.01 0.81-1.25 1.12 0.91-1.36 3.71 3.32-4.14 4.90 4.36-5.44 2 866
Papillary adenocarcinoma of nasopharynx NE – NE – NE – NE – NE
EPITHELIAL TUMOURS OF MAJOR SALIVARY GLANDS 3.29 2.92-3.69 3.57 3.18-3.99 13.69 12.92-14.49 21.44 20.21-22.67 12 466
AND SALIVARY GLAND TYPE TUMOURS
Epithelial tumours of major salivary glands 2.18 1.88-2.52 2.24 1.93-2.57 8.85 8.24-9.50 14.54 13.49-15.59 8 464
Salivary gland type tumours of head and neck 1.10 0.89-1.35 1.33 1.10-1.60 4.84 4.39-5.32 7.19 6.49-7.90 4 184
EPITHELIAL TUMOURS OF HYPOPHARYNX AND LARYNX 14.88 14.08-15.71 17.23 16.37-18.13 70.43 68.68-72.22 98.31 95.74-100.89 56 626
Squamous cell carcinoma with variants of hypopharynx 1.49 1.25-1.77 1.00 0.80-1.24 4.31 3.89-4.77 5.15 4.62-5.68 2 964
Squamous cell carcinoma with variants of larynx 13.39 12.63-14.18 16.24 15.41-17.11 66.18 64.48-67.91 93.16 90.65-95.68 53 662
EPITHELIAL TUMOURS OF OROPHARYNX 4.60 4.16-5.08 4.33 3.90-4.79 15.68 14.86-16.54 19.10 18.06-20.15 11 070
Squamous cell carcinoma with variants of oropharynx 4.34 3.91-4.80 4.18 3.76-4.63 14.95 14.15-15.78 18.19 17.17-19.21 10 543
EPITHELIAL TUMOURS OF ORAL CAVITY AND LIP 9.47 8.83-10.14 9.96 9.30-10.64 38.09 36.80-39.41 51.34 49.52-53.15 29 842
Squamous cell carcinoma with variants of oral cavity 6.83 6.29-7.40 6.68 6.15-7.24 24.45 23.43-25.51 31.15 29.78-32.52 18 075
Squamous cell carcinoma with variants of lip 2.30 1.99-2.64 2.98 2.63-3.37 12.15 11.43-12.91 16.66 15.65-17.68 9 726
EPITHELIAL TUMOURS OF MIDDLE EAR 0.05 0.01-0.12 0.05 0.01-0.12 0.17 0.10-0.28 0.28 0.14-0.42 163
Squamous cell carcinoma with variants of middle ear 0.03 0.01-0.10 0.01 0.00-0.06 0.07 0.03-0.15 0.12 0.02-0.21 69
Adenocarcinoma with variants of middle ear 0.01 0.00-0.06 0.01 0.00-0.06 0.06 0.02-0.13 0.07 0.01-0.13 40
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE
PREVALENCE
EPITHELIAL TUMOURS OF HEAD AND NECK. Observed prevalence (proportion per 100,00 and 95% confidence interval
- 95% CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete prevalence. Estimated preva-
lent cases in 2010 in Italy.
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EPITHELIAL TUMOURS
OF HEAD AND NECK
According to the RARECARE project,1 this group includes cancers
originating from body sites that are very close to each other. Given
the heterogeneous types of tissues and organs included in the head
and neck, aetiology and pathogenesis are extremely different. How-
ever, head and neck cancers, as defined here, include only epithelial
cancers originating from the oral cavity, nasal cavity and sinuses, na-
sopharynx, salivary glands, pharynx, and larynx (these two latter are
sometimes grouped with trachea and lung cancers in other publica-
tions). This is because the list of rare cancers proposed by the
RARECARE project1 separates epithelial and non-epithelial tumours
in addition to combining topographies and morphologies to define
a specific tumour. Thus, non-epithelial tumours, such as sarcomas,
neuroendocrine tumours, and lymphomas of the head and neck, are
not included and will be described in the sarcoma, neuroendocrine
tumours, and lymphoma grouping.
The definition of rare cancer is based on the incidence of a specific
tumour in the European population. According to the European
RARECAREnet database (www.rarecarenet.eu), all head and neck
cancers have an incidence that is lower than 6 per 100,000 and are
rare. Thus, even though in Italy some head and neck cancer types
(such as larynx cancers) have an incidence >6 per 100,000, they
are considered rare cancers because the definition is based on the
European and not on the country-specific incidence rate.
Epithelial head and neck tumours comprise the following:
 epithelial tumours of nasal cavity and sinuses
(squamous cell carcinomas, lymphoepithelial carcinoma, undif-
ferentiated carcinoma, intestinal type adenocarcinoma); 
 epithelial tumours of nasopharynx
(squamous cell carcinomas, papillary adenocarcinoma); 
 epithelial tumours of major salivary glands and salivary
gland type tumours (epithelial tumours of major salivary
glands, salivary gland type tumours of head and neck); 
 epithelial tumours of hypopharynx (squamous cell carcinomas);
 epithelial tumours of larynx (squamous cell carcinomas);
 epithelial tumours of oropharynx (squamous cell carcinomas);
 epithelial tumours of oral cavity and lip (squamous cell 
carcinomas); 
 epithelial tumours of middle ear (squamous cell carcinomas,
adenocarcinomas).
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Head and neck squamous cell carcinoma is the 6th most prevalent
type of cancer worldwide and arises in the mucosa of the upper
aerodigestive tract.2 Incidence shows large variations across Europe
and between sexes.1 In Italy, incidence is higher in the Northern
regions and the risk is much higher in men than women. These dif-
ferences reflect differences in the diffusion of the main risk factors:
smoking, alcohol, viruses (Human Papilloma virus – HPV, Ep-
stein-Barr virus – EBV) and occupational exposures. Smoking and
alcohol consumption are strong risk factors for larynx and oro-hy-
popharynx cancers,3 intestinal-type carcinomas of the nasal cavity
and ethmoid cancers have a high attributable fraction due to oc-
cupational exposure to wood, leather, dusts, and formaldehyde.4
Nasopharynx carcinomas are related to EBV infection, while
oropharynx carcinomas are related to HPV type 16 infection.4
Even though most of the known risk factors are more frequent in
males than in females, incidence is much higher in males than ex-
pected based on the prevalence of the listed risk factors.4
Prognosis is very different depending on disease site, and in some
cases aetiology (HPV-related cancers have better prognosis if ap-
propriately treated).1
Primary treatment varies with the anatomic site and stage of dis-
ease. For most early cancers, surgical resection is the cornerstone
of treatment. However, for certain anatomic sites such as tonsils,
base of tongue and floor of the mouth, as well as for all locally ad-
vanced cancers, radiotherapy is used, either alone or combined
with surgery. Chemotherapy may be used in addition to radiother-
apy. Nasopharynx carcinoma is sensitive to both radiation therapy
and chemotherapy. The responsiveness of nasopharyngeal carci-
noma to both radiotherapy and chemotherapy distinguishes it
from other head and neck cancers, which are typically insensitive
to chemotherapy.5
Because tumours of different localisations are managed differently,
epidemiological data reflecting clinically relevant tumour grouping
are essential.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
The majority of cases of head and neck cancers in Italy (incidence
table, p. 34) arise from the larynx (37%), followed by the oral cavity
(19%), oropharynx (15%), salivary glands (6%), lip (6%), hy-
popharynx (5%), nasopharynx (5%), salivary gland type tumours
of head and neck (3%), nasal cavity and sinuses (3%), and finally
by the very rare cancers of the middle ear (0.1%). For all sites, males
have a higher risk than females: from 10-fold for larynx to 1.4-fold
for salivary glands. The incidence rate (IR) increases with age for
all cancer sites, with the exception of the nasopharynx, where the
age-specific IR shows a plateau from intermediate age upward
(data not shown). In children, head and neck cancers are extremely
rare and are mostly epithelial tumours of the major salivary glands,
squamous cell carcinoma of nasopharynx and oral cavity (data not
shown). These results are similar to those observed in Europe in the
RARECAREnet database (www.rarecarenet.eu), with the exception
of tumours of nasopharynx and larynx which have a higher inci-
dence in Italy than in Europe. This is most likely due to the
different distribution of the previously listed risk factors.
Survival
Five-year overall relative survival (RS) is 59%. Five-year RS ranges
from 31% for squamous cell carcinoma of the hypopharynx to
89% for squamous cell carcinoma of the lip. Between these ex-
tremes, 5-year RS for squamous cell carcinoma of the larynx is
71%, for salivary gland type tumours it is 68%, and for squamous
cell carcinoma of the middle ear it is 67% (based on 32 cases only).
Squamous cell carcinomas of all other sites have similar 5-year RS
(about 50%). Undifferentiated carcinoma of the nasal cavity and
sinuses has a 5-year RS of 33%, based on 63 cases (survival figure,
p. 35). Differences in survival among sites reflect the availability
of effective surgical and radiotherapy treatments, responsiveness of
the major histotypes to chemotherapy, and stage at diagnosis:
some cancers give symptoms at a very early stage (oropharynx) and
others remain asymptomatic until advanced stage (nasopharynx).4
Five-year RS rates are similar to those observed in Europe in the
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RARECAREnet database, with the exception of 5-year RS of lar-
ynx cancer, which in Europe is slightly lower than in Italy (61%
vs. 71%, respectively). Five-year RS rates in Europe differ between
geographic areas and countries, ranging (excluding larynx cancer)
from 46.5% in Northern Europe to 28% in Eastern Europe,6 prob-
ably reflecting different mix of head and neck sites and aetiologies,
as well as different access to adequate treatment.
Prevalence
Around 116,000 persons were estimated to be living with a diagnosis
of head and neck epithelial tumours in 2010. About 32,000 cases had
survived more than 15 years after diagnosis. 
Squamous cell carcinoma with variants of larynx are the most frequent
(46% of all prevalent cases), followed by squamous cell carcinoma
with variants of oral cavity (16%), squamous cell carcinoma with vari-
ants of oropharynx (10%), squamous cell carcinoma with variants of
lip (8%), epithelial tumours of major salivary glands (7%), salivary
gland type tumours of head and neck (4%), epithelial tumours of na-
sopharynx (3%), squamous cell carcinoma with variants of hypophar-
ynx (3%), epithelial tumours of nasal cavity and sinuses (2%), and fi-
nally epithelial tumours of middle ear (0.1%).
These results may be different from previous AIRTUM-published fig-
ures of incidence and prevalence, due to different selections of topo-
graphical and morphological codes. For Head and Neck group, this
monograph includes only epithelial cancers (which account for most
cancers of head and neck) and salivary gland types of head and neck
cancer are not included within each site but in a distinct group,
«salivary gland type tumours of head and neck». Because of this, in-
cidence and prevalence estimates will be slightly lower for most head
and neck sites. In addition, for larynx, oropharynx, and oral cavity,
prevalence estimates are slightly higher compared to AIRTUM pub-
lished data on prevalence because the methodology used to calculate
complete prevalence is different (for more details, see «Materials and
Methods», pp. 14-21).
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100%80%60%40%20%0%
TUMOURS OF THE EYE 1 283
EPITHELIAL TUMOURS OF EYE AND ADNEXA 110
Squamous cell carcinoma with variants of eye and adnexa 68
Adenocarcinoma with variants of eye and adnexa 14 NE
MALIGNANT MELANOMA OF UVEA 1 173
NE: not estimable because 30 or less incident cases were observed
TUMOURS OF THE EYE. One and 5-year relative survival. Error bars are 95% confidence interval. Cohort approach (complete analysis),
period of diagnosis 2000-2008.
SURVIVAL
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
TUMOURS OF THE EYE 0.69 0.66-0.73 1 530 100% 0.70 0.65-0.75 0.68 0.64-0.73 0.26 0.23-0.28 1.21 1.08-1.35 1.85 1.72-1.98 451
EPITHELIAL TUMOURS OF EYE AND ADNEXA 0.06 0.05-0.07 133 NA 0.09 0.07-0.11 0.04 0.03-0.05 0.03 0.02-0.04 0.07 0.04-0.11 0.17 0.13-0.21 41
Squamous cell carcinoma with variants of eye 0.03 0.03-0.04 77 NA 0.05 0.04-0.07 0.02 0.01-0.03 0.01 0.01-0.02 0.05 0.03-0.08 0.11 0.08-0.14 24
and adnexa
Adenocarcinoma with variants of eye and adnexa <0.01 0.00-0.01 18 NA 0.01 0.01-0.02 <0.01 0.00-0.01 <0.01 0.00-0.01 <0.01 0.00-0.03 0.02 0.01-0.04 5
MALIGNANT MELANOMA OF UVEA 0.63 0.60-0.66 1 397 NA 0.61 0.56-0.66 0.65 0.60-0.70 0.23 0.21-0.26 1.14 1.02-1.28 1.68 1.56-1.80 410
NA: not applicable
INCIDENCE
TUMOURS OF THE EYE. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed cases and proportion
of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015 in Italy.
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AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
TUMOURS 
OF THE EYE 
TUMOURS OF THE EYE 1.57 1.32-1.86 1.89 1.62-2.21 6.89 6.35-7.47 10.11 9.28-10.93 5 869
EPITHELIAL TUMOURS OF EYE AND ADNEXA 0.15 0.08-0.26 0.09 0.04-0.18 0.52 0.38-0.69 0.78 0.55-1.01 454
Squamous cell carcinoma with variants of eye and adnexa 0.10 0.05-0.20 0.06 0.02-0.13 0.38 0.26-0.53 0.48 0.31-0.64 271
Adenocarcinoma with variants of eye and adnexa 0.01 0.00-0.06 0.01 0.00-0.06 0.05 0.01-0.12 0.06 0.00-0.13 39
MALIGNANT MELANOMA OF UVEA 1.42 1.18-1.70 1.80 1.53-2.11 6.37 5.86-6.93 9.33 8.54-10.12 5 415
PREVALENCE
TUMOURS OF THE EYE. Observed prevalence (proportion per 100,00 and 95% confidence interval - 95% CI) by duration
(≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete prevalence. Estimated prevalent cases in 2010
in Italy.
PROPORTION 95% CI PROPORTION 95% CI PROPORTION 95% CI PROPORTION 95% CI
AIRTUM POOL
COMPLETE PREVALENCE
≤2 YEARS 2-5 YEARS ≤15 YEARS
OBSERVED PREVALENCE BY DURATION
ITALY
ITALY
ESTIMATED
NEW CASES  
2015
ESTIMATED 
PREVALENT
CASES 
2010
I tumori in Italia • Rapporto AIRTUM 2015
Epidemiol Prev 40 (1) Suppl 2:1-120  Ulteriori dati disponibili sul sito: www.registri-tumori.it41
TUMOURS
OF THE EYE
This group of tumours includes the major cancers occurring in the
eye: 
 epithelial tumours and adnexa; 
 uveal melanoma. 
Both are extremely rare, with annual incidence rates (IR) <0.5 per
100,000year.1 These exceptional cancers have already been de-
scribed in previous papers based on two large datasets, the EURO-
CARE study and the RARECARE project.2-4 These two large
population-based studies used data from almost 100 cancer reg-
istries, thus providing solid measures of incidence, survival, and
prevalence for these very rare cancers in Europe.
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Uveal melanoma is an adult intraocular tumour, arising from
melanocytes in the uvea. Adnexal skin tumours are extremely di-
verse group of neoplasms, arising from cutaneous appendages,
particularly the sebaceous, apocrine, and eccrine glands. Because
of their rarity, even the basic descriptive epidemiology of these tu-
mour types is sparse.4
Uveal melanoma is the most common ocular tumour. A very large
study based on data published in Cancer Incidence In 5 Continents,
Volumes VI-VIII covering a long period of registration (1983 to
1997) showed the highest IR in Northern Europe and Australia
and the lowest rates among Asian, Hispanic, and black popula-
tions, consistent with other observations of lower rates in pig-
mented race and a positive association with fair skin.5 One of the
largest European studies2 confirmed the results of the previous pa-
per, but added that IR increased with age and reached a plateau
after 75 years. A few hypotheses were provided for this levelling
off in older age: susceptible individuals develop cancer due to en-
vironmental exposure in adulthood and the pattern is due to a 1-
to 2-decade biological lag between the beginning of the exposure
and the clinical onset of uveal melanoma; the internal environ-
ment of the eye is less stimulating for malignant cells after age 70;
or tumour ascertainment is lower for elderly people.
Epidemiological studies have demonstrated that individual expo-
sure to UV radiation is related to the risk of these cancers.6 Lesions
were reported to occur more often on the left than the right side
of the face, and the left side is expected to receive more UV radi-
ation through the driver’s side window.7 Individuals treated with
ionizing radiation as children or adolescents may be at particularly
high risk. From the early 1920s to the late 1950s, ionizing radia-
tion was commonly used to treat acne or other inflammatory and
benign conditions of the head and neck in the US.8
Organ transplant recipients who are immunosuppressed have a
greatly increased risk of cutaneous appendageal tumours compared
with apparently immunocompetent individuals. In addition, their
tumours are more likely to be malignant and of sebaceous origin.9
The International Agency for Research on Cancer (IARC) has
classified welding with sufficient evidence and solar radiation with
limited evidence as risk factors for epithelial tumours of the eye.
Occupational exposure to ultraviolet radiation has been described
to increase uveal melanoma in workers exposed during outdoor
occupational activities and welders.10
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
In 2015, we estimate 451 tumours of the eye, most of them are
uveal melanoma (No. 410). The crude annual (IRs) per 100,000
are 0.1 for epithelial tumours of the eye and adnexa, and 0.6 for
uveal melanoma. Slightly more than 50% of cases are over 65 years
of age.
Incidence increases with age: in people over 65 years old, IRs are
0.2 and 1.7 for epithelial tumour and melanoma, respectively. The
occurrence of uveal melanoma shows an increase from 1.7 in
cases in the 65-69 age group, up to 1.9 in cases aged 75-79, then
incidence decreases to 1.2 (data not shown).
No difference between genders is relevant statistically. From the
SEER program database in the US11 and the RARECARE data-
base in Europe4 the same IRs were reported for uveal melanoma
for the periods 1973-2008 and 1995-2002, respectively. The age-
adjusted incidence trend remained unchanged in the US from
1973 to 2008.11 Cutaneous appendageal carcinoma IRs were re-
ported to increase in the US, especially for sebaceous carcinoma.
The authors attributed the increase in trends to improved recog-
nition and classification, and did not exclude factors such as UV
exposure and immunosuppression.12
Survival
Based on about 1,300 cases, survival analysis shows good 5-year rel-
ative survival for both epithelial tumours of the eye and uveal
melanoma. Relative survival at 1 and 5 years is 93% and 95%, and
74% and 75%, respectively. Squamous cell carcinoma is charac-
terised by the best prognosis: 82% at 5 years (based on 68 cases).
Treatments of uveal melanoma have changed with the progressive
introduction of conservative management for smaller tumours
during the 1980s.11,13 With this therapeutic shift, 5-year RS is re-
ported to be stable both in the US and in Europe.11,13
The Collaborative Ocular Melanoma Study (COMS) demon-
strated that metastatic disease survival rate and overall survival was
not significantly different between those treated with enucleation
and radiotherapy (brachytherapy). Treatment of epithelial tu-
mours of the eye and uveal melanoma is concentrated in high-vol-
ume and specialized hospitals.4 Patients for which treatments are
not available should enter clinical trials. In consideration of the
rarity of the disease, international cooperation for research should
be arranged.1 
Prevalence
Around 6,000 persons were estimated to be living with a diagnosis of
epithelial tumours of the eye and uveal melanoma in Italy in 2010.
The majority of these persons (>90%) have a previous diagnosis of
uveal melanomas. Our prevalence estimates of uveal melanoma differ
from those published in the AIRTUM prevalence monograph,14 be-
cause of the different sites and morphology definition. Here we in-
cluded ICD-O-3 topographies C69.3-C69.4 and morphologies
M8000, M8001, M8720-M8780; the AIRTUM prevalence mono-
graph included ICD-10 C69 + ICD-O-3 morphologies M8720-
M8790.14
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RARE EPITHELIAL TUMOURS 26.11 25.89-26.32 57 891 16% 32.11 31.78-32.45 20.48 20.22-20.74 3.74 3.64-3.83 40.15 39.40-40.91 93.99 93.08-94.90 17 532
OF THE DIGESTIVE SYSTEM
EPITHELIAL TUMOURS OF OESOPHAGUS 3.38 3.30-3.45 7 488 81% 5.35 5.21-5.49 1.53 1.46-1.60 0.63 0.59-0.67 6.90 6.60-7.22 10.59 10.29-10.90 2 262
Squamous cell carcinoma with variants of oesophagus 2.44 2.37-2.50 5 405 3.74 3.63-3.86 1.21 1.15-1.28 0.47 0.43-0.50 5.43 5.15-5.71 7.33 7.07-7.58 1 619
Adenocarcinoma with variants of oesophagus 0.90 0.86-0.94 1 993 1.54 1.47-1.62 0.30 0.26-0.33 0.15 0.13-0.17 1.41 1.27-1.55 3.14 2.97-3.31 616
Salivary gland type tumours of oesophagus <0.01 0.00-0.00 4 NE – NE – NE – NE – NE – 2
Undifferentiated carcinoma of oesophagus 0.04 0.03-0.05 86 0.06 0.04-0.07 0.02 0.01-0.03 <0.01 0.00-0.01 0.07 0.04-0.11 0.13 0.10-0.17 27
RARE EPITHELIAL TUMOURS OF STOMACH 0.40 0.37-0.42 879 1% 0.50 0.46-0.54 0.30 0.27-0.33 0.06 0.05-0.07 0.62 0.53-0.72 1.42 1.31-1.53 271
Squamous cell carcinoma with variants of stomach 0.09 0.08-0.11 204 0.14 0.12-0.17 0.04 0.03-0.06 0.01 0.01-0.02 0.18 0.14-0.24 0.31 0.26-0.37 62
Salivary gland type tumours of stomach <0.01 0.00-0.00 2 NE – NE – NE – NE – NE – 1
Undifferentiated carcinoma of stomach 0.30 0.28-0.33 673 0.35 0.32-0.39 0.26 0.23-0.29 0.05 0.04-0.06 0.43 0.36-0.51 1.11 1.01-1.21 208
EPITHELIAL TUMOURS OF SMALL INTESTINE 1.02 0.98-1.06 2 261 56% 1.15 1.09-1.22 0.90 0.84-0.95 0.20 0.18-0.22 1.40 1.26-1.55 3.60 3.42-3.78 696
Adenocarcinoma with variants of small intestine 0.78 0.74-0.81 1 722 0.91 0.85-0.97 0.65 0.61-0.70 0.16 0.14-0.19 1.19 1.06-1.32 2.62 2.47-2.77 521
Squamous cell carcinoma with variants of small intestine <0.01 0.01-0.01 21 0.01 0.01-0.02 <0.01 0.00-0.01 <0.01 0.00-0.00 <0.01 0.00-0.03 0.04 0.02-0.06 6
RARE EPITHELIAL TUMOURS OF COLON 0.13 0.12-0.15 293 0.2% 0.11 0.09-0.13 0.15 0.13-0.17 0.05 0.04-0.06 0.18 0.14-0.24 0.38 0.32-0.44 87
Squamous cell carcinoma with variants of colon 0.03 0.03-0.04 74 0.02 0.01-0.03 0.04 0.03-0.06 0.01 0.01-0.02 0.06 0.03-0.09 0.10 0.07-0.13 23
Fibromixoma and low grade 0.10 0.09-0.11 219 0.09 0.07-0.11 0.11 0.09-0.13 0.04 0.03-0.05 0.13 0.09-0.18 0.28 0.23-0.33 65
mucinous adenocarcinoma of the appendix
RARE EPITHELIAL TUMOURS OF RECTUM 0.14 0.13-0.16 318 1% 0.08 0.06-0.10 0.20 0.18-0.23 0.05 0.04-0.06 0.20 0.15-0.26 0.43 0.37-0.50 97
Squamous cell carcinoma with variants of rectum 0.14 0.13-0.16 318 0.08 0.06-0.10 0.20 0.18-0.23 0.05 0.04-0.06 0.20 0.15-0.26 0.43 0.37-0.50 97
EPITHELIAL TUMOURS OF ANAL CANAL 1.69 1.64-1.75 3 750 97% 1.40 1.33-1.47 1.97 1.89-2.05 0.47 0.43-0.50 2.53 2.35-2.73 5.36 5.15-5.58 1 143
Squamous cell carcinoma with variants of anal canal 0.92 0.88-0.96 2 042 0.56 0.52-0.61 1.26 1.19-1.32 0.34 0.31-0.37 1.52 1.38-1.68 2.52 2.38-2.68 611
Adenocarcinoma with variants of anal canal 0.60 0.57-0.64 1 338 0.71 0.66-0.77 0.50 0.46-0.54 0.10 0.08-0.12 0.85 0.74-0.96 2.18 2.04-2.32 411
Paget’s disease of anal canal <0.01 0.00-0.01 8 NE – NE – NE – NE – NE – 2
RARE EPITHELIAL TUMOURS OF PANCREAS 0.11 0.10-0.12 241 1% 0.12 0.10-0.14 0.10 0.08-0.12 0.04 0.03-0.05 0.17 0.12-0.22 0.32 0.27-0.38 71
Squamous cell carcinoma with variants of pancreas 0.02 0.01-0.02 39 0.02 0.01-0.03 0.01 0.01-0.02 <0.01 0.00-0.01 0.03 0.01-0.05 0.05 0.03-0.08 12
Acinar cell carcinoma of pancreas 0.04 0.03-0.05 94 0.06 0.05-0.08 0.02 0.02-0.04 0.01 0.01-0.02 0.08 0.05-0.13 0.12 0.09-0.16 28
Mucinous cystadenocarcinoma of pancreas 0.03 0.02-0.03 56 0.02 0.01-0.03 0.03 0.02-0.04 <0.01 0.00-0.01 0.03 0.01-0.06 0.08 0.06-0.11 16
Intraductal papillary mucinous carcinoma 0.02 0.01-0.02 34 0.02 0.01-0.03 0.01 0.01-0.02 <0.01 0.00-0.01 0.03 0.01-0.05 0.05 0.03-0.08 10
invasive of pancreas
Solid pseudopapillary carcinoma of pancreas <0.01 0.00-0.01 13 NE – NE – NE – NE – NE – 4
Serous cystadenocarcinoma of pancreas <0.01 0.00-0.00 3 NE – NE – NE – NE – NE – 1
Carcinoma with osteoclast-like giant cells of pancreas <0.01 0.00-0.00 2 NE – NE – NE – NE – NE – 1
EPITHELIAL TUMOURS OF LIVER 11.05 10.91-11.19 24 497 53% 16.32 16.08-16.57 6.10 5.96-6.25 1.53 1.47-1.59 18.62 18.11-19.14 38.93 38.35-39.52 7 291
AND INTRAHEPATIC BILE TRACT
Hepatocellular carcinoma of liver and IBT 9.37 9.25-9.50 20 784 14.22 14.00-14.45 4.83 4.70-4.96 1.22 1.17-1.28 15.63 15.17-16.11 33.39 32.85-33.94 6 195
Hepatocellular carcinoma, fibrolamellar of liver and IBT 0.09 0.07-0.10 189 0.13 0.11-0.16 0.04 0.03-0.06 0.01 0.01-0.02 0.13 0.09-0.18 0.30 0.26-0.36 55
Cholangiocarcinoma of IBT 0.90 0.86-0.94 2 003 1.09 1.03-1.16 0.73 0.68-0.78 0.18 0.16-0.20 1.65 1.50-1.81 2.91 2.76-3.08 593
Adenocarcinoma with variants of liver and IBT 0.65 0.61-0.68 1 432 0.83 0.77-0.88 0.48 0.44-0.52 0.11 0.09-0.13 1.14 1.02-1.28 2.17 2.04-2.32 422
Undifferentiated carcinoma of liver and IBT 0.02 0.01-0.02 40 0.02 0.02-0.03 0.01 0.01-0.02 <0.01 0.00-0.01 0.04 0.02-0.07 0.06 0.04-0.09 12
Squamous cell carcinoma with variants of liver and IBT 0.02 0.01-0.02 36 0.02 0.01-0.03 0.01 0.01-0.02 <0.01 0.00-0.00 0.02 0.01-0.04 0.07 0.04-0.09 11
Bile duct cystadenocarcinoma of IBT <0.01 0.00-0.01 13 NE – NE – NE – NE – NE – 4
EPITHELIAL TUMOURS OF GALLBLADDER 7.99 7.87-8.11 17 715 99% 6.84 6.68-7.00 9.07 8.89-9.24 0.66 0.62-0.70 9.15 8.79-9.52 32.37 31.84-32.91 5 483
AND EXTRAHEPATIC BILIARY TRACT
Adenocarcinoma with variants of gallbladder 2.03 1.97-2.09 4 498 1.31 1.24-1.38 2.71 2.61-2.80 0.20 0.18-0.23 3.14 2.93-3.36 7.59 7.34-7.85 1 328
Adenocarcinoma with variants of EBT 2.24 2.17-2.30 4 960 2.54 2.44-2.64 1.95 1.87-2.04 0.31 0.28-0.34 3.67 3.44-3.90 7.94 7.68-8.21 1 479
Squamous cell carcinoma of gallbladder and EBT 0.04 0.03-0.05 84 0.02 0.02-0.04 0.05 0.04-0.07 <0.01 0.00-0.01 0.06 0.04-0.10 0.14 0.11-0.18 25
MESOTHELIOMA OF PERITONEUM 0.20 0.18-0.22 449 NA 0.25 0.22-0.28 0.16 0.14-0.18 0.06 0.05-0.07 0.38 0.31-0.46 0.59 0.52-0.66 132
NE: not estimable because 15 or less incident cases were observed      IBT: intrahepatic bile tract     EBT: extrahepatic bile tract      NA: not applicable
INCIDENCE
RARE EPITHELIAL TUMOURS OF THE DIGESTIVE SYSTEM. Crude incidence (rate per 100,000/year) and 95% confidence interval
(95% CI), observed cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated
new cases at 2015 in Italy.
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AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
RARE EPITHELIAL TUMOURS
OF THE DIGESTIVE SYSTEM 
ESTIMATED
NEW CASES  
2015
ITALY
RARE EPITHELIAL TUMOURS OF THE DIGESTIVE SYSTEM 48 274
EPITHELIAL TUMOURS OF OESOPHAGUS 6 500
Squamous cell carcinoma with variants of oesophagus 4 716
Adenocarcinoma with variants of oesophagus 1 711
Salivary gland type tumours of oesophagus 3 NE
Undifferentiated carcinoma of oesophagus 74
RARE EPITHELIAL TUMOURS OF STOMACH 772
Squamous cell carcinoma with variants of stomach 176
Salivary gland type tumours of stomach 2 NE
Undifferentiated carcinoma of stomach 594
EPITHELIAL TUMOURS OF SMALL INTESTINE 1 815
Adenocarcinoma with variants of small intestine 1 416
Squamous cell carcinoma with variants of small intestine 16 NE
RARE EPITHELIAL TUMOURS OF COLON 234
Squamous cell carcinoma with variants of colon 60
Fibromixoma and low grade mucinous adenocarcinoma of the appendix 174
RARE EPITHELIAL TUMOURS OF RECTUM 246
Squamous cell carcinoma with variants of rectum 246
EPITHELIAL TUMOURS OF ANAL CANAL 3 084
Squamous cell carcinoma with variants of anal canal 1 706
Adenocarcinoma with variants of anal canal 1 078
Paget’s disease of anal canal 8 NE
RARE EPITHELIAL TUMOURS OF PANCREAS 192
Squamous cell carcinoma with variants of pancreas 31
Acinar cell carcinoma of pancreas 78
Mucinous cystadenocarcinoma of pancreas 46
Intraductal papillary mucinous carcinoma invasive of pancreas 22 NE
Solid pseudopapillary carcinoma of pancreas 12 NE
Serous cystadenocarcinoma of pancreas 1 NE
Carcinoma with osteoclast-like giant cells of pancreas 2 NE
EPITHELIAL TUMOURS OF LIVER AND IBT 20 478
Hepatocellular carcinoma of liver and IBT 17 524
Hepatocellular carcinoma, fibrolamellar of liver and IBT 181
Cholangiocarcinoma of IBT 1 604
Adenocarcinoma with variants of liver and IBT 1 099
Undifferentiated carcinoma of liver and IBT 33
Squamous cell carcinoma with variants of liver and IBT 30 NE
Bile duct cystadenocarcinoma of IBT 11 NE
EPITHELIAL TUMOURS OF GALLBLADDER AND EBT 14 644
Adenocarcinoma with variants of gallbladder 3 820
Adenocarcinoma with variants of EBT 4 130
Squamous cell carcinoma of gallbladder and EBT 75
MESOTHELIOMA OF PERITONEUM 382
RARE EPITHELIAL TUMOURS OF THE DIGESTIVE SYSTEM. One and 5-year relative survival. Error bars are 95% confidence interval.
Cohort approach (complete analysis), period of diagnosis 2000-2008.
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SURVIVAL
RARE EPITHELIAL TUMOURS
OF THE DIGESTIVE SYSTEM I tumori in Italia • Rapporto AIRTUM 2015
NE: not estimable because 30 or less incident cases were observed      IBT: intrahepatic bile tract     EBT: extrahepatic bile tract
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100%
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
RARE EPITHELIAL TUMOURS OF THE DIGESTIVE SYSTEM 28.41 27.3-29.55 17.74 16.87-18.65 65.73 64.04-67.46 74.38 71.54-75.42 43 452
EPITHELIAL TUMOURS OF OESOPHAGUS 3.69 3.30-4.12 1.69 1.43-1.98 7.72 7.15-8.33 8.70 8.04-9.36 5 013
Squamous cell carcinoma with variants of oesophagus 2.63 2.30-3.00 1.16 0.94-1.41 5.54 5.05-6.06 6.31 5.74-6.87 3 629
Adenocarcinoma with variants of oesophagus 1.03 0.83-1.26 0.48 0.35-0.65 2.09 1.80-2.42 2.28 1.95-2.61 1 319
Salivary gland type tumours of oesophagus NE – NE – NE – NE – NE
Undifferentiated carcinoma of oesophagus 0.03 0.01-0.10 0.05 0.01-0.12 0.09 0.04-0.18 0.11 0.03-0.19 65
RARE EPITHELIAL TUMOURS OF STOMACH 0.21 0.13-0.33 0.17 0.09-0.28 0.82 0.64-1.03 0.96 0.73-1.18 556
Squamous cell carcinoma with variants of stomach 0.05 0.01-0.12 0.09 0.04-0.18 0.34 0.23-0.48 0.36 0.23-0.49 207
Salivary gland type tumours of stomach NE – NE – NE – NE – NE
Undifferentiated carcinoma of stomach 0.17 0.09-0.28 0.07 0.03-0.16 0.48 0.35-0.65 0.59 0.41-0.78 349
EPITHELIAL TUMOURS OF SMALL INTESTINE 1.02 0.82-1.26 0.87 0.69-1.09 3.16 2.80-3.56 4.35 3.83-4.88 2 517
Adenocarcinoma with variants of small intestine 0.86 0.68-1.08 0.79 0.61-1.00 2.79 2.45-3.16 3.77 3.29-4.26 2 187
Squamous cell carcinoma with variants of small intestine 0.01 0.00-0.06 NE – 0.02 0.00-0.08 0.04 0.00-0.10 23
RARE EPITHELIAL TUMOURS OF COLON 0.24 0.15-0.37 0.25 0.16-0.38 0.83 0.65-1.04 0.92 0.71-1.14 589
Squamous cell carcinoma with variants of colon 0.02 0.00-0.08 0.02 0.00-0.08 0.08 0.03-0.17 0.10 0.03-0.17 58
Fibromixoma and low grade mucinous adenocarcinoma of the appendix 0.22 0.13-0.34 0.23 0.14-0.35 0.75 0.58-0.95 0.83 0.62-1.03 531
RARE EPITHELIAL TUMOURS OF RECTUM 0.23 0.14-0.36 0.18 0.11-0.30 0.80 0.62-1.01 1.10 0.83-1.37 651
Squamous cell carcinoma with variants of rectum 0.23 0.14-0.36 0.18 0.11-0.30 0.80 0.62-1.01 1.10 0.83-1.37 651
EPITHELIAL TUMOURS OF ANAL CANAL 3.01 2.66-3.40 2.79 2.45-3.16 10.11 9.45-10.80 13.24 12.36-14.13 7 735
Squamous cell carcinoma with variants of anal canal 1.85 1.58-2.16 1.92 1.64-2.23 6.57 6.04-7.13 9.18 8.41-9.94 5 397
Adenocarcinoma with variants of anal canal 1.05 0.84-1.28 0.76 0.58-0.96 3.05 2.69-3.44 3.81 3.35-4.28 2 196
Paget’s disease of anal canal NE – 0.01 0.00-0.06 0.05 0.01-0.12 0.06 0.00-0.11 34
RARE EPITHELIAL TUMOURS OF PANCREAS 0.14 0.07-0.24 0.15 0.08-0.26 0.40 0.28-0.56 0.57 0.37-0.76 329
Squamous cell carcinoma with variants of pancreas NE – 0.01 0.00-0.06 0.05 0.01-0.12 0.08 0.00-0.16 45
Acinar cell carcinoma of pancreas 0.06 0.02-0.13 0.09 0.04-0.18 0.17 0.10-0.28 0.24 0.11-0.36 138
Mucinous cystadenocarcinoma of pancreas 0.02 0.00-0.08 0.04 0.01-0.10 0.11 0.06-0.21 0.17 0.06-0.27 97
Intraductal papillary mucinous carcinoma invasive of pancreas 0.05 0.01-0.12 0.01 0.00-0.06 0.06 0.02-0.13 0.07 0.01-0.14 42
Solid pseudopapillary carcinoma of pancreas 0.01 0.00-0.06 NE – 0.01 0.00-0.06 0.01 0.00-0.03 7
Serous cystadenocarcinoma of pancreas NE – NE – NE – NE – NE
Carcinoma with osteoclast-like giant cells of pancreas NE – NE – NE – NE – NE
EPITHELIAL TUMOURS OF LIVER 13.32 12.56-14.10 8.09 7.57-8.78 27.12 26.04-28.24 27.97 26.68-28.94 16 092
AND INTRAHEPATIC BILE TRACT
Hepatocellular carcinoma of liver and IBT 11.86 11.15-12.61 7.46 7.08-8.25 24.82 23.78-25.89 25.55 24.47-26.63 14 690
Hepatocellular carcinoma, fibrolamellar of liver and IBT 0.03 0.01-0.10 0.08 0.05-0.20 0.14 0.07-0.24 0.18 0.07-0.28 103
Cholangiocarcinoma of IBT 0.98 0.79-1.22 0.33 0.20-0.45 1.55 1.30-1.83 1.60 1.33-1.87 922
Adenocarcinoma with variants of liver and IBT 0.43 0.31-0.60 0.21 0.03-0.16 0.59 0.44-0.77 0.61 0.44-0.77 347
Undifferentiated carcinoma of liver and IBT NE – NE – NE – NE – NE
Squamous cell carcinoma with variants of liver and IBT NE – 0.02 0.00-0.08 0.02 0.00-0.08 0.03 0.00-0.08 19
Bile duct cystadenocarcinoma of IBT NE – NE – 0.01 0.00-0.06 0.02 0.00-0.05 11
EPITHELIAL TUMOURS OF GALLBLADDER  6.40 5.88-6.95 3.48 3.00-3.79 14.46 13.68-15.29 16.65 15.73-17.57 9 669
AND EXTRAHEPATIC BILIARY TRACT
Adenocarcinoma with variants of gallbladder 1.98 1.69-2.30 1.43 1.14-1.64 5.64 5.15-6.16 6.52 5.94-7.10 3 792
Adenocarcinoma with variants of EBT 2.55 2.23-2.91 1.60 1.37-1.92 5.98 5.47-6.51 6.76 6.18-7.34 3 887
Squamous cell carcinoma of gallbladder and EBT 0.03 0.01-0.10 NE – 0.05 0.01-0.12 0.05 0.00-0.10 29
MESOTHELIOMA OF PERITONEUM 0.16 0.09-0.27 0.11 0.07-0.23 0.38 0.26-0.54 0.52 0.34-0.70 300
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE
IBT: intrahepatic bile tract     EBT: extrahepatic bile tract
PREVALENCE
RARE EPITHELIAL TUMOURS OF THE DIGESTIVE SYSTEM. Observed prevalence (proportion per 100,00 and 95%
confidence interval - 95% CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete preva-
lence. Estimated prevalent cases in 2010 in Italy.
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RARE EPITHELIAL TUMOURS
OF THE DIGESTIVE SYSTEM 
This group includes epithelial tumours of:
 oesophagus (squamous cell carcinoma, adenocarcinoma,
salivary gland type, undifferentiated carcinoma);
 stomach (squamous cell carcinoma, salivary gland type, 
undifferentiated carcinoma);
 small intestine (adenocarcinoma and squamous
cell carcinoma); 
 colon (squamous cell carcinoma, fibromyxoma 
and low grade mucinous adenocarcinoma of appendix);
 rectum (squamous cell carcinoma);
 anal canal (squamous cell carcinoma, adenocarcinoma,
Paget’s disease);
 liver and intrahepatic bile duct (hepatocellular carcinoma,
fibrolamellar hepatocellular carcinoma, cholangiocarcinoma,
adenocarcinoma, undifferentiated carcinoma, squamous cell
carcinoma, bile duct cystoadenocarcinoma);
 gallbladder and extrahepatic biliary tract (adenocarcinoma,
squamous cell carcinoma);
 pancreas (squamous cell carcinoma, acinar cell carcinoma,
mucinous cystoadenocarcinoma, intraductal papillary mucinous
carcinoma, serous cystoadenocarcinoma, carcinoma with 
osteoclastic-like giant cells, solid pseudopapillary carcinoma).
Among the rare cancers of the digestive tract we also describe 
 peritoneal mesothelioma.
All together, rare epithelial cancers account for 16% of all cancers
of the digestive system. Non epithelial tumours such as neuroen-
docrine tumours or sarcomas of the digestive system are not in-
cluded here but in the sarcoma (p. 84) and neuroendocrine tumour
(p. 90) groupings described in this monograph.
RARE EPITHELIAL TUMOURS OF STOMACH,
COLON AND RECTUM AND EPITHELIAL TUMOURS
OF OESOPHAGUS, SMALL INTESTINE AND ANAL CANAL
WHAT DO WE KNOW ABOUT THESE CANCERS? 
All these cancers share similar risk factors: smoking, alcohol, and
lifestyle habits, such as consumption of red meat, flour, and refined
sugars, overweight, and limited physical activity.1 Additional site-
specific risk factors are: exposure to mycotoxins, human papillo-
mavirus (HPV)2 infection, and familial predisposition for squamous
cell carcinoma of oesophagus; Barrett’s oesophagus, gastroe-
sophageal reflux, and bile reflux for adenocarcinoma of oesophagus;3
Helicobacter pylori (HP) for epithelial tumours of stomach;4
Crohn’s disease, familial adenomatous polyposis for small intestine;5
family history and hereditary syndromes for colon;6 HPV infection
(strains 16 and 18) for anal canal.
In the oesophagus squamous cell carcinoma is more frequent in
the upper middle third part while adenocarcinoma occurs mainly
in the lower third because of the different risk factors.
In the stomach squamous cell carcinoma and salivary gland type
tumours are very rare. Undifferentiated carcinoma of the stomach
is characterised by lesions that lack any differentiated features be-
yond an epithelial phenotype.
In the small intestine adenocarcinoma is the most common his-
totype and is located mainly in the second part of the duodenum.
Diagnosis is often difficult, but recently videocapsule endoscopy
has shown promising results in the diagnosis of disorders and tu-
mours of the small intestine.
Rectal squamous cell carcinoma is more aggressive than adenocar-
cinoma and has a worse prognosis.
Anal canal cancers, because of their localisation, are often diagnosed
when the disease is localised to the locoregional area. It has been
shown that chemoradiation in squamous cell carcinoma of the anal
canal may offer a good chance of cure without surgery. On the con-
trary, all other sites are rarely diagnosed as a localised disease. The
number of randomised trials is scarce and the data to support evi-
dence-based decisions are very limited. No effective and satisfactory
treatment for this disease really exists, thus it is recommended to re-
fer patients with these rare cancers to specialised centres.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
All epithelial tumours of the oesophagus are rare even if all together
the epithelial tumours represent the 81% of all the tumours of the
oesophagus. All epithelial tumours of the small intestine and of the
anal canal are rare and represent the 56% and 97% of all tumours
of small intestine and anal canal, respectively (incidence table, p.
44). In the stomach, colon, and rectum, rare epithelial cancers are
1.5%, 0.2%, and 1%, respectively, based on AIRTUM data.
The most frequent rare epithelial histotype is squamous cell carci-
noma, but even common adenocarcinomas in some sites (oesoph-
agus, small intestine, and anal canal) are rare. Most rare epithelial
cancers of the colon are low grade mucinous adenocarcinoma of
the appendix. The other histotypes (salivary gland type tumours,
Paget’s disease) are extremely rare. Squamous cell carcinoma is more
frequent than adenocarcinoma in the oesophagus and anal canal;
in the small intestine it is the opposite. We found an unexpectedly
high frequency of adenocarcinomas among anal canal cancers. In
hospital series they are exceptional, suggesting that some low rectal
cancers were classified generically as anal canal cancers.
Rare epithelial tumours of the oesophagus, stomach, and small in-
testine are more common in males than females. The opposite is
true for rare epithelial tumours of the colon, rectum, and anal
canal. All these tumours are typical of old ages (>65 years old). Ital-
ian and European data of the RARECAREnet database
(www.rarecarenet.eu) are similar, but in Italy the incidence of
adenocarcinoma of the oesophagus is lower than in Europe and the
incidence of adenocarcinoma of the anus is higher.
Survival
Survival of epithelial tumours of the oesophagus, stomach, and
small intestine is poor. Five-year relative survival (RS) for these sites,
regardless of the histotype, is 13% for the oesophagus, 18% for the
stomach, and 29% for the small intestine. RS of rare epithelial tu-
mours of the colon, rectum, and anal canal is slightly better, with
almost half of patients alive after 5 years from diagnosis. However,
squamous cell carcinoma of the colon has a 5-year RS of 31%,
while that of low grade mucinous adenocarcinoma of the appendix
is 66% (survival figure, p. 45). Thus, the latter mainly influence the
survival of rare epithelial tumours of the colon. Italian and Euro-
pean data of the RARECAREnet database are similar.
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Prevalence
About 7,700 persons were estimated to be living with a diagnosis of
anal canal tumour (about two thirds with squamous cell carcinomas)
at the beginning of 2010. Persons living with a diagnosis of rare ep-
ithelial tumours of the oesophagus were about 5,000; among these,
squamous cell carcinomas are the most frequent (mainly for their rel-
atively high incidence). 
Persons with a diagnosis of small intestine tumours were about 2,500
(87% with adenocarcinoma). Estimated numbers of prevalent cases of
rare tumours of the stomach, colon, and rectumwere 550, 600, and 650,
respectively. Among prevalent cases, the proportion of patients that sur-
vived more than 15 years from diagnosis is similar among sites, lower than
30%. Prevalence estimates are coherent with the relatively low incidence
and poor prognosis of the majority of these tumours. Prevalence estimates
for the oesophagus are a bit higher than those published in the AIRTUM
monograph on prevalence7 because of the different methodology used (see
«Materials and methods», pp. 14-21). The other sites are difficult to com-
pare with published data because rare epithelial tumours represent only
a small fraction of all the tumours of the site.
RARE EPITHELIAL TUMOURS OF PANCRES
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Pancreatic cancer is an aggressive disease with an extremely poor prog-
nosis. It is mainly diagnosed in advanced stage; however, increased
use of radiological modalities has led to incidental findings of pan-
creatic cancer, as well as the detection of precursor lesions which can
be monitored and/or resected as necessary. A combination of bio-
chemical tests, radiological imaging, endoscopic ultrasound fine nee-
dle aspiration and multidisciplinary discussion in specialised centres
is necessary for accurate diagnosis, staging, and for the definition of
the appropriate management plan. An example of this approach is the
experience of the Province of Reggio Emilia (Emilia-Romagna Re-
gion, Central Italy), where since 2012 it has been possible to submit
all cases of pancreatic tumours that access the various hospitals in the
province to multidisciplinary discussion, both through regular meet-
ings and using a specially created discussion blog.
Risk factors include:8 excess body weight, chronic inflammation of
the pancreas, diabetes, family history of genetic syndromes, per-
sonal or family history of pancreatic cancer, smoking.
Squamous cell carcinoma clinical presentation is similar to that of
adenocarcinoma. 
Acinar cell carcinoma shows different clinical symptoms at presen-
tation, different morphological features, different outcomes, and dif-
ferent molecular alterations, creating difficulties in the clinical and
pathological diagnosis and in the therapeutic choice.9Mucinous cys-
tadenocarcinoma is the malignant form of a mucinous cystic neo-
plasm. Correct and early characterisation of a premalignant or ma-
lignant mucinous cystic neoplasm with surgical resection offers a
favourable prognosis. However, once it has become invasive or
metastasised, the outcome of a cystic pancreatic carcinoma is poor. 
Intraductal papillary mucinous carcinomas comprise a histologic
spectrum ranging from adenoma with mild dysplasia to invasive
carcinoma. Although the overall outcome is good, a significant pro-
portion of resected patients develop pancreatic adenocarcinoma in
the pancreatic remnant. 
Solid pseudopapillary carcinoma derives from a solid-pseudopap-
illary neoplasm; it has been recognised with increasing frequency
in recent years. It is characterised by tumour recurrence and/or
metastasis. 
Serous cystadenocarcinoma of the pancreas is a malignant cystic
tumour which, in most cases, shows synchronous or metachronous
liver metastases. 
Carcinoma with osteoclast-like giant cells is an extraskeletal tu-
mour containing multinucleated osteoclast-like giant cells, which
morphologically resemble those found in giant cell tumours of the
bone. The clinical features of these tumours remain obscure, as
many cases are already advanced when detected. Long-term follow-
up of patients with these rare tumours is essential in order to com-
pile a body of literature to help guide treatment, since the rarity
of this tumour renders prospective studies unlikely. The develop-
ment of specialist registries can strongly contribute to the study of
pancreatic diseases and the identification of an appropriate ap-
proach for diagnosis and treatment.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Rare epithelial cancers include several histotypes, which all together
represent only 1% of pancreatic tumours. The proportion of rare
cancers is so low partly because histological proof is not always ob-
tained. In the AIRTUM database less than 50% of cases have his-
tological verification. This is a problem which leads to an under-
estimation of the rare histotypes of the pancreas. In addition,
57% of pancreatic cancers have a non-specified morphology,
which means that often pathologists do not report/identify the spe-
cific histotype, contributing to underestimate the real incidence of
rare tumours. 
In Italy in the AIRTUM database, in 11 years, 241 cases of rare ep-
ithelial tumours of pancreas were observed. The most common his-
totype is acinar cell carcinoma (39% of cases), followed by muci-
nous cystadenocarcinoma (23%), squamous cell carcinoma (16%),
and invasive intraductal papillary mucinous carcinoma (14%).
The other histotypes are extremely rare, with 13 or fewer cases ob-
served in 11 years. Rare epithelial pancreatic cancers are more fre-
quent in males than females and are typical of old age (65-75 years
old). Italian and European (RARECAREnet database) are similar. 
Survival
Survival of rare epithelial pancreatic cancers is low for all histotypes.
Mucinous cystoadenocarcinoma and acinar cell carcinoma have the
best 5-year relative survival (RS), which, in any case, is 33% and
25%, respectively. The number of cases of the other histotypes is
not enough to provide reliable estimates (see figure p. 45). How-
ever, the estimates of the wider RARECAREnet database confirm
the poor prognosis expected for solid pseudopapillary carcinoma,
which has a 5-year RS of 65% (based on 42 cases only). Again, in
the RARECAREnet database the number of cases was not enough
to estimate the RS of serous cystadenocarcinoma and carcinoma
with osteoclast-like giant cells.
Prevalence
Slightly more than 300 people were estimated to be alive in 2010 with
a diagnosis of rare epithelial tumours of the pancreas, with acinar cell
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carcinomas being the most prevalent cases (42%). The prevalence es-
timates are low because of the rarity and poor prognosis of these tu-
mours.
EPITHELIAL TUMOURS OF LIVER AND INTRAHEPATIC
BILE DUCT AND OF GALLBLADDER 
AND EXTRAHEPATIC BILIARY TRACT
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Over 70% of primary liver cancers are attributable to Hepatitis C
virus (HCV), Hepatitis B virus (HBV), alcohol, smoking, and, for
cholangiocarcinoma, primary sclerosing cholangitis (PSC), cirrho-
sis, diabetes, obesity, and Caroli’s disease.10,11
For gallbladder cancer the most common risk factors are gallstones,
porcelain gallbladder, gallbladder adenoma, bile duct cysts, and ab-
normalities of the biliopancreatic junction. The risk increases in the
case of obesity and a diet high in carbohydrates and low in fibres. 
For cancer of the bile ducts the risk factors are chronic inflamma-
tion of the bile duct, bile duct cysts, congenital dilatation of intra-
hepatic bile ducts and cirrhosis.12
Histological proof is not always easy to obtain for these sites.
Liver, extrahepatic bile duct, and gallbladder are not easily acces-
sible, therefore biopsy and surgery are infrequently performed. In
the absence of histological verification, diagnosis is based on op-
erative findings or medical imaging. In the AIRTUM database,
60% of patients have a liver cancer and 40% have a gallbladder
cancer diagnosed without histological verification. The proportion
of unspecified morphology is high (>40%) and increases in older
people (>65 years). Thus, some concerns regarding our analysis
should be noted, as the high proportion of unspecified morphology
may lead to underestimation of rare liver and gallbladder cancers
(which are defined by the combination of topography and mor-
phology). The accuracy of diagnosis of these tumours should in-
crease regardless of the poor prognosis of liver cancers.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
All epithelial tumours of liver and gallbladder are rare because rare
cancers are defined on the basis of the European population and
not of the country-specific incidence rate. Thus, even hepatocel-
lular carcinoma of the liver and all tumours of the gallbladder,
which in Italy are not perceived as rare, fall into the rare category,
since in Europe their incidence is 3 and 4 per 100,000, respectively.
Among the epithelial tumours of liver and intrahepatic bile duct
(IBTs), the hepatocellular is the most frequent (85%) followed by
cholangiocarcinoma (8%), and adenocarcinoma (6%) (see table
p. 44). Around 200 cases of fibrolamellar hepatocellular carcinoma
were observed in 11 years in the AIRTUM database. The other en-
tities are extremely rare. All histotypes are more common in males
than females and are typical of the older age group (>65 years).
The incidence of all epithelial tumours of the liver does not in-
clude the unspecified morphology, which for this site is high. All
liver histotypes show higher rates in Italy than in Europe
(RARECAREnet database).
Epithelial tumours of gallbladder and extrahepatic bile duct
(EBTs) are mainly adenocarcinomas; only 84 cases of squamous
cell carcinoma were observed in 11 years in the AIRTUM database.
Even in these sites there is a high proportion of unspecified mor-
phologies, however, contrary to liver cancers, the incidence of ep-
ithelial tumours of the gallbladder includes the unspecified types
(this is the reason why the sum of the proportion of adenocarci-
nomas of the gallbladder and EBTs do not add up to 100%). The
incidence is slightly higher in females, especially for gallbladder tu-
mours and increases with age. The incidence in Italy is slightly
higher than in Europe (RARECAREnet database).
Survival
Prognosis of epithelial tumours of the liver, IBTs, epithelial tu-
mours of the gallbladder, and EBTs is poor. One-year RS is 76%
and 58% for fibrolamellar hepatocellular carcinoma and hepato-
cellular carcinoma, respectively. However for all other epithelial tu-
mours of the liver and gallbladder, IBTs, and EBTs, 1-year RS is
≤44%. Survival drops to ≤20% 5 years after diagnosis (except for
fibrolamellar hepatocellular carcinoma, for which it is 36%) (see
figure p. 45). Survival estimates of undifferentiated carcinoma,
squamous cell carcinoma, and bile duct cystadenocarcinoma of
liver and IBTs are based on a limited number of cases. In Italy, sur-
vival for all these tumours is slightly higher than in Europe, prob-
ably because of the screening of high-risk patients (chronic HCV
or HBC infection). Moreover, great attention is paid in Italy to the
prevention of viral infections through blood work and blood
products, donated organs and tissues, and all medical and surgical
procedures. 
Prevalence
Around 16,000 people were estimated to be alive in Italy in 2010 with
a diagnosis of epithelial tumours of the liver. The prevalent cases are
mainly due to the relatively high incidence of hepatocellular carcino-
mas. These data are slightly lower than those presented in the AIR-
TUM monograph on prevalence,7 because we do not include cases
with unspecified morphology of the liver, which are a high number.
Around 9,700 people were estimated to be alive with a diagnosis of
epithelial tumours of the gallbladder and were mainly people with ade-
nocarcinomas of gallbladder and EBTs.
MESOTHELIOMA OF PERITONEUM
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Peritoneal mesothelioma can have the same morphology as pleural
forms (epithelioid, sarcomatoid, and mixed). The tumour may
grow, giving only nonspecific signs and symptoms. Patients with
peritoneal mesothelioma access different hospital departments
from those used by patients with lung mesothelioma. Thus, many
different structures must be investigated in epidemiological survey
of these tumours (internal medicine and general surgery, as well as
thoracic surgery).
Asbestos is the main risk factor for peritoneal mesothelioma. An ad-
ditional risk factor is radiation used for diagnosis and treatment
(Thorotrast) and irradiation of abdominal lymph nodes in prostate
cancer.13 People exposed to asbestos have a risk of mesothelioma of
the peritoneum that appears to constantly grow over time, even af-
ter cessation of exposure.
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THE EPIDEMIOLOGICAL DATA IN ITALY
Only 449 cases of mesothelioma of the peritoneum were observed in
the AIRTUM database in 11 years. One-year RS is 43% and drops
to 11% at five years. In some population-based studies, a shorter me-
dian survival was observed in peritoneal as compared with pleural
mesothelioma, but in others there were contrasting results. A possible
explanation is that peritoneal mesothelioma has both a shorter survival
in most cases and a larger proportion of long-term survivors.14
GENERAL REMARKS 
In general, if you consider the number of observed cases in the AIR-
TUM database during the period 2000-2010 and expected cases in
2015 (see table p. 44), you may notice that there are entities with less
than 100 yearly diagnosed patients in Italy. The treatment of rare neo-
plastic conditions is challenging, especially because studies providing
high levels of evidence are often lacking especially for the small num-
ber of incident cases.15
The current reality, for better or for worse, is that patients with a rare
tumour consult different hospital centres, and thus the already few in-
cident cases disperse more; also, each hospital centre may lead to use
different existing therapies off-label, and although the response to such
treatments may be either overwhelmingly positive or negative, there is
currently no systematic way to collect this clinical information and
learn from it. The creation of a network of centres that deal with special
rare cancers, capitalizing on the access of patients in all centres, could
serve as a basis to accumulate and consolidate knowledge of the natural
history, molecular biology, and treatment of rare cancers: as more drugs
and treatments for rare cancers emerge, there will still remain a need
for randomised trials or observational studies to compare strategies.16
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RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY 10 097
EPITHELIAL TUMOURS OF TRACHEA 323
Squamous cell carcinoma with variants of trachea 157
Adenocarcinoma with variants of trachea 59
Salivary gland type tumours of trachea 21 NE
RARE EPITHELIAL TUMOURS OF LUNG 4 793
Adenosquamous carcinoma of lung 640
Large cell carcinoma of lung 3 566
Salivary gland type tumours of lung 122
Sarcomatoid carcinoma of lung 465
EPITHELIAL TUMOURS OF THYMUS 656
Malignant thymoma 504
Squamous cell carcinoma of thymus 37
Undifferentiated carcinoma of thymus 9 NE
Lymphoepithelial carcinoma of thymus 4 NE
Adenocarcinoma with variants of thymus 6 NE
MESOTHELIOMA OF PLEURA AND PERICARDIUM 4 327
NE: not estimable because 30 or less incident cases were observed
RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY. One and 5-year relative survival. Error bars
are 95% confidence interval. Cohort approach (complete analysis), period of diagnosis 2000-2008.
SURVIVAL
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100%
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
RARE EPITHELIAL TUMOURS 5.42 5.33-5.52 12 027 8% 8.57 8.39-8.74 2.48 2.39-2.57 0.87 0.82-0.92 10.14 9.77-10.53 18.08 17.69-18.49 3 590
OF THE THORACIC CAVITY
EPITHELIAL TUMOURS OF TRACHEA 0.17 0.15-0.19 374 95% 0.27 0.24-0.30 0.07 0.06-0.09 0.03 0.02-0.04 0.33 0.27-0.41 0.55 0.48-0.62 113
Squamous cell carcinoma with variants of trachea 0.08 0.07-0.09 175 0.14 0.11-0.16 0.03 0.02-0.04 0.01 0.01-0.02 0.16 0.12-0.22 0.26 0.21-0.31 53
Adenocarcinoma with variants of trachea 0.03 0.02-0.04 64 0.05 0.04-0.06 0.01 0.01-0.02 <0.01 0.00-0.01 0.08 0.05-0.12 0.08 0.06-0.11 19
Salivary gland type tumours of trachea 0.01 0.01-0.02 26 0.01 0.01-0.02 0.01 0.01-0.02 <0.01 0.00-0.01 0.02 0.01-0.04 0.03 0.02-0.05 8
RARE EPITHELIAL TUMOURS OF LUNG 2.58 2.51-2.65 5 722 4% 4.37 4.24-4.49 0.91 0.85-0.96 0.40 0.36-0.43 4.97 4.71-5.25 8.57 8.30-8.85 1 699
Adenosquamous carcinoma of lung 0.41 0.38-0.44 909 0.66 0.61-0.71 0.18 0.15-0.20 0.06 0.05-0.08 0.76 0.66-0.87 1.39 1.28-1.50 268
Large cell carcinoma of lung 1.84 1.78-1.89 4 071 3.18 3.07-3.29 0.58 0.54-0.62 0.26 0.23-0.28 3.53 3.31-3.76 6.20 5.97-6.43 1 213
Salivary gland type tumours of lung 0.06 0.05-0.07 140 0.09 0.07-0.11 0.04 0.03-0.05 0.03 0.02-0.04 0.12 0.09-0.17 0.15 0.11-0.19 41
Sarcomatoid carcinoma of lung 0.27 0.25-0.29 602 0.44 0.40-0.48 0.11 0.09-0.13 0.05 0.04-0.06 0.56 0.48-0.66 0.85 0.76-0.94 177
EPITHELIAL TUMOURS OF THYMUS 0.36 0.34-0.39 804 97% 0.41 0.38-0.45 0.32 0.28-0.35 0.18 0.16-0.20 0.73 0.64-0.84 0.75 0.67-0.84 232
Malignant thymoma 0.28 0.25-0.30 612 0.31 0.28-0.35 0.24 0.21-0.27 0.15 0.13-0.17 0.56 0.47-0.65 0.54 0.47-0.61 175
Squamous cell carcinoma of thymus 0.02 0.02-0.03 46 0.02 0.02-0.03 0.02 0.01-0.03 <0.01 0.00-0.01 0.06 0.04-0.10 0.05 0.03-0.08 13
Undifferentiated carcinoma of thymus <0.01 0.00-0.01 9 NE – NE – NE – NE – NE – 2
Lymphoepithelial carcinoma of thymus <0.01 0.00-0.01 6 NE – NE – NE – NE – NE – 2
Adenocarcinoma with variants of thymus <0.01 0.00-0.01 7 NE – NE – NE – NE – NE – 2
MESOTHELIOMA OF PLEURA AND PERICARDIUM 2.31 2.25-2.38 5 127 74% 3.51 3.40-3.63 1.19 1.12-1.25 0.27 0.24-0.29 4.10 3.86-4.35 8.21 7.94-8.48 1 546
NE: not estimable because 15 or less incident cases were observed
INCIDENCE
RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY. Crude incidence (rate per 100,000/year) and 95% confidence interval
(95% CI), observed cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated
new cases at 2015 in Italy.
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SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
RARE EPITHELIAL TUMOURS
OF THE THORACIC CAVITY
ESTIMATED
NEW CASES  
2015
ITALY
RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY 6.69 6.16-7.25 2.79 2.45-3.16 14.22 13.44-15.04 17.29 16.31-18.27 9 933
EPITHELIAL TUMOURS OF TRACHEA 0.15 0.08-0.26 0.09 0.04-0.18 0.34 0.23-0.49 0.42 0.27-0.57 240
Squamous cell carcinoma with variants of trachea 0.07 0.03-0.15 0.03 0.01-0.10 0.14 0.07-0.24 0.15 0.06-0.23 80
Adenocarcinoma with variants of trachea 0.01 0.00-0.06 0.01 0.00-0.06 0.03 0.01-0.10 0.04 0.00-0.08 24
Salivary gland type tumours of trachea 0.05 0.01-0.12 0.02 0.00-0.08 0.13 0.06-0.23 0.20 0.08-0.32 120
RARE EPITHELIAL TUMOURS OF LUNG 2.87 2.53-3.25 1.44 1.20-1.72 7.34 6.78-7.93 9.12 8.40-9.84 5 218
Adenosquamous carcinoma of lung 0.40 0.28-0.56 0.21 0.12-0.33 0.94 0.75-1.17 1.12 0.88-1.37 635
Large cell carcinoma of lung 2.05 1.76-2.37 0.99 0.79-1.23 5.32 4.84-5.82 6.72 6.09-7.34 3 841
Salivary gland type tumours of lung 0.11 0.06-0.21 0.13 0.06-0.23 0.41 0.29-0.57 0.56 0.37-0.74 318
Sarcomatoid carcinoma of lung 0.31 0.20-0.45 0.11 0.06-0.21 0.67 0.51-0.86 0.73 0.54-0.91 425
EPITHELIAL TUMOURS OF THYMUS 0.72 0.56-0.93 0.57 0.43-0.76 2.46 2.14-2.81 3.31 2.86-3.76 1 921
Malignant thymoma 0.61 0.46-0.80 0.48 0.35-0.65 2.15 1.85-2.48 2.93 2.50-3.36 1 698
Squamous cell carcinoma of thymus 0.03 0.01-0.10 0.02 0.00-0.08 0.06 0.02-0.13 0.09 0.01-0.18 52
Undifferentiated carcinoma of thymus NE – NE – 0.01 0.00-0.06 0.01 0.00-0.03 6
Lymphoepithelial carcinoma of thymus 0.01 0.00-0.06 NE – 0.02 0.00-0.08 0.03 0.00-0.08 21
Adenocarcinoma with variants of thymus NE – NE – NE – NE – NE
MESOTHELIOMA OF PLEURA AND PERICARDIUM 2.94 2.59-3.32 0.68 0.52-0.88 4.08 3.67-4.53 4.44 3.97-4.90 2 554
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE
PREVALENCE
RARE EPITHELIAL TUMOURS OF THE THORACIC CAVITY. Observed prevalence (proportion per 100,00 and 95% con-
fidence interval - 95% CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete prevalence.
Estimated prevalent cases in 2010 in Italy.
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RARE EPITHELIAL TUMOURS
OF THE THORACIC CAVITY
Rare epithelial tumours represent 8% of all tumours of the thoracic
cavity and include:
 epithelial tumours of trachea (squamous cell carcinoma,
adenocarcinoma, and salivary gland type tumours);
 rare epithelial tumours of lung (adenosquamous carcinoma,
large cell carcinoma, salivary gland type tumours, sarcomatoid
carcinoma);
 epithelial tumours of thymus (malignant thymoma,
squamous cell carcinoma, undifferentiated carcinoma,
lymphoepithelial carcinoma, adenocarcinoma).
In this group we also describe 
 malignant pleural and pericardial mesothelioma.
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Apart from mesothelioma, little information is available on patterns
of incidence and survival for these tumours. This is largely because
in the routine statistics these tumours are grouped together with
other sites. Tumours of the trachea are grouped with lung and
bronchus and tumours of the thymus are often grouped together
with those of the heart, mediastinum, and pleura.1 These tumour
types have a different aetiology. Cancer of the trachea is associated
with active and passive smoking, occupational exposure (to arsenic,
asbestos, chromium, welding fumes) and environmental exposure
(air pollution from traffic and industrial emissions).2 Its usually in-
sidious onset often leads to a delay in diagnosis, making these po-
tentially treatable lesions difficult to treat and often fatal. Thus, early
diagnosis is the most important factor affecting survival. Cigarette
smoking is the most important risk factor of lung cancer, including
its rare epithelial forms, together with occupational or environmen-
tal exposure to radon, asbestos, and heavy metals such as chromium,
cadmium, and arsenic.3 Adenosquamous carcinoma of the lung ex-
hibits highly aggressive biological behaviour with early lymph node
metastasis (46%) and its prognosis is worse than that of both squa-
mous cell carcinoma and adenocarcinoma.4 Large cell carcinomas
often occur in the outer regions of the lungs and tend to grow rap-
idly and spread more quickly than some other forms of non-small
cell lung cancer: they are more strongly associated with smoking
than some other types of non-small cell lung cancers.
Many autoimmune syndromes are associated with thymic epithe-
lial tumours (TETs); myasthenia gravis is the most common one,
followed by autoimmune pure red cell aplasia, hypogammaglob-
ulinaemia, and paraneoplastic autoimmune syndromes.5 According
to the 2004 World Health Organization classification, TETs are di-
vided into thymomas (Ts: A, A/B, B1, B2, B3 subtypes) and
thymic carcinomas (TCs: C) depending on cancer cell shape, de-
gree of atypia, and extent of intratumoural thymocytes.6 Available
data demonstrate a poor prognosis for lesions classified as B3 and
C, intermediate prognosis for B2, and favourable outcomes for A,
AB, and B1 tumours. Squamous, undifferentiated, and lymphoep-
ithelial carcinomas are not included among TETs, but are included
in the list of rare cancers proposed by RARECARE as separate en-
tities.1 All subtypes of malignant mesothelioma (MM) of the
pleura and pericardium are rare. In Italy, population-based regis-
tration of MM is carried out by the AIRTUM general cancer reg-
istries and by the Italian National Mesothelioma Registry (ReNaM)
(https://ricercascientifica.inail.it/renam/Index.asp). The main risk
factor of pleural MM is asbestos exposure. Other risk factors im-
plicated in the pathogenesis of MM are ionising radiation and ex-
posure to Thorotrast 9. Family clusters linked to the polymorphism
of the genes involved in the repair process of DNA11,12 seem to
make patients more vulnerable, still in the presence of asbestos ex-
posure.7 Pericardial mesothelioma cases have been associated with
chest radiation treatment.8 Microscopic diagnosis, which today has
standardised the immunohistochemical panel, recognises three
main subtypes of MM: epithelioid (more than half of the cases of
MM), sarcomatoid (a worse prognosis), and biphasic (both com-
ponents).
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
All cancers of the trachea are rare and overall only 374 cases were
observed in the AIRTUM database in 11 years (2000-2010).
Squamous cell carcinoma is the most common histotype (47%),
followed by adenocarcinoma. Salivary gland type tumours repre-
sent a particularly rare histological type (only 26 cases in the
period 2000-2010) (incidence table, p. 52). All histotypes are
more common in males than females and their incidence increases
with age, peaking in the 75-84-year age group (data not shown).
Approximately 110 Italians are estimated to be diagnosed with can-
cers of the trachea in 2015.
Rare epithelial tumours of the lung represent only 4% of all can-
cers of this site. Among the rare forms, large cell carcinoma is the
most common (71%), followed by adenosquamous carcinoma
(16%), sarcomatoid carcinoma (11%), and salivary gland type tu-
mours (2%). As in the case of the more frequent forms, even rare
epithelial tumours of the lung are more common in males and in-
crease with age (see table p. 52). Often the morphology of these
tumours is not well specified: the percentage of unspecified forms,
though reduced in the last few years, is still very high (29% of can-
cers of the lung; 35% in people >65 years old; data not shown).
This is important because it could lead to an underestimation of
the incidence of the rare epithelial cancer described here. In 2015,
1,699 new cases were estimated (see table p. 52).
Thymus cancers are all rare. Malignant thymoma is the most com-
mon form (76%), followed by squamous cell carcinoma (6%). Un-
differentiated carcinoma, lymphoepithelial carcinoma, and adeno-
carcinoma represent particularly rare histological types (only 9, 6,
and 7 cases were observed in the period 2000-2010, respectively).
Malignant thymoma is more frequent in males than females; in-
cidence peaks in the 65-74-year age group (data not shown).
Squamous cell carcinoma incidence is similar in males and females;
it has the highest incidence rate in the 60-69-year age group (data
not shown). Even in Europe these cancers are extremely rare. Ap-
proximately 230 Italians are estimated to be diagnosed with cancers
of the thymus in 2015.
The incidence of pleural and pericardial MM is higher in males than
in females and in the over 65 age group. In the period 2000-2010,
5,127 cases were observed in the AIRTUM dataset (see table p. 52).
The occurrence of MM showed an increasing trend in recent decades;
in Italy different models have predicted a peak in incidence between
2010 and 2020.9 All cancers of the thoracic cavity have a slightly
higher incidence in Italy than in Europe (RARECAREnet database,
www.rarecarenet.eu), except large cell carcinoma and salivary gland
type tumours of the lung.
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RARE EPITHELIAL TUMOURS
OF THE THORACIC CAVITY
Survival
Prognosis of patients diagnosed with an epithelial tumour of the
trachea is poor, with less than half of the patients surviving the first
year, and 12% alive 5 years after diagnosis. All histotypes share this
poor prognosis, except salivary gland type tumours (survival figure,
p. 52). In the AIRTUM database we do not have an appropriate
number of cases of salivary gland tumours to estimate 5-year rel-
ative survival (RS); however, according to the European
RARECAREnet database, it is 70%. Prognosis of patients with a
tracheal malignancy is poor, however, surgical treatment can lead
to good survival rates. Thus, the lower prognosis of these rare can-
cers is due to delay in diagnosis (due to its aspecific and asthma-
mimicking symptoms), advanced stage at diagnosis, and limited
experience among clinicians. Centralising the care and treatment
of tracheal cancers could make surgery accessible to a larger num-
ber of patients, leading to better survival of these patients.10 One-
year and 5-year RS of rare epithelial tumours of the lung is 47%
and 19%, respectively. Salivary gland type tumours have the high-
est 1- and 5-year RS (74% and 44%, respectively, see figure p. 52).
For these rare forms, as well as for the most common cancers of
the lung, no significant improvements in survival were reported
over the last decades.11 The worse prognosis of these cancers is
mainly due to the more advanced stage at diagnosis and advanced
age of the patients, which often condition radical surgery. For the
early forms, if well treated, survival is significantly higher than the
advanced forms.12,13 However, there is considerable heterogeneity
in the management of these patients, sometimes even in the same
region.14 Relative survival is rather good for patients diagnosed with
an epithelial tumour of the thymus, with a 1- year RS of 85% and
a 5-year RS of 68% (see figure p. 52). A combination of stage and
histologic subtype should be considered in predicting survival.
Types A, AB, and B1 have an excellent overall survival rate of be-
tween 90% and 95% at 10 years. Five-year RS for types B2, B3,
and C is 75%, 70%, and 48%, respectively. Thymomas rarely
metastasise, whereas TCs display a more aggressive phenotype, with
distant metastases in liver, lymph nodes, and bones.15 It is difficult
to trace a standard treatment for thymomas. Although thymomas
have a relatively good prognosis, they include a heterogeneous
group of histologies, with different prognosis and for which there
are no clear guidelines; so even for thymoma it would be appro-
priate to support a network that brings together experts to define
common guidelines for better treatment. In France there is a na-
tional initiative named RYTHMIC, Réseau tumeurs THYmiques
et Cancer (www.rythmic.org); in Italy, a network for thymic ma-
lignancies, TYME (TYmic MalignanciEs), was launched by the
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, in
2014. One-year and 5-year RS of pleural and pericardial MM is
50% and 7%, respectively (see figure p. 52). Tools for early diag-
nosis and effective screening programs regarding MM are not
available. Chest radiography and computer tomography (CT)
were evaluated as ineffective in screening for MM in asbestos-ex-
posed workers.16,17 For pleural MM an optimal strategy is far
from being standardised. Management of this disease requires a
multidisciplinary team and it is recommended that patients who
are considered candidates for a multimodal approach be included
in a prospective trial at a specialised centre. 
Among rare epithelial tumours of the thoracic cavity, squamous cell
carcinoma of the thymus and mesothelioma of the pleura and peri-
cardium show the most important differences between 1- year and
5-year RS (46 and 43 points, respectively).
Italian data and European RARECAREnet data are similar for all
these tumours, except for pleural MM which has slightly higher
survival in Italy than in Europe.
Prevalence
About 10,000 persons were estimated alive in 2010 with a diagnosis
of rare epithelial tumours of the thoracic cavity in Italy. Most prevalent
cases are patients with a previous diagnosis of large cell carcinomas of
the lung, mainly because of the relatively high incidence of these tu-
mours compared to the others. The distribution of prevalence by time
since diagnosis is fairly similar for the different types of tumours, ex-
cept for those with poor prognosis (large cell carcinoma and sarcoma-
toid carcinoma of lung and mesothelioma of pleura and pericardium),
that show a higher proportion of prevalent cases in the two years just
after diagnosis.
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RARE TUMOURS 18.55 18.37-18.73 41 141 17% 0.08 0.07-0.10 35.86 35.52-36.21 8.12 7.98-8.27 30.77 30.12-31.44 46.70 46.06-47.34 11 970
OF THE FEMALE GENITAL SYSTEM
RARE EPITHELIAL TUMOURS OF BREAST 4.75 4.65-4.84 10 522 6% 0.08 0.06-0.10 9.12 8.94-9.29 1.94 1.87-2.01 7.77 7.45-8.11 12.47 12.14-12.80 3 093
Mammary Paget’s disease of breast 0.43 0.41-0.46 963 0.01 0.01-0.02 0.83 0.78-0.88 0.16 0.14-0.18 0.72 0.63-0.83 1.21 1.11-1.32 283
Special types of adenocarcinoma of breast 4.12 4.04-4.21 9 138 0.06 0.05-0.08 7.92 7.76-8.09 1.70 1.64-1.77 6.75 6.44-7.06 10.77 10.47-11.09 2 687
Metaplastic carcinoma of breast 0.12 0.10-0.13 256 0.00 0.00-0.01 0.22 0.20-0.25 0.05 0.04-0.06 0.17 0.12-0.23 0.30 0.25-0.36 75
Salivary gland type tumours of breast 0.07 0.06-0.09 165 0.00 0.00-0.01 0.14 0.12-0.17 0.03 0.02-0.04 0.14 0.10-0.19 0.18 0.14-0.22 48
RARE EPITHELIAL TUMOURS OF CORPUS UTERI 0.86 0.82-0.90 1 907 7% 1.67 1.59-1.74 0.11 0.10-0.13 1.65 1.50-1.81 2.93 2.77-3.10 553
Squamous cell carcinoma with variants of corpus uteri 0.10 0.09-0.11 222 0.19 0.17-0.22 0.03 0.02-0.04 0.22 0.16-0.28 0.27 0.23-0.33 65
Adenoid cystic carcinoma of corpus uteri <0.01 0.00-0.01 1 NE – NE – NE – NE – 0
Clear cell adenocarcinoma, NOS of corpus uteri 0.15 0.13-0.16 327 0.29 0.26-0.32 0.02 0.02-0.03 0.23 0.18-0.30 0.51 0.45-0.59 94
Serous (papillary) carcinoma of corpus uteri 0.20 0.18-0.22 447 0.39 0.36-0.43 0.01 0.01-0.02 0.43 0.35-0.51 0.72 0.64-0.80 129
Mullerian mixed tumours of corpus uteri 0.41 0.38-0.44 910 0.79 0.74-0.85 0.05 0.04-0.06 0.77 0.67-0.89 1.42 1.31-1.54 264
EPITHELIAL TUMOURS OF CERVIX UTERI 3.94 3.85-4.02 8 726 90% 7.62 7.46-7.78 2.80 2.72-2.89 5.88 5.59-6.17 6.61 6.37-6.85 2 499
Squamous cell carcinoma with variants of cervix uteri 3.13 3.05-3.20 6 932 6.06 5.91-6.20 2.24 2.16-2.32 4.68 4.42-4.94 5.20 4.99-5.42 1 987
Adenocarcinoma with variants of cervix uteri 0.78 0.74-0.81 1 721 1.50 1.43-1.58 0.55 0.51-0.59 1.17 1.04-1.30 1.31 1.20-1.42 491
Undifferentiated carcinoma of cervix uteri 0.02 0.02-0.03 47 0.04 0.03-0.05 0.01 0.01-0.02 0.03 0.01-0.06 0.05 0.03-0.08 14
Mullerian mixed tumours of cervix uteri 0.01 0.01-0.02 26 0.02 0.01-0.03 <0.01 0.00-0.01 <0.01 0.00-0.02 0.05 0.03-0.07 8
EPITHELIAL TUMOURS OF OVARY 6.68 6.58-6.79 14 819 65% 12.94 12.74-13.15 2.78 2.69-2.86 13.28 12.85-13.72 15.97 15.60-16.35 4 283
AND FALLOPPIAN TUBE
Adenocarcinoma with variants of ovary 5.53 5.43-5.63 12 261 10.71 10.52-10.90 2.25 2.17-2.32 11.11 10.72-11.52 13.30 12.96-13.65 3 550
Mucinous adenocarcinoma of ovary 0.60 0.57-0.63 1 326 1.16 1.10-1.22 0.31 0.28-0.34 0.94 0.83-1.07 1.37 1.26-1.48 380
Clear cell adenocarcinoma of ovary 0.25 0.23-0.28 565 0.49 0.45-0.54 0.14 0.13-0.16 0.61 0.52-0.71 0.41 0.36-0.48 163
Primary peritoneal serous/papillary carcinoma of ovary 0.05 0.04-0.06 115 0.10 0.08-0.12 0.02 0.01-0.02 0.08 0.05-0.13 0.16 0.13-0.20 33
Mullerian mixed tumours of ovary 0.10 0.09-0.12 231 0.20 0.18-0.23 0.02 0.01-0.03 0.23 0.18-0.30 0.32 0.27-0.38 66
Adenocarcinoma with variants of falloppian tube 0.14 0.13-0.16 321 0.28 0.25-0.31 0.04 0.03-0.05 0.30 0.24-0.37 0.40 0.35-0.47 91
NON EPITHELIAL TUMOURS OF OVARY 0.19 0.17-0.21 424 2% 0.37 0.34-0.41 0.21 0.19-0.24 0.17 0.12-0.22 0.14 0.11-0.18 115
Sex cord tumours of ovary 0.07 0.06-0.08 155 0.14 0.11-0.16 0.05 0.04-0.06 0.14 0.10-0.19 0.10 0.07-0.14 45
Malignant/Immature teratomas of ovary 0.05 0.04-0.05 100 0.09 0.07-0.11 0.06 0.05-0.07 0.01 0.00-0.04 0.02 0.01-0.04 26
Germ cell tumours of ovary 0.08 0.07-0.09 169 0.15 0.13-0.17 0.11 0.09-0.12 0.01 0.00-0.03 0.01 0.01-0.03 44
EPITHELIAL TUMOURS OF VULVA AND VAGINA 2.12 2.06-2.18 4 697 95% 4.10 3.99-4.22 0.25 0.22-0.27 2.03 1.86-2.20 8.59 8.31-8.86 1 414
Squamous cell carcinoma with variants of vulva 1.77 1.71-1.82 3 921 3.43 3.32-3.53 0.19 0.17-0.22 1.63 1.48-1.79 7.24 6.99-7.50 1 176
and vagina
Adenocarcinoma with variants of vulva and vagina 0.06 0.05-0.08 142 0.12 0.10-0.15 0.02 0.01-0.03 0.08 0.05-0.13 0.21 0.17-0.25 42
Paget's disease of vulva and vagina 0.09 0.08-0.10 202 0.18 0.15-0.20 0.01 0.01-0.02 0.15 0.10-0.20 0.33 0.27-0.38 58
Undifferentiated carcinoma of vulva and vagina 0.01 0.00-0.01 16 0.01 0.01-0.02 <0.01 0.00-0.00 0.01 0.00-0.03 0.03 0.02-0.05 5
TROPHOBLASTIC TUMOURS OF PLACENTA 0.02 0.02-0.03 46 82% 0.04 0.03-0.05 0.03 0.02-0.04 <0.01 0.00-0.02 <0.01 0.00-0.01 12
Choriocarcinoma of placenta 0.02 0.01-0.03 45 0.04 0.03-0.05 0.03 0.02-0.04 <0.01 0.00-0.02 <0.01 0.00-0.01 12
EPITHELIAL TUMOURS OF MALE BREAST 1 604 100% 1.50 1.42-1.57 0.31 0.27-0.35 2.63 2.36-2.93 5.65 5.31-6.00 246
NE: not estimable because 15 or less incident cases were observed     NOS: not otherwise specified
INCIDENCE
RARE TUMOURS OF THE FEMALE GENITAL SYSTEM. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI),
observed cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases
at 2015 in Italy.
I tumori in Italia • Rapporto AIRTUM 2015
Epidemiol Prev 40 (1) Suppl 2:1-120  Ulteriori dati disponibili sul sito: www.registri-tumori.it57
RATE 95% CI RATE 95% CI RATE 95% CI RATE 95% CI RATE 95% CI RATE 95% CI
O
BS
ER
VE
D
 C
A
SE
S
(N
o.
)
RA
RE
 C
A
N
CE
RS
BY
 S
IT
E 
(%
)
AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
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ITALY
100%80%60%40%20%0%
RARE TUMOURS OF THE FEMALE GENITAL SYSTEM 34 228
RARE EPITHELIAL TUMOURS OF BREAST 8 657
Mammary Paget’s disease of breast 810
Special types of adenocarcinoma of breast 7 503
Metaplastic carcinoma of breast 206
Salivary gland type tumours of breast 138
RARE EPITHELIAL TUMOURS OF CORPUS UTERI 1 567
Squamous cell carcinoma with variants of corpus uteri 186
Adenoid cystic carcinoma of corpus uteri 1 NE
Clear cell adenocarcinoma, NOS of corpus uteri 281
Serous (papillary) carcinoma of corpus uteri 330
Mullerian mixed tumours of corpus uteri 769
EPITHELIAL TUMOURS OF CERVIX UTERI 7 360
Squamous cell carcinoma with variants of cervix uteri 5 906
Adenocarcinoma with variants of cervix uteri 1 397
Undifferentiated carcinoma of cervix uteri 45
Mullerian mixed tumours of cervix uteri 23 NE
EPITHELIAL TUMOURS OF OVARY AND FALLOPPIAN TUBE 12 426
Adenocarcinoma with variants of ovary 10 313
Mucinous adenocarcinoma of ovary 1 115
Clear cell adenocarcinoma of ovary 458
Primary peritoneal serous/papillary carcinoma of ovary 99
Mullerian mixed tumours of ovary 190
Adenocarcinoma with variants of falloppian tube 261
NON EPITHELIAL TUMOURS OF OVARY 350
Sex cord tumours of ovary 135
Malignant/Immature teratomas of ovary 81
Germ cell tumours of ovary 134
EPITHELIAL TUMOURS OF VULVA AND VAGINA 3 929
Squamous cell carcinoma with variants of vulva and vagina 3 305
Adenocarcinoma with variants of vulva and vagina 126
Paget's disease of vulva and vagina 172
Undifferentiated carcinoma of vulva and vagina 15 NE
TROPHOBLASTIC TUMOURS OF PLACENTA 37
Choriocarcinoma of placenta 36
EPITHELIAL TUMOURS OF MALE BREAST 1 345
NE: not estimable because 30 or less incident cases were observed   NOS: not otherwise specified
RARE TUMOURS OF THE FEMALE GENITAL SYSTEM. One and 5-year relative survival. Error bars are 95% confidence interval. Cohort
approach (complete analysis), period of diagnosis 2000-2008.
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No. OF CASES 
INCLUDED 
IN THE ANALYSIS
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
RARE TUMOURS OF THE FEMALE GENITAL SYSTEM 34.26 33.04-35.51 39.74 38.42-41.08 161.23 158.58-163.92 264.54 259.45-269.62 154 397
RARE EPITHELIAL TUMOURS OF BREAST 10.58 9.90-11.28 14.46 13.67-15.28 58.22 56.63-59.84 80.24 77.60-82.89 46 858
Mammary Paget’s disease of breast 0.94 0.75-1.17 1.25 1.03-1.51 4.78 4.33-5.26 6.81 6.14-7.49 3 961
Special types of adenocarcinoma of breast 9.29 8.66-9.95 12.84 12.10-13.62 51.48 49.98-53.01 70.99 68.46-73.52 41 472
Metaplastic carcinoma of breast 0.23 0.14-0.35 0.20 0.11-0.31 0.74 0.57-0.95 1.02 0.76-1.27 595
Salivary gland type tumours of breast 0.11 0.06-0.21 0.17 0.10-0.28 1.22 1.00-1.47 1.42 1.14-1.71 830
RARE EPITHELIAL TUMOURS OF CORPUS UTERI 1.63 1.37-1.92 1.25 1.03-1.51 4.92 4.47-5.41 6.45 5.78-7.12 3 742
Squamous cell carcinoma with variants of corpus uteri 0.13 0.06-0.23 0.18 0.11-0.30 0.67 0.51-0.86 1.12 0.82-1.42 643
Adenoid cystic carcinoma of corpus uteri NE – NE – 0.01 0.00-0.06 0.08 0.00-0.33 46
Clear cell adenocarcinoma, NOS of corpus uteri 0.36 0.24-0.51 0.30 0.20-0.44 1.11 0.90-1.36 1.38 1.10-1.65 821
Serous (papillary) carcinoma of corpus uteri 0.31 0.20-0.45 0.29 0.19-0.42 0.77 0.59-0.97 0.80 0.61-1.00 460
Mullerian mixed tumours of corpus uteri 0.84 0.65-1.05 0.48 0.35-0.65 2.36 2.05-2.71 3.07 2.64-3.50 1 772
EPITHELIAL TUMOURS OF CERVIX UTERI 6.98 6.43-7.55 8.59 7.99-9.23 40.14 38.82-41.50 92.32 88.80-95.84 53 952
Squamous cell carcinoma with variants of cervix uteri 5.52 5.04-6.04 7.16 6.61-7.74 33.33 32.13-34.57 76.94 73.72-80.16 44 975
Adenocarcinoma with variants of cervix uteri 1.43 1.19-1.71 1.43 1.19-1.71 6.77 6.24-7.34 15.12 13.71-16.53 8 819
Undifferentiated carcinoma of cervix uteri NE – 0.02 0.00-0.08 0.07 0.03-0.16 0.20 0.04-0.37 117
Mullerian mixed tumours of cervix uteri 0.02 0.00-0.08 0.01 0.00-0.06 0.05 0.01-0.12 0.06 0.00-0.12 41
EPITHELIAL TUMOURS OF OVARY AND FALLOPPIAN TUBE 11.56 10.86-12.30 11.39 10.69-12.12 42.61 41.25-44.01 61.30 59.24-63.36 35 633
Adenocarcinoma with variants of ovary 9.50 8.86-10.17 9.20 8.58-9.86 33.32 32.12-34.56 45.94 44.21-47.66 26 690
Mucinous adenocarcinoma of ovary 1.08 0.87-1.32 1.09 0.88-1.33 5.68 5.19-6.21 10.56 9.57-11.55 6 157
Clear cell adenocarcinoma of ovary 0.39 0.27-0.55 0.54 0.40-0.72 1.94 1.66-2.25 2.59 2.19-2.99 1 497
Primary peritoneal serous/papillary carcinoma of ovary 0.11 0.06-0.21 0.13 0.06-0.23 0.26 0.17-0.40 0.27 0.16-0.38 159
Mullerian mixed tumours of ovary 0.17 0.10-0.28 0.16 0.09-0.27 0.42 0.30-0.58 0.62 0.41-0.82 357
Adenocarcinoma with variants of falloppian tube 0.31 0.20-0.45 0.28 0.18-0.41 0.99 0.79-1.22 1.34 1.05-1.62 774
NON EPITHELIAL TUMOURS OF OVARY 0.44 0.31-0.60 0.45 0.32-0.61 2.38 2.06-2.72 5.04 4.31-5.77 2 970
Sex cord tumours of ovary 0.21 0.12-0.33 0.17 0.10-0.28 0.95 0.76-1.18 1.32 1.03-1.61 787
Malignant/Immature teratomas of ovary 0.08 0.03-0.17 0.10 0.05-0.20 0.40 0.28-0.56 0.98 0.61-1.35 590
Germ cell tumours of ovary 0.15 0.08-0.25 0.17 0.10-0.28 1.02 0.82-1.26 2.74 1.92-3.56 1 595
EPITHELIAL TUMOURS OF VULVA AND VAGINA 3.13 2.76-3.52 3.63 3.24-4.05 13.27 12.52-14.06 18.62 17.54-19.70 10 906
Squamous cell carcinoma with variants of vulva and vagina 2.77 2.43-3.14 3.18 2.82-3.58 11.38 10.69-12.11 16.44 15.41-17.47 9 645
Adenocarcinoma with variants of vulva and vagina 0.05 0.01-0.12 0.09 0.04-0.18 0.41 0.28-0.57 0.56 0.37-0.74 329
Paget's disease of vulva and vagina 0.15 0.08-0.26 0.20 0.11-0.31 0.83 0.65-1.04 0.95 0.72-1.17 546
Undifferentiated carcinoma of vulva and vagina NE – NE – 0.01 0.00-0.06 0.01 0.00-0.04 8
TROPHOBLASTIC TUMOURS OF PLACENTA 0.02 0.00-0.08 0.09 0.04-0.18 0.26 0.17-0.40 0.56 0.28-0.83 335
Choriocarcinoma of placenta 0.02 0.00-0.08 0.09 0.04-0.18 0.26 0.17-0.40 0.56 0.28-0.83 335
EPITHELIAL TUMOURS OF MALE BREAST 3.11 2.60-3.69 3.58 3.03-4.20 12.94 11.87-14.07 15.41 14.11-16.71 4 334
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE
NOS: not otherwise specified
PREVALENCE
RARE TUMOURS OF THE FEMALE GENITAL SYSTEM.Observed prevalence (proportion per 100,00 and 95% confidence
interval - 95% CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete prevalence. Esti-
mated prevalent cases in 2010 in Italy.
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This group includes heterogeneous invasive cancers with different
behaviour and prognosis:
 rare epithelial breast cancers of females
(mammary Paget’s disease, special types of adenocarcinoma of
breast, metaplastic carcinoma of breast, salivary gland type tu-
mours of breast);
 epithelial breast cancers of males 
(all histotypes are rare, including ductal and lobular carcinomas);
 rare epithelial tumours of corpus and cervix uteri
(squamous cell carcinoma of cervix and corpus uteri; 
Mullerian mixed tumour of cervix and corpus uteri;
clear cell adenocarcinoma; NOS of corpus uteri;
serous/papillary carcinoma of corpus uteri; adenoid cystic
carcinoma of corpus uteri; adenocarcinoma with variants
of cervix uteri and undifferentiated carcinoma of cervix uteri);
 epithelial tumours of ovary and falloppian tubes
(adenocarcinoma with variants of ovary, mucinous adenocarci-
noma of ovary, clear cell adenocarcinoma of ovary, primary peri-
toneal serous/papillary carcinoma of ovary, MMMT of ovary,
and adenocarcinoma with variants of the fallopian tubes);
 non epithelial tumours of ovary and falloppian tubes
(sex cord, germ cell tumours, and immature teratomas);
 epithelial tumours of vulva and vagina (squamous cell 
carcinoma with variants of vulva and vagina, adenocarcinoma
with variants of vulva and vagina, and Paget’s disease of vulva 
and vagina);
 trophoblastic placenta tumours.
With a number of 41,141 incident cases (in the period 2000-
2010), rare cancers represent 17% of all female genital system can-
cers, corresponding to about 12,000 new cases per year in Italy
(incidence table, p. 57). It must be noted that, as reported in the
«Materials and methods» chapter (pp. 14-21), rates are provided
for both sexes with the exception of male breast cancer. In any
case, sex-specific incidence rates are provided in the incidence
table.
RARE EPITHELIAL BREAST CANCERS
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Mammary Paget’s disease (PD) occurs almost exclusively in
women. The typical pathologic finding is represented by Paget cells
within the epidermis of the nipple.1
Special types of adenocarcinoma of the breast are a mixture of dif-
ferent types (tubular, mucinous, medullary, papillary, secretory,
glycogen-rich clear cell, lipid-rich and oncocytic carcinoma).
Metaplastic carcinoma of the breast: part or all of the carcinoma-
tous epithelium is transformed into a nonglandular (metaplastic)
growing tissue; these tumours are often clinically palpable, large,
and appear well circumscribed. Metaplastic carcinomas are mainly
negative for oestrogen and progesterone receptors and for
HER2/neu overexpression.2
Salivary gland type tumour of the breast is a very rare histological
type including adenoid cystic carcinoma, mucoepidermoid carci-
noma, acinic cell carcinoma, and polymorphous low-grade adeno-
carcinoma; a high percentage of triple negative breast cancer is re-
ported, too.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Rare epithelial breast cancers (10,522 cases) account for 26% of
rare cancers of the female genital system, but only 6% of breast
cancer. Special types of adenocarcinoma are the most common
(87%), followed by mammary PD (9%), metaplastic carcinoma
(2%), and salivary gland type tumours (2%). Distribution of the
different types is similar to that observed in the European data
from RARECAREnet (www.rarecarenet.eu), except for special
types of adenocarcinoma, showing a slightly higher rate in Italy
than in Europe (4% vs. 3%, respectively). More than 50% (5,425)
of cases involves subjects aged over 65 years, with the highest rate
in the 80-84 age class (24.5 per 100,000, data not shown).
In males, all breast tumours are rare and have a sex-specific IR of
1.5 per 100,000. The age trend is similar to that observed for fe-
males (see table p. 57). Approximately 3,500 Italians were estimated
to be diagnosed with a rare cancer of the breast in 2015; of these
250 were males.
Survival
Five-year relative survival (RS) for rare female breast cancer is rel-
atively high and varies from 88% for mammary PD to 72% for
metaplastic carcinoma (survival figure, p. 58). Lower prognosis of
metaplastic carcinoma is due to more advanced stage at diagnosis
and the high percentage of “triple negative” subtypes.3 One-year
RS is similar to 5-year RS except for mammary PD and metaplastic
tumours. Rare epithelial cancers of the breast have a similar prog-
nosis to the more common ductal and lobular invasive carcinomas
of the breast (85% at 5 years in European RARECAREnet data).
Prognosis is worse in males than in females, probably because of
the different biological patterns in males compared to females.4
This result highlights the need for new treatment protocols for
these specific cancers.
Prevalence
Around 47,000 persons were estimated to be alive in 2010 with a past
diagnosis of one of these rare epithelial tumours of the breast in Italy.
RARE EPITHELIAL TUMOURS
OF CORPUS AND CERVIX UTERI
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Squamous cell carcinoma with variants of corpus and cervix
uteri include different types of cancers (papillary squamous cell car-
cinoma, squamous cell carcinoma NOS, keratinizing and nonker-
atinizing squamous cell carcinoma, spindle cell squamous cell
carcinoma, lymphoepithelial carcinoma) and is more frequent in
the cervix than in the corpus uteri. Based on histopathology, mo-
lecular profile and clinical course of endometrial cancers are di-
vided into two categories.
Uterine clear-cell carcinoma (UCC) is a type II endometrial
cancer (not hormone dependent and usually grade III endometri-
oid adenocarcinomas, papillary serous and clear cell carcinomas
and carcinosarcomas, or malignant mixed Mullerian tumours)
and it typically occurs in older patients, as it is not hormone de-
pendent. These tumours are generally more aggressive and have a
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worse prognosis than type I endometrial cancer (typically low-
grade (I-II) adenocarcinomas that are usually oestrogen related, di-
agnosed early, and with a favourable prognosis) and usually display
p53 mutations.5
Serous (papillary) carcinoma of corpus uteri (USC) is charac-
terised by nipple-shaped structures (papillae) with fibrovascular
cores, marked nuclear atypia, psammoma bodies, and cilia. It has
been associated with women of African-American ethnicity, tamox-
ifen use, and BRCA gene mutations.6 About 60% of USCs over-
express the HER2/neu protein, showing some benefits with
trastuzumab (Herceptin) treatment.7
Malignant mixed Mullerian tumour (MMMT) of the uterine cor-
pus and cervix is an extremely rare and aggressive malignancy with
a dedifferentiated or metaplastic form containing both carcinoma-
tous and sarcomatous components, affecting postmenopausal
women. Risk factors for the development of MMMT are similar
to those of endometrial carcinoma and include nulliparity, ad-
vanced age, obesity, exposure to exogenous estrogens, pelvic irra-
diation, and long-term use of tamoxifen.4
Adenocarcinoma of the cervix is a mixture of different cancer types
(adenocarcinoma NOS, adenocarcinoma with squamous metapla-
sia, mucinous, clear cell, or endometrioid adenocarcinoma, serous
cystadenocarcinoma, signet ring cell, mesonephroma, villous, in-
testinal type and mixed cell adenocarcinoma) showing an incidence
increase over time, probably attributable to cervix screening imple-
mentation. The causal role of human papillomavirus (HPV) in all
cancers of the uterine cervix has been firmly established both bi-
ologically and epidemiologically. The status of current tobacco
smoking is associated with an increased risk of squamous cell
adenocarcinoma but not of adenocarcinoma in the cervix. No dif-
ferences between the two most common histological types of in-
vasive cervical cancer with respect to the role of number of sexual
partners, age at first intercourse, age at first birth, body mass
index, or use of oral contraceptives were observed.9
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
In the cervix, squamous carcinoma represents 79% of epithelial tu-
mours, followed by adenocarcinoma (20%) (see table p. 57). The
other histotypes are very rare. In the corpus uteri, MMMT are the
most common (48%) followed by USC (23%), UCC (17%),
and squamous cell carcinoma (12%). The other histotypes are very
rare. The same distribution is reported in the European
RARECAREnet data. Rare epithelial cancers of corpus uteri are
typical of elderly, with the highest incidence rate in the 80-84 age
class (3.6 per 100,000, data not shown). Epithelial cancers of cervix
uteri show a bimodal distribution with two peaks: one in the per-
imenopausal age group 45-49 years (6.1 per 100,000, data not
shown) and the other in the 80-84-year age group (8.1 per
100,000, data not shown). Approximately 3,000 Italians were es-
timated to be diagnosed with rare cancers of the uterus in 2015.
Survival
One-year and 5-year RS of cervix uteri cancer are 89% and 69%,
respectively. These results are mainly due to squamous cell carci-
noma and adenocarcinoma of cervix uteri (see figure p. 58). The
RS of undifferentiated carcinomas is much lower at both 1 and 5
years after diagnosis: 59% and 43%, respectively (based on 45
cases). It is not possible to provide an RS of MMMT because of
the few cases available for analysis. However, in RARECAREnet
data, 5-year RS is 34%. The RS of corpus uteri cancer is 78% at
1 year, but goes down to 46% at 5 years. This pattern is constant
for all histotypes. After 5 years from diagnosis the RS is highest for
UCC (61%), followed by squamous cell carcinoma (54%), USC,
and MMMT (40%) (see figure p. 58). The results are coherent
with European RARECAREnet data. Adenoid cystic carcinoma of
the corpus uteri is so rare that no data are available in Italy and Eu-
rope. The availability of improved genetic and/or pathological
characterisation by specialized laboratories could improve the
prognosis of these rare tumours, enabling the development of
specific therapeutic protocols.
Prevalence
Around 54,000 persons were estimated to be alive in 2010 with a past
diagnosis of epithelial tumours of the cervix (43% survived more than
15 years from diagnosis) and around 4,000 with a diagnosis of rare ep-
ithelial tumours of the corpus uteri (76% survived more than 15 years
from diagnosis).
EPITHELIAL TUMOURS OF OVARY AN FALLOPPIAN TUBES
AND NON EPITHELIAL TUMOURS OF OVARY
The list of rare cancers separate epithelial and non epithelial tu-
mours. Thus, this group includes epithelial tumours of the ovary
and fallopian tubes and non epithelial tumours of the ovary.
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Epithelial ovarian cancers (EOC) are a heterogeneous group of tu-
mours. To explain this heterogeneity a new classification is used
distinguishing type I and type II ovarian carcinoma. Type I in-
cludes low-grade carcinomas, frequently diagnosed in early stages,
with indolent behaviour. Type II includes high-grade carcinomas,
diagnosed in advanced stages, and characterised by genomic insta-
bility. Recent evidence suggests that the different histotypes of ep-
ithelial ovarian cancers originate from three different sites (fimbria,
endometrial tissue, and tubal-mesothelium junction), while serous
ovarian cancer originates from the fallopian tubes.10 New prom-
ising molecular targeted drugs are bevacizumab (monoclonal an-
tibody directed against VEGF) and PARP inhibitor.11
MMMT of the ovary is an exceedingly rare cancer, accounting for
1% to 3% of ovarian malignancies. These tumours are carcinosar-
coma characterised by malignant epithelial and stromal elements.
MMMTs are very aggressive tumours usually diagnosed at an
older age and at advanced stages.12 MMMT diagnosis is difficult;
there are no useful biochemical markers and diagnostic imaging
methods do not provide specific data.13
Sex cord tumours of the ovary include malignant granulosa cell
tumour, Sertoli-Leydig cell tumour, poorly differentiated and ma-
lignant steroid cell tumour, which show areas with unequivocal go-
nadal stromal differentiation.14
Ovarian germ cell tumours (OGCT) include several types of
cancer (dysgerminoma/seminoma, yolk sac tumour, mixed germ
cell tumour, embryonal adenocarcinoma, choriocarcinoma, and
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polyembryoma). Most OGCTs are benign, unilateral with the ex-
ception of dysgerminomas, are usually diagnosed at stage I, and are
responsive to chemotherapy. Several reports suggest a genetic sus-
ceptibility.15
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
The risk for EOCs increases with age: the highest incidence rate
(IR) occurs in postmenopausal women, with 47% of all cases di-
agnosed in patients older than 65 years (data not shown). Adeno-
carcinoma of the ovary is the most common histotype, with
12,261 incident cases in the period 2000-2010, followed by mu-
cinous adenocarcinoma, clear cell adenocarcinoma, and MMMT
(see table p. 57). Primary peritoneal serous/papillary carcinoma of
the ovary is very rare (115 cases in 11 years). The relative frequency
of histological variants observed in the Italian database is similar
to the one documented by RARECAREnet. Fallopian tube in-
cludes all rare cancers and it is rare per se.
Non EOCs typically affect young people, with a peak of incidence
in the 15-19 age group (0.47 per 100,000 data not shown).
OGCT represents the most frequent subtype (40%), although Eu-
ropean RARECAREnet data showed a higher frequency of sex cord
tumours of the ovary (50%) compared to OGCT. Around 4,500
Italians were estimated to be diagnosed with rare cancers of the
ovary in 2015. 
Survival
EOC 1- and 5-year RS is 82% and 46%. All epithelial tumours
of the ovary have a poor prognosis, with a 5-year RS ranging from
62% for clear cell adenocarcinoma to 25% for MMMT. This is
probably due to the fact that the majority of these tumours are ag-
gressive and become symptomatic at advanced stage. The Italian
database shows better RS for EOC than European RARECAREnet
data (70% and 37% at 1 and 5 years, respectively).
Non EOC has better prognosis than EOC, probably attributable
to young age and early-stage at diagnosis and to the fact that the
majority of these tumours are germ cell tumours, which are among
the most curable diseases (see figure p. 58).
Prevalence
Around 35,000 persons were estimated to be alive in 2010 with a past
diagnosis of EOC; 30% survived more than 15 years from diagnosis.
Most prevalent cases were adenocarcinomas, mainly because of their
relatively higher incidence compared to the other histotypes.
Around 3,000 persons were estimated to be alive with a diagnosis of
Non EOC; 53% survived more than 15 years from diagnosis, coher-
ently with young age at diagnosis and prognosis (prevalence table, p.
59).
EPITHELIAL TUMOURS OF VULVA AND VAGINA
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Squamous cell carcinoma originates from epidermal squamous
cells. 
Vulvar adenocarcinoma most often originates from cells of the
Bartholin glands, although it is often very difficult to identify the
site of origin.16
Vaginal adenocarcinoma arises from the glandular (secretory)
cells in the lining of the vagina. Clear cell adenocarcinoma is as-
sociated with in utero exposure to diethylstilbestrol (DES). The
peak of incidence of DES-associated adenocarcinoma is at young
ages (less than 30 years), otherwise these tumours occur primarily
in post menopause. Human papillomavirus (HPV) infection in as-
sociated to development of vulvar and vaginal cancers.17
Paget’s disease of vulva and vagina is an uncommon cancer char-
acterised by a chronic eczema-like rash of the skin around the
anogenital regions. It microscopically looks like mammary Paget’s
disease and is predominantly an intraepithelial lesion, even though
it may be associated with an underlying invasive adenocarci-
noma.18
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Vulvar and vaginal cancers most commonly occur in people over
65 years old, with adenocarcinomas occurring a decade earlier than
squamous cancers (see table p. 57). Squamous cell carcinomas are
the most common histotype in Italy (83%) and Europe
(RARECAREnet database 85%). Paget’s disease is typical of older
people (>70 years of age) (data not shown). About 1,500 rare ep-
ithelial tumours of the vulva and vagina are estimated to occur dur-
ing 2015 in Italy; few cases (4%) are Paget’s disease (see table p. 57).
Survival
One- and 5-year RS is 79% and 56%, respectively. Adenocarci-
noma has the worse outcomes (67% and 45% RS at 1 and 5 years,
respectively) (see figure p. 58). The number of cases of undiffer-
entiated carcinomas is too low to estimate survival; however, ac-
cording to the RARECAREnet data, 5-year RS is 26% (based on
85 cases). Five-year RS of Paget’s disease is very good (91%),
most likely because it is not aggressive. Italian and European
RARECAREnet data are the same.
Prevalence
In Italy, around 11,000 persons were estimated to be alive in 2010
with a past diagnosis of epithelial tumours of vulva and vagina, and
72% were still alive more than 15 years after diagnosis. The most
prevalent were squamous cell carcinomas because of the relatively high
incidence and survival (see table p. 59).
TROPHOBLASTIC TUMOURS OF PLACENTA
Trophoblastic tumours of placenta (TTP) are very rare. There were
only 46 cases in 11 years (2000-2010) in Italy (see table p. 57).
These tumours are highly curable malignancies arising in relation
to pregnancy. Treatment of TTP is a success story in medical on-
cology. When treated by surgery alone, the cure rate is only 40%.19
With the use of chemotherapeutic agents, outcome becomes excel-
lent for more than 98% of women.20 Survival in Italy is 94%
(based on 34 cases), whereas according to RARECAREnet, which
has a higher number of cases to base an estimate on, it is 89%. 
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RARE EPITHELIAL TUMOURS 2.88 2.81-2.95 6 394 6% 4.17 4.05-4.29 1.68 1.60-1.75 0.34 0.31-0.37 4.09 3.86-4.34 10.84 10.54-11.15 1 948
OF THE URINARY SYSTEM
RARE EPITHELIAL TUMOURS OF KIDNEY 0.06 0.05-0.07 132 0.04% 0.09 0.07-0.11 0.03 0.02-0.04 0.02 0.01-0.02 0.10 0.07-0.15 0.18 0.14-0.23 39
Squamous cell carcinoma spindle cell type of kidney 0.02 0.02-0.03 50 0.03 0.02-0.05 0.01 0.01-0.02 <0.01 0.00-0.01 0.04 0.02-0.08 0.06 0.04-0.09 15
Squamous cell carcinoma with variants of kidney 0.04 0.03-0.05 82 0.06 0.04-0.07 0.02 0.01-0.03 <0.01 0.00-0.01 0.06 0.03-0.10 0.12 0.09-0.16 25
EPITHELIAL TUMOURS OF PELVIS AND URETER 2.07 2.01-2.14 4 600 99% 2.94 2.84-3.05 1.26 1.20-1.33 0.22 0.20-0.25 3.00 2.80-3.21 7.84 7.58-8.10 1 394
Transitional cell carcinoma of pelvis and ureter 1.80 1.74-1.86 3 989 2.57 2.47-2.66 1.08 1.02-1.14 0.19 0.17-0.22 2.67 2.48-2.88 6.75 6.51-7.00 1 200
Squamous cell carcinoma with variants of pelvis 0.02 0.02-0.03 50 0.02 0.02-0.03 0.02 0.01-0.03 <0.01 0.00-0.01 0.02 0.01-0.05 0.09 0.07-0.13 15
and ureter
Adenocarcinoma with variants of pelvis and ureter 0.04 0.03-0.05 83 0.06 0.04-0.07 0.02 0.01-0.03 <0.01 0.00-0.01 0.08 0.05-0.12 0.12 0.09-0.16 25
EPITHELIAL TUMOURS OF URETHRA 0.13 0.12-0.15 292 95% 0.21 0.18-0.24 0.06 0.04-0.07 0.03 0.02-0.04 0.14 0.10-0.20 0.48 0.42-0.55 91
Transitional cell carcinoma of urethra 0.08 0.07-0.10 183 0.15 0.12-0.17 0.02 0.02-0.03 0.01 0.01-0.02 0.08 0.05-0.12 0.32 0.27-0.38 57
Squamous cell carcinoma with variants of urethra 0.02 0.01-0.02 40 0.03 0.02-0.04 <0.01 0.00-0.02 <0.01 0.00-0.01 0.03 0.01-0.05 0.06 0.04-0.08 12
Adenocarcinoma with variants of urethra 0.01 0.01-0.02 33 0.02 0.01-0.03 0.01 0.01-0.02 <0.01 0.00-0.01 0.04 0.02-0.07 0.03 0.02-0.06 10
RARE EPITHELIAL TUMOURS OF BLADDER 0.62 0.59-0.65 1 370 2% 0.93 0.87-0.99 0.33 0.29-0.36 0.07 0.06-0.09 0.85 0.74-0.96 2.34 2.20-2.49 424
Squamous cell carcinoma with variants of bladder 0.24 0.22-0.26 537 0.32 0.29-0.36 0.17 0.14-0.19 0.03 0.03-0.05 0.30 0.24-0.37 0.92 0.83-1.01 168
Adenocarcinoma with variants of bladder 0.38 0.35-0.40 833 0.61 0.56-0.65 0.16 0.14-0.19 0.04 0.03-0.05 0.55 0.46-0.64 1.42 1.31-1.54 256
Salivary gland type tumours of bladder 0.00 – 0 NE – NE – NE – NE – NE – NE
NE: not estimable because 15 or less incident cases were observed
INCIDENCE
RARE EPITHELIAL TUMOURS OF THE URINARY SYSTEM. Crude incidence (rate per 100,000/year) and 95% confidence interval
(95% CI), observed cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated
new cases at 2015 in Italy.
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AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
RARE EPITHELIAL TUMOURS
OF THE URINARY SYSTEM 
100%80%60%40%20%0%
RARE EPITHELIAL TUMOURS OF THE URINARY SYSTEM 5 334
RARE EPITHELIAL TUMOURS OF KIDNEY 110
Squamous cell carcinoma spindle cell type of kidney 46
Squamous cell carcinoma with variants of kidney 64
EPITHELIAL TUMOURS OF PELVIS AND URETER 3 833
Transitional cell carcinoma of pelvis and ureter 3 347
Squamous cell carcinoma with variants of pelvis and ureter 39
Adenocarcinoma with variants of pelvis and ureter 70
EPITHELIAL TUMOURS OF URETHRA 247
Transitional cell carcinoma of urethra 157
Squamous cell carcinoma with variants of urethra 33
Adenocarcinoma with variants of urethra 28 NE
RARE EPITHELIAL TUMOURS OF BLADDER 1 147
Squamous cell carcinoma with variants of bladder 450
Adenocarcinoma with variants of bladder 697
Salivary gland type tumours of bladder 0 NE
NE: not estimable because 30 or less incident cases were observed
RARE EPITHELIAL TUMOURS OF THE URINARY SYSTEM. One and 5-year relative survival. Error bars are
95% confidence interval. Cohort approach (complete analysis), period of diagnosis 2000-2008.
SURVIVAL
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100%
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
ESTIMATED
NEW CASES  
2015
ITALY
% OF RARE EPITHELIAL
TUMOURS 
OUT OF ALL TUMOURS
IN EACH SITE
RARE EPITHELIAL TUMOURS OF THE URINARY SYSTEM 4.90 4.45-5.39 4.47 4.04-4.94 17.55 16.68-18.45 22.90 21.74-24.06 13 254
RARE EPITHELIAL TUMOURS OF KIDNEY 0.06 0.02-0.13 0.01 0.00-0.06 0.14 0.07-0.25 0.16 0.07-0.25 97
Squamous cell carcinoma spindle cell type of kidney 0.03 0.01-0.10 0.01 0.00-0.06 0.08 0.03-0.17 0.10 0.03-0.17 60
Squamous cell carcinoma with variants of kidney 0.02 0.00-0.08 NE – 0.06 0.02-0.14 0.06 0.01-0.12 37
EPITHELIAL TUMOURS OF PELVIS AND URETER 3.86 3.46-4.29 3.61 3.22-4.03 14.11 13.33-14.92 18.23 17.20-19.27 10 533
Transitional cell carcinoma of pelvis and ureter 3.39 3.01-3.80 3.38 3.00-3.79 12.95 12.20-13.73 16.64 15.66-17.63 9 599
Squamous cell carcinoma with variants of pelvis and ureter 0.05 0.01-0.12 NE – 0.06 0.02-0.13 0.07 0.01-0.14 44
Adenocarcinoma with variants of pelvis and ureter 0.14 0.07-0.24 0.05 0.01-0.12 0.28 0.18-0.41 0.31 0.19-0.44 181
EPITHELIAL TUMOURS OF URETHRA 0.31 0.20-0.45 0.15 0.08-0.26 0.80 0.63-1.02 1.03 0.78-1.27 600
Transitional cell carcinoma of urethra 0.22 0.13-0.34 0.11 0.06-0.21 0.56 0.42-0.74 0.71 0.51-0.92 415
Squamous cell carcinoma with variants of urethra 0.06 0.02-0.13 0.02 0.00-0.08 0.13 0.06-0.23 0.15 0.06-0.23 84
Adenocarcinoma with variants of urethra 0.01 0.00-0.06 NE – 0.03 0.01-0.10 0.04 0.00-0.08 23
RARE EPITHELIAL TUMOURS OF BLADDER 0.67 0.51-0.87 0.70 0.54-0.90 2.52 2.19-2.87 3.48 3.01-3.95 2 025
Squamous cell carcinoma with variants of bladder 0.24 0.15-0.37 0.30 0.20-0.44 0.80 0.62-1.01 1.11 0.84-1.37 640
Adenocarcinoma with variants of bladder 0.43 0.31-0.60 0.40 0.28-0.56 1.71 1.45-2.01 2.36 1.98-2.74 1 376
Salivary gland type tumours of bladder NE – NE – NE – 0.01 0.00-0.04 0
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE
PREVALENCE
RARE EPITHELIAL TUMOURS OF THE URINARY SYSTEM. Observed prevalence (proportion per 100,00 and 95% con-
fidence interval - 95% CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete prevalence.
Estimated prevalent cases in 2010 in Italy.
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This group includes the following tumours of the urinary system:
 rare epithelial tumours of kidney (squamous cell carcinoma,
adenocarcinoma, and spindle cell type squamous cell carcinoma);
 epithelial tumours of pelvis and ureter (squamous cell carci-
noma, adenocarcinoma and transitional cell carcinoma);
 epithelial tumours of urethra (squamous cell carcinoma and
adenocarcinoma and transitional cell carcinoma);
 rare epithelial tumours of bladder (squamous cell carcinoma,
adenocarcinoma, and salivary gland type tumours).
These tumours are usually well defined in terms of morphology,
because they are diagnosed by imaging (cystoscopy, urography, or
a computerised tomography scan for the kidney) and histopatho-
logical examination. 
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Squamous-cell carcinoma originates from squamous cells. These
cells are typical of the epidermis of the skin, but can be found in dif-
ferent body sites for which symptoms at diagnosis, natural history,
prognosis, and response to treatment can be extremely heteroge-
neous.1 Adenocarcinoma is an undifferentiated and consequently
malignant cancer of the epithelial tissue, which originates from the
glandular epithelium.2 It includes different histological types:
tubulovillous, papillary, mucinous, and non-intestinal. The
tubulovillous and mucinous variants are the most frequent and ac-
count for over 90% of cases.3 Transitional cell carcinoma (also
urothelial cell carcinoma) originates from the urothelium (layer of
cells that lines the walls of the urinary tract: renal calices and pelvis,
ureter, bladder, proximal urethra).1 It can be diagnosed in the lower
urinary tract (bladder and urethra) or in the upper urinary tract (re-
nal calices, renal pelvis, and ureter). Upper tract urothelial carcinoma
(UTUC) is rare and accounts for only 5%-10% of urothelial cancer.
The estimated annual incidence of UTUC in Western countries is
about two new cases per 100,000 inhabitants.2 Cancers of the renal
pelvis are about two times more common than ureteral tumours.4
Spindle cell tumours of the kidney include a wide range of unrelated
neoplasms with overlapping morphologic features and different
prognostic/therapeutic implications. Diagnosis is supported mainly
by the application of ancillary techniques, such as immunohisto-
chemistry (IH) and in-situ hybridization (FISH). An accurate di-
agnosis is essential because early management by complete resection
and adjuvant chemotherapy improves prognosis dramatically.5
Tobacco and occupational exposure to certain aromatic amines2 re-
main the principal exogenous risk factors for the development of
transitional cell carcinomas. For urethral cancers, various predis-
posing factors have been reported, including urethral strictures,
chronic irritation after intermittent catheterisation/urethroplasty,
external beam irradiation therapy, radioactive seed implantation,
and chronic urethral inflammation/urethritis following sexually
transmitted diseases.6 In female patients, urethral diverticula and
recurrent urinary tract infections have been associated with primary
carcinoma.7 For the renal pelvis and ureter, use of laxatives and
analgesics are recognised risk factors.8
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
All rare epithelial tumours of the urinary system (kidney, renal
pelvis, ureter, urethra, and bladder) are more common in males
than females and are typical of the older age groups. The most
common rare epithelial tumours of the urinary system are those of
the renal pelvis and ureter (72%), followed by rare epithelial tu-
mours of the bladder (21%), urethra (5%), and kidney (2%). 
All cancers of the renal pelvis and ureter are rare and the most fre-
quent morphology is transitional cell carcinoma (87%). The other
two morphologies are squamous cell carcinoma and adenocarci-
noma (1 and 1.8%, respectively). In the bladder, rare epithelial tu-
mours represent only 2% of all bladder tumours and adenocarci-
noma is the most frequent morphology (61%). In the AIRTUM
database, no cases of salivary gland type cancers of the bladder were
observed in Italy in the years 2000-2010; in the European
RARECAREnet database (www.rarecarenet.eu) 7 cases were ob-
served in Europe in the period 2000-2008, confirming the rarity
of this entity. All cancers of the urethra are rare and the most fre-
quent morphology is transitional cell carcinoma (63%), followed
by squamous cell carcinoma (14%) and adenocarcinoma (11%).
The latter two have a very similar incident rate. Finally, rare ep-
ithelial tumours of the kidney (squamous cell carcinomas and spin-
dle cell carcinomas) are the rarest of urinary system cancers and
represent only 0.4% of all tumours of the kidney. All these tu-
mours, in each site, are more common in males than females and
have a peak of incidence in the 70-79-year age groups (data not
shown). Epithelial tumours of the urethra show the highest male
to female ratio, probably because of the longer length of the male
urethra (15-20 cm versus 3-4 cm in females). The male to female
ratio of cancer of the renal pelvis and ureter is 2.3 in this study and
much lower than for bladder cancer in European data from Globo-
can (M/F: 4.7).8 This different male to female ratio suggests a dif-
ferent importance of the various aetiological factors. Smoking is the
most important factor for bladder cancer. Although smoking is also
a risk factor for cancer of the renal pelvis and ureter, long-term use
of analgesics and laxatives, which is a strong risk factor for cancer
of the renal pelvis and ureter and which is probably as widespread
among females as among males, reduces the male to female ratio.9
The incidence results described are in line with those observed in
Europe in the RARECAREnet database. The incidence of epithelial
tumours of the renal pelvis and ureter is slightly higher in Italy than
in Europe (2.07 vs. 1.58), but the morphological distribution is the
same in the two databases. It is worth mentioning that for cancer
of the renal pelvis, ureter or urethra, comparison with other reg-
istries outside Italy may be biased by differences in registration and
classification practices. In the 9th edition of the International Clas-
sification of Diseases and the 1st edition of the International Clas-
sification of Diseases for Oncology, these cancers are grouped to-
gether with kidney cancer and many registries still report these
cancers combined. Approximately 2,000 cases of rare epithelial tu-
mours of the urinary tract are estimated to be diagnosed in Italy in
2015: 1,394 epithelial tumours of the renal pelvis and ureter, 424
rare epithelial tumours of the bladder, 91 epithelial tumours of the
urethra, and only 39 cases of rare epithelial tumours of the kidney.
Survival
One- and 5-year relative survival (RS) of rare epithelial tumours
of the urinary system is 77% and 54%, respectively.
Epithelial tumours of the renal pelvis and ureter and epithelial tu-
mours of the urethra are those with the highest RS: 81% after 1
RARE EPITHELIAL TUMOURS
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year and 60% (renal pelvis and ureter) and 56% (urethra) after 5
years from diagnosis. Transitional carcinomas are those with the
highest RS at 1 and 5 years after diagnosis, followed by adenocar-
cinoma and squamous cell carcinoma. The RS of rare epithelial tu-
mours of the bladder is the third highest survival rate among uri-
nary system cancers (65% and 39% at 1 and 5 years after diagnosis,
respectively), with adenocarcinoma having higher survival than
squamous cell carcinoma. Finally, survival of rare epithelial tu-
mours of the kidney is 39% after 1 year and falls to 18% after 5
years from diagnosis. In the kidney, squamous cell carcinoma has
higher survival than spindle cell carcinoma.
In Italy, the RS of these tumours is slightly higher than that observed
in Europe in the RARECAREnet database. Regarding the survival
differences between transitional, squamous cell carcinoma, and
adenocarcinoma observed in Italy and in Europe (RARECAREnet
database), several studies have pointed out that the stage distribution
of squamous cell carcinoma and adenocarcinoma of the renal pelvis
and ureter is relatively unfavourable in comparison to transitional
cell carcinoma, with consequent poor survival.10 However, the rea-
son for this unfavourable stage distribution is unclear. Possibly,
transitional cell carcinoma causes bleeding at an earlier stage and
therefore is discovered earlier. 
Considering that roughly half of the patients with these cancers do
not survive their illness and that these are very rare cancers, as al-
ready suggested at European level, centralisation of treatment to
a select number of specialist centres should be promoted.10
Prevalence
Over 13,000 persons were estimated to be living with a diagnosis of
rare epithelial cancers of the urinary system in Italy in 2010; 23% of
these cases were diagnosed 15 years or more from prevalence date.
Most prevalent cases are represented by patients with a previous di-
RARE EPITHELIAL TUMOURS
OF THE URINARY SYSTEM 
agnosis of transitional cell carcinoma of the renal pelvis and ureter. 
Surgery remains the mainstay treatment for renal pelvis and ureter
cancer. Conservative surgery of the urethra is technically demanding
and, when indicated, requires highly specialised surgeons. Centres that
display a high surgical volume of treatment for renal, ureteral, and
retroperitoneal tumours and that involve a multidisciplinary team in
the decisional process should be contacted for primary care, or at least
for a second opinion prior to undergoing treatment. At any rate, as
cancer registries come to collect more information on stage and treat-
ment and place of treatment, evaluation of this recommendation
should become a priority.
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0.02
RARE TUMOURS  4.08 4.00-4.17 9 049 6% 8.36 8.19-8.54 – – 4.60 4.49-4.71 2.29 2.11-2.47 3.43 3.25-3.60 2 413
OF THE MALE GENITAL SYSTEM
RARE EPITHELIAL TUMOURS OF PROSTATE 0.17 0.15-0.19 374 0.3% 0.35 0.31-0.39 – – <0.01 0.00-0.01 0.24 0.18-0.30 0.68 0.60-0.76 116
Squamous cell carcinoma with variants of prostate 0.01 0.00-0.01 16 0.01 0.01-0.02 – – 0.00 – 0.01 0.00-0.03 0.03 0.02-0.05 5
Infiltrating duct carcinoma of prostate 0.11 0.09-0.12 234 0.22 0.19-0.25 – – <0.01 0.00-0.01 0.16 0.11-0.21 0.42 0.36-0.49 72
Transitional cell carcinoma of prostate 0.05 0.04-0.06 119 0.11 0.09-0.13 – – <0.01 0.00-0.01 0.06 0.03-0.10 0.22 0.18-0.27 38
Basal cell adenocarcinoma of prostate <0.01 0.00-0.01 5 NE – – – NE – NE – NE – 1
TESTICULAR AND PARATESTICULAR TUMOURS 3.10 3.03-3.18 6 877 96% 6.41 6.26-6.56 – – 4.27 4.17-4.38 0.83 0.72-0.94 0.50 0.43-0.57 1 746
Paratesticular adenocarcinoma with variants <0.01 0.00-0.00 2 NE – – – NE – NE – NE – 1
Non seminomatous testicular tumours 1.07 1.02-1.11 2 363 2.20 2.11-2.29 – – 1.53 1.47-1.60 0.12 0.08-0.17 0.06 0.04-0.08 586
Seminomatous testicular tumours 1.70 1.65-1.76 3 777 3.52 3.41-3.64 – – 2.35 2.27-2.42 0.55 0.47-0.65 0.22 0.17-0.26 964
Spermatocytic seminoma 0.05 0.04-0.06 103 0.10 0.08-0.12 – – 0.04 0.03-0.05 0.03 0.02-0.06 0.08 0.05-0.11 29
Teratoma with malignant transformation <0.01 0.00-0.01 5 NE – – – NE – NE – NE – 1
Testicular sex cord tumours 0.02 0.02-0.03 55 0.05 0.04-0.07 – – 0.03 0.02-0.03 0.02 0.01-0.05 0.03 0.01-0.04 15
EPITHELIAL TUMOURS OF PENIS 0.68 0.65-0.72 1 509 96% 1.41 1.34-1.48 – – 0.15 0.13-0.18 1.16 1.03-1.29 2.19 2.05-2.33 473
Squamous cell carcinoma with variants of penis 0.63 0.60-0.67 1 406 1.31 1.24-1.38 – – 0.14 0.13-0.16 1.10 0.98-1.23 2.02 1.89-2.16 438
Adenocarcinoma with variants of penis <0.01 0.00-0.01 13 NE – – – NE – NE – NE – 4
EXTRAGONADAL GERM CELL TUMOURS 0.13 0.11-0.14 284 0.02% 0.19 0.16-0.22 – – 0.16 0.14-0.18 0.06 0.04-0.10 0.05 0.03-0.08 76
Non seminomatous germ cell tumours 0.06 0.05-0.08 142 0.08 0.07-0.10 – – 0.07 0.06-0.09 0.04 0.02-0.08 0.04 0.02-0.06 38
Seminomatous germ cell tumours 0.01 0.01-0.02 29 0.02 0.02-0.04 – – 0.02 0.01-0.03 <0.01 0.00-0.03 0.00 – 8
Germ cell tumours of Central Nervous System (CNS) 0.04 0.03-0.05 81 0.06 0.04-0.07 – – 0.05 0.04-0.06 <0.01 0.00-0.02 <0.01 0.00-0.02 22
MESOTHELIOMA OF TUNICA VAGINALIS <0.01 0.00-0.01 5 NE – – – NE – NE – NE – 1
NE: not estimable because 15 or less incident cases were observed
INCIDENCE
RARE TUMOURS OF THE MALE GENITAL SYSTEM. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI),
observed cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases
at 2015 in Italy.
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AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
RARE TUMOURS OF THE
MALE GENITAL SYSTEM 
ESTIMATED
NEW CASES  
2015
ITALY
100%80%60%40%20%0%
RARE TUMOURS OF THE MALE GENITAL SYSTEM 7 494
RARE EPITHELIAL TUMOURS OF PROSTATE 303
Squamous cell carcinoma with variants of prostate 14 NE
Infiltrating duct carcinoma of prostate 192
Transitional cell carcinoma of prostate 94
Basal cell adenocarcinoma of prostate 3 NE
TESTICULAR AND PARATESTICULAR TUMOURS 5 702
Paratesticular adenocarcinoma with variants 2 NE
Non seminomatous testicular tumours 1 972
Seminomatous testicular tumours 3 133
Spermatocytic seminoma 76
Teratoma with malignant transformation 3 NE
Testicular sex cord tumours 50
EPITHELIAL TUMOURS OF PENIS 1 257
Squamous cell carcinoma with variants of penis 1 177
Adenocarcinoma with variants of penis 10 NE
EXTRAGONADAL GERM CELL TUMOURS 230
Non seminomatous germ cell tumours 113
Seminomatous germ cell tumours 25 NE
Germ cell tumours of Central Nervous System (CNS) 69
MESOTHELIOMA OF TUNICA VAGINALIS 5 NE
NE: not estimable because 30 or less incident cases were observed
RARE TUMOURS OF THE MALE GENITAL SYSTEM. One and 5-year relative survival. Error bars are 95% confidence interval. Cohort ap-
proach (complete analysis), period of diagnosis 2000-2008.
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SURVIVAL
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No. OF CASES 
INCLUDED 
IN THE ANALYSIS
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
RARE TUMOURS OF THE MALE GENITAL SYSTEM 7.83 7.26-8.44 9.93 9.28-10.62 41.95 40.60-43.34 88.72 84.78-92.66 51 030
RARE EPITHELIAL TUMOURS OF PROSTATE 0.21 0.12-0.33 0.18 0.11-0.30 0.88 0.70-1.11 0.93 0.72-1.14 539
Squamous cell carcinoma with variants of prostate 0.01 0.00-0.06 NE – 0.02 0.00-0.08 0.02 0.00-0.06 14
Infiltrating duct carcinoma of prostate 0.14 0.07-0.24 0.06 0.02-0.13 0.56 0.42-0.74 0.58 0.42-0.74 333
Transitional cell carcinoma of prostate 0.06 0.02-0.13 0.13 0.06-0.23 0.30 0.20-0.44 0.33 0.20-0.45 192
Basal cell adenocarcinoma of prostate NE – NE – NE – NE – NE
TESTICULAR AND PARATESTICULAR TUMOURS 6.27 5.76-6.82 8.54 7.94-9.18 35.66 34.42-36.94 78.39 74.62-82.17 45 055
Paratesticular adenocarcinoma with variants NE – NE – NE – NE – NE
Non seminomatous testicular tumours 1.92 1.64-2.23 2.80 2.46-3.18 11.86 11.14-12.60 29.53 26.37-32.69 16 779
Seminomatous testicular tumours 3.87 3.47-4.31 5.06 4.60-5.55 21.49 20.52-22.48 44.49 41.55-47.42 25 649
Spermatocytic seminoma 0.06 0.02-0.13 0.09 0.04-0.18 0.42 0.30-0.59 1.33 0.76-1.91 23 047
Teratoma with malignant transformation NE – NE – 0.01 0.00-0.06 0.01 0.00-0.04 6
Testicular sex cord tumours NE – 0.06 0.02-0.13 0.20 0.11-0.31 0.41 0.21-0.60 232
EPITHELIAL TUMOURS OF PENIS 1.17 0.96-1.42 0.99 0.79-1.22 4.39 3.96-4.86 6.16 5.54-6.78 3 562
Squamous cell carcinoma with variants of penis 1.15 0.93-1.40 0.95 0.76-1.18 4.22 3.80-4.68 5.85 5.25-6.45 3 377
Adenocarcinoma with variants of penis NE – NE – 0.01 0.00-0.06 0.01 0.00-0.04 7
EXTRAGONADAL GERM CELL TUMOURS 0.18 0.11-0.30 0.22 0.13-0.34 1.02 0.82-1.26 3.23 2.30-4.16 1 874
Non seminomatous germ cell tumours 0.08 0.03-0.17 0.09 0.04-0.18 0.47 0.34-0.64 1.11 0.73-1.49 652
Seminomatous germ cell tumours 0.03 0.01-0.10 0.05 0.01-0.12 0.17 0.10-0.28 0.25 0.12-0.39 150
Germ cell tumours of Central Nervous System (CNS) 0.06 0.02-0.13 0.05 0.01-0.12 0.30 0.20-0.44 0.42 0.22-0.62 244
MESOTHELIOMA OF TUNICA VAGINALIS NE – NE – NE – NE – NE
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE
PREVALENCE
RARE TUMOURS OF THE MALE GENITAL SYSTEM. Observed prevalence (proportion per 100,00 and 95% confidence in-
terval - 95% CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete prevalence. Estimated
prevalent cases in 2010 in Italy.
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This group includes a heterogeneous number of rare cancers:
 rare epithelial tumours of the prostate (squamous cell
carcinoma, infiltrating duct carcinoma, transitional cell
carcinoma, basal cell adenocarcinoma);
 testicular cancers (paratesticular adenocarcinoma,
non-seminomatous testicular cancer, seminomatous testicular
cancer; spermatocytic seminoma, teratoma with malignant
transformation, testicular sex cord cancers);
 epithelial tumours of the penis (squamous cell carcinomas,
adenocarcinomas);
 extragonadal germ cell tumours (non-seminomatous germ
cell tumours, seminomatous germ cell tumours, and germ cell
tumours of the Central Nervous System);
 mesothelioma of the tunica vaginalis testis.
Extragonadal germ cell tumours include a few entities that occur
even in women; these are also considered in this group since
clinical management is the same for females as for males. Overall,
rare cancers account for 6% of all male genital system cancers.
RARE EPITHELIAL TUMOURS OF THE PROSTATE 
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Tumours with squamous cell differentiation may arise from the
urothelial cells of the prostatic urethra, the periurethral glands, as
from a stem cell.1 They may be in the pure squamous carcinoma
form, which usually does not express serum PSA,2 or associated
with acinar adenocarcinoma (adenosquamous carcinoma), urothe-
lial carcinoma, or sarcoma;1 they are associated with early devel-
opment of osteolytic metastases and poor responsiveness to antian-
drogen therapy.2
Regarding infiltrating duct carcinomas, the mixed variant (adeno-
carcinoma-ductal carcinoma) is more common than pure ductal
carcinoma; the latter arises in periurethral prostatic ducts and
shows Gleason score 8;2 this histotype may have a prevalent pap-
illary, or solid or complex cribriform pattern of growth, and is more
likely to metastasise to testis and penis.2 Transitional cell carci-
noma in the absence of bladder carcinoma may arise from the pro-
static urethra or major prostatic ducts, which are lined by urothelial
epithelium; it is often difficult to distinguish the origin of this neo-
plasm, due the possibility of an intraprostatic extension from
bladder carcinoma.
Basal cell adenocarcinoma of the prostate is a very rare histological
type described for the first time in 1974; it arises in the basal cell
layer of the prostate gland and is very likely to cause urinary ob-
structive symptoms at clinical presentation; it is reported to behave
less aggressively than other histotypes.2 It is frequently associated
with the acinar variant and only about 50 cases are described in the
literature.3
Risk factors associated with common prostatic adenocarcinoma
(age, familiarity, obesity, lifestyle, environmental exposure) most
likely have a role even in the aetiology of rare prostatic cancers, ex-
cept for squamous cell carcinoma. About half of squamous cell car-
cinomas arise after androgen deprivation therapy or radiation
treatment for a conventional adenocarcinoma. However, some
cases have been reported as de novo cancers in patients without
prostate disease.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Infiltrating duct carcinoma is the most common (63%), followed
by transitional carcinoma (32%), squamous (4%), and basal cell
adenocarcinoma (1%). Like the common acinar adenocarcinoma
of the prostate, even these rare epithelial tumours are typical of ad-
vanced age (>65 years), with exceptional cases of early-onset prostate
cancer (diagnosed <55 years). Approximately 120 Italians were es-
timated to be diagnosed with rare tumours of the prostate in 2015.
Survival
Infiltrating duct carcinoma and transitional carcinomas have a good
prognosis (5-year relative survival: 74% and 69%, respectively). In
the AIRTUM database, the number of cases is too limited to
provide survival of squamous cell carcinoma and basal cell adeno-
carcinoma. However, data from the European RARECAREnet
database (www.rarecarenet.eu) show that squamous cell carcinomas
have a poor survival rate (40% at 5 years), while basal cell adeno-
carcinoma have a good survival rate (80%).
The European RARECAREnet data show that rare epithelial can-
cers of the prostate are characterised by a worse prognosis than the
common acinar adenocarcinoma of the prostate (88%). The lower
prognosis of these rare cancers seems mainly due to the more ad-
vanced stage at diagnosis and some resistance to treatment, partic-
ularly to hormonal therapy. They usually occur in people older
than those diagnosed with acinar adenocarcinoma and survival de-
creases with increasing age.
Prevalence
In Italy, slightly more than 500 persons were estimated to be alive in
2010 with a diagnosis of rare epithelial tumours of the prostate. The
most prevalent cases are infiltrating duct carcinomas of the prostate,
followed by transitional cell carcinomas.
TESTICULAR CANCERS 
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Testicular cancers are all rare, but are the most common cancers in
young men, and their incidence is increasing.4 The incidence varies
in different geographical areas, thus testicular cancer may not be per-
ceived as rare in countries of Northern and Western Europe.4 How-
ever, as described in «Material and methods» (pp. 14-21), the defi-
nition of rarity is based on the European population and not on the
country-specific incidence. Thus, even though the country-specific
incidence rate of testicular cancer can be higher than 6 in some coun-
tries, testicular cancer is considered rare because its incidence is <6
per 100,000 in the EU.
Seminomatous and non-seminomatous cancers are the most
common germ cell tumours of the testis. Seminomatous cancers
are more often localised, metastasise via the lymphatic system, and
are radiosensitive; they occur in somewhat older patients. By con-
trast, non-seminomatous cancers are prone to haematogenous as
well as lymphatic spread and are less radiosensitive.4 Spermatocytic
seminoma is clinically and pathologically distinct from classic
seminomatous cancer, in particular for its almost complete inability
to metastasise.4 On rare occasions, teratomas undergo somatic ma-
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lignant transformation.5 The most common transformations are to
sarcoma, primitive neuroectodermal tumour, and adenocarcinoma.
Most sex cord cancers have a benign clinical course following sur-
gery, but about 20% are metastatic at diagnosis and 10%-12% be-
have aggressively, often with fatal outcome.4
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Seminomatous testicular cancer is the most common entity (55%),
followed by non-seminomatous testicular cancer (34%). The other
germ cell tumours are very rare. For seminomatous cancers, the in-
cidence rate (IR) peaks in the 30-34 age group (0.5 per 100,000;
data not shown). For non-seminomatous cancers, the IR peaks in
the 25-29 age group (4 per 100,000; data not shown). Until
around 24 years of age non-seminomatous cancers are the predom-
inant histologic type, after around 29 years of age seminomas are
more common than non seminomas. Among the elderly (65 years
and over) 62% of germ cell tumours are seminomas. A total of
1,746 testicular cancers were estimated to be diagnosed in Italy at
2015; 90% of these cancers are germ cell tumours.
Survival
Among testicular and paratesticular cancers, seminomas and sper-
matocytic seminoma have the highest survival, followed by non
seminomas. Five-year relative survival (RS) is also good for sex cord
tumours. Survival differences between seminomatous and non-
seminomatous cancers are explained by their different biology. The
good prognosis of spermatocytic seminoma and sex cord tumours
is mainly explained by their benign clinical course. The AIRTUM
database has too few cases to provide survival of the other entities.
However, regarding teratoma with malignant transformation,
studies suggest that transformation has a negative impact on prog-
nosis compared to the non-transformed counterpart.5
Prevalence
Around 45,000 persons were estimated to be living with a diagnosis
of testicular cancers in Italy in 2010. The most prevalent testicular can-
cers are seminomatous and non-seminomatous cancers. Young age of
patients may play an important role in so relatively high prevalence
figures. For testicular cancers, however, the high survival rate appears
as the most important contributor to the prevalence. Our estimates
are slightly higher than those published in the AIRTUM monograph
on prevalence6 because of the different methodology used (see «Ma-
terials and methods», pp.14-21 ).
EPITHELIAL TUMOURS OF THE PENIS
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Epithelial tumours of the penis are all rare. Risk factors for the de-
velopment of penile cancer are multifactorial and include: phimosis,
infection with human papilloma virus (HPV), HIV infection, ciga-
rette smoking, history of trauma and chronic balanitis, lichen sclero-
sus, and PUVA treatment.2 Circumcision in infancy is associated with
a protective effect for penile cancer.2 Penile cancer is a very rare
tumour for which a referral to a centre of expertise is recommended,
since it deserves special attention in the diagnosis process and treat-
ment options. Penectomy is disfiguring and can have an intense
effect on the patient’s quality of life, sexual function, self-esteem, and
general mental health. Therefore, there is an increased trend for
penile preserving strategies (radiotherapy), despite the fact that recur-
rence rates may be higher than those of radical surgical procedures.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Cancer of the penis is the rarest cancer of the male genital system. The
IR in Italy is 0.7 per 100,000 and it is equal to that observed in the
European RARECAREnet database. As HPV infection is an impor-
tant risk for penile cancer and circumcision is protective, the inter-
mediate position of Italy and Europe can be explained by moderate
rates of HPV-infection in a generally uncircumcised male population.
Squamous cell carcinoma is the most common morphological
type of penis cancer (93%). This tumour is very rare before 50 years
old; the IR increases with age, with the highest IR in patients 75
years or older. About 470 penile cancers were estimated to be di-
agnosed in Italy in 2015.
Survival
Survival of squamous cell carcinoma of the penis is good and similar
to that observed in the European RARECAREnet database. In the
AIRTUM database the number of cases is too limited to provide data
for adenocarcinoma of the penis. The European RARECAREnet
database reports a 5-year RS of 50%. Although survival for penile can-
cers is relatively good, it has not improved in the past few years, prob-
ably because of the limited advances in curative treatment and the lim-
ited centralisation of treatment.7,8
Prevalence
In Italy, 3,500 persons were estimated to be alive with a diagnosis of
penile cancer in 2010. The most prevalent penile cancer is squamous
cell carcinoma. 
EXTRAGONADAL GERM CELL TUMOURS (EGCTs) 
WHAT DO WE KNOW ABOUT THESE CANCERS?
Extragonadal germ cell tumours are all rare. Germ cell tumours
of the CNS are typical of children and adolescents and, therefore,
are mainly managed by paediatric oncologists. EGCTs represent
a minor part of all germ cell tumours and are more aggressive than
those of the gonads. They usually occur along the midline of the
body along which the primordial germ cells migrate from the prox-
imal epiblast to the genital ridge. 
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
EGCTs account for 4% of all germ cell tumours in the AIRTUM
database (data not shown). EGCTs are more common in males
than females and, in all sites, non seminoma is the predominant
histology. Germ cell tumours of the CNS are typical of children
and adolescents (10-19 years old). Non seminomas have a first in-
cidence peak in the 0-4-year age group and a second in the 25-29-
year age group. Seminomas are very rare and have an incidence
peak in the 35-39-year age group. Sites are predominantly the me-
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diastinum (29%), CNS (17%), endocrine system (12%), female
genital system (9%), retroperitoneum (5%), with primary site un-
known in 3%. The remaining cases occur at disparate sites includ-
ing head and neck, digestive tract, lung, prostate, urinary tract, and
other not specified sites (ICD-O3 C76.0-76.8).
Survival
Five-year RS of EGCTs is always worse than that of gonadal germ
cell tumours. Five-year RS is 71% for CNS EGCTs and 60% for
non-seminomatous EGCTs (data not shown). Among the latter,
those of the mediastinum (most common site in the AIRTUM data-
base) has the worst survival. This could be due to generally large tu-
mour bulk at diagnosis, resistance to chemotherapy, difficulty of re-
moving all residual disease after chemotherapy, and a predisposition
to develop haematologic neoplasia and other non-germ cell malig-
nancies. In the AIRTUM database the number of cases is too
limited to provide data for seminomatous EGCTs. However, the Eu-
ropean RARECAREnet database reports a 5-year RS of 85%.
Prevalence
About 1,900 persons were estimated to be living with a diagnosis of
extragonadal germ cell cancer in Italy in 2010.
MESOTHELIOMA OF THE TUNICA VAGINALIS TESTIS
Only 5 cases of malignant mesothelioma of the tunica vaginalis
(MTVT) were observed in the AIRTUM database in the period of
diagnosis 2000-2010, confirming the extreme rarity of this tumour.
The data of the National Italian malignant Mesothelioma Registry
(ReNAM) reported 51 cases of MTVT diagnosed in the period
1993-2008, corresponding to 0.3% of all mesothelioma cases in
Italy.9 Differences in number of cases observed are due to the na-
tional coverage of the ReNAM, which is a mesothelioma-dedicated
registry, and the partial coverage of the AIRTUM registries (which
are general registries). The highest incidence is observed in the 65-
75-year age group.
An Italian study found exposure to asbestos in 67% of cases of
MTVT and clarified that the difference in the percentage of as-
bestos-related MTVT reported in the literature (30%-40%) might
be the result of an incomplete investigation of exposure history for
MTVT patients.10 Thus, asbestos exposure is the main risk factor
for MTVT, as well as for malignant mesotheliomas that occur at
other sites, although the mechanism of involvement of the tunica
vaginalis by asbestos fibres still remains unclear. 
In the AIRTUM database the number of cases is too limited to es-
timate survival. However, according to the literature, survival is very
bad, ranging from a minimum of 18 months without treatment11
to a maximum of 23 months for patients treated with surgery.12
REFERENCES
1. Arva NC, Das K. Diagnostic dilemmas of squamous differentiation in prostate carcinoma case
report and review of the literature. Diagn Pathol 2011;6: 46.
2. Epstein JI, Cubilla AL, Humphrey P A. AFIP Atlas of Tumor Pathology Series 4. Tumour of the
Prostate Gland, Seminal Vesicles, Penis and Scrotum. 2011; pp. 239-298.
3. Ahuja A, Das P, Kumar N, Saini AK, Seth A, Ray R. Adenoid cystic carcinoma of the prostate: case
report on a rare entity and review of the literature. Pathol Res Pract 2011;207(6):391-394.
4. Trama A, Mallone S, Nicolai N, et al. Burden of testicular, paratesticular and extragonadal germ
cell tumours in Europe. Eur J Cancer 2012;48(2):159-169.
5. Necchi A, Colecchia M, Nicolai N, et al. Towards the definition of the best management and
prognostic factors of teratoma with malignant transformation: a single-institution case series
and new proposal. BJU Int 2011;107(7):1088-1094.
6. AIRTUM Working Group. Italian Cancer Figures – Report 2014. Prevalence and cure of cancer
in Italy. Epidemiol Prev 2014;38(6) Suppl 1:1-144.
7. Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in
Europe. Eur J Cancer 2012;48(4):456-464.
8. Trama A, Foschi R, Larrañaga N, et al. Survival of male genital cancers (prostate, testis and penis)
in Europe 1999-2007: Results from the EUROCARE-5 study. Eur J Cancer 2015, pii: S0959-
8049(15)00707-8. 
9. Marinaccio A, Binazzi A, Branchi C, et al. Il registro nazionale dei mesoteliomi (ReNAM). Quarto
rapporto. Milano, INAIL, 2012.
10. Mensi C, Pellegatta M, Sieno C, Consonni D, Riboldi L, Bertazzi PA. Mesothelioma of tunica
vaginalis testis and asbestos exposure. BJU Int 2012;110(4):533-537.
11. Gupta NP, Agrawal AK, Sood S, Hemal AK, Nair M. Malignant mesothelioma of the tunica vagi-
nalis testis: a report of two cases and review of literature. J Surg Oncol 1999;70(4):251-254.
12. Plas E, Riedl CR, Pflüger H. Malignant mesothelioma of the tunica vaginalis testis: review of
the literature and assessment of prognostic parameters. Cancer 1998;83(12):2437-2446.
RARE TUMOURS OF THE
MALE GENITAL SYSTEM 
0 5
100% 89%
75%
RARE SKIN 
TUMOURS
AND MALIGNANT
MELANOMA
OF MUCOSA
INCIDENCE
532
ESTIMATED NEW CASES  
ITALY, 2015
1
YEARS AFTER DIAGNOSIS
PREVALENCE
4 403
ESTIMATED PREVALENT CASES 
ITALY, 2010
SURVIVAL
3.4ADNEXAL CARCINOMA OF SKIN424
0.04MALIGNANT MELANOMAOF MUCOSA (EXTRACUTANEOUS)108 %  OF RARE TUMOURS
OUT OF ALL TUMOURS 
IN EACH SITE
0.2%
OF TUMOURS
OF THE SKIN AND
OF THE MUCOSA
ARE RARE
SOURCE: AIRTUM. ITALIAN CANCER FIGURES–REPORT 2015
100%80%60%40%20%0%
RARE SKIN TUMOURS AND MALIGNANT MELANOMA OF MUCOSA. One and 5-year relative survival. Error bars are 95% confidence
interval. Cohort approach (complete analysis), period of diagnosis 2000-2008.
SURVIVAL
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
RARE SKIN TUMOURS 0.77 0.73-0.80 1 699 0.2% 0.83 0.78-0.89 0.70 0.66-0.75 0.13 0.11-0.15 0.93 0.82-1.05 2.86 2.70-3.02 532
AND MALIGNANT MELANOMA OF MUCOSA
MALIGNANT MELANOMA OF MUCOSA 0.16 0.14-0.18 356 0.04% 0.12 0.10-0.15 0.19 0.17-0.22 0.04 0.03-0.05 0.25 0.19-0.31 0.54 0.47-0.61 108
(EXTRACUTANEOUS)
ADNEXAL CARCINOMA OF SKIN 0.61 0.57-0.64 1 343 3.4% 0.71 0.66-0.76 0.51 0.47-0.55 0.09 0.08-0.11 0.68 0.59-0.79 2.32 2.18-2.47 424
INCIDENCE
RARE SKIN TUMOURS AND MALIGNANT MELANOMA OF MUCOSA. Crude incidence (rate per 100,000/year) and 95% confidence
interval (95% CI), observed cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age.
Estimated new cases at 2015 in Italy.
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SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
RARE SKIN TUMOURS
AND MALIGNANT 
MELANOMA OF MUCOSA
RARE SKIN TUMOURS 1.40 1.16-1.67 1.70 1.44-2.00 5.66 5.17-6.18 7.50 6.83-8.17 4 403
AND MALIGNANT MELANOMA OF MUCOSA
MALIGNANT MELANOMA OF MUCOSA (EXTRACUTANEOUS) 0.25 0.16-0.38 0.16 0.09-0.27 0.61 0.46-0.80 0.87 0.63-1.11 524
ADNEXAL CARCINOMA OF SKIN 1.15 0.93-1.40 1.54 1.29-1.82 5.05 4.59-5.55 6.63 6.00-7.25 3 879
PREVALENCE
RARE SKIN TUMOURS AND MALIGNANT MELANOMA OF MUCOSA. Observed prevalence (proportion per 100,00
and 95% confidence interval - 95% CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and
complete prevalence. Estimated prevalent cases in 2010 in Italy.
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AIRTUM POOL
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≤2 YEARS 2-5 YEARS ≤15 YEARS
OBSERVED PREVALENCE BY DURATION
ESTIMATED
NEW CASES  
2015
ITALY
ESTIMATED 
PREVALENT
CASES 
2010
ITALY
RARE SKIN TUMOURS AND MALIGNANT MELANOMA OF MUCOSA 1 349
MALIGNANT MELANOMA OF MUCOSA (EXTRACUTANEOUS) 284
ADNEXAL CARCINOMA OF SKIN 1 065
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RARE SKIN TUMOURS
AND MALIGNANT 
MELANOMA OF MUCOSA
This group includes two tumour types which are rare and under-
studied:
 malignant melanoma of the mucosa;
 skin adnexal tumours.
Because of their rarity, even the basic descriptive epidemiology of
these tumour types is sparse, restricted to specific anatomic sites
and confined to case reports or clinical series.
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Primary mucosal melanomas arise from melanocytes located in
mucosal membranes. Although a majority of mucosal melanomas
originate from the mucosa of the nasal cavity and accessory sinuses,
oral cavity, anorectum, vulva, and vagina, they can arise in almost
any part of mucosal membranes. In particular, primary oral
melanomas may arise from nevi and pigmented areas such as
amalgam tattoos, or post inflammatory pigmentations due to to-
bacco usage or drugs aberrant reactions.1 Most mucosal melanomas
occur in occult sites, which together with the lack of early and spe-
cific signs contribute to late diagnosis and poor prognosis. Because
of their rareness the knowledge about their pathogenesis and risk
factors is insufficient, and moreover there are no well-established
protocols for staging and treatment. Surgery is the mainstay of
treatment, with trends toward more conservative treatment since
radical surgery has not proven an advantage for survival. Radiother-
apy can provide better local control in some locations, but did not
show improvement in survival. There is no effective systemic ther-
apy for these aggressive tumours. Compared with cutaneous and
ocular melanoma, mucosal melanomas have the lowest percentage
of five-year survival. Recently revealed molecular changes under-
lying mucosal melanomas offer new hope for development of
more effective systemic therapy for mucosal melanomas.2
Skin adnexal tumours (SATs) are a large and diverse group of
benign and malignant neoplasms, which exhibit morphological
differentiation towards one of the different types of adnexal epithe-
lium present in normal skin: apocrine-eccrine differentiation (tu-
mours of the sweat glands, mammary and extramammary Paget’s dis-
ease ); follicular (tumours of hairs); and sebaceous (tumours of Zeis
glands and meibomian glands of the eyelid). The histogenesis of ad-
nexal tumours is still uncertain; however, the possibility of origin
from a pluripotent stem cell is suggestive.3-6
Most SATs are benign, and local complete surgical excision is
curative. However, diagnosing some of these tumours has impor-
tant implications, as they might be markers for syndromes associ-
ated with internal malignancies, such as trichilemmomas in Cow-
den syndrome and sebaceous tumours in Muir-Torre syndrome.7,8
Benign lesions are typical of the young. A malignant counterpart
of almost every SAT has been described. These tumours are rare,
locally aggressive, and have the potential for nodal involvement and
distant metastasis, with a poor clinical outcome. Therefore, estab-
lishing a diagnosis of malignancy in SAT is important for thera-
peutic and prognostic purposes. Because pathologists may not fre-
quently encounter SATs, and owing to their different derivation
and broad histogenesis, diagnosing these tumours may be challeng-
ing even to an experienced pathologist. SATs appear as single
nodular lesions resembling dermal melanocytic nevi, epidermoid
cysts, and basal cell carcinoma. Thus, their diagnosis relies on his-
tological evaluation, including immunohistochemistry to support
differential diagnosis (podoplanin (D2-40) to distinguish basal cell
carcinoma from trichoepithelioma, monoclonal antibody Ber-
EP4 to reliably discriminate between microcystic adnexal carci-
noma and basal cell carcinoma).8
In this study, we conducted the first comprehensive and largest analy-
sis, to our knowledge, of incidence, prevalence and survival of these
rare tumours in the Italian population. In the list of rare cancers pro-
posed by RARECARE,9 extramammary Paget’s disease is not in-
cluded among SATs, as it is often an epiphenomenon of another in-
vasive malignancy and because the actual invasiveness of the lesion
is still debated. Mammary Paget’s disease is included and described
among the rare cancers of the breast.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
All mucosal melanomas are rare and are so rare that only 350 cases
were observed in Italy in 11 years. These tumours are slightly more
common in females than males and are typical of older people (peak
in the eighth decade of life). In the AIRTUM database, mucosal
melanoma occurs most frequently in the female genital tract and
in the head and neck, as previously reported in Europe1 and the
USA.10
All SATs are rare and 1,300 cases were observed in Italy in the pe-
riod 2000-2010 in the AIRTUM database. SATs are more common
in males than females and the incidence rate (IR) increases expo-
nentially with age, with peak frequencies in the eighth decade of life.
The most frequent SATs are those with apocrine and eccrine dif-
ferentiation, followed by sebaceous tumours and adenoid cystic car-
cinoma with skin appendage carcinoma, NOS, accounting for
20%. These results are similar to those observed in the SEER data-
base (period of diagnosis 2001-2006), which reports a high IR of
apocrine and eccrine followed by sebaceous and, differently from
the Italian results, microcystic adnexal carcinoma. Skin appendage
carcinoma, NOS, is lower in the SEER database (about 10%).11 In-
teresting is the absence of follicular tumours in both the AIRTUM
and SEER databases. 
Survival
Five-year relative (RS) of mucosal melanomas is 30%, most likely
because of the late diagnosis and the lack of protocols for their
treatment. Survival of SAT is good, as it is 95% after 1 year and
88% after 5 years from diagnosis. This is probably due to the fact
that these tumours are mainly locally aggressive tumours. In the
AIRTUM database there is no information on stage; however, ac-
cording to the SEER database, 5-year RS is 99% in local SATs,
93% in SATs with regional involvement (which are 15% of all
SATs) and 43% in SATs with distant metastases (which are very
rare; 1.6% out of all SATs observed in the SEER database in the
period 1992-2004). With regard to survival for the different dif-
ferentiations, it seems that 5-year RS is slightly lower for tumours
with sebaceous differentiation.11
These results are in line with those observed in Europe in the
RARECAREnet database (www.rarecarenet.eu). As expected, for
both mucosal melanomas and SATs, the observed survival (not
shown in table) is lower than the relative one because these tu-
mours affect mainly old people.
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RARE SKIN TUMOURS
AND MALIGNANT 
MELANOMA OF MUCOSA
Prevalence
Around 4,400 persons were estimated to be alive in 2010 with a past
diagnosis of one of these rare cancers in Italy. The most prevalent can-
cers are SATs (88% of cases), coherently with the high incidence and
survival of these tumours.
GENERAL REMARKS
SATs affect mainly old people, have high survival, are rarely metastatic
at diagnosis, and surgery is the mainstay treatment. However, diag-
nosing these tumours may be challenging. Survival of mucosal
melanoma is low because of lack of treatment protocols and delay in
diagnosis.
A possible solution to address the challenges for diagnosis and treat-
ment of these tumours is the identification of an expert centre, with
a multidisciplinary team, able to support the therapeutic decision for
locally advanced and metastatic SATs and mucosal melanoma. The ex-
pert centre should also be able to provide a second pathological opin-
ion to ensure the appropriate diagnosis of SATs. For melanoma of the
mucosa, revision of the pathological sample is important, but not as
essential as for SATs.
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EMBRYONAL TUMOURS. One and 5-year relative survival. Error bars are 95% confidence interval. Cohort ap-
proach (complete analysis), period of diagnosis 2000-2008.SURVIVAL
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100%
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
EMBRYONAL TUMOURS 0.39 0.36-0.41 859 100% 0.41 0.37-0.45 0.37 0.34-0.41 5.92 5.46-6.41 0.65 0.54-0.77 0.06 0.05-0.07 234
NEUROBLASTOMA AND 0.17 0.15-0.18 370 NA 0.19 0.16-0.22 0.15 0.12-0.17 2.88 2.56-3.23 0.29 0.22-0.38 <0.01 0.00-0.01 99
GANGLIONEUROBLASTOMA
NEPHROBLASTOMA 0.11 0.10-0.13 248 NA 0.10 0.08-0.12 0.12 0.10-0.15 1.67 1.43-1.94 0.30 0.23-0.38 <0.01 0.00-0.01 68
RETINOBLASTOMA 0.05 0.04-0.06 111 NA 0.05 0.04-0.06 0.05 0.04-0.07 1.03 0.84-1.24 0.02 0.01-0.06 0.00 – 30
HEPATOBLASTOMA 0.02 0.01-0.02 40 NA 0.02 0.01-0.03 0.01 0.01-0.02 0.28 0.19-0.40 0.02 0.01-0.06 <0.01 0.00-0.01 11
PLEUROPULMONARY BLASTOMA <0.01 0.00-0.00 2 NA NE – NE – NE – NE – NE – 1
PANCREATOBLASTOMA <0.01 0.00-0.01 5 NA NE – NE – NE – NE – NE – 1
OLFACTORY NEUROBLASTOMA 0.03 0.03-0.04 71 NA 0.04 0.03-0.05 0.03 0.02-0.04 0.02 0.00-0.07 <0.01 0.00-0.03 0.04 0.03-0.05 20
ODONTOGENIC MALIGNANT TUMOURS <0.01 0.00-0.01 12 NA NE – NE – NE – NE – NE – 4
NE: not estimable because 15 or less incident cases were observed NA: not applicable
INCIDENCE
EMBRYONAL TUMOURS. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed cases and proportion
of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015 in Italy.
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AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-4 yrs 5-14 yrs 15+ yrs
EMBRYONAL
TUMOURS
EMBRYONAL TUMOURS 0.76 0.59-0.96 0.87 0.69-1.09 3.74 3.35-4.17 9.46 3.78-15.15 6 085
NEUROBLASTOMA AND GANGLIONEUROBLASTOMA 0.38 0.26-0.53 0.34 0.23-0.49 1.47 1.23-1.75 2.89 1.78-3.99 1 922
NEPHROBLASTOMA 0.17 0.10-0.28 0.24 0.15-0.37 1.16 0.94-1.41 2.36 1.41-3.31 1 638
RETINOBLASTOMA 0.08 0.03-0.16 0.09 0.04-0.18 0.53 0.39-0.70 0.70 0.40-1.00 543
HEPATOBLASTOMA 0.05 0.01-0.12 0.08 0.03-0.17 0.18 0.11-0.30 2.63 0.00-8.08 1 474
PLEUROPULMONARY BLASTOMA 0.01 0.00-0.06 NE – 0.01 0.00-0.06 0.01 0.00-0.01 6
PANCREATOBLASTOMA NE – NE – 0.01 0.00-0.06 0.34 0.00-1.01 180
OLFACTORY NEUROBLASTOMA 0.05 0.01-0.12 0.11 0.06-0.21 0.36 0.24-0.51 0.47 0.30-0.64 276
ODONTOGENIC MALIGNANT TUMOURS 0.02 0.00-0.08 NE – 0.02 0.00-0.08 0.06 0.00-0.15 47
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE
PREVALENCE
EMBRYONAL TUMOURS. Observed prevalence (pro-
portion per 100,00 and 95% confidence interval - 95%
CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence
date (1st January 2007), and complete prevalence. Esti-
mated prevalent cases in 2010 in Italy.
PROPORTION 95% CI PROPORTION 95% CI PROPORTION 95% CI PROPORTION 95% CI
AIRTUM POOL
COMPLETE PREVALENCE
≤2 YEARS 2-5 YEARS ≤15 YEARS
OBSERVED PREVALENCE BY DURATION
EMBRYONAL TUMOURS 710
NEUROBLASTOMA AND GANGLIONEUROBLASTOMA 298
NEPHROBLASTOMA 208
RETINOBLASTOMA 93
HEPATOBLASTOMA 33
PLEUROPULMONARY BLASTOMA 2 NE
PANCREATOBLASTOMA 5 NE
OLFACTORY NEUROBLASTOMA 64
ODONTOGENIC MALIGNANT TUMOURS 8 NE
NE: not estimable because 30 or less incident cases were observed
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EMBRYONAL
TUMOURS
Embryonal cancers are a heterogeneous group of cancers. They oc-
cur mainly in children, with the exception of some very rare types
(olfactory neuroblastoma, odontogenic tumours). Several studies
indicate that the incidence of embryonal cancer is increasing.1-3 The
risk of developing embryonal cancer is higher in children with cer-
tain genetic syndromes or congenital malformations,4-6 which ac-
count for no more than 5% of all cases. Environmental factors,
such as ionising radiation, toxic therapies, herbicides, tobacco
smoke, and diet, have been investigated as potential causes of em-
bryonal cancers, particularly for exposure in the womb or at a very
young age.1,2,7 Changing foetal growth conditions related to in-
creasing age at first pregnancy, exposure to sex hormones, and in-
creasing birth weight have also been investigated.7 Childhood
cancers such as nephroblastoma and retinoblastoma have been in-
tensely studied: their clinical and biological characteristics are
well known and numerous clinical trials have been conducted by
cooperative groups, resulting in the development of effective ther-
apies. By contrast, hepatoblastoma, pulmonary blastoma, pancre-
atoblastoma, olfactory neuroblastoma, and odontogenic tumours
are rare, even among childhood cancers;8 nevertheless, they, too,
have been investigated by cooperative research programs9 either in
the context of rare paediatric tumours as a group, or as individual
entities.
The embryonal tumours considered in this monograph are:
 neuroblastoma and ganglioneuroblastoma;
 nephroblastoma;
 retinoblastoma;
 hepatoblastoma;
 olfactory neuroblastoma;
 pleuropulmonary blastoma;
 pancreatoblastoma;
 odontogenic tumours.
NEUROBLASTOMA AND GANGLIONEUROBLASTOMA
Incidence
About 100 new diagnoses are estimated in 2015 in Italy. Incidence
is 10% more frequent in boys than girls (not significant). The ma-
jority of cases occurs in children aged <5 years, with an incidence
rate (IR) of 2.9 per 100,000. The annual crude IR is 0.2 per
100,000, higher than the IR observed if the European
RARECAREnet database (www.rarecarenet.eu) (0.1 per 100,000).
In Europe, incidence in children significantly increased between
1978 and 1997.10
Survival
Survival significantly drops after the first year of diagnosis, from
92% to 68% at 5 years. Data from EUROCARE-511 show 5-year
relative survival (RS) to be excellent in infants (91%) and worse
in children 1-14 years of age, between 52% and 59%. Actually, the
majority of low-risk neuroblastomas are among infants, most
likely for the propensity of neuroblastomas of infancy to undergo
spontaneous regression. According to the RARECAREnet data-
base, 5-year RS in children is slightly better in Italy than in Europe
(71% vs. 79%). In Europe from 1999 to 2007 no progress was re-
ported for neuroblastoma in children.11
Prevalence
Around 2,000 patients were estimated to be living with a diagnosis of
neuroblastoma and ganglioblastoma in 2010. Almost 50% of prevalent
cases were diagnosed 15 or more years before the prevalence date.
NEPHROBLASTOMA
Incidence
In Italy, about 70 children and adults are diagnosed with nephrob-
lastoma each year; most (99%) nephroblastomas are diagnosed in
children aged less than 5 years. The highest IR is in the first 2 years
of life. Thus, the annual IR per 100,000 decreases from 1.7 to 0.01
across ages.
Incidence is slightly higher among females than males. European
childhood IRs significantly increased among girls and among chil-
dren aged 5 or less years only.10
According to the RARECAREnet database (www.rarecarenet.eu),
there are no differences between Italian and European rates. 
Survival
One- and 5-year RS are 97% and 89%, respectively. In Europe, 5-
year RS is better in children (92%) than in adults (64%).12 Accord-
ing to the RARECAREnet database, there are no differences in
prognosis between Europe and Italy, for the period 2000-2007.
Prevalence
Around 1,600 people were estimated to be living with a diagnosis of
nephroblastoma in 2010. Almost 50% of prevalent cases were diag-
nosed 15 or more years before the prevalence date.
RETINOBLASTOMA
Incidence
In Italy, approximately 30 children are diagnosed with retinoblastoma
each year, with almost 95% occurring before five years of age. The an-
nual IR per 100,000 for the period 2000-2007 is 1.0, in children <5
years of age. There are no differences between genders. The overall IR
is 0.05 per 100,000 in Italy and Europe, according to the
RARECAREnet database. In Europe, age-standardized rates were
higher in Northern and Southern Europe and in the UK and Ireland.12
Survival
The outcome of children diagnosed with retinoblastoma in the period
2000-2007 is favourable, with 99% alive five years after diagnosis.
Prevalence
Slightly more than 500 people were estimated to be living with a di-
agnosis of retinoblastoma in 2010.
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TUMOURS
HEPATOBLASTOMA
Incidence
About 10 new cases are diagnosed in Italy each year, all occurring
in children. The peak is in those aged <5 years, with an IR of about
3 cases per million. Incidence is slightly higher among boys than
girls. There are no differences between the Italian and European
rates, according to the RARECAREnet database. The incidence of
hepatoblastoma increased during the period 1975-1995 in the
US, while no increment was reported for Europe.10,13
Survival
Based on 33 cases, 1- and 5-year RS are 85% and 70%, respectively.
According to the RARECAREnet database, RS is slightly lower in Italy
than Europe (76% at 5 years). There was an impressive progress in Eu-
rope: 5-year RS increased from 59% (1995-1999) to 82% (2004-
2007). Cooperative research programs, such as the International Child-
hood Liver Tumour Strategy Group (SIOPEL), on hepatoblastoma are
responsible for the excellent progress.9
Prevalence
Around 1,500 children were estimated to be living with a diagnosis of
hepatoblastoma in Italy in 2010; most of them were diagnosed 15 or
more years before the prevalence date.
OLOFACTORY NEUROBLASTOMA
Incidence
In Italy, about 20 cases of olfactory neuroblastoma are diagnosed
each year.
Survival
Based on 64 cases, 1- and 5-year RS are 86% and 76%, respectively.
According to the RARECAREnet database, RS is slightly better in
Italy than Europe (1- and 5-year RS: 81% and 64%, respectively).
Prevalence
Around 300 persons were estimated to be living with a diagnosis of ol-
factory neuroblastoma in Italy in 2010.
PLEUROPULMONARY BLASTOMA,
PANCREATOBLASTOMA,
AND ODONTOGENIC TUMOURS
These tumours are so rare that in 11 years (2000-2010) in the AIR-
TUM dataset only 2, 5, and 12 cases, respectively, were observed.
In the RARECAREnet database, in the period 2000-2007, there
were 9, 39, and 69 cases. It is not possible to provide estimates of
survival for these tumours on the basis of the Italian data. According
to the RARECAREnet database, 5-year RS for pancreatoblastoma
is 34% (based on 35 cases) and for odontogenic tumours it is 62%
(based on 69 cases).
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SARCOMAS 9.03 8.90-9.15 20 019 100% 9.54 9.35-9.72 8.55 8.38-8.72 4.75 4.65-4.87 12.72 12.30-13.15 21.37 20.94-21.81 5 883
SOFT TISSUE SARCOMAS 6.27 6.17-6.38 13 914 NA 5.95 5.80-6.09 6.58 6.43-6.73 3.49 3.40-3.59 9.23 8.87-9.60 13.97 13.62-14.33 4 072
Soft tissue sarcomas of head and neck 0.31 0.29-0.33 683 0.41 0.37-0.45 0.21 0.19-0.24 0.13 0.12-0.15 0.39 0.32-0.47 0.85 0.77-0.94 206
Soft tissue sarcomas of limbs 1.27 1.23-1.32 2 823 1.38 1.31-1.45 1.17 1.11-1.24 0.67 0.63-0.71 1.74 1.58-1.90 3.05 2.88-3.21 827
Soft tissue sarcomas of superficial trunk 0.69 0.65-0.72 1 526 0.81 0.76-0.86 0.57 0.53-0.62 0.33 0.30-0.36 1.09 0.97-1.22 1.68 1.56-1.81 447
Soft tissue sarcomas of mediastinum 0.04 0.03-0.04 79 0.04 0.03-0.05 0.03 0.02-0.04 0.02 0.01-0.02 0.07 0.04-0.11 0.08 0.06-0.11 23
Soft tissue sarcomas of heart 0.01 0.01-0.02 32 0.01 0.01-0.02 0.02 0.01-0.02 <0.01 0.00-0.01 0.02 0.01-0.05 0.03 0.02-0.05 9
Soft tissue sarcomas of breast 0.24 0.22-0.27 543 <0.01 0.00-0.02 0.47 0.43-0.51 0.17 0.15-0.19 0.38 0.31-0.46 0.42 0.36-0.48 160
Soft tissue sarcomas of uterus 0.69 0.65-0.72 1 525 0.00 – 1.33 1.27-1.40 0.50 0.46-0.54 1.21 1.09-1.35 1.01 0.92-1.11 447
Other soft tissue sarcomas of genitourinary tract 0.27 0.25-0.29 596 0.26 0.23-0.29 0.28 0.25-0.31 0.11 0.09-0.13 0.43 0.35-0.51 0.71 0.64-0.80 176
Soft tissue sarcomas of viscera 0.53 0.50-0.56 1 183 0.62 0.57-0.67 0.45 0.42-0.49 0.17 0.15-0.20 0.84 0.73-0.96 1.57 1.46-1.70 350
Soft tissue sarcomas of paratestis 0.05 0.04-0.06 120 0.11 0.09-0.13 0.00 – 0.02 0.01-0.02 0.10 0.07-0.14 0.16 0.12-0.20 37
Soft tissue sarcomas of retroperitoneum and peritoneum 0.54 0.51-0.57 1 198 0.53 0.49-0.58 0.55 0.50-0.59 0.19 0.17-0.21 1.08 0.96-1.21 1.40 1.29-1.52 349
Soft tissue sarcomas of pelvis 0.21 0.19-0.23 463 0.22 0.20-0.25 0.20 0.17-0.22 0.11 0.10-0.13 0.35 0.28-0.43 0.45 0.39-0.52 137
Soft tissue sarcomas of skin 0.78 0.74-0.82 1 731 0.87 0.82-0.93 0.69 0.65-0.74 0.58 0.54-0.62 0.75 0.65-0.86 1.48 1.37-1.60 502
Soft tissue sarcomas of paraorbit <0.01 0.00-0.01 8 NE – NE – NE – NE – NE – 2
Soft tissue sarcomas of brain and other parts 0.14 0.13-0.16 318 0.16 0.14-0.19 0.12 0.10-0.15 0.10 0.08-0.11 0.22 0.17-0.28 0.26 0.21-0.31 91
of nervous system
Embryonal rhabdomyosarcoma of soft tissue 0.05 0.04-0.06 116 0.06 0.05-0.08 0.04 0.03-0.05 0.07 0.06-0.09 <0.01 0.00-0.03 <0.01 0.00-0.02 32
Alveolar rhabdomyosarcoma of soft tissue 0.04 0.03-0.05 87 0.04 0.03-0.05 0.04 0.03-0.05 0.05 0.04-0.06 0.03 0.01-0.06 0.03 0.01-0.04 25
Ewing’s sarcoma of soft tissue 0.08 0.07-0.09 179 0.09 0.07-0.11 0.08 0.06-0.09 0.08 0.06-0.09 0.10 0.06-0.14 0.08 0.06-0.11 49
BONE SARCOMAS 0.80 0.76-0.84 1 770 NA 0.93 0.87-0.99 0.67 0.63-0.72 0.67 0.63-0.72 0.88 0.78-1.00 1.17 1.07-1.28 499
Osteogenic sarcoma 0.17 0.16-0.19 383 0.19 0.17-0.22 0.15 0.13-0.18 0.18 0.16-0.20 0.12 0.08-0.17 0.18 0.14-0.23 106
Chondrogenic sarcomas 0.24 0.22-0.26 536 0.27 0.24-0.30 0.22 0.19-0.25 0.14 0.12-0.16 0.41 0.34-0.49 0.49 0.43-0.56 153
Notochordal sarcomas, chordoma 0.08 0.07-0.09 170 0.10 0.08-0.12 0.05 0.04-0.07 0.03 0.03-0.04 0.13 0.09-0.18 0.19 0.15-0.24 49
Vascular sarcomas 0.01 0.01-0.02 28 0.02 0.01-0.03 <0.01 0.00-0.01 <0.01 0.00-0.01 0.01 0.00-0.04 0.03 0.01-0.04 8
Ewing’s sarcoma 0.12 0.11-0.14 277 0.16 0.14-0.19 0.09 0.07-0.11 0.17 0.15-0.20 0.03 0.01-0.06 0.02 0.01-0.03 74
Epithelial tumours, adamantinoma 0.01 0.01-0.02 32 0.02 0.01-0.03 0.01 0.01-0.02 0.01 0.01-0.02 0.01 0.00-0.04 0.02 0.01-0.04 9
Other high grade sarcomas 0.02 0.01-0.02 36 0.01 0.01-0.02 0.02 0.01-0.03 0.01 0.01-0.02 0.03 0.01-0.05 0.03 0.02-0.05 10
(fibrosarcoma, malignant fibrous histiocytoma)
GASTROINTESTINAL STROMAL TUMOURS 0.59 0.56-0.62 1 307 NA 0.66 0.61-0.71 0.53 0.48-0.57 0.17 0.15-0.20 1.12 1.00-1.25 1.68 1.56-1.81 386
KAPOSI SARCOMA 1.37 1.32-1.42 3 028 NA 2.00 1.92-2.09 0.77 0.72-0.82 0.42 0.38-0.45 1.48 1.34-1.63 4.54 4.35-4.75 927
NE: not estimable because 15 or less incident cases were observed NA: not applicable
INCIDENCE
SARCOMAS. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed cases and proportion of rare cancers
on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015 in Italy.
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AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
SARCOMAS
ESTIMATED
NEW CASES  
2015
ITALY
SARCOMAS
SARCOMAS 16 558
SOFT TISSUE SARCOMAS 11 526
Soft tissue sarcomas of head and neck 559
Soft tissue sarcomas of limbs 2 370
Soft tissue sarcomas of superficial trunk 1 265
Soft tissue sarcomas of mediastinum 69
Soft tissue sarcomas of heart 25 NE
Soft tissue sarcomas of breast 449
Soft tissue sarcomas of uterus 1 255
Other soft tissue sarcomas of genitourinary tract 504
Soft tissue sarcomas of viscera 985
Soft tissue sarcomas of paratestis 105
Soft tissue sarcomas of retroperitoneum and peritoneum 1 015
Soft tissue sarcomas of pelvis 378
Soft tissue sarcomas of skin 1 439
Soft tissue sarcomas of paraorbit 7 NE
Soft tissue sarcomas of brain and other parts of nervous system 271
Embryonal rhabdomyosarcoma of soft tissue 95
Alveolar rhabdomyosarcoma of soft tissue 76
Ewing’s sarcoma of soft tissue 161
BONE SARCOMAS 1 488
Osteogenic sarcoma 323
Chondrogenic sarcomas 446
Notochordal sarcomas, chordoma 141
Vascular sarcomas 23 NE
Ewing’s sarcoma 245
Epithelial tumours, adamantinoma 28 NE
Other high grade sarcomas (fibrosarcoma, malignant fibrous histiocytoma) 29 NE
GASTROINTESTINAL STROMAL TUMOURS 1 059
KAPOSI SARCOMA 2 505
NE: not estimable because 30 or less incident cases were observed
SARCOMAS. One and 5-year relative survival. Error bars are 95% confidence interval. Cohort approach (complete analysis), period of diagnosis
2000-2008.
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SURVIVAL
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No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100%
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
SARCOMAS 17.34 16.48-18.24 18.76 17.86-19.70 71.31 69.55-73.11 118.50 114.87-122.14 68 931
SOFT TISSUE SARCOMAS 12.67 11.93-13.44 12.52 11.78-13.28 49.46 47.99-50.96 85.25 82.67-87.84 49 580
Soft tissue sarcomas of head and neck 0.68 0.52-0.87 0.56 0.41-0.74 2.42 2.11-2.77 4.04 3.49-4.59 2 387
Soft tissue sarcomas of limbs 2.69 2.35-3.05 3.35 2.98-3.76 11.54 10.83-12.27 18.55 17.40-19.71 10 719
Soft tissue sarcomas of superficial trunk 1.50 1.26-1.78 1.20 0.99-1.46 4.91 4.46-5.40 9.20 8.31-10.09 5 368
Soft tissue sarcomas of mediastinum 0.03 0.01-0.10 0.03 0.01-0.10 0.10 0.05-0.20 0.28 0.08-0.49 161
Soft tissue sarcomas of heart 0.02 0.00-0.08 0.01 0.00-0.06 0.06 0.02-0.13 0.23 0.00-0.46 130
Soft tissue sarcomas of breast 0.57 0.42-0.75 0.63 0.48-0.82 2.86 2.52-3.24 4.59 3.99-5.18 2 681
Soft tissue sarcomas of uterus 1.15 0.93-1.40 1.28 1.05-1.54 4.90 4.45-5.39 8.70 7.72-9.69 5 096
Other soft tissue sarcomas of genitourinary tract 0.50 0.37-0.68 0.41 0.29-0.57 1.73 1.47-2.03 3.22 2.70-3.74 1 882
Soft tissue sarcomas of viscera 0.90 0.71-1.12 0.86 0.68-1.08 3.10 2.74-3.50 4.09 3.60-4.58 2 372
Soft tissue sarcomas of paratestis 0.07 0.03-0.15 0.15 0.08-0.26 0.59 0.44-0.77 0.68 0.49-0.87 384
Soft tissue sarcomas of retroperitoneum and peritoneum 1.08 0.87-1.32 0.85 0.66-1.06 3.16 2.80-3.56 3.79 3.34-4.25 2 185
Soft tissue sarcomas of pelvis 0.34 0.23-0.49 0.36 0.24-0.51 1.35 1.11-1.61 3.13 2.40-3.86 1 820
Soft tissue sarcomas of skin 2.07 1.78-2.39 2.05 1.76-2.37 9.00 8.38-9.65 15.36 14.20-16.53 8 901
Soft tissue sarcomas of paraorbit 0.02 0.00-0.08 0.01 0.00-0.06 0.07 0.03-0.15 0.35 0.03-0.67 206
Soft tissue sarcomas of brain and other parts of nervous system 0.25 0.16-0.38 0.24 0.15-0.37 0.98 0.78-1.21 1.93 1.51-2.35 1 136
Embryonal rhabdomyosarcoma of soft tissue 0.10 0.05-0.20 0.07 0.03-0.15 0.41 0.28-0.56 1.79 0.57-3.02 1 026
Alveolar rhabdomyosarcoma of soft tissue 0.11 0.06-0.21 0.05 0.01-0.12 0.23 0.14-0.35 0.37 0.18-0.56 256
Ewing’s sarcoma of soft tissue 0.21 0.12-0.33 0.10 0.05-0.20 0.46 0.33-0.63 1.15 0.70-1.59 672
BONE SARCOMAS 1.20 0.98-1.46 1.69 1.42-1.98 6.39 5.87-6.95 11.41 10.41-12.41 6 639
Osteogenic sarcoma 0.23 0.14-0.35 0.29 0.19-0.42 1.32 1.09-1.58 3.41 2.67-4.16 1 990
Chondrogenic sarcomas 0.41 0.29-0.57 0.62 0.46-0.81 2.27 1.96-2.61 4.42 3.78-5.05 2 570
Notochordal sarcomas, chordoma 0.11 0.06-0.21 0.23 0.14-0.35 0.64 0.48-0.83 0.75 0.55-0.94 428
Vascular sarcomas 0.02 0.00-0.08 NE – 0.10 0.05-0.20 0.19 0.06-0.31 102
Ewing’s sarcoma 0.23 0.14-0.35 0.31 0.20-0.45 1.08 0.87-1.32 2.13 1.30-2.96 1 284
Epithelial tumours, adamantinoma 0.01 0.00-0.06 0.02 0.00-0.08 0.09 0.04-0.18 0.15 0.04-0.25 83
Other high grade sarcomas (fibrosarcoma, malignant fibrous histiocytoma) 0.02 0.00-0.08 0.02 0.00-0.08 0.14 0.08-0.25 0.29 0.13-0.45 158
GASTROINTESTINAL STROMAL TUMOURS 1.20 0.98-1.45 1.62 1.36-1.91 3.75 3.36-4.18 4.83 4.26-5.39 2 788
KAPOSI SARCOMA 2.28 1.98-2.63 2.96 2.60-3.34 11.84 11.12-12.58 17.01 14.73-19.30 9 924
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE
PREVALENCE
SARCOMAS. Observed prevalence (proportion per 100,00 and 95% confidence interval - 95% CI) by duration (≤2, 2-5, ≤15
years) prior to prevalence date (1st January 2007), and complete prevalence. Estimated prevalent cases in 2010 in Italy.
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SARCOMAS
Sarcoma is a malignant neoplasm arising from mesenchymal cells;
it includes a heterogeneous group of tumours. It can be split up
into dozens of histological categories, and it can occur in virtually
any anatomic site. This gives rise to a huge number of possible
combinations of histology and primary site which are of clinical
importance. The anatomic site influences the therapeutic choice,
in particular making surgery more or less viable or even impossible,
but histology also influences prognosis and responsiveness to
chemotherapy. It is important to consider the primary site as well
as the histologic type when presenting soft tissue sarcomas (STSs)
statistics.1 These characteristics have made it almost impossible up
now to have reliable statistics on incidence, mortality, prevalence,
and survival per single type of sarcoma in each site even at the na-
tional level. In this study, for the first time we have the opportunity
to estimate reliable incidence, prevalence, and survival statistics
even for very rare sarcomas.
In this monograph we present:
 soft tissue sarcomas (STS) of organ-specific sites
(head and neck, limbs, superficial trunk, mediastinum, heart,
breast, uterus, genitourinary tract, viscera, paratestis,
retroperitoneum and peritoneum, pelvis, skin, paraorbit,
brain and other parts of the nervous system, embryonal
rhabdomyosarcoma of soft tissue, alveolar rhabdomyosarcoma
of soft tissue, Ewing’s sarcoma of soft tissue);
 bone sarcomas (osteogenic and chondrogenic sarcomas,
chordoma, vascular sarcomas, Ewing’s sarcoma of bone,
adamantinoma, other high grade sarcomas);
 gastrointestinal stromal tumours (GIST);
 Kaposi sarcoma (KS).
The latter is described in the group of sarcomas even if it is not
properly a sarcoma.
We adopted the same classification used in the RARECARE proj-
ect.2 This classification renders the clinical importance of both
anatomic site of origin and histology in these tumours.2
WHAT DO WE KNOW ABOUT THESE CANCERS?
STSs represent less than 1% of malignant tumours and show a
broad range of differentiation according to the anatomic site they
occur in: smooth muscle (leiomyosarcoma), adipocyte (liposar-
coma), striated muscle (rhabdomyosarcoma), endothelium (an-
giosarcoma), or fibroblast (dermatofibrosarcoma).3 In the last two
decades, cytogenetic findings have provided a valuable and repro-
ducible tool for STS classification. The use of the molecular clas-
sification makes it possible to report variation in incidence patterns
of STS by histologic type, supporting the notion that these tu-
mours are aetiologically distinct and that they should be considered
separately in analytic studies. 
Little is known about their aetiology, however few risk factors are
known: ionising radiation, especially in the form of radiotherapy
for a previous cancer, environmental factors (e.g., herbicides, diox-
ins), immunodeficiency (e.g., AIDS), and viral infections (Epstein
Barr virus, human herpes virus type 8).4-8 Several heritable syn-
dromes are associated with increased risk of sarcomas. Those
which account for the largest number of cases are neurofibromato-
sis 1 (nerve sheath tumours), heritable retinoblastoma (osteosar-
coma and various STSs), and Li-Fraumeni syndrome (osteosar-
coma and STS).9
KS is a virus-related malignancy which most frequently arises in the
skin, though mucosal sites, lymph nodes, and viscera can also be in-
volved. Infection with Kaposi sarcoma herpes virus (KSHV, previ-
ously known as human herpes virus type 8, HHV-8) is required for
the development of KS. Historically, KS occurred as two clinically
and epidemiologically distinct subtypes, classic and endemic. Classic
KS is predominantly a disease of the elderly of Mediterranean or
Middle Eastern origin without apparent immunosuppression; never
smoking, diabetes, and use of oral corticosteroids are risk factors. En-
demic KS occurs almost entirely in sub-Saharan Africa and it is dif-
ficult to disentangle endemic KS and HIV-related KS.10
Strong geographic variations have been observed for sarcoma sur-
vival among European countries. These differences are usually in-
terpreted as differences in accessibility to effective care. In partic-
ular, the expertise of the centre has been recognised to be important
for the outcome.2 Sarcoma clinical management should be carried
out in centres of expertise for sarcomas and/or within reference net-
works sharing multidisciplinary expertise and treating a high num-
ber of patients annually. This centralised referral should be pursued
as early as the time of the clinical suspicion of sarcoma. 
This is the first time that data on all sarcomas are shown separately
and by site. Usually cancer statistics (ITACAN, GLOBOCAN,
NORDCAN, SEER) give data only by site, and tumours of soft
tissue and bone represent the best proxy to describe soft tissue and
bone sarcomas.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
STSs are the most frequent (70%) sarcomas; altogether, they are
slightly higher in females than in males, but this is due to the rel-
atively high incidence rate of sarcomas of the uterus and breast. In
the other non-gender specific sites, sarcomas are slightly higher in
males than females. The most frequent sites are limbs, followed by
skin, uterus, and superficial trunk. Bone sarcomas and GIST are
9% and 7% of all sarcomas, respectively (incidence table, p. 85).
Regarding GIST, the AIRTUM incidence rate (IR) is of 0.6 per
100,000 (see table p. 85). This result is close to the IR of 0.7 per
100,000 observed in an Italian population-based study based on
a pathology review,11 but still slightly below the IR (range of 1.0-
1.5 per 100,000) reported in other population-based studies based
on pathological reviews and performed in various European coun-
tries.2 The IR increases with age for most STSs. The main excep-
tions are: embryonal rhabdomyosarcoma, which is the most fre-
quent histology at age 0-14, with an IR of 0.3 per 100,000 and
occurs mainly in the first 4 years of life, and alveolar rhab-
domyosarcoma, which also occurs mainly at ages 0-14; soft tissue
sarcomas of uterus have a peak at ages 45-49, Ewing’s sarcomas of
soft tissue shows an almost flat incidence curve with age (data not
shown). The overall age incidence pattern for bone sarcomas is bi-
modal, with peaks at ages 10-19 and 65+. Of the three most fre-
quent subtypes, osteosarcoma and Ewing’s sarcoma of the bone
have their highest incidence at ages 10-19 and incidence of chon-
drogenic sarcomas is greatest at age 65+.
KS is relatively frequent in Italy, with an IR of 1.4 per 100,000. The
relatively high incidence of classic KS in Italy is known12 and is con-
firmed even in our data, which show the highest IR of KS (4.5 per
100,000) in those aged 65+ (see table p. 85).
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SARCOMAS
Survival
Five-year relative survival (RS) is 62% for STSs, 60% for bone sar-
comas, 67% for GIST. STSs of paratestis and skin (mainly der-
matofibrosarcoma protuberans) have the highest survival rate
(92% and 91%, respectively), while STSs of mediastinum have
survival rates of 20%. Five-year RS from STSs of the uterus is 56%
(survival figure, p. 86). In Europe 5-year RS from STSs of the
uterus was 49% overall, but it was 65% for tumours of stromal his-
tology (mainly endometrial stromal tumour) and 42% for other
types, predominantly leiomyosarcoma and sarcoma NOS (not
otherwise specified).2
In Italy, among bone sarcomas, survival rate is highest for chon-
drogenic sarcomas and chordoma (66%). The number of cases is
too limited in the AIRTUM database to estimate 5-year RS of the
rare adamantinoma and vascular sarcomas; however, according to
previous European published data, the 5-year RS of these rare sar-
comas was 83% and 34%, respectively.2 There is general agreement
that treatment of sarcomas should be concentrated in specialist
centres with multidisciplinary expertise and knowledge of the dis-
ease, though the effect of such a policy on survival has seldom been
evaluated. As cancer registries come to collect more information
on stage and treatment and place of treatment, the evaluation of
such a policy should become a priority.
ForGIST, 5-year RS (67%; see figure p. 86) is similar to previous
published data at European level,2 thanks to the introduction of
molecularly targeted therapies. It will be interesting to look at epi-
demiological data on GIST, when they become available from can-
cer registries in the next few years, to see how a major breakthrough
involving a targeted agent can translate into prognostic improve-
ments on a population basis in different settings. An important
challenge for cancer registries will be to develop the ability to track,
at the population level, the highly selective improvements resulting
from this kind of “histology-driven” or “molecularly-driven” ther-
apy, affecting single histologies or clinical presentations with low
numbers of eligible patients. A proper pathologic diagnosis on a
population basis would be crucial in this regard, and it is well
known that this is still a challenge.
Five-year RS of KS (86%; see figure p. 86) is slightly higher in Italy
than in Europe, but similar to that observed in Southern Europe.10
Higher survival in Southern Europe (including Italy) may partially
reflect predominantly less aggressive disease in patients with classic
KS and greater clinical experience as a consequence of the higher
incidence of both major subtypes of KS.10
Prevalence
About 69,000 persons were estimated to be alive in 2010 with a past
diagnosis of sarcoma in Italy. The most prevalent sarcomas were STSs
(about 50,000 cases), followed by bone sarcomas (about 7,000 cases).
The distribution of prevalence by time since diagnosis was fairly
similar for the different sarcomas. We estimated about 10,000 preva-
lent cases of KS, which is slightly higher than the estimates published
in the AIRTUM monograph on prevalence.13 This is due to the
method used to estimate complete prevalence, which leads to an
overestimation of tumours, such as KS, which have different incidence
across Italian areas (see «Materials and methods», pp. 14-21).
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100%
OF NEUROENDOCRINE
TUMOURS
ARE RARE
SOURCE: AIRTUM. ITALIAN CANCER FIGURES–REPORT 2015
100%80%60%40%20%0%
NEUROENDOCRINE TUMOURS 4.15 4.06-4.23 9 196 NA 4.31 4.18-4.43 4.00 3.88-4.12 1.49 1.42-1.55 7.37 7.05-7.70 11.27 10.95-11.58 2 697
GEP, well-differentiated not functioning  0.89 0.85-0.93 1 970 0.97 0.91-1.03 0.81 0.76-0.87 0.34 0.31-0.37 1.58 1.44-1.74 2.34 2.20-2.49 576
endocrine carcinoma
GEP, well-differentiated functioning endocrine carcinoma 0.02 0.01-0.03 41 0.02 0.01-0.03 0.02 0.01-0.03 <0.01 0.01-0.02 0.06 0.03-0.09 0.03 0.01-0.05 12
GEP, poorly-differentiated endocrine carcinoma 1.01 0.97-1.05 2 233 1.20 1.13-1.26 0.83 0.78-0.89 0.31 0.28-0.34 1.87 1.72-2.04 2.85 2.69-3.01 655
GEP, mixed endocrine-exocrine carcinoma <0.01 0.00-0.01 17 <0.01 0.00-0.01 <0.01 0.00-0.02 <0.01 0.00-0.01 <0.01 0.00-0.03 0.01 0.01-0.03 5
Neuroendocrine carcinoma of thyroid gland 0.51 0.48-0.54 1 125 0.38 0.34-0.42 0.63 0.58-0.67 0.30 0.27-0.33 1.05 0.93-1.18 0.88 0.80-0.97 320
Neuroendocrine carcinoma of skin 0.34 0.32-0.37 759 0.33 0.30-0.37 0.35 0.32-0.39 0.03 0.02-0.04 0.34 0.28-0.42 1.42 1.31-1.54 238
Typical and atypical carcinoid of the lung 0.60 0.57-0.63 1 328 0.56 0.51-0.60 0.64 0.59-0.68 0.27 0.24-0.30 1.17 1.05-1.31 1.37 1.26-1.49 378
Neuroendocrine carcinoma of other sites 0.71 0.68-0.75 1 585 0.77 0.72-0.83 0.66 0.61-0.71 0.18 0.16-0.21 1.16 1.03-1.29 2.26 2.12-2.41 474
Pheochromocytoma, malignant 0.04 0.03-0.05 94 0.04 0.03-0.06 0.04 0.03-0.05 0.03 0.02-0.04 0.08 0.05-0.12 0.07 0.05-0.10 27
Paraganglioma 0.02 0.01-0.03 44 0.02 0.02-0.03 0.02 0.01-0.03 0.01 0.01-0.02 0.05 0.03-0.08 0.03 0.02-0.05 13
NA: not applicable           GEP: gastroenteropancreatic tract
INCIDENCE
NEUROENDOCRINE TUMOURS. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed cases and pro-
portion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015 in Italy.
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AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
NEUROENDOCRINE
TUMOURS
NEUROENDOCRINE TUMOURS
GEP, well-differentiated not functioning endocrine carcinoma 1 606
GEP, well-differentiated functioning endocrine carcinoma 31
GEP, poorly-differentiated endocrine carcinoma 1 779
GEP, mixed endocrine-exocrine carcinoma 17 NE
Neuroendocrine carcinoma of thyroid gland 907
Neuroendocrine carcinoma of skin 604
Typical and atypical carcinoid of the lung 1 083
Neuroendocrine carcinoma of other sites 1 277
Pheochromocytoma malignant 75
Paraganglioma 38
NE: not estimable because 30 or less incident cases were observed   GEP: gastroenteropancreatic tract
NEUROENDOCRINE TUMOURS. One and 5-year relative survival. Error bars are 95% confidence interval. Co-
hort approach (complete analysis), period of diagnosis 2000-2008.SURVIVAL
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100%
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
NEUROENDOCRINE TUMOURS 7.38 6.82-7.97 7.65 7.08-8.25 28.18 27.07-29.31 40.73 38.95-42.50 23 937
GEP, well-differentiated not functioning endocrine carcinoma 1.70 1.43-1.99 2.08 1.78-2.40 8.54 7.94-9.18 12.89 11.96-13.82 7 427
GEP, well-differentiated functioning endocrine carcinoma NE – 0.03 0.01-0.10 0.20 0.11-0.31 0.33 0.16-0.49 195
GEP, poorly-differentiated endocrine carcinoma 1.35 1.11-1.61 1.30 1.07-1.56 3.43 3.05-3.84 3.49 3.09-3.89 2 140
GEP, mixed endocrine-exocrine carcinoma 0.02 0.00-0.08 0.01 0.00-0.06 0.05 0.01-0.12 0.09 0.01-0.18 51
Neuroendocrine carcinoma of thyroid gland 1.24 1.01-1.49 1.48 1.24-1.76 4.93 4.47-5.42 9.45 8.51-10.39 5 455
Neuroendocrine carcinoma of skin 0.76 0.59-0.96 0.48 0.35-0.65 1.90 1.62-2.21 2.34 1.98-2.70 1 369
Typical and atypical carcinoid of the lung 1.33 1.10-1.60 1.38 1.14-1.65 6.07 5.57-6.61 8.34 7.62-9.06 4 995
Neuroendocrine carcinoma of other sites 0.96 0.77-1.19 0.76 0.59-0.96 2.77 2.43-3.14 3.16 2.76-3.56 1 932
Pheochromocytoma, malignant 0.02 0.00-0.08 0.08 0.03-0.17 0.28 0.18-0.41 0.47 0.28-0.66 275
Paraganglioma NE – 0.05 0.01-0.12 0.09 0.04-0.18 0.17 0.05-0.28 98
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE    GEP: gastroenteropancreatic tract
PREVALENCE
NEUROENDOCRINE TUMOURS.Observed prevalence
(proportion per 100,00 and 95% confidence interval -
95% CI) by duration (≤2, 2-5, ≤15 years) prior to preva-
lence date (1st January 2007), and complete prevalence.
Estimated prevalent cases in 2010 in Italy.
PROPORTION 95% CI PROPORTION 95% CI PROPORTION 95% CI PROPORTION 95% CI
AIRTUM POOL
COMPLETE PREVALENCE
≤2 YEARS 2-5 YEARS ≤15 YEARS
OBSERVED PREVALENCE BY DURATION
ESTIMATED
NEW CASES  
2015
ITALY
ESTIMATED 
PREVALENT
CASES 
2010
ITALY
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The list of rare cancers proposed by the European RARECARE
project (www.rarecare.eu) is based on a combination of ICD-O-
3 morphologies and topographies. This is appropriate for all rare
cancers and especially for neuroendocrine tumours. Morphologic
analyses, immunohistochemical studies, and, more recently, mo-
lecular studies have attempted to classify this family of neoplasms.
These classifications properly group neuroendocrine tumours
(NETs) according to grading, but diagnosis, treatment, and prog-
nosis also depend on the site of origin. Thus, in addition to grad-
ing, the site of origin should always be considered to understand
the different behaviour, clinical presentations, and prognosis of
these tumours and to properly describe them. 
The NET grouping proposed by RARECARE combines mor-
phologies (as a proxy of the grading) and topographies as follows:
 gastroenteropancreatic (GEP), well-differentiated non function-
ing endocrine carcinoma;
 GEP, well-differentiated functioning endocrine carcinoma;
 GEP, poorly differentiated endocrine carcinoma;
 GEP, mixed endocrine-exocrine carcinoma;
 neuroendocrine carcinoma of thyroid gland;
 neuroendocrine carcinoma of skin;
 typical and atypical carcinoid of the lung;
 neuroendocrine carcinoma of other sites;
 malignant pheochromocytoma;
 paraganglioma.
Poorly differentiated endocrine carcinoma of the lung is not con-
sidered in this monograph, because it is not considered rare by the
RARECARE cancer list (since its incidence is >6 per 100,000 at
EU level).
WHAT DO WE KNOW ABOUT THESE CANCERS?
NETs are neoplasms that originate from the diffuse neuroen-
docrine cell system which is in many different organs, sharing com-
mon expression of neuroendocrine markers and characterised by
amine, neuropeptide, or hormone production. NETs are rare tu-
mours and aetiological factors are unknown, apart from familial
syndromes like multiple endocrine neoplasia (MEN) and the re-
ported familial risk for gastrointestinal carcinoids.1 About 20% of
thyroid neuroendocrine carcinomas are related to MEN. No asso-
ciation was found with smoking for lung NETs, which are asso-
ciated with MEN in 8% of cases.2 Neuroendocrine carcinoma of
the skin is mostly represented by Merkel carcinoma, which is char-
acterised by an aggressive behaviour. Ultraviolet radiation exposure
plays an important role for the development of this cancer. Patients
with AIDS have a higher risk to develop this tumour.3 Poly-
omavirus infection has been detected in Merkel carcinoma and
seems to be a contributing factor to its development.4 Pheochro-
mocytoma and paraganglioma are both very rare and have similar
basic histopathological characteristics, but pheochromocytoma
arises from the adrenal medulla and paraganglioma from nerve
ganglia, mainly located in the head and neck. About 24%-27% of
pheochromocytoma or paraganglioma are associated with known
genetic mutations, which in children reach a prevalence of 40%.5
NETs have in general been considered indolent tumours with low
metastatic potential; however, some NET subtypes are highly ma-
lignant and carry a bad prognosis with the possibility to metastasise
to regional lymph nodes and distant organs. In general, the current
WHO guidelines divide NETs into well-differentiated, tradition-
ally referred to as carcinoids and pancreatic islet cell tumours, and
poorly differentiated tumours, with different prognosis.6,7 Most
poorly differentiated NETs (about 50%) have metastatic disease at
diagnosis, in contrast with well-differentiated NETs (20%).8
NET incidence is in constant, gradual increase in the Western pop-
ulations.7-9 Improvement in classification and new immunohisto-
chemical techniques could have contributed to this increase, but
it is still unclear if this trend is due to an increased awareness
among physicians and pathologists, improved diagnostic tools, or
an actual real increase in NET incidence.8 Furthermore, increasing
clinical and biological knowledge has led to changes in the classi-
fication of these tumours, which could be responsible for the ge-
ographical differences in incidence reported in the literature, to-
gether with different awareness of clinicians, different expertise of
pathologists, and availability of markers to identify these tumours
across countries.9 It should also be considered that registration is
based on a morphology code of the ICD-O-10 with a malignant
behaviour, so data may partly vary between clinical trial and pop-
ulation-based cancer registries. 
Incidence rate and distribution by anatomic site are widely variable
in the literature, depending on the specific code included in the
studies, so it is very difficult to compare the results. As the pathol-
ogy report is the basis for a correct diagnosis and for a correct iden-
tification and classification of NETs, it is essential that the patho-
logical report contains all the necessary information to identify the
NET and their different subtypes. Despite the lack of some clinical
and histopathological variables, such as associated syndromes
(ICD-O does not include any code for secretor function) or pro-
liferation index or grading, the association of ICD-O-3 codes
with the different sites proposed in this report properly captures
the different clinical behaviours of these tumours and thus repre-
sents the first unselected study from a large population in Italy to
describe the burden of these heterogeneous neoplasms in Italy. 
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
NETs included in this monograph are all rare cancers. In Italy 9,197
cases were registered in the period 2000-2010 leading to an inci-
dence rate (IR) of 4.15 per 100,000 (incidence table, p. 91). The
incidence of all NETs is slightly higher in Italy than in the European
RARECAREnet database (IR 3.5) (www.rarecarenet.eu), mainly
due to a slightly higher incidence in Italy than in Europe of poorly
differentiated GEP carcinoma, thyroid NETs, and well-differenti-
ated carcinoids of the lung. NETs occur with similar frequency in
males and females, except for neuroendocrine carcinoma of the thy-
roid, which has higher incidence in females than males, with an IR
of 0.63 vs. 0.38, respectively (see table p. 91) and poorly differen-
tiated GEP carcinoma, which is more frequent in males than fe-
males. The IR of NETs increases with age. In Italy about 2,700 new
cases are expected in 2015. About 46% of NETs are in the GEP sys-
tem with a marked heterogeneity in terms of biologic behaviour and
histological differentiation.
Tumours can be functioning, causing a specific syndrome, or non-
functioning. For tumours that arise mostly from the pancreas it is
possible to attribute a specific code of functioning tumours, for
other NETs it is not possible to identify syndrome-affected patients
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(about 10%, variable in relation to the stage and primary site).
The most frequent primary GEP sites are the small intestine (25%),
pancreas (22%), colon (19%), stomach (17%), and rectum (10%).
NETs of the appendix comprise only 5% of all GEP NETs (data
not shown). It is important to stress that carcinoid tumours of un-
certain malignant potential of the appendix are not included in the
data presented here. The most frequent morphologies of GEP
NETs are poorly differentiated carcinoma (52%) and well-differ-
entiated non functioning endocrine carcinoma (46%); well-differ-
entiated functioning endocrine carcinomas are very rare, probably
in part because of the lack of a code for functioning NETs arising
in sites other than the pancreas. Typical and atypical carcinoids of
lung are the second in order of frequency (14% of NETs). These
tumours occur mainly in the over-54-year age group, with only a
slight increase in those aged over 65 years, with an IR of 1.2 and
1.4, respectively (see table p. 91). Other lung NETs are not rare, and
are therefore not included in this report. Neuroendocrine carcinoma
of thyroid (12% of NETs) is mostly represented by medullary car-
cinoma, and occurs mainly in the fourth and fifth decade of life,
with an IR of 1.1 (see table p. 91). NETs of skin (8% of NETs) typ-
ically occur in people over 64 years of age, with an IR of 1.4 (see
table p. 91). Pheochromocytoma and paraganglioma are very rare
tumours, with 94 and 44 cases observed over 11 years of observation
in Italy. Neuroendocrine carcinoma of other sites is a very hetero-
geneous group including various primary sites, but also NETs of un-
known origin, and represent in total about 18% of NETs, with an
IR of 0.7 (see table p. 91). Of these, 13% are from the bladder, 11%
from the breast, 9% from the female genital tract, 9% from the res-
piratory tract, 7% from head and neck, 3% from the prostate, 2%
from the thymus, and 46% unknown origin. About 90% of all
NETs of other sites have poorly differentiated morphology (data not
shown).
Survival
In Italy, 1- and 5-year relative survival (RS) of NETs is 79% and 63%,
respectively (survival figure, p. 91); slightly higher than the European
RARECAREnet database (71% and 54% at 1 and 5-year, respec-
tively). Five-year RS is slightly higher in Italy than in the European
RARECAREnet database for GEP poorly differentiated, well-differ-
entiated functioning and non-functioning, for NETs of thyroid,
and for typical and atypical carcinoids of the lung. For the others, no
major differences are observed between Italy and Europe. For GEP
NETs a great difference in 5-year RS is observed between well-dif-
ferentiated non functioning carcinoma (RS: 76%) and poorly differ-
entiated tumours (RS: 44%) (see figure p. 91). This result is due to
the aggressiveness of poorly differentiated NETs. The small intestine
is the NET site with the best prognosis, as reported in the literature,8
which shows only a slight difference in RS between well-differentiated
NETs (1-year RS: 90%; 5-year RS: 77%) and poorly differentiated
NETs (1-year RS: 85%, 5-year RS: 71%) (data not shown). Absence
of symptoms in non functioning GEP NETs can lead to a delay in
diagnosis and increased probability of metastatic disease, which
make surgical treatment with curative intent impossible. The very
complex treatment, requiring multidisciplinary integration, may
lead to a heterogeneous care of these patients that could partially ex-
plain the geographical difference in survival observed across European
countries. One- and 5-year RS of typical and atypical carcinoids of
the lung is high (1-year RS: 94%, 5-year RS: 84%) see figure p. 91),
reflecting the good prognosis of these tumours. Survival is strongly
influenced by the possibility of receiving surgery, since surgery is the
only curative approach.11 Neuroendocrine carcinoma of thyroid
gland has a good prognosis, with 1- and 5-year RS >90% (see figure
p. 91). Age and stage at diagnosis are strictly correlated with survival.
NETs of skin have an RS of 85% at 1 year, which drops to 57% at
five years (see figure p. 91) This could be attributed to the aggres-
siveness of this tumour.
Diagnosis of metastasised disease in elderly patients could limit
treatments.12 Pheochromocytoma has an RS of 85% at 1 year and
70% at 5 years from diagnosis (see figure p. 91). Therapy of choice
is surgical resection after appropriate preoperative preparation. Ra-
diotherapy with MIBG could have a role in diffuse metastatic dis-
ease.13 Paraganglioma has a relatively good survival, although esti-
mates are based on 38 cases only. The worst RS is observed for
NETs of other sites (RS 56% at one year and 30% at five years) (see
figure p. 91), slightly better than European data (RS 48% and 24%,
respectively). The large proportion of NETs of unknown primary
site and of poorly differentiated NETs in this group can contribute
to explain their low RS.
Prevalence
About 25,000 persons were estimated to be living with a NET diag-
nosis in Italyin 2010. GEP, well-differentiated, non functioning en-
docrine carcinomas are the most prevalent NETs, followed by neuroen-
docrine carcinomas of the thyroid gland, typical and atypical carcinoid
of the lung, GEP, poorly differentiated endocrine carcinoma, and
NETs of the skin. The remaining NETs accounted for a limited num-
ber of prevalent cases. The distribution of prevalent cases by time since
diagnosis varied between the different tumour entities, depending on
the prognosis of the specific histotype, site of origin, and mean age of
incidence.
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100%80%60%40%20%0%
TUMOURS OF THE CENTRAL NERVOUS SYSTEM (CNS) 7.19 6.64-7.78 4.28 3.86-4.74 19.14 18.23-20.08 45.66 42.34-48.98 26 610
TUMOURS OF THE CNS 6.93 6.39-7.50 3.93 3.53-4.37 17.61 16.74-18.51 39.70 36.84-42.63 23 121
Astrocytic tumours of the CNS 5.46 4.98-5.97 2.22 1.92-2.55 11.47 10.77-12.21 28.98 26.30-31.66 16 882
Oligodendroglial tumours of the CNS 0.91 0.72-1.13 0.72 0.56-0.93 2.82 2.47-3.19 3.45 3.01-3.89 1 973
Ependymal tumours of the CNS 0.39 0.27-0.55 0.61 0.46-0.80 2.45 2.13-2.80 6.09 5.14-7.05 3 565
Neuronal and mixed neuronal-glial tumours NAV – NAV – NAV – NAV – NAV
Choroid plexus carcinoma of the CNS NE – 0.03 0.01-0.10 0.03 0.01-0.10 0.25 0.00-0.57 145
Malignant meningiomas 0.17 0.10-0.28 0.35 0.23-0.50 0.85 0.67-1.07 1.21 0.93-1.49 701
EMBRYONAL TUMOURS OF THE CNS 0.26 0.17-0.40 0.35 0.24-0.50 1.53 1.28-1.81 5.93 4.29-7.56 3 489
NE: not estimable in observed prevalence if no cases were observed within ≤2, 2-5, ≤15 years prior to prevalence date, in complete prevalence if the 15-year prevalence is NE         NAV: not available
PREVALENCE
TUMOURS OF THE CENTRAL NERVOUS SYSTEM.
Observed prevalence (proportion per 100,00 and 95%
confidence interval - 95% CI) by duration (≤2, 2-5, ≤15
years) prior to prevalence date (1st January 2007), and
complete prevalence. Estimated prevalent cases in 2010 in
Italy. PROPORTION 95% CI PROPORTION 95% CI PROPORTION 95% CI PROPORTION 95% CI
AIRTUM POOL
COMPLETE PREVALENCE
≤2 YEARS 2-5 YEARS ≤15 YEARS
OBSERVED PREVALENCE BY DURATION
TUMOURS OF THE CENTRAL NERVOUS SYSTEM (CNS) 10 798
TUMOURS OF THE CNS 10 377
Astrocytic tumours of the CNS 8 998
Oligodendroglial tumours of the CNS 699
Ependymal tumours of the CNS 423
Neuronal and mixed neuronal-glial tumours NAV
Choroid plexus carcinoma of the CNS 10 NE
Malignant meningiomas 240
EMBRYONAL TUMOURS OF THE CNS 421
NE: not estimable because 30 or less incident cases were observed NAV: not available
TUMOURS OF THE CENTRAL NERVOUS SYSTEM. One and 5-year relative survival. Error bars are 95%
confidence interval. Cohort approach (complete analysis), period of diagnosis 2000-2008.SURVIVAL
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100% 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
TUMOUR OF THE CENTRAL 5.89 5.79-6.00 13 071 100% 6.99 6.84-7.15 4.87 4.74-4.99 3.17 3.08-3.26 11.64 11.24-12.05 11.67 11.36-12.00 3 725
CENTRAL NERVOUS SYSTEM (CNS)
TUMOURS OF THE CNS 5.67 5.57-5.77 12 566 NA 6.70 6.54-6.85 4.70 4.58-4.83 2.86 2.77-2.94 11.58 11.18-11.99 11.62 11.30-11.94 3 588
Astrocytic tumours of the CNS 4.92 4.83-5.01 10 904 5.89 5.74-6.03 4.01 3.90-4.13 2.24 2.17-2.32 10.42 10.04-10.81 10.67 10.37-10.98 3 125
Oligodendroglial tumours of the CNS 0.38 0.35-0.40 836 0.43 0.40-0.48 0.32 0.29-0.36 0.33 0.30-0.36 0.64 0.55-0.74 0.39 0.33-0.45 231
Ependymal tumours of the CNS 0.23 0.21-0.25 504 0.24 0.21-0.27 0.21 0.19-0.24 0.23 0.21-0.26 0.29 0.23-0.36 0.18 0.14-0.22 139
Neuronal and mixed neuronal-glial tumours NAV NAV NAV NAV – NAV – NAV – NAV – NAV – NAV
Choroid plexus carcinoma of the CNS <0.01 0.00-0.01 13 NE – NE – NE – NE – NE – 4
Malignant meningiomas 0.13 0.12-0.15 299 0.12 0.10-0.14 0.15 0.13-0.17 0.05 0.04-0.06 0.22 0.17-0.29 0.37 0.32-0.43 86
EMBRYONAL TUMOURS OF THE CNS 0.23 0.21-0.25 505 NA 0.30 0.26-0.33 0.16 0.14-0.19 0.31 0.28-0.34 0.06 0.03-0.10 0.05 0.03-0.08 137
NE: not estimable because 15 or less incident cases were observed NAV: not available NA: not applicable
INCIDENCE
TUMORUS OF THE CENTRAL NERVOUS SYSTEM. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), ob-
served cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases
at 2015 in Italy.
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Primary central nervous system tumours (CNS) are of ecto- and
mesodermal origin and arise from the brain, cranial nerves,
meninges, pituitary, pineal and vascular elements. The standard
definition of CNS tumours is that of the 2007 WHO classifica-
tion,1 which is based on histological characteristics and lists approx-
imately 100 subtypes of CNS malignancies in seven categories with
different molecular biology, clinical behaviour, and, presumably,
aetiology. Statistics on CNS tumours are estimated by grouping all
malignancies arising in all CNS anatomic sites (ICD-10 topogra-
phy codes C70-C72). However, rare tumours are more appropri-
ately defined as a combination of topographical and morphological
characteristics, according to the International Classification of
Diseases for Oncology (ICD-O).
Thus, based on an adaptation of the WHO classification and fur-
ther work by RARECAREnet:2
CNS tumours have been divided into:
 tumours of the CNS (major histological groups (astrocytic tu-
mours, oligodendroglial tumours, ependymal tumours, neuronal
and mixed neuronal-glial tumours, choroid plexus carcinoma,
malignant meningiomas);
 embryonal tumours (including pineoblastoma).
The results presented in this section refer exclusively to malignant
tumours of the CNS. Epidemiological features of the carcinomas
of the pituitary gland are described in the endocrine tumours
grouping.
WHAT DO WE KNOW ABOUT THESE CANCERS? 
The aetiology of CNS tumours is not well established; common
risk factors for other cancers (e.g., diet, smoking, physical activity,
alcohol) do not seem to play a significant role. A relationship with
exposure to chemical carcinogens has been reported, but the only
environmental factor unequivocally associated with an increased
risk is therapeutic irradiation, especially in children; exposure to
non-ionizing radiation by cellular phones is controversial.3 Finally,
an increased risk is also attributed to hereditary syndromes.4
According to the WHO grading scheme, CNS tumours can be
stratified by degree of malignancy:
Grade I: lesions with low proliferative potential and the possibility
of cure by surgical resection alone;
Grade II: infiltrative neoplasms with low proliferative activity,
but tendency to recur and progress to a higher grade; 
Grade III: lesions with histological evidence of malignancy;
Grade IV: cytologically malignant, mitotically active, necrosis-
prone, fatal neoplasms with rapid evolution.
Astrocytomas include a heterogeneous group of histotypes. WHO
grade I refers to low-grade astrocytomas, such as pilocytic astrocy-
toma, pleomorphic xanthoastrocytoma, and subependymal giant
cell astrocytoma. WHO Grade II includes infiltrating neoplasms
such as pilomyxoid, diffuse, protoplasmic astrocytoma, as well as
oligoastrocytoma. Negative prognostic factors include age ≥40
years, astrocytoma histology, maximum diameter ≥6 cm, baseline
neurologic deficits, residual mass after surgery >1 cm. WHO Grade
III includes anaplastic astrocytoma, which is (with glioblastoma, see
next) one of the most common primary malignant brain tumours
in adults.4 WHO Grade IV includes glioblastoma (the most lethal
brain tumour), gliosarcoma, and giant cell glioblastoma.
Oligodendroglial tumours express different levels of clinical aggres-
siveness: this category includes oligodendroglioma (WHO Grade
II) and anaplastic oligodendroglioma (WHO Grade III), both de-
riving from the oligodendrocytic cell line. Highly prevalent cyto-
genetic alterations, namely mutations of the isocitrate dehydroge-
nase-1 (IDH1) and chromosomal arm 1p and 19q codeletion, are
predictors of more favourable prognosis of these tumours.6
Ependymal tumours are derived from ependymal glial cells and in-
clude different subtypes, with varying degree of differentiation and
malignancy: WHO Grade I: subependymoma, myxopapillary
ependymoma; WHO Grade II/III: ependymoma NOS; WHO
Grade III/IV: anaplastic ependymoma. 
Neuronal and mixed neuronal-glial tumours are very rare and
characterised by a variable degree of neuronal differentiation, with
neoplastic neuronal cells alone (e.g., gangliocytoma) or mixed to
neoplastic glial cells. 
Primary choroid plexus carcinomas are rare aggressive WHO
grade III tumours which usually occur in children under 12 years
of age and account for nearly 20% of all choroid plexus tumours.4,7
Since the choroid plexus is the neuroepithelial tissue that produces
cerebrospinal fluid, these tumours are mostly located in the lateral
ventricle (mainly in children) and less frequently in the fourth ven-
tricle (mainly in adults). 
Malignant meningiomas are WHO Grade III with a low tendency
to metastasise but a high rate of recurrence and progression.4,8
Higher grade meningiomas are often associated with neurofibro-
matosis type 2 (NF2) mutation, loss of chromosome 22, and ad-
ditional chromosomal aberrations.6 Prior radiation therapy to
head and neck can be a risk factor.
Embryonal tumours include several tumours of embryonal origin
– typically occurring in infants and young children – characterised
by high malignancy and therefore classified as WHO Grade IV:
medulloblastoma (MB) and its variants: e.g., desmoplastic/nodu-
lar-, anaplastic-, large cell-MB; primitive neuroectodermal tumours
(PNETs) and variants: e.g., neuroblastoma, ganglioneuroblastoma,
neuroepithelioma, medulloepithelioma; atypical teratoid/rhabdoid
tumours (ATRTs).
Pineoblastomas are also included among embryonal tumours, al-
though separately classified by WHO as pineal tumours (Grade
IV). In summary: MBs, PNETs, ATRTs, and pineoblastomas
probably represent biologically distinct entities, so the classification
of embryonal tumours, currently debated, may be susceptible to
further revisions.4
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
All CNS tumours are rare and are more frequent in males than in
females, with an M/F ratio ranging from 1.14 to 1.81, with the sole
exception of malignant meningiomas (M/F: 0.81). The most fre-
quent histotype is astrocytoma – which accounts for 83% of the
total –, followed by oligodendroglial tumours (6.4%), ependymal
and embryonal tumours (both at 3.9%), and malignant menin-
giomas (2.3%). 
Incidence of all tumours tends to increase after age 40 years, with
a peak in the 65-75-year age group; however, astrocytomas and em-
bryonal tumours also occur in young children. In particular, em-
bryonal neoplasms in the first 15 years of age account for nearly
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50% of all embryonal neoplasms at all ages. Among these, medul-
loblastomas – located exclusively in the cerebellum – are the most
common (70%), followed by primitive neuroectodermal tumours
(PNETs, 20%). Pineoblastoma (a malignant pineal parenchymal tu-
mour) is very rare and accounts for less than 3% of all rare CNS
tumours.
The Italian estimates for each subtype are fully in line with the cor-
responding European incidence estimates based on the
RARECAREnet database (www.rarecarenet.eu). 
The proportion of NOS cancer cases in the AIRTUM database in
the study period (2000-2010) is estimated at 37%, with a differ-
ential distribution across age, ranging from 20% in the 0-24-year
age group to 52% in the over 65 age group. This raises the issue
of a potential underestimation of true incidence, mostly in the eld-
erly, but does not jeopardise the overall description of the frequency
of CNS tumours here presented.
Survival
One and 5-year relative survival (RS) of CNS tumours is 55% and
21%, respectively. However, these results are strongly affected by
astrocytic tumours, which are both the most common among these
tumours and those with the worst survival (49% and 13% at 1 and
5 years, respectively). There is a striking difference in relative sur-
vival between each of the other CNS tumours and astrocytomas;
namely, 5-year RS is 76% for ependymal tumours and 56%-57%
for all other histotypes. 
The poor prognosis of astrocytomas is at least partially explained
by the high proportion (64%) of WHO grade IV tumours in this
group. On the contrary, ependymal tumours and oligoden-
drogliomas have a high proportion of WHO grade II tumours
(82% and 71%, respectively); oligodendrogliomas have a higher
proportion of WHO grade III tumours compared to ependymal
tumours, which can contribute to explain the estimated difference
in survival between these two histotypes.
Italian estimates are in line with the corresponding European sur-
vival estimates based on the RARECAREnet database for most of
the subtypes, with the only exceptions of astrocytomas (in which
1-year survival is 48% in Italy vs. 41% in Europe) and – to a lesser
extent – oligodendroglial tumours. This finding is consistent with
other reports where geographical differences have been measured;2
whether this can be attributed to different case-mix, timeliness of
diagnosis, access to treatment (especially radiotherapy) or is rather
the effect of differential case selection or classification should be
further investigated. 
Prevalence
About 27,000 persons were alive in Italy in 2010 with a past diagnosis
of CNS tumours; of these, about 3,500 had an embryonal tumour of
CNS in their clinical history, while the others had been diagnosed with
any of the tumours of the CNS (astrocytic, oligodendroglial, ependy-
mal, neuronal and mixed neuronal-glial, choroid plexus carcinoma,
malignant meningioma). Astrocytic tumours were the most common
among prevalent CNS cancers, followed by ependymal and oligoden-
droglial tumours.
The prevalence estimates well reflect the different incidence and sur-
vival of these tumours. Interestingly, very long-term survivors, those
who survived more than 15 years after diagnosis, were on average 56%
among prevalent cases of the heterogeneous group of tumours of the
CNS, and 74% among cases of embryonal tumours of the CNS. A
possible explanation for the proportion of long-term survivors is the
high frequency of low-grade tumours which have a good prognosis.2
The estimates here presented are slightly lower than those previously
published in the AIRTUM prevalence monograph, mainly because
undefined tumours (such as ICD-O M8000 and M8001) are not in-
cluded in our definition.
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100%80%60%40%20%0%
TUMOURS OF THE ENDOCRINE ORGANS 0.37 0.35-0.40 830 100% 0.39 0.35-0.42 0.36 0.33-0.40 0.20 0.18-0.23 0.51 0.43-0.60 0.88 0.80-0.97 244
CARCINOMAS OF PITUITARY GLAND 0.03 0.03-0.04 76 NA 0.04 0.03-0.05 0.03 0.02-0.04 0.02 0.01-0.03 0.04 0.02-0.07 0.08 0.05-0.11 22
CARCINOMAS OF PARATHYROID GLAND 0.05 0.04-0.06 110 NA 0.05 0.04-0.06 0.05 0.04-0.07 0.02 0.02-0.03 0.08 0.05-0.13 0.12 0.09-0.16 33
CARCINOMAS OF ADRENAL CORTEX 0.29 0.27-0.31 644 NA 0.30 0.27-0.33 0.28 0.25-0.31 0.16 0.14-0.18 0.38 0.31-0.46 0.68 0.61-0.77 189
NA: not applicable
INCIDENCE
TUMOURS OF THE ENDOCRINE ORGANS. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed
cases and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015
in Italy.
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TUMOURS OF THE ENDOCRINE ORGANS 653
CARCINOMAS OF PITUITARY GLAND 61
CARCINOMAS OF PARATHYROID GLAND 86
CARCINOMAS OF ADRENAL CORTEX 506
TUMOURS OF THE ENDOCRINE ORGANS. One and 5-year relative survival. Error bars are 95% confidence interval. Cohort approach (com-
plete analysis), period of diagnosis 2000-2008.
SURVIVAL
No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100%
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
TUMOURS OF THE ENDOCRINE ORGANS 0.46 0.33-0.63 0.56 0.42-0.74 2.33 2.02-2.67 3.74 3.21-4.27 2 222
CARCINOMAS OF PITUITARY GLAND 0.05 0.01-0.12 0.21 0.12-0.33 0.62 0.47-0.81 1.07 0.77-1.36 627
CARCINOMAS OF PARATHYROID GLAND 0.08 0.03-0.17 0.11 0.06-0.21 0.47 0.34-0.64 0.77 0.53-1.01 448
CARCINOMAS OF ADRENAL CORTEX 0.33 0.22-0.48 0.24 0.15-0.37 1.24 1.02-1.50 1.91 1.54-2.27 1 147
PREVALENCE
TUMOURS OF THE ENDOCRINE ORGANS. Observed prevalence (proportion per 100,00 and 95% confidence interval -
95% CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete prevalence. Estimated
prevalent cases in 2010 in Italy.
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The list of rare cancers proposed by the European RARECARE
project (surveillance of rare cancers in Europe, www.rarecare.eu)
considers thyroid cancer arising from the follicular epithelium rare,
reporting an incidence rate lower than 6 per 100,000 in Europe.
Even if rare at European level, thyroid carcinoma is not presented
in the endocrine grouping of this monograph. This choice is due
to the fact that the methodological assumptions used to estimate
the epidemiological indicators for rare cancers (many of them ex-
tremely rare) are not applicable to thyroid cancer epidemiology in
Italy (see «Materials and Methods», pp. 14-21).
This section deals in detail with tumours that arise from hormone-
secreting endocrine glands, which are all rare:
 carcinomas of pituitary gland;
 carcinomas of parathyroid gland;
 carcinomas of adrenal cortex.
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Pituitary tumours are indolent tumours representing approximately
15%-20% of intracranial neoplasms.1 They can be characterised by
pituitary dysfunction, neurological deficits (especially visual impair-
ment), and/or invasion of the parasellar compartment and/or the
sphenoid sinuses. Initially considered as sporadic tumours, some of
them are associated with familial syndromes such as multiple en-
docrine neoplasia type 1, Carney complex, or familial isolated pitu-
itary adenomas. Pituitary tumours can be typed based on their hor-
mone-secreting properties into lactotropic (prolactin secreting, 35%),
gonadotropic (follicle-stimulating hormone and luteinizing hormone,
35%), somatotropic (growth hormone, GH, 10%-15%), and other
tumour types, including tumours with mixed secreting patterns and
non-secreting adenomas. Primary pituitary carcinoma is a rare entity
defined as any tumour of adenohypophyseal origin with demon-
strated craniospinal and/or extracranial metastatic dissemination,
fortunately very uncommon and accounting for only 0.1% of all pi-
tuitary tumours.2 Both hormonally active (ACTH-, GH-, and PRL-
producing) and hormonally inactive forms of pituitary carcinoma
have been reported. Pituitary carcinoma can present in patients with
preexisting pituitary adenomas with initial indistinguishable clinical
course. The majority of adrenal cancers arise sporadically but can de-
velop as a part of a constellation of tumours in inherited familial can-
cer syndromes such as Li Fraumeni syndrome, Beckwith-Widerman
syndrome, Gardner syndrome, and multiple endocrine neoplasia type
1, each syndrome is associated with unique germ-line mutation.3
Steroid overproduction is present in over 60% of patients with
adrenal cancers. Despite radical surgery with curative intent, the ma-
jority of patients with localised adrenal cancers will develop metastases
within 6-24 months from resection.4Parathyroid carcinoma is a rare
cause of primary hyperparathyroidism. It can occur either sporadically
or in family members affected by hyperparathyroidism-jaw tumour
syndrome or associated with multiple endocrine neoplasia.5 Most
parathyroid cancers secrete parathyroid hormone and cause hyper-
calcaemia. An increase in incidence (from 0.03 to 0.05) was observed
in a population-based study in the USA in the period 1988-2003,
probably due to increased serum calcium screening.6
Pituitary, adrenal, and parathyroid carcinomas are rare, and popula-
tion-based studies are scarce. Thus, this population-based analysis,
which uses data from the pool of the AIRTUM cancer registries, offers
the first opportunity to describe the burden of these cancers in Italy.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Incidence Rate per 100,000 (IR) of endocrine tumours is 0.37; 244
new cases of endocrine tumours are expected in 2015. The first tumour
in order of frequency is adrenal cortex cancer. With 189 cases expected,
it represents 78% of endocrine tumours considered, with an IR of
0.29 (incidence table, p. 99), slightly higher than the RARECAREnet
database (IR 0.22) (www.rarecarenet.eu) and equally distributed by
sex. The IR progressively increases with age.
One hundred and ten cases of parathyroid cancers were detected,
with an IR of 0.05 (see table p. 99), slightly higher compared to
the European RARECAREnet database (IR of 0.03) representing
13% of this group of rare tumours. Despite the few cases, the in-
cidence seems to increase with age, with no differences between
sexes. Since only pituitary carcinoma, based on a morphology code
of the ICD-O with a malignant behaviour, has been included in
the analysis, only 76 cases of pituitary tumours were detected, with
an IR of 0.03 (see table p. 99) similar to that observed in the larger
RARECAREnet database. 
Survival
Relative survival (RS) of endocrine tumours is 66% at 1 year and
46% at 5 years. This value is influenced by the lower survival of ad-
renal cortex tumours compared to other endocrine tumours. Despite
surgical, medical, and chemotherapeutic advances, patients with ad-
renal cancer show a poor prognosis, with an RS of 38% at 5 years
(survival figure, p. 99) in line with European data of the
RARECAREnet database. This prognosis is most probably due to
the high tendency to metastasise within 6-24 months from resection.
Parathyroid cancer has an RS of 89% and 70% at 1 and 5 years, re-
spectively (see figure p. 99). Morbidity and mortality for this cancer
usually are caused by metabolic complications rather than tumour
burden. Similar RS was observed for pituitary tumours (RS 82% at
1 year and 73% at 5 years) (see figure p. 99). These results are similar
to those observed in the wider European RARECAREnet database. 
Prevalence
Slightly more than 2,000 persons are estimated to be living in 2010
with a diagnosis of carcinoma of the endocrine organs (excluding thy-
roid cancer), of whom more than 50% have a diagnosis of adrenal cor-
tex carcinoma (prevalence table, p. 99). The distribution of prevalent
cases by time since diagnosis shows that cases where time since diag-
nosis is over 15 years are 42% for pituitary carcinoma, 38% for
parathyroid carcinoma, and 35% for adrenal cortex carcinoma.
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RARE HAEMATOLOGICAL DISEASES 41.08 40.81-41.35 91 094 74% 45.43 45.03-45.84 37.00 36.65-37.36 16.17 15.97-16.38 53.07 52.21-53.94 118.92 117.9-119.94 27 084
RARE LYMPHOID DISEASES 26.78 26.56-27.00 59 384 48% 29.33 29.00-29.65 24.39 24.11-24.68 11.96 11.78-12.13 36.78 36.06-37.50 71.32 70.54-72.12 17 464
Hodgkin lymphoma, classical 3.50 3.43-3.58 7 769 3.84 3.73-3.96 3.18 3.08-3.29 3.73 3.64-3.83 2.59 2.40-2.78 3.29 3.12-3.46 2 101
Hodgkin lymphoma nodular lymphocyte predominance 0.14 0.12-0.16 309 0.18 0.16-0.21 0.10 0.08-0.12 0.14 0.12-0.16 0.18 0.13-0.24 0.12 0.09-0.16 85
Precursor B/T lymphoblastic leukaemia/lymphoma 1.86 1.80-1.92 4 127 2.23 2.14-2.32 1.52 1.45-1.59 1.91 1.84-1.98 1.31 1.17-1.45 2.05 1.92-2.19 1 168
(and Burkitt leukaemia/lymphoma)
T cutaneous lymphoma 1.07 1.02-1.11 2 363 1.40 1.33-1.47 0.76 0.71-0.81 0.38 0.35-0.41 1.92 1.76-2.09 2.88 2.73-3.04 700
(Sezary syndrome, Mycosis fungoides)
Other T cell lymphomas and NK cell neoplasms 0.87 0.83-0.91 1 922 1.09 1.03-1.16 0.66 0.61-0.70 0.41 0.38-0.44 1.25 1.13-1.40 2.19 2.05-2.33 563
Diffuse large B-cell lymphoma 6.94 6.83-7.05 15 393 7.24 7.08-7.40 6.67 6.52-6.82 2.44 2.37-2.52 9.31 8.95-9.68 20.87 20.45-21.31 4 568
Follicular lymphoma 2.85 2.78-2.92 6 320 2.80 2.70-2.90 2.90 2.80-3.00 1.28 1.23-1.34 5.90 5.61-6.20 6.32 6.09-6.56 1 849
Hairy cell leukaemia 0.44 0.42-0.47 985 0.72 0.67-0.77 0.19 0.16-0.21 0.24 0.21-0.26 0.86 0.76-0.98 0.89 0.80-0.98 292
Plasmacytoma/Multiple Myeloma 8.36 8.24-8.48 18 545 8.75 8.58-8.93 8.00 7.83-8.16 1.27 1.22-1.33 12.11 11.70-12.53 30.31 29.80-30.83 5 643
(and Heavy chain diseases)
Mantle cell lymphoma 0.72 0.68-0.75 1 588 1.04 0.98-1.10 0.42 0.38-0.46 0.15 0.13-0.17 1.32 1.19-1.46 2.29 2.15-2.44 476
Prolymphocytic leukaemia, B cell 0.03 0.02-0.04 63 0.04 0.03-0.05 0.02 0.01-0.03 <0.01 0.00-0.01 0.03 0.01-0.05 0.11 0.08-0.15 20
ACUTE MYELOID LEUKAEMIA 5.34 5.24-5.44 11 837 10% 5.80 5.66-5.95 4.90 4.78-5.03 1.73 1.67-1.80 6.12 5.83-6.42 17.19 16.81-17.58 3 572
AND RELATED PRECURSOR NEOPLASMS
Acute promyelocytic leukaemia (AML) 0.23 0.21-0.25 513 0.23 0.20-0.26 0.23 0.21-0.26 0.19 0.17-0.22 0.26 0.20-0.33 0.35 0.30-0.41 145
with t(15;17) and variants
Acute myeloid leukaemia 4.79 4.70-4.88 10 620 5.22 5.09-5.36 4.38 4.26-4.51 1.49 1.43-1.55 5.60 5.32-5.88 15.58 15.21-15.95 3 204
MYELOPROLIFERATIVE NEOPLASMS 5.47 5.37-5.56 12 119 10% 6.27 6.12-6.42 4.71 4.58-4.84 2.02 1.95-2.09 7.67 7.34-8.00 15.90 15.53-16.28 3 610
Chronic myeloid leukaemia 1.61 1.56-1.66 3 566 1.87 1.79-1.95 1.36 1.30-1.43 0.65 0.61-0.69 2.09 1.92-2.27 4.59 4.39-4.79 1 075
Other myeloproliferative neoplasms 3.80 3.72-3.88 8 425 4.34 4.21-4.47 3.29 3.19-3.40 1.32 1.27-1.38 5.50 5.22-5.79 11.22 10.91-11.53 2 499
Mast cell tumours 0.06 0.05-0.07 128 0.06 0.05-0.08 0.05 0.04-0.07 0.04 0.03-0.06 0.08 0.05-0.12 0.10 0.07-0.13 36
MYELODYSPLASTIC SYNDROME 3.39 3.31-3.46 7 511 6% 3.90 3.78-4.02 2.91 2.81-3.01 0.35 0.32-0.39 2.44 2.26-2.63 14.36 14.01-14.72 2 371
AND MYELODYSPLASTIC/MYELOPROLIFERATIVE 
DISEASES
Myelodysplastic syndrome with 5q syndrome 0.02 0.01-0.03 41 0.01 0.01-0.02 0.02 0.02-0.03 <0.01 0.00-0.01 0.02 0.01-0.04 0.08 0.05-0.11 12
Other myelodysplastic syndrome 3.04 2.96-3.11 6 733 3.45 3.34-3.57 2.64 2.55-2.74 0.32 0.29-0.35 2.18 2.01-2.36 12.86 12.53-13.20 2 129
Chronic myelomonocytic leukaemia 0.31 0.29-0.34 694 0.41 0.37-0.45 0.22 0.19-0.25 0.03 0.02-0.04 0.22 0.17-0.28 1.35 1.24-1.46 216
Atypical chronic myeloid leukaemia BCR/ABL negative 0.02 0.01-0.02 39 0.02 0.01-0.03 0.01 0.01-0.02 <0.01 0.00-0.01 0.01 0.00-0.04 0.07 0.04-0.09 12
HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS 0.11 0.10-0.12 243 0.2% 0.13 0.11-0.16 0.09 0.07-0.11 0.11 0.09-0.13 0.07 0.04-0.10 0.14 0.11-0.18 68
Histiocytic malignancies 0.08 0.07-0.09 181 0.10 0.08-0.12 0.06 0.05-0.08 0.10 0.08-0.11 0.03 0.02-0.06 0.07 0.04-0.09 50
Lymph node accessory cell tumours 0.03 0.02-0.04 62 0.03 0.02-0.04 0.03 0.02-0.04 0.01 0.01-0.02 0.03 0.02-0.06 0.08 0.05-0.11 18
NK: natural killer
INCIDENCE
RARE HAEMATOLOGICAL DISEASES. Crude incidence (rate per 100,000/year) and 95% confidence interval (95% CI), observed cases
and proportion of rare cancers on all (common + rare) cancers by site. Rates with 95% CI by sex and age. Estimated new cases at 2015 in
Italy.
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RATE 95% CI
RATE 95% CI RATE 95% CI RATE 95% CI RATE 95% CI RATE 95% CI
AIRTUM POOL (period of diagnosis 2000-2010)
SEX AGE
MALE FEMALE 0-54 yrs 55-64 yrs 65+ yrs
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RARE HAEMATOLOGICAL DISEASES 74 553
RARE LYMPHOID DISEASES 49 133
Hodgkin lymphoma, classical 6 406
Hodgkin lymphoma nodular lymphocyte predominance 259
Precursor B/T lymphoblastic leukaemia/lymphoma (and Burkitt leukaemia/lymphoma)3 464
T cutaneous lymphoma (Sezary syndrome, Mycosis fungoides) 2 078
Other T cell lymphomas and NK cell neoplasms 1 607
Diffuse large B-cell lymphoma 12 669
Follicular lymphoma 5 151
Hairy cell leukemia 834
Plasmacytoma/Multiple Myeloma (and Heavy chain diseases) 15 347
Mantle cell lymphoma 1 315
Prolymphocytic leukaemia, B cell 52
ACUTE MYELOID LEUKAEMIA AND RELATED PRECURSOR NEOPLASMS 9 696
Acute promyelocytic leukaemia (AML) with t(15;17) and variants 445
Acute myeloid leukaemia 8 731
MYELOPROLIFERATIVE NEOPLASMS 9 836
Chronic myeloid leukaemia 2 989
Other myeloproliferative neoplasms 6 742
Mast cell tumours 106
MYELODYSPLASTIC SYNDROME 5 778
AND MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES
Myelodysplastic syndrome with 5q syndrome 34
Other myelodysplastic syndrome 5 144
Chronic myelomonocytic leukaemia 569
Atypical chronic myeloid leukaemia BCR/ABL negative 29
HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS 197
Histiocytic malignancies 146
Lymph node accessory cell tumours 51
NK: natural killer
RARE HAEMATOLOGICAL DISEASES. One and 5-year relative survival. Error bars are 95% confidence interval. Cohort approach (complete
analysis), period of diagnosis 2000-2008.
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No. OF CASES 
INCLUDED 
IN THE ANALYSIS
0% 20% 40% 60% 80% 100%
 1-YEAR RELATIVE SURVIVAL
 5-YEAR RELATIVE SURVIVAL
RARE HAEMATOLOGICAL DISEASES 71.79 70.02-73.59 68.28 66.56-70.04 253.26 249.92-256.62 277.80 271.10-284.50 225 872
RARE LYMPHOID DISEASES 47.76 46.31-49.23 49.20 47.73-50.69 187.44 184.58-190.34 298.94 290.05-307.84 178 237
Hodgkin lymphoma, classical 6.83 6.29-7.40 8.99 8.37-9.64 37.95 36.66-39.26 78.56 75.58-81.54 45 356
Hodgkin lymphoma nodular lymphocyte predominance 0.26 0.17-0.40 0.33 0.22-0.48 1.25 1.03-1.51 3.32 2.35-4.30 1 974
Precursor B/T lymphoblastic leukaemia/lymphoma 2.66 2.33-3.03 2.71 2.38-3.08 12.19 11.46-12.94 56.49 48.73-64.26 33 843
(and Burkitt leukaemia/lymphoma)
T cutaneous lymphoma (Sezary syndrome, Mycosis fungoides) 2.62 2.29-2.98 3.44 3.06-3.86 13.35 12.6-14.15 18.57 17.43-19.70 11 173
Other T cell lymphomas and NK cell neoplasms 1.01 0.81-1.25 1.02 0.82-1.25 3.64 3.25-4.07 4.61 4.10-5.13 2 817
Diffuse large B-cell lymphoma 10.61 9.94-11.32 10.78 10.10-11.49 41.36 40.02-42.73 48.29 46.71-49.88 29 550
Follicular lymphoma 6.54 6.02-7.10 6.01 5.51-6.55 23.61 22.6-24.65 27.28 26.06-28.51 16 815
Hairy cell leukaemia 0.98 0.78-1.21 1.33 1.10-1.60 5.05 4.59-5.54 7.59 6.73-8.46 4 637
Plasmacytoma/Multiple Myeloma (and Heavy chain diseases) 14.70 13.91-15.53 13.20 12.45-13.98 43.70 42.32-45.11 47.76 46.23-49.30 28 229
Mantle cell lymphoma 1.51 1.26-1.79 1.36 1.12-1.62 5.46 4.98-5.97 6.25 5.68-6.81 3 731
Prolymphocytic leukaemia, B cell 0.05 0.01-0.12 0.08 0.03-0.17 0.16 0.09-0.27 0.19 0.09-0.29 112
ACUTE MYELOID LEUKAEMIA AND RELATED PRECURSOR NEOPLASMS 4.47 4.03-4.93 2.73 2.40-3.10 12.48 11.75-13.25 18.94 17.79-20.09 11 146
Acute promyelocytic leukaemia (AML) with t(15;17) and variants 0.37 0.25-0.52 0.43 0.30-0.59 1.62 1.36-1.91 1.79 1.49-2.09 1 039
Acute myeloid leukaemia 3.82 3.42-4.26 2.15 1.85-2.48 10.05 9.39-10.74 16.53 15.40-17.67 10 481
MYELOPROLIFERATIVE NEOPLASMS 12.21 11.49-12.97 12.06 11.34-12.81 38.95 37.65-40.28 45.30 43.64-46.96 26 243
Chronic myeloid leukaemia 2.42 2.10-2.77 3.00 2.65-3.39 9.98 9.33-10.67 10.76 10.04-11.49 6 221
Other myeloproliferative neoplasms 9.68 9.04-10.35 8.86 8.24-9.50 28.49 27.38-29.63 33.88 32.45-35.32 19 620
Mast cell tumours 0.11 0.06-0.21 0.21 0.12-0.33 0.48 0.35-0.65 0.97 0.64-1.29 579
MYELODYSPLASTIC SYNDROME 7.17 6.62-7.76 4.17 3.76-4.63 13.90 13.12-14.70 15.87 14.96-16.78 9 213
AND MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES
Myelodysplastic syndrome with 5q syndrome 0.09 0.04-0.18 0.05 0.01-0.12 0.15 0.08-0.26 0.17 0.08-0.27 102
Other myelodysplastic syndrome 6.52 5.99-7.08 3.83 3.43-4.26 12.67 11.93-13.44 13.52 12.72-14.32 7 965
Chronic myelomonocytic leukaemia 0.54 0.40-0.72 0.30 0.20-0.44 1.03 0.83-1.27 1.37 1.07-1.67 803
Atypical chronic myeloid leukaemia BCR/ABL negative 0.02 0.00-0.08 0.00 0.00-0.04 0.05 0.01-0.12 0.05 0.00-0.10 28
HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS 0.22 0.13-0.34 0.13 0.06-0.23 0.77 0.60-0.98 1.68 1.19-2.17 1 033
Histiocytic malignancies 0.11 0.06-0.21 0.11 0.06-0.21 0.64 0.49-0.84 1.45 0.99-1.92 895
Lymph node accessory cell tumours 0.10 0.05-0.20 0.01 0.00-0.06 0.13 0.06-0.23 0.23 0.09-0.37 138
NK: natural killer
PREVALENCE
RARE HAEMATOLOGICAL DISEASES. Observed prevalence (proportion per 100,00 and 95% confidence interval - 95%
CI) by duration (≤2, 2-5, ≤15 years) prior to prevalence date (1st January 2007), and complete prevalence. Estimated prevalent
cases in 2010 in Italy.
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The classification of lymphoproliferative disorders includes various
entities divided according to cytohistological features, im-
munephenotype, molecular characteristics, and clinical relevance.
Overall, about 74% of haematological cancers are rare (incidence
table, p. 102). This group includes:
 rare lymphoid diseases (classic Hodgkin lymphoma,
Hodgkin lymphoma with nodular lymphocyte predominance,
precursor B/T lymphoblastic leukaemia/lymphoma, Burkitt’s
leukaemia/lymphoma, T cutaneous lymphoma – Sezary syn-
drome, Mycosis fungoides, other T-cell lymphomas
and NK-cell neoplasms, diffuse large B-cell lymphoma,
follicular lymphoma, hairy cell leukaemia,
plasmacytoma/multiple myeloma and heavy chain diseases,
mantle cell lymphoma, B-cell prolymphocytic leukaemia);
 acute myeloid leukaemia (acute promyelocytic leukaemia
with t(15;17) translocation and variants, acute myeloid
leukaemia);
 myeloproliferative neoplasms (chronic myeloid leukaemia,
other myeloproliferative neoplasms, mast cell tumours);
 myelodysplastic syndrome and myelodysplastic/
myeloproliferative diseases (myelodysplastic syndrome with 5q
syndrome, other myelodysplastic syndrome, chronic
myelomonocytic leukaemia, atypical chronic myeloid leukaemia
BCR/ABL negative);
 histiocytic and dendritic cell neoplasms
(histiocytic malignancies, accessory cell tumours). 
It is worth mentioning that variations in classification between
ICD-O-2 and ICD-O-3 mainly concern these diseases and especially
the group of myeloproliferative neoplasms (MPNs) and the group
of myelodysplastic/myeloproliferative diseases (MDS/MPDs). Many
of the tumours included in these 2 groups changed behaviour (be-
coming malignant invasive) with the ICD-O-3, which was intro-
duced in the year 2000. Thus, cancer registries (CRs) started to reg-
ister these entities only from 2000 on and at different paces. In
addition, information sources used by CRs to identify cancer cases
do not properly capture all cases of haematological diseases. All this
translates into an underestimation in our data of these diseases. 
However, the proportion of haematological diseases with «not
otherwise specified» (NOS) morphology across Italian CRs was be-
low 30%, which is the cut-off used by international studies to ex-
clude CRs from analyses because of low quality.1
In addition to the proportion of NOS morphologies, we also
looked at the incidence trends of MPNs and MDS/MPD across
the different Italian CRs. In this exploratory analysis of the inci-
dence trend, two groups of CRs were identified: the first included
CRs with lower than average (4 per 100,000) age-standardised in-
cidence rates for MPN during the 2000-2010 period, whereas the
second included CRs with higher than average rates. The first
group had a very low incidence rate, which increased after 2000
without reaching, in 2010, the incidence rate of the other AIR-
TUM CRs, for both MPN and MDS/MPD. The incidence rate
in the second group of CRs increased up to 2010 to almost double
the rate of the CRs of the first group for both MPNs and
MDS/MPDs. It is very likely that in the first group there are CRs
which tend to not properly record all cases of MPNs and/or
MDS/MPDs. Nevertheless, the incidence rate obtained consider-
ing only the second group of CRs is substantially comparable to
the one obtained combining together the two groups of CRs.
Thus, all CRs were considered in order to include the largest pos-
sible number of cases in the analysis of these tumours, which, for
the first time, are described in Italy in such morphological detail. 
This is an opportunity to provide estimates to discuss with clini-
cians and CRs how to improve registration.
RARE LYMPHOID DISEASES
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Lymphoid diseases comprise a heterogeneous group of disorders
originating from clonal proliferation of B or T lymphocytes and
covering both Hodgkin and non-Hodgkin disease. These are con-
sidered in this group, clinical management is rapidly evolved and
various treatments (in terms of drugs employed and intensity of ap-
proaches) are now applied according to different entities and char-
acteristics of patients: the new targeted therapy inhibits the proto-
oncogenes which signal cells to proliferate, differentiate, and
survive, and whose overactivity results in malignancy.2
About one-third of non-Hodgkin lymphomas (NHL) arise from
sites other than lymph nodes, spleen, or bone marrow, and even
from sites which normally contain no native lymphoid tissue. In
principle, as for primary nodal disease, treatment strategies depend
on the patient's clinical conditions, the extent and/or location of
the disease, and the histological type.3 However, in the list of rare
haematological diseases proposed by RARECARE,4 extranodal
lymphomas are not separated from the others. 
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Rare lymphoid diseases account for 65% of all rare haematological
diseases (see table p. 102). About a third of rare lymphoid diseases
(31%) are plasma cell tumours, followed by diffuse large B-cell
lymphoma (26%), classic Hodgkin lymphoma (13%), and follic-
ular lymphoma (11%). The other lymphoid diseases represent a
minority of cases ranging from 1% to 7% of all rare lymphoid dis-
eases. The rarest is prolymphocytic leukaemia, B-cell (see table p.
102). Most rare lymphoid diseases are diagnosed in people aged 50
years and older, with a few exceptions. Classic Hodgkin lymphoma
has the highest incidence in the 15-29 year age group and precursor
B/T lymphoblastic leukaemia/lymphoma has the highest incidence
in children (0-14 years) (data not shown). The former represent
64% of all rare lymphoid diseases in adolescents and young adults
(15-29 years) and the latter account for 77% of all rare lymphoid
diseases in children (data not shown).
The highest male to female ratio (M/F ratio) is observed for hairy
cell leukaemia and mantle cell lymphoma (M/F ratio: 3.8 and 2.5,
respectively). About 17,000 new cases of rare lymphoid diseases are
expected in Italy in 2015 (see table p. 102). Among young adults,
about 600 cases of rare lymphoid diseases are expected, of which 500
are classic Hodgkin lymphoma. Among children, about 330 cases
of rare lymphoid diseases are expected in 2015, of which 250 are pre-
cursor B/T lymphoblastic leukaemias/lymphomas (data not shown).
The incidence rate (IR) of rare lymphoid diseases in Italy is much
higher than the IR observed in the European RARECAREnet
database (www.rarecarenet.eu) (IR 26.8 per 100,000 in Italy vs.
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18.1 per 100,000 in Europe), because in Italy the IR of diffuse large
B-cell lymphoma and multiple myeloma is higher than in Europe.
Thus, these two diseases are rare in Europe but not in Italy (see «The
burden of rare cancers in Italy», pp. 22-27).
Survival
Rare lymphoid diseases have a good survival rate 1 year after diag-
nosis (79%), which decreases after 5 years from diagnosis (59%)
(survival figure, p. 103). However, 5-year relative survival (RS) dif-
fers across diseases, and is 80%-90% for classic Hodgkin lym-
phoma, follicular lymphoma, nodular lymphocyte predominant
Hodgkin lymphoma, T cutaneous lymphoma, and hairy cell
leukaemia (HCL) (see figure p. 103) and around 40% for other T-
cell lymphomas and NK-cell neoplasms, plasmacytoma/multiple
myeloma and prolymphocytic leukaemia, B cell. The lower survival
observed in the latter diseases could be due to the fact that they
mainly arise in the elderly (>70 years), thus in people who are likely
to have comorbidities and are more difficult to treat.
These results are similar to those observed in Europe, where a sig-
nificant increase of survival over time (from 1997 to 2008) for all
lymphoid malignancies, with the greatest increases for follicular
lymphoma and diffuse large B-cell lymphoma was also reported.5
The survival increase for follicular lymphoma and diffuse large B-
cell leukaemia are probably a result of the adoption of RITUX-
IMAB, which is safe and effective in older as well as younger
patients.1,2 Improved supportive care with better control of comor-
bidities, especially for older patients, might also have contributed
to improve survival for lymphoid malignancies in general.5
Five-year RS for rare lymphoid diseases is 86% and 85% among
children and young adults, respectively (data not shown). In chil-
dren, 5-year RS is 89% for precursor B/T lymphoblastic
leukaemias/lymphomas; among young adults, 5-year RS is 94% for
classic Hodgkin lymphoma (data not shown).
Prevalence
Around 178,000 persons were estimated to be living with a previous
diagnosis of rare lymphoid diseases in Italy in 2010; 37% of these cases
had survived more than 15 years from diagnosis. Most prevalent
cases are represented by patients with a previous diagnosis of classic
Hodgkin lymphoma (25%) and precursor B/T lymphoblastic
leukaemia/lymphoma (19%), diffuse large B-cell lymphoma (17%),
and plasmacytoma/multiple myeloma (16%). This is due to the high
survival for classic Hodgkin lymphoma and relatively high IR for the
other entities, which have a 5-year RS rate ranging from 50% to 40%.
ACUTE MYELOID LEUKAEMIA 
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder
(differentiation arrest or malignant proliferation) of haemopoietic
progenitor cells, in particular myeloid precursors in the bone mar-
row and blood.6 The new 2008 WHO classification7 divides them,
according to their cellular and molecular characteristics, into mye-
locytic, myelogenous, or non-lymphocytic disorders. Furthermore,
they are classified as primary (or de novo) or secondary, if they arise
after an MDS or MDS/MPN, or a blast transformation in a pre-
viously diagnosed MPN, or as consequence of exposure to toxic
substances and/or chemotherapy. 
However, AML has long been recognised as a nosological entity,
thus the criteria for disease definition are stable over time. In the
past twenty years, there has been little improvement in chemother-
apeutic regimens with the exception of the treatment of acute
promyelocytic leukaemia (APL), in which all trans-retinoic acid
(ATRA) is used.8 Thus, within the RARECARE4 project it was de-
cided to identify two major groups of AML on the basis of the dif-
ferent way in which they are treated. 
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
AML and related precursor neoplasms account for 13% of rare
haematological diseases. AML mainly occurs in the over 65 pop-
ulation (see table p. 102), the IR is 5 per 100,000 per year in those
aged 50-55 and 7 per 100,000 per year in those aged 60-64 (data
not shown). The IR is very low <1 per 100,000 in children (0-14
years) and increases slightly from 1 per 100,000 (in those aged 20-
24 years) to 2 per 100,000 (in those aged 40-44 years) confirming
that AML is typical of the elderly (data not shown). 
APL with t(15;17) translocation and variants accounts for 4% of
all AML. Its IR increases with age, and is very low in children (IR
0.1 per 100,000; data not shown) and highest in the elderly (see
table p. 102). However, APL is typical of children and young
adults, representing in the 0-29 year age class 14% of all AML,
compared to only 2% of all AML in those aged >65 years (data not
shown). 
The M/F ratio is 1.2, and approximately 3,600 cases of AML and
related precursor neoplasms are estimated in Italy in 2015 (see table
p. 102).
The IR of AML in Italy is slightly higher than that observed in the
European RARECAREnet database (IR 5.3 per 100,000 in Italy
vs. 3.8 per 100,000 in Europe).
Survival
Survival is different for the two observed entities. APL has a better
prognosis at 1 year and 5 years after diagnosis (74% and 64%, re-
spectively) compared to AML (39% and 18%, respectively) (see fig-
ure p. 103). The relatively good prognosis of APL is mainly attrib-
utable to the use of trans retinoic acid (ATRA) and is consistent with
previous findings8 and the new results observed in Europe.5
Unfortunately, in the past twenty years, there has been little im-
provement in chemotherapeutic regimens and hence in the overall
survival for patients with AML (other than APL). The major im-
provements in AML treatment during the last two decades have not
come from the introduction of new therapeutic agents, but rather
from improved use of well-known drugs. However, the limit of ac-
ceptable toxicity for standard chemotherapeutic drugs used in
AML therapy has been reached and new therapeutic strategies are
therefore needed.8
Prevalence
Around 11,000 persons were estimated to be living with a previous
diagnosis of AML and related precursor neoplasms in Italy in 2010;
this is due to the relatively high IR of AML rather than to RS, which
is low for AML.
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MYELOPROLIFERATIVE NEOPLASMS
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Myeloproliferative neoplasms (MPNs) comprise clonal blood dis-
orders, such as chronic myeloid leukaemia (CML), polycythaemia
vera, essential thrombocythaemia, primary myelofibrosis, and
mast cell tumours and are characterised by increased production
of terminally differentiated myeloid cells. These disorders are clas-
sified according to rearrangements or mutations of genes (i.e. Ph-
chromosome-positive, the BCR-ABL1 fusion gene, in CML, and
JAK2-, CALR-, MPL-, and KIT-mutation-positive in the other
neoplasms).9,10
The management of these tumours with targeted treatments is
based on clinical, biologic, cytogenetic, and molecular character-
istics. The prognosis of CML has dramatically improved since the
availability of IMATINIB in current practice.
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
MPNs represent 13% of all rare haematological diseases. These
pathologies are mainly diagnosed in the over 65 population (see
table p. 102). The majority of these diseases is represented by the
group of «other myeloproliferative neoplasms», which include
primary myelofibrosis, essential thrombocythaemia, polycythaemia
vera, which together account for 75% of the «other myeloprolif-
erative neoplasms» group (data not shown).
CML represents the second most common MPN (see table p.
102).
The M/F ratio is 1.3, with no differences among the different dis-
eases. New cases of MPNs are estimated to be around 3,500 in Italy
in 2015 (see table p. 102). Selecting only CRs with the higher in-
cidence rates (see definition of group two in the introduction to
the present chapter), the number of estimated new cancer cases
would be of about 4,500 in Italy in 2015.
The IR of these diseases is, in any case, higher in Italy than in the
European RARECAREnet database (IR 5.5 per 100,000 in Italy
vs. 3.0 per 100,000 in Europe). Probably, the main reason for the
low rates in Europe is the not yet standardised and complete reg-
istration in Europe of MPNs other than CML, as they were only
recognised as malignant in the ICD-O-3 classification. The discov-
ery of the JAK2-V617F mutation, which is a clue in the diagnosis
of primary myelofibrosis essential thrombocythaemia and poly-
cythaemia vera, will make it easier than in the past to diagnose
these diseases. This will likely increase the systematic registration
of essential thrombocythaemia and polycythaemia vera, and will
probably lead to an increase of the reported incidence.
Low incidence rates in Europe for MPNs with a relatively indolent
behaviour might also be due to the fact that most CRs use infor-
mation of pathology labs and hospital discharge records as their
main notification source. Information from outpatient depart-
ments is not always systematically notified and thus a large pro-
portion of patients with polycythaemia vera and essential throm-
bocythaemia, which often lack pathological confirmation and
are outpatients only, are not registered by those CRs. This can ex-
plain also the difference between the IR observed in the two
groups of CRs in Italy (see definition of group one and two in «A
guide to the cancer-specific data sheets», pp. 28-31).
Survival
MPNs have a good prognosis at 1 and 5 years after diagnosis (90%
and 75%, respectively), with differences across the specific disease
subtype. The highest 5-year RS was observed for mast cell tumours
and other myeloproliferative neoplasms (76% and 81%, respec-
tively) (see figure p. 103). The latter group includes entities with
high survival, such as essential thrombocythaemia (5-year RS
94%) and polycythaemia vera (5-year RS 92%), as well as entities
with poor survival, such as primary myelofibrosis (5-year RS
54%) (data not shown). 
The 5-year RS of patients with CML was 59% (see figure p.
103).The treatment of CML has been significantly modified since
the discovery of IMATINIB, a targeted molecule that inhibits the
tyrosine kinase activity of the neo protein resulting from the BCR
ABL fusion gene. The prognosis of CML has dramatically im-
proved since the availability of IMATINIB in current practice. In
Europe, an increase in survival was observed, from 32% in the pe-
riod 1997-1999 to 54% in the period 2006-2008.5 Thus, these
data confirm, for the first time even in Italy, the great impact that
the introduction of IMATINIB has had at the population level.
Prevalence
Around 26,000 persons were estimated to be living with a previous
diagnosis of MPNs in Italy in 2010; 14% of these cases had survived
more than 15 years from diagnosis. 
MYELODYSPLASTIC SYNDROME AND MYELODYSPLASTIC/
MYELOPROLIFERATIVE DISEASES 
WHAT DO WE KNOW ABOUT THESE CANCERS? 
Myelodysplastic syndrome and myelodysplastic/myeloproliferative
diseases (MDS/MPD) comprise a heterogeneous group of disor-
ders originating from clonal hematopoietic stem cells. These are
characterised by ineffective haematopoiesis, peripheral cytopoenias,
and a variable propensity for leukaemic transformation.11 The
classification is based on genetic mutations: for example, chronic
myelomonocytic leukaemia (CMML) is associated with diverse
pathways that include mutations of signal transduction, DNA
methylation, transcriptional regulation, chromatin modification,
and the RNA splicing machinery.12 Though the general approach
for the treatment is tailored to symptoms of patients, some ther-
apeutic approaches, including lenalidomide, azacitidine, erythro-
poiesis stimulating agents and iron chelation have been demon-
strated to alter the natural history of these disease in selected
MDS patients.13
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
MDS/MPDs represent 8% of all rare haematological diseases (see
table p. 102). The majority of these tumours are represented by the
group of «other myelodysplastic syndromes», which includes, in de-
creasing order: refractory anaemia (18%), refractory anaemia with ex-
cess of blasts (12%), refractory cytopoenia with multilineage dysplasia
(4%), refractory anaemia with sideroblasts (3%), myelodysplastic syn-
drome NOS (64%) (data not shown). The other specific disease sub-
types are very rare. This group of diseases has a high IR in the elderly,
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however, chronic myelomonocytic leukaemia is much more common
in children than in the elderly: it represents 26% of all MDS/MPDs
in children compared to 9% in those aged >65 years (data not shown).
The highest M/F ratio is observed for CML (1.9) while myelodysplastic
syndrome with 5q syndrome is more common among females than
males. Around 2,500 cases of MDS/MPD are expected in 2015 in Italy
(see table p. 102). Selecting only CRs with higher incidence rates (see
definition of group two in the introduction to the present chapter), the
number of estimated cancer cases in Italy would be of about 3,000 in
2015. The IRs observed in Italy are slightly higher than those reported
by the European RARECAREnet database (IR 3.4 per 100,000 in Italy
vs. 2.5 per 100,000 in Europe). As for myeloproliferative neoplasms,
even for this group of diseases the lower IR in Europe could be due to
heterogeneity in the registration of these entities across European CRs.
Survival
In general, these disorders do not have a good prognosis: 1-year RS
is 73%, but 5-year RS decreases to 38%. Five-year RS is highest for
myelodysplastic syndrome with 5q syndrome (55%) and lowest for
chronic myelomonocytic leukaemia (23%) (see figure p. 103). Ma-
jor changes in treatment are attributable to the introduction of new
drugs such as lenalidomide, azacytidine, and decitabine. However,
their effect on survival in the general population has not been ob-
served yet. At the European level, the 5-year RS is higher (48%)
than in Italy, but no major changes were observed from 2003-2005
to 2006-2008.5
Prevalence
Around 9,000 persons were estimated to be living with a previous di-
agnosis of MDS/MPD in Italy in 2010; 12% of these cases had sur-
vived more than 15 years from diagnosis.
HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS 
WHAT DO WE KNOW ABOUT THESE CANCERS? 
These disorders include Langerhans cell histiocytosis, histiocytic
sarcoma, follicular dendritic cell sarcoma, interdigitating cell sar-
coma, indeterminate cell sarcoma, and fibroblastic reticular cell tu-
mours. Histiocytic and dendritic cell neoplasms are very rare and
should be diagnosed with a combination of morphology review
and a battery of immunohistochemistry to rule out mimics such
as carcinoma, lymphoma, and neuroendocrine tumours, and to
better sub-classify these hard-to-diagnose lesions.14 The treatment
for localised disease is surgical resection and the role of adjuvant
therapy is unclear. In patients with multiple areas of involvement,
multimodality treatment at tertiary care centres is likely needed.15
THE EPIDEMIOLOGICAL DATA IN ITALY
Incidence
Histiocytic and dendritic cell neoplasms represent only 0.3% of all rare
haematological diseases (see table p. 102). Histiocytic malignancies
have the highest IR in children and in particular in those aged <4
years. They represent 99% of histiocytic and dendritic cell neoplasms
in children compared to 45% in those aged >65 years. On the con-
trary, accessory cell tumours have the highest IR in the elderly (>65
years) and are extremely rare in children (IR 0.1 per 100,000) (data
not shown). The M/F ratio is 1.6 for histiocytic malignancies, while
no differences exist between males and females for accessory cell tu-
mours. About 70 cases of histiocytic and dendritic cell neoplasm cases
are estimated in 2015 in Italy (see table p. 102). In the European
RARECAREnet database, the IR is lower (IR 0.1 per 100,000 in Italy
vs. 0.05 per 100,000 in Europe).
Survival
Overall, histiocytic and dendritic cell neoplasms have a good 1-year
RS (84%), which decreases after 5 years from diagnosis (67%). How-
ever, differences exist between the specific disease subtype. Five-year
RS is highest for histiocytic malignancies (77%) and lowest for
lymph node accessory cell tumours (35%) (see figure p. 103). This
could be partially due to the fact that the latter are typical of the eld-
erly, and poor survival in elderly patients is generally attributed to
the inability to give potentially curative treatments because patients
are frail or have comorbidities. Late diagnosis and under-evaluation
of disease symptoms could also play a part. Finally, most clinical trials
do not include older patients or those with low performance status,
so treatment protocols are not optimised for the elderly.
Prevalence
Around 1,000 persons were estimated to be living with a previous di-
agnosis of histiocytic and dendritic cell neoplasms in Italy in 2010; 54%
of these cases had survived more than 15 years from diagnosis and were
represented by histiocytic malignancies because of both high incidence
and high 5-year RS compared to lymph node accessory cell tumours.
REFERENCES
1. Sant M, Allemani C, Tereanu C et al. Incidence of hematologic malignancies in Europe by mor-
phologic subtype: results of the HAEMACARE project. Blood 2010;116(19):3724-3734. 
2. Bhatt V, Alejandro L, Michael A, Ganetsky A. The promising impact of ibrutinib, a Bruton’s ty-
rosine kinase inhibitor, for the management of lymphoid malignancies. Pharmacotherapy
2014;34(3):303-314. 
3. Zucca E, Gregorini A, Cavalli F. Management of non-Hodgkin lymphomas arising at extranodal
sites. Ther Umsch 2010;67(10):517-525.
4. Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden
in Europe. Eur J Cancer 2011;47(17):2493-2511.
5. Sant M, Minicozzi P, Mounier M et al. Survival for haematological malignancies in Europe
between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
Lancet Oncol 2014;15(9):931-942. 
6. Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 2015;373(12):
1136-52.
7. Swerdlow SH, Campo E, Harris NL et al (eds). WHO Classification of Tumours of Haematopoietic
and Lymphoid Tissues. Lyon, IARC Press, 2008. Available from: http://apps.who.int/bookorders/
anglais/detart1.jsp?codlan=1&codcol=70&codcch=4002
8. Visser O, Trama A, Maynadié M et al. Incidence, survival and prevalence of myeloid malignancies
in Europe. Eur J Cancer 2012;48(17):3257-3266.
9. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008;112(6):2190-2198.
10. Pemmaraju N, Moliterno AR. From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Dis-
covery on Risk Stratification and Management. Am Soc Clin Oncol Educ Book 2015:139-145.
11. Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and
management. Am J Hematol 2015;90(9):831-41.
12. Kohlmann A, Grossmann V, Klein HU et al. Next-generation sequencing technology reveals a char-
acteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by de-
tecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28(24):3858-3865.
13. Odenike O, Onida F, Padron E. Myelodysplastic syndromes and myelodysplastic/myeloprolifer-
ative neoplasms: an update on risk stratification, molecular genetics, and therapeutic ap-
proaches including allogeneic hematopoietic stem cell transplantation. Am Soc Clin Oncol Educ
Book 2015:e398-e412.
14. Dalia S, Shao H, Sagatys E, Cualing H, Sokol L. Dendritic cell and histiocytic neoplasms: biology,
diagnosis, and treatment. Cancer Control 2014;21(4):290-300.
15. Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic characteristics and outcomes
of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty
five years. Cancers (Basel) 2014;6(4):2275-2295.
COMMENTS
FROM OTHER 
SCIENTIFIC ASSOCIATIONS 
AND PATIENTS’ 
ORGANISATIONS
COMMENTI
DA ALTRE ASSOCIAZIONI 
SCIENTIFICHE E DI PAZIENTI
I tumori in Italia • Rapporto AIRTUM 2015
Epidemiol Prev 40 (1) Suppl 2:1-120  Ulteriori dati disponibili sul sito: www.registri-tumori.it110
Italian Federation of Volunteer-Based Cancer Organisations (FAVO)
considers the data presented in this monograph to be very valuable and
important to outline the burden of rare cancers in Italy, which weigh heav-
ily on the national health budget, and provide a fundamental prerequisite
to adequately support people who have to face an uncommon cancer di-
agnosis and treatment.
In 2010, 360,000 persons were diagnosed with cancer in Italy. Of these,
89,000 (25%) were diagnosed with a rare type of cancer. The monograph
adds that the majority of rare cancers (139 out of 198) are very rare (in-
cidence rate <0.5 per 100,000) and affect only 7,100 individuals, or about
2% of the total number of people with cancer. This is important, because
low incidence is a major obstacle to conducting clinical trials to develop
effective treatments.
This monograph includes another important result. Five cancers consid-
ered rare on the basis of the European incidence rate are not rare in Italy
(diffuse large B-cell lymphoma, multiple myeloma, hepatocellular carci-
noma or HCC, larynx and thyroid cancer). These 5 cancers affect around
30,000 individuals in Italy and do not seem to be as critical as the other
types, thereby presenting a countertrend compared to European figures.
Rare cancers imply late diagnosis and hence late treatment, limited access
to appropriate treatments, including compassionate use of drugs, reduced
number of centres with specialised experience and expertise, lack of in-
formation on the disease and difficulties to carry out clinical trials on the
efficacy of a new treatment.
FAVO provides information on the available centres with specialised expe-
rience and expertise in rare cancers both in Italy and in Europe, and pro-
duces and disseminates information on diagnosis and treatment through
ad-hoc designed materials (for more information, please call the toll-free
number 800-903789, write to info@favo.it, or visit the website:
www.favo.it). FAVO has also played a major role in the performance of joint
research projects supported by the Italian Ministry of Health and carried
out in collaboration with the Fondazione IRCCS, Istituto Nazionale dei Tu-
mori of Milan (Rare Cancers in Italy, Surveillance and evaluation of access
to diagnosis and treatment – RITA2 project, Interaction Framework be-
tween patient advocacy groups and sarcoma cancer centres as a model for
rare cancers).
FAVO has partnered with the European Cancer Patient Coalition (ECPC)
within the RARECAREnet (Information Network on Rare Cancers) re-
search project financed by the European Commission and coordinated by
the Fondazione IRCCS, Istituto Nazionale dei Tumori of Milan. As part of
this project, ECPC drafted a list of 144 rare cancer patient organisations in
Europe with the aim to build a good network to support patients with rare
cancers. The list, which is available on the RARECAREnet website
(http://www.rarecarenet.eu/rarecarenet/index.php/patient-organisations),
provides details such as name, country, contact details, and website of each
organisation. ECPC also collected information materials on most rare
cancers identified by RARECAREnet experts, thereby creating an online li-
brary (available on the RARECAREnet website) that patients can query to
find information on diagnosis, treatment, and follow-up of any rare type of
cancer.To help patients with rare cancers to deal with the numerous disease-
related issues, FAVO has joined the Rare Disease Inter-Parliamentary Group
chaired by Parliament member Mrs. Binetti, and used their connections with
scientific societies, academia, scientific institutions, etc. to form a group of
stakeholders. The result of this joint effort was a Rare Cancer Paper that Mrs.
Binetti discussed in Parliament through a specific motion, soon followed by
numerous others. All motions were approved unanimously by the Chamber
of Deputies with the Government’s consent.
The approved motions call on the Italian Government to:
 encourage initiatives aimed at ensuring continuity and institutionalisa-
tion of the Rare Cancer Network operation (for further information,
please refer to «The Italian Rare Cancer Network», p. 116) and its inclusion
in the National Health System;
 formalise a rare cancer list;
 initiate a pathway leading to the definition of rare cancer centre accred-
itation criteria in order to centralise treatment locally and serve as an in-
terface between treatment centres within the specific joint networks to
achieve maximum effectiveness;
 set up a rare cancer working group under the Ministry of Health with
the participation of cancer registries and cancer patient organisations;
 facilitate rare cancer patient access to compassionate use of drugs
through amendment of Ministerial Decree May 8, 2003 (Therapeutic use
of a drug undergoing clinical trial);
 invest on clinical research on rare cancers and their inclusion in public
health programs;
 make sure that representatives from rare cancer patient organisations
with recognised experience and expertise are involved in all rare cancer
forums;
 facilitate patient referral to the Network centres in the early treatment
phases through a widespread information system in which cancer patient
organisations play a leading role; 
 facilitate access to off-label drugs through the Italian Agency for
Drugs’s (AIFA) research fund, even by involving patients’ caring physi-
cians, to ensure ongoing, effective care, even though, so far, certain, de-
finitive solutions are lacking.
For rare cancer patients, the activation of cross-border health care is ex-
tremely important. To this end, the Cross-Border Directive set as a priority
for rare disease and rare cancers the creation of European Reference Net-
works (ERNs), to connect centres with specialised experience and expertise
in specific diseases from the various Member States. ERNs can help treat
patients with rare diseases for whose treatment it would be impossible to
establish new treatment centres in all European Member States. ERNs can
facilitate patient mobility among the Member States, above all to allow them
to have access to particularly complex or specific health services for the treat-
ment of rare diseases, including rare cancers. 
The role of cancer patient organisations as advocates 
for people with rare types of cancer
Il ruolo delle organizzazioni di pazienti oncologici in difesa di chi è affetto da tumore raro
Federazione italiana delle associazioni di volontariato in oncologia (FAVO)
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Rare cancers are neoplasms with an annual incidence of less than
6 cases per 100,000 inhabitants; altogether, they account for as
many as 25% of all cancer cases.1,2
Rare tumours pose particular problems for health system organi-
sation, assistance, research, and new drug approval and reim-
bursement.2,3
Following current methodologies, clinical trials need a high num-
ber of patients to reach statistical significance, and it is not easy to
collect such a number for uncommon tumours.
As a consequence, clinical evidence is more complicated to reach
in rare than in frequent cancers. The final result is a high level of
uncertainty in the whole process of decision making.2-4
Lack of evidence, low levels of recommendations, poor expertise
of pathologists and clinicians lead, in general, to worse treatment
results and worse survival in patients with rare cancers, compared
to those recorded for common tumours.1-4
However, there is a great variance in incidence, natural history, and
treatment outcomes among the groups of rare cancers.5
For instance, the highest 5-year survival level is recorded in testic-
ular tumours, whereas, at the other extreme, mesothelioma has the
lowest; both are considered rare cancers.5-7
Late diagnosis, incomplete or wrong pathological reports, and sub-
optimal treatment are frequent in uncommon tumours.2-4
For about 15 years, efforts have been made to improve knowledge
and outcomes in rare cancers.1-4
As with more frequent types of cancer, decision making should be
addressed rationally. Clinical studies must provide physicians, pa-
tients, and families with informative results which can be useful in
the choice of the right therapy.2,3,5,6
A structure comprised of referral centres (hubs) with a higher ex-
pertise in a specific rare cancer, leading minor centres (spokes)
grouped in a reference network, is at present the most accepted so-
lution in health organisation.1-5
Earlier and more precise identification and diagnosis of an uncom-
mon tumour and consequent decision making are essential to cure
a higher percentage of patients, increase the number of long-term
survivors, and lower the costs of management.2-4
A review of the pathologic diagnosis performed in hub centres is
the first, fundamental step in the treatment of a rare tumour.2-4,9
Concordance between initial diagnosis and referral centre review
is required.9
The exchange of experience, with ongoing communication be-
tween the hub and spokes, is crucial.2,3,11
However, the «rare tumour» label groups many entities, different for
histology, anatomic presentation, natural history, and prognosis.5
The best example comes from soft tissue sarcomas (STS), one of
the most studied groups of rare tumours. They can arise from fat,
muscles, tendons, vessels, peripheral nervous system, and visceral
organs. Almost all anatomic sites can be involved and more than
50 different histological types are recognised.8
Such a complexity requires a high level of expertise from a variety of
specialists: pathologists for a correct diagnosis, surgeons performing
interventions, orthopaedists for STS of the extremities and girdles,
gynaecologists for uterine sarcomas, abdominal surgeons for retroperi-
toneal sarcomas, thoracic surgeons for lung and chest sarcomas, and
otolaryngologists for head and neck sarcomas.2,3,9
Radiotherapy and medical treatment also require a particular ex-
pertise.
Since rare cancers include more than 200 entities, it is easy to un-
derstand that nobody can be a global expert in all these tumours.1,2
Searching for a referral centre, very often the patient has to move
from the area of residence to a distant specialised hospital, in
order to get the highest level of care. This solution increases per-
sonal and family costs.
In the hub/spoke system, on the other hand, the patient has to
move to the referral centre only for brief phases of treatment, re-
quiring high expertise. Ordinary therapies can be offered at the
closest spoke hospital connected with the hub.2-4
How many referral centres should be planned in Italy to cope with
all rare cancers?
Grouping the uncommon cancer by anatomic site, it is conceivable
that a centre every 15-20 million inhabitants could be planned.2-4
In any case, the rarity of these tumours and the uncertainty in di-
agnosis and treatment do not modify the process of decision mak-
ing applied in more frequent tumours.2
A multidisciplinary approach is the preferred model of health organ-
isation in uncommon tumours,2-4,9 with certain limitations: if the
multidisciplinary group is unbalanced with expertise levels varying be-
tween the components, results can be less than optimal.2-4
Adequate training of all members of the group, steady communi-
cation with referral centres, and a periodical review of final results
are necessary. Implementation and sharing of approved guidelines
and constant monitoring of outcomes are fundamental to increase
the group’s experience and skills.2-4
Precise pathological diagnosis, well-defined staging of disease, and ac-
curate clinical evaluation of the patient can lead to precise planning
Necessary steps to cope with rare cancers in Italy
Passi necessari per affrontare i tumori rari in Italia
Associazione italiana di oncologia medica (AIOM)
AIOM
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of treatment. The complete evaluation of a treatment’s risks and ben-
efits must be shared with patients and their family and patient pref-
erence must be taken into account in the final decisions.2-4,10
Rare tumours have a specific profile in clinical studies, too. Because
of the low number of patients, low levels of evidence are normally
reached. When large and randomised trials are not feasible, evi-
dence can be derived from single case reports, uncontrolled trials,
and observational studies.2,11
Observational studies on selected patient subgroups can make it
possible to collect important pieces of information on natural his-
tory and clinical characteristics in tumours which sometimes have
only a pathological description.2,8,11 National and international col-
laborations should be pursued.2,11
Another solution is to use non-frequentist or Bayesian statistical
approaches.11,12 Each piece of data must be recorded to increase
knowledge: to this purpose, a wide and well-equipped data net-
work is crucial in rare cancer cooperation.11
Quality control programs between hub and spokes should be
planned in order to ensure data quality. Research networks must
improve the knowledge and level of care of rare cancers.2,5,9,11
Collaborative studies involving hub and spokes can prove impor-
tant to improve the quality of diagnosis and treatment.11
In rare cancers, planning clinical studies on new agents is strongly
encouraged and pharmacological companies receive support to de-
velop orphan drugs.11
Patients should be informed about ongoing trials and close coop-
eration with patient advocacies is mandatory.2,3,11
Sometimes, off-label application of a new treatment, if ethically
correct, could be considered as a solution in order to shorten the
time of approval of an innovative therapy.11
On the other hand, regulatory agencies, national health systems,
and insurance companies have to guarantee equality among pa-
tients with common and rare tumours.
In rare cancers, less strict rules on compassionate use, approval, and
reimbursement of new drugs is recommended, taking into consid-
eration the higher level of uncertainty in rare cancers.2
The role of scientific societies such as the Italian Association of
Medical Oncology (AIOM) is to support modern, high-quality can-
cer treatment, encouraging in rare cancers a multidisciplinary and
multispecialty approach. The care of patients must be carefully
planned and coordinated from the outset with all specialists meeting
together.
Another important role of AIOM is to act as a stakeholder to eval-
uate the treatment of rare cancers in order to cooperate with the
Italian Agency for Drugs (AIFA) and reduce procedures and
timing in introducing new active drugs.
The assessment of orphan drugs must be encouraged to facilitate
pricing and payback for a new treatment.
Furthermore, AIOMmust support the role and function of the sci-
entific societies created to study rare tumours, actively cooperating with
national and international organisations such as the Italian Network
for Rare Tumours (RTR) or European Society for Medical Oncology
(ESMO) – Rare Cancer in Europe.
But the highest commitment of AIOM is to improve the educa-
tional level of oncologists by promoting, editing, and implement-
ing national guidelines on rare tumours.
AIOM has recently produced six National Guidelines on Rare
Cancers on:
 neuroendocrine tumours;
 CNS tumours;
 soft tissue sarcomas, GIST and gynaecologic sarcomas;
 oesophageal cancer;
 bile duct and gallbladder cancer;
 testicular tumours.
The next step will be the completion of guidelines on more rare
tumours, such as mesothelioma, thymoma, salivary gland tumours,
small intestine and appendicular tumours, vulvar and penile car-
cinomas.
Close cooperation with other Italian scientific societies, such as the
Associations of radiotherapists and pathologists, and various sur-
gical societies, is necessary.
The final goal is to transform the present AIOM guidelines into
national, multidisciplinary, shared guidelines, approved by the
Ministry of Health, to be used academically in Italian schools of
medicine and specialisation. 
Finally, the guidelines should be translated into English, to facil-
itate diffusion in other countries.
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Most haematological malignancies (HMs) are rare cancers, and their
appropriate characterisation often requires an expert haematologist,
a committed pathologist, and the integration of consolidated clin-
ical, morphological, and phenotypic data with the rapidly progress-
ing molecular knowledge. It is conceivable that the forthcoming
new World Health Organization’s classification will provide further
insights in this setting, assigning even more importance to the mo-
lecular characterisation of these diseases. However, as the availability
of molecular techniques and, more importantly, their standardisa-
tion, is not homogeneously applied throughout the country, finding
an appropriate balance between accuracy of diagnosis and complete-
ness of case recording will be a major issue for cancer registries
(CRs). Indeed, for some HMs, as in the case of fusion genes
PML/RAR in acute promyelocytic leukaemia (APL), BCR/ABL in
chronic myeloid leukaemia (CML), and adult acute lymphoblastic
leukaemia (ALL), FIP1L1-PDGFRA in hypereosinophilic syn-
dromes, and mutations of JAK2/MPL/CALR in myeloproliferative
neoplasms (MPNs), molecular biology is already mandatory for di-
agnosis according to the 2016 WHO criteria. In other situations,
for instance mutations of NPM1 and FLT3 for acute myeloid
leukaemia (AML), BRAF for hairy cell leukaemia (HCL), MYD88
for Waldenstrom’s macroglobulinaemia (WM), and c-KIT for
mast-cell disorders, these exams represent, when available, the
strongest support for a correct diagnosis and/or a useful tool to strat-
ify patients into different risk groups or to select the most appro-
priate treatment. Centralising biological samples for molecular
analysis at referral laboratories (according to the model employed
in other Europen countries) could be a possible solution. In Italy,
a national network for CML (Labnet) is currently active and others
are developing for MPNs and AML.
Thus, rare haematological cancers should, ideally, be diagnosed in
onco-haematologic centres with recognised clinical skills and ad-
equate diagnostic facilities. Diagnosis provided by centres with less
expertise and not specifically involved in HMs (e.g., transfusion
services and units of general medicine or geriatrics) should be con-
sidered with caution, and every effort to have appropriate confir-
mation should be pursued. As a consequence, reported incidence
of some rare HMs might change in the future because of more
stringent diagnostic criteria, and this should be taken into account
when comparisons are made with previous data.
Another important issue will be the availability of novel agents,
many of which, in the last years, have gained (or will soon acquire)
a place in the real-world treatment of several HMs, for instance
new proteasome inhibitors and IMIDs for multiple myeloma
(MM); PI3K and Bruton-kinase inhibitors for mantle and follic-
ular lymphoma; arsenic trioxide for APL; brentuximab-vedotin
and anti-PD1 agents for Hodgkin’s disease (HD); brentuximab-ve-
dotin for anaplastic lymphoma; JAK inhibitors for PMF and
other MPNs; hypomethylating agents for elderly AML; azacitidine
and lenalidomide for myelodysplastic syndromes (MDS). In this
setting, the most brilliant example is likely to be CML, where re-
cently updated OS curves of patients enrolled in clinical trials show
an >90% long-term survival. This is likely due to the availability
of novel TK-inhibitors, which have substantially improved the per-
centage and quality of molecular response in these patients. We ex-
pect that such an improvement in survival may be observed in a
short time not only in clinical studies, but also in real life. Preva-
lence of this disease (and that of other rare HMs potentially ben-
efitting from novel therapies in terms of survival) will likely
increase accordingly. 
Finally, in order to avoid duplications, particular attention should
by paid to the possible evolution from an initial HM into other,
more aggressive ones, such as AML after MDS or MPN; primary
myelofibrosis (PMF) after essential thrombocythemia (ET) or
polycythemia vera (PV); aggressive lymphoma after indolent lym-
phoma; MM after MGUS/asymptomatic myeloma; plasma cell
leukaemia after MM; WM after MGUS. 
Looking to the near future, some additional considerations are here
reported in relationship to specific rare HMs.
MPN.Data on PMF, ET, and PV should be separately reported. In
this setting, bone marrow biopsy and driver mutation assessment
are fundamental and require expertise in the evaluation. It should
also be considered that mast cell disorders include a variety of neo-
plasms with different characteristics, ranging from indolent disor-
ders to very aggressive forms; this would warrant that they should
probably be better defined. More comprehensive data on chronic
eosinophilic neoplasms should also be specifically collected.
MDS.A diagnosis of MDS should, ideally, always be performed by
an expert haematologist on both marrow aspirate and peripheral
blood smears. Though recommended by European guidelines,
bone marrow biopsy is not always performed on a routine basis;
however, it may be useful and necessary in selected cases. Perls’s
staining (to identify ring sideroblasts) and karyotype (which has
a relevant prognostic value and selects patients eligible for azaci-
tidine – high risk – or lenalidomide – del5q – therapy) should be
considered mandatory in most cases and possibly registered, while
flow cytometry is not useful for MDS in current clinical practice. 
It should also be outlined that overall survival of MDS may range
from a few months to many years, based on available prognostic
Registering rare haematological tumours: it is time 
for a breakthrough!
La registrazione dei tumori ematologici rari: è tempo di una svolta!
Società italiana di ematologia (SIE)
SIE
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models. Therefore, a more detailed analysis with respect to risk needs
to be implemented. Furthermore, while awaiting new WHO criteria,
“true”MDS (too simply defined here as «other myelodysplastic syn-
dromes»: they represent the large majority!) should be clearly sepa-
rated from “mixed” MDS/MPD, as these are disorders with over-
lapping characteristics based on different genomic abnormalities.
Finally, 5q-syndrome is a well defined MDS associated with recog-
nised clinical and morphological features, deletion of the long arm
of chromosome 5 (del5q) as single cytogenetic abnormality, low-risk
profile, and response to lenalidomide. CR operators should bear in
mind, however, that del5q may occur in many other subtypes of
MDS (including higher risk MDS), which must not be confused
with the 5q- syndrome identified by WHO as a specific entity.
AML. As in MDS, a diagnosis of AML should be urgently per-
formed by an expert haematologist on both marrow aspirate and
peripheral blood smears and possibly integrated by flow cytometry.
Cytogenetic and molecular data are also critical for risk assessment
and guide treatment decision making.With the exception of APL,
overall survival in AML is generally disappointing, with less than
20% of patients becoming long-survivors. However, when the
analysis is performed by age, it should be noted that long-term sur-
vival in younger (15-60 year-old) patients, in whom intensive treat-
ments, including allogeneic stem cell transplantation, can be de-
livered, is currently 35%-40%. In addition, selected groups of
patients with favourable cytogenetic and molecular features may
have an even better outcome.
OTHER LEUKAEMIAS. Adult ALL represents another rare HM requir-
ing particular attention, while it would also be of some interest to col-
lect data on blastic plasmacytoid dendritic cell leukaemia, a very un-
common entity currently included by WHO among AMLs. 
LYMPHOMAS. Each diagnosis of lymphoma should always derive
from an adequate surgical biopsy (preferably an entire lymph node)
with appropriate histologic, immune-histochemical and, when re-
quired, cytogenetic and molecular evaluation. Core-needle biopsy
may be useful in selected situations, while relying on simple fine-nee-
dle biopsy to make a diagnosis of lymphoma is not recommended. 
Lymphoma evaluation should include approaches for clear differen-
tiation between B and T-cell neoplasms (Burkitt’s lymphoma/
leukaemia should also be analysed separately from T-lymphoblastic/
leukaemia), as well as a further identification of aggressive vs. indolent
forms. Within aggressive lymphomas, specific subtypes with clinical
and biological peculiar characteristics should also be considered; for
instance, variants of diffuse large B-cell lymphomas (DLBCL), such
as primary mediastinal, leg-type, activated vs. germinal centre, and c-
myc positive DLBCL. Among indolent lymphomas, lympho-plasmo-
cytic (WM, if an IgM component is present) and splenic, nodal, and
extra-nodal marginal zone lymphomas should be detailed. 
Among T-cell lymphomas, anaplastic ALK+ lymphoma should be
differentiated from ALK-subtypes. In addition, it should be con-
sidered that other T-cell lymphomas (in particular lymphoblastic,
angio-immunoblastic, and peripheral T-cell-NOS), as well as NK
neoplasms, also have distinctive features, treatments, and survival.
Again, they should be analysed separately.
MM. Based on available criteria, symptomatic myelomas, which re-
quire treatment, should be well distinguished from asymptomatic/
smouldering myelomas, which do not require therapy and have a
different outcome; likewise, localised plasmacytomas (bone or ex-
tramedullary), as well as primary and secondary forms of plasma
cell leukaemia, should be separately detailed. Primary AL amyloi-
dosis should also be considered.
SIE has recently activated an easily accessible IT platform, which
provides specialists with timely updated national guidelines for sev-
eral HMs. In addition, SIE and AIRTUM are closely collaborating
in order to define (and refine) the most useful criteria for register-
ing all HMs within cancer registries in Italy, aiming to improve
quality and completeness of data and provide a breakthrough in
recording. Training of dedicated personnel, identification of new,
non-conventional and more appropriate sources (e.g., pharmacies
for specific drugs and haematology units for well-documented di-
agnoses) and integration of central and regional specific haemato-
logical expertise within the registering teams will represent the new
backbone for the development of these activities.  
Last, but not least, following the virtuous example of other reg-
istries (e.g., SEER in the US), more accurate registrations of rare
HMs could also provide a unique scientific opportunity. Such a
qualitative change requires attention to additional data, such as the
role of specific clinical and biological prognostic factors, environ-
mental and professional exposures, the role of viral or bacterial in-
fections, and therapies delivered. By depicting as complete as pos-
sible a scenario of these tumours in Italy, we aim at carrying out
solid population-based studies with numbers not otherwise attain-
able outside a cancer registry.
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Surgery is the mainstay of therapy in solid rare cancer care.
RARECAREnet project data have shown that 65% of adult solid
rare tumours (which represent 60% of all rare tumours) can be
treated by surgery alone, compared to 35% which require radio-
therapy and 28% which can be treated with chemotherapy. If we
consider the preferred first line therapeutic strategy by stage, 82%
of patients with localised disease can be treated by surgery.
The great surgical challenge concerning rare tumours is the ubiq-
uitous diffusion in the human body: for this reason a “rare cancer
surgeon”, i.e. a surgeon expert in all rare cancers, cannot exist.
Moreover, a fair amount of rare cancers arise in “common” sites,
leading the surgeon, though expert in that particular organ or dis-
trict, to act as for frequent tumours, in a climate of uncertainty.
The final result can be overtreatment, undertreatment or a harmful
intervention which can dramatically change the patient’s prognosis
and quality of life.
Frequent cancers, which can be cured by surgery, are frequently
treated according to validated guidelines or diagnostic-therapeutic
pathways which can be in some way standardised. Guidelines
have shown to improve outcomes even in some rare cancers: a con-
tinuous, repeated referral to guidelines might have a highly valuable
educational impact, enhancing awareness of a standardised work-
up among inexperienced clinicians. Unfortunately, guidelines cov-
ering the entire clinical pathway from diagnosis to treatment, in-
cluding relevant referrals for the whole range of rare cancer families,
are not always available and/or are difficult to access.
The key issue for rare tumours is a correct preoperative diagnosis
and appropriate therapeutic planning within a multidisciplinary
environment. The expert surgeon’s role in a multidisciplinary
team is crucial, because the surgeon can assess the quality and fea-
sibility of the planned surgical act, taking into account the biolog-
ical aggressiveness of the disease, and matching the possible surgical
outcome with different therapeutic alternatives.
Rare tumours require a deep knowledge of their natural history and
biological characteristics. Such knowledge can be available only in
centres in which high volumes of rare cancers are observed and
treated. This is the only way to overcome uncertainty and develop
the best possible, tailor-made treatments. One of the main obsta-
cles to this strategy lies in the difficulty in defining accreditation
criteria for centres of this kind, which focus on the peculiar aspects
of rare cancers.
In Italy, the Italian Society of Surgical Oncology (SICO) is working
with the main oncological scientific societies to pinpoint and de-
fine the criteria upon which a national excellence network can be
built. The first step, which is currently being worked on with the
Italian government, is to define a toolkit of indicators to enable:
 identification and accreditation of reference centres for rare tu-
mours to which patients can be referred for an appropriate surgery,
a second opinion concerning the pathological diagnosis, or preop-
erative treatment planning;
 definition of the fundamentals of a national excellence network
in which reference centres act as hubs for referral, education, and
knowledge, facilitating the integration of existing working groups;
 adequate empowerment and informing of patients and general
practitioners, as well as primary care hospitals;
 prospective collection of data on a nationwide basis concerning
quality of care and outcomes.
Defining criteria to build a national excellence network
Definire i criteri per costruire una rete nazionale di eccellenza
Società italiana di chirurgia oncologica (SICO)
SICO
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Italy has a population of over 60 million. The total number of new
cancer cases each year is about 360,000; of these, 89,000 – more
than 25% – are rare. If the group of rare cancers is split up into all
paediatric cancer cases, all haematological cancers except lym-
phomas (which are not rare, unless they are further split into sub-
groups), and rare adult solid cancers, the latter account for about
60,000 new cases each year. The Italian health system is region-
based, with 20 regions. The new cases of rare adult solid cancers in
each region range from slightly more than 100 to almost 10,000,
i.e. there is a difference by a factor of 100 in the number of new
cases seen region by region. The smallest region parallels a small city,
the largest ones are tantamount to some European countries. 
It is useful to single out rare adult solid cancers because Italian pae-
diatric cancer patients have a number of centres available that are
highly specialised in their care and have pooled efforts effectively
over the last decades. Collaboration between these centres has led
to “large” clinical studies, in a research context which has always
been marked by a kind of overlap between research and healthcare.
This means that quality of care for paediatric cancer is assured by
a system of dedicated centres of reference that are used to collab-
orating with each other. A similar situation occurs for haematolog-
ical neoplasms, since clinical haematology has always had a strong
academic tradition in Italy. Again, there are several high-level ref-
erence centres, which, likewise, have been able to collaborate on
clinical research in recent years. Unfortunately, the same cannot be
said for rare adult solid cancers, at least if one considers them col-
lectively, even though there are reference centres for each of the rare
cancer “families”. Although these institutions, too, have developed
collaborations for research purposes, each group of rare cancers has
its own research network and we lack a framework accommodating
all of them to reach critical mass. Even more importantly, these ef-
forts have not affected healthcare. 
This is why, in 1997, the Rete Tumori Rari (Italian Rare Cancer
Network) was set up, with the aim of covering rare adult solid can-
cers. The overall number of this type of cancers has been men-
tioned above, and this AIRTUM monograph provides detailed fig-
ures about them. Due to the main clinical interest of the
coordinating group at the Fondazione IRCCS Istituto Nazionale
Tumori of Milan, sarcomas were the Network’s first and main fo-
cus, but over the years other groups of rare adult solid cancers have
been incorporated. The core work of the Italian Rare Cancer Net-
work is to share clinical cases between distant institutions, namely
between a cancer facility handling a rare cancer case and a centre
of reference specialising in treatment of that cancer. This happens
at the national level, given the numbers reported by the AIRTUM
monograph, which clearly show that in most regions the number
of cases for each group of rare cancers is definitely low, too low to
allow development of centres of expertise. It goes without saying
that this results in a significant degree of health migration linked
to rare cancers. This occurs despite the fact that the Italian health-
care system has high-quality cancer facilities spread across the
entire country, which would certainly be able to handle rare cancer
cases, if they were properly connected with centres of reference.
This was the idea which led to the creation of the Italian Rare Can-
cer Network several years ago and which has proved to work effec-
tively in a number of cases which currently averages one thousand
each year. Of course, with about 60,000 new rare adult solid can-
cers each year in Italy, the Network would have a tangible impact
on a population basis only if this number could be increased by a
factor of 10. Indeed, several cancer facilities regularly sharing
cases over the Network have been able in a way to specialise on rare
adult solid cancers, in the sense that they are able to deal with some
rare cancer cases by actively sharing information with centres of ref-
erence. They cannot develop the expertise of a reference centre, but
have developed the ability to interact with reference centres effec-
tively.
The Italian Rare Cancer Network is a bottom-up effort that, as
such, has proved to be effective on thousands of individual patients.
The challenge is now to make it grow to reach the numbers re-
quired to exert a population impact, first by covering most rare
adult solid cancer groups and secondly by reaching out to a higher
number of patients in each region. The first aim is currently being
pursued by increasing the reference centres available in the Net-
work, the second by stepping up the Network’s organisational
model, in collaboration with the Italian Health Ministry and the
Conference of Regions. This is a work in progress, which involved
incorporation of the Network into the national Healthcare objec-
tives in 2012, with the goal to eventually incorporate it into the
National Healthcare System. The main challenge is that the trans-
formation of a bottom-up process into a framework endorsed by
the national and regional healthcare authorities naturally implies
an active transfer of resources, primarily to the facilities providing
their expertise, as well as, to a lesser extent, the institutions request-
ing teleconsultation. A health research project will try to formally
assess the Network’s model, including its economic aspects and its
current and potential impact on the healthcare system, while con-
comitantly improving it. At the same time, a working group at the
Italian Ministry of Health, including representatives of each region,
will try to work out the best ways to finally incorporate the Italian
Rare Cancer Network into the National Health System, with the
goal of improving the effectiveness of rare cancer care in Italy on
a population basis and significantly reduce healthcare migration.
The Italian Rare Cancer Network
La rete italiana dei tumori rari
Rete Tumori Rari
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